10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

0001193125-15-290039.txt : 20150813 0001193125-15-290039.hdr.sgml : 20150813 20150813161912 ACCESSION NUMBER: 0001193125-15-290039 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150813 DATE AS OF CHANGE: 20150813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37471 FILM NUMBER: 151050943 BUSINESS ADDRESS: STREET 1: LISE-MEITNER-STRASSE 30 CITY: FREISING-WEIHENSTEPHAN STATE: 2M ZIP: 85354 BUSINESS PHONE: 49 81 6114 11400 MAIL ADDRESS: STREET 1: LISE-MEITNER-STRASSE 30 CITY: FREISING-WEIHENSTEPHAN STATE: 2M ZIP: 85354 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 10-Q 1 d947317d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37471

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Nevada		30-0784346
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Lise-Meitner-Strasse 30 Freising-Weihenstephan, Germany		85354
(Address of principal executive offices)		(Zip Code)

+49 81 6114 11400

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ¨ Yes x No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of August 13, 2015 was 39,732,258.

PIERIS PHARMACEUTICALS, INC.

FORM 10-Q — QUARTERLY REPORT

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015

TABLE OF CONTENTS


	Page

PART I – FINANCIAL INFORMATION		4
Item 1. Financial Statements
Condensed Consolidated Balance Sheets at June 30, 2015 (unaudited) and December 31, 2014		4
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three and six months ending June 30, 2015 and June 30, 2014		6
Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ending June 30, 2015 and June 30, 2014		8
Notes to Condensed Consolidated Financial Statements (unaudited)		9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		24
Item 3. Quantitative and Qualitative Disclosures about Market Risk		36
Item 4. Controls and Procedures		36

PART II – OTHER INFORMATION
Item 1. Legal Proceedings		36
Item 1A. Risk Factors		38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		39
Item 3. Defaults Upon Senior Securities		39
Item 4. Mine Safety Disclosures		39
Item 5. Other Information		39
Item 6. Exhibits		40

SIGNATURES		41

Currency Presentation and Currency Translation

Unless otherwise indicated, all references to “dollars,” “$,” “U.S. $” or “U.S. dollars” are to the lawful currency of the United States. All references in this Report to “euro” or “€” are to the currency introduced at the start of the third stage of the European Economic and Monetary Union pursuant to the Treaty establishing the European Community, as amended. We prepare our financial statements in U.S. dollars.

The functional currency for our operations is the euro. With respect to our financial statements, the translation from the euro to U.S. Dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet date and for revenue and expense accounts using a weighted average exchange rate during the period. The resulting translation adjustments are recorded as a component of other comprehensive income.

Where in this Report we refer to amounts in euros, we have for your convenience also in certain cases provided a conversion of those amounts to U.S. Dollars in parentheses. Where the numbers refer to a specific balance sheet account date or financial statement account period, we have used the exchange rate that was used to perform the conversions in connection with the applicable financial statement. In all other instances, unless otherwise indicated, the conversions have been made using the noon buying rate of €1.00 to U.S. $1.1154 in The City of New York for cable transfers of euro as certified for customs purposes by the Federal Reserve Bank of New York as of June 30, 2015.

Forward Looking Statements

This section and other parts of this Quarterly Report on Form 10-Q contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve risks and uncertainties, principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding future events, our future financial performance, expectations for growth and revenues, anticipated timing and amounts of milestone and other payments under collaboration agreements, business strategy and plans, objectives of management for future operations, timing and outcome of legal and other proceedings, and our ability to finance our operations are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “ongoing,” “could,” “estimates,” “expects,” “intends,” “may,” “appears,” “suggests,” “future,” “likely,” “goal,” “plans,” “potential,” “projects,” “predicts,” “should,” “would,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Risk Factors” or elsewhere in our most recent Annual Report on Form 10-K, which may cause our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements to differ materially.

Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from our forward-looking statements due to a number of factors, including, without limitation, risks related to: the results of our research and development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and ongoing or planned clinical testing of our drug candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial additional funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our future financial performance; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators; our ability to successfully market and sell our drug candidates in the future as needed; the size and growth of the potential markets for any of our approved drug candidates, and the rate and degree of market acceptance of any of our approved drug candidates; competition in our industry; and regulatory developments in the U.S. and foreign countries.

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report on Form 10-Q. Before you invest in our securities, you should be aware that the occurrence of the events described in Part I, Item 1A (Risk Factors) of our Form 10-K filed on March 30, 2015 could negatively affect our business, operating results, financial condition and stock price. All forward-looking statements included in this document are based on information available to us on the date hereof, and except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our statements to actual results or changed expectations.

iii

PART I — FINANCIAL INFORMATION

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30,		December 31,
	2015		2014
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	10,027,305	$	18,474,211
Other current assets		1,866,180		1,207,072
Prepaid expenses		732,221		109,332
Income tax receivable		16,015		14,810

Total current assets		12,641,721		19,805,425

Property and equipment, net		1,811,356		2,052,221
Deferred tax asset		24,446		26,522

Total assets	$	14,477,523	$	21,884,168

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30,			December 31,
	2015			2014
	(unaudited)
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Trade accounts payable	$	2,058,458		$	1,260,015
Accrued expenses		635,561			743,865
Other current liabilities		304,012			242,755
Bank loan		—			1,270,605
Deferred tax liabilities		24,446			26,522

Total current liabilities		3,022,477			3,543,762

Other long-term liabilities		307,850			333,988

Total liabilities		3,330,327			3,877,750


Stockholders’ equity

Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014		29,430			29,280
Additional paid-in capital		85,503,241			84,627,283
Accumulated other comprehensive loss		(1,343,694	)		(843,097	)
Accumulated deficit		(73,041,781	)		(65,807,048	)

Total stockholders’ equity		11,147,196			18,006,418

Total liabilities and stockholders’ equity	$	14,477,523		$	21,884,168

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014

Revenue	$	160,244		$	698,227		$	377,864		$	2,071,106

Operating costs and expenses
Research and development		(1,725,592	)		(1,118,920	)		(3,250,222	)		(2,341,666	)
General and administrative		(1,969,082	)		(2,349,232	)		(4,363,405	)		(3,170,582	)

		(3,694,674	)		(3,468,152	)		(7,613,627	)		(5,512,248	)

Loss from operations		(3,534,430	)		(2,769,925	)		(7,235,763	)		(3,441,142	)

Other income (expense)
Interest expense		(53	)		(113,793	)		(4,223	)		(223,083	)
Other income, net		4,484			2,081			5,253			2,665

Loss before income taxes		(3,529,999	)		(2,881,637	)		(7,234,733	)		(3,661,560	)
Income tax benefit		—			—			—			18

Net loss	$	(3,529,999	)	$	(2,881,637	)	$	(7,234,733	)	$	(3,661,542	)


Net loss per share
Basic and diluted	$	(0.12	)	$	(0.24	)	$	(0.25	)	$	(0.31	)

Weighted average number of common shares outstanding
Basic and diluted		29,429,522			11,828,974			29,361,566			11,828,974

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)


	Three months ended June 30						Six months ended June 30,
	2015			2014			2015			2014
Net loss	$	(3,529,999	)	$	(2,881,637	)	$	(7,234,733	)	$	(3,661,542	)

Other comprehensive loss
Foreign currency translation adjustments		102,135			6,654			(500,597	)		3,027

Total other comprehensive loss, after tax		102,135			6,654			(500,597	)		3,027

Comprehensive loss	$	(3,427,864	)	$	(2,874,983	)	$	(7,735,330	)	$	(3,658,515	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	Six months ended June 30,
	2015			2014
Cash flows from operating activities:
Net loss	$	(7,234,733	)	$	(3,661,542	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation		154,555			189,463
Non-cash interest expense		—			181,951
Stock-based compensation expense		485,374			—
Non-cash Restricted shares		390,734			—
Changes in operating assets and liabilities:
Restricted cash		—			13,091
Trade accounts receivable		—			68,553
Prepaid expenses		(628,723	)		(72,570	)
Other assets		(768,905	)		(240,743	)
Trade accounts payable		897,130			487,595
Accrued and other liabilities		30,481			(422,410	)
Income taxes		(2,365	)		49,668

Net cash used in operations		(6,676,452	)		(3,406,942	)
Cash flows from investing activities:
Purchase of property and equipment		(74,286	)		(4,961	)

Net cash used in investing activities		(72,286	)		(4,961	)
Cash flows from financing activities:
Proceeds of loans		—			1,361,460
Repayment of debt		(1,171,170	)		(136,900	)

Net cash (used in)/provided by financing activities		(1,171,170	)		1,224,560

Effect of exchange rate change on cash and cash equivalents		(524,998	)		(17,033	)
Net decrease in cash and cash equivalents		(8,446,906	)		(2,204,376	)
Cash and cash equivalents at beginning of period		18,474,211			3,689,382

Cash and cash equivalents at end of period	$	10,027,305		$	1,485,006


Supplemental cash flow disclosures:
Cash paid for interest	$	4,224		$	41,132
Cash received for income taxes	$	(1,206	)	$	(18	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.	Corporate Information

Pieris Pharmaceuticals, Inc. is a holding company incorporated in May 2013 under the name Marika Inc. On December 17, 2014 Pieris AG (a German company which was founded in 2001 by Prof. Dr. Arne Skerra, Professor at the Technical University of Munich, Germany, and Claus Schalper) became a wholly owned subsidiary of Pieris Pharmaceuticals, Inc., pursuant to the Acquisition (described below). The registered office of Pieris Pharmaceuticals, Inc. and the corporate headquarters and research facility of Pieris AG are located in Freising-Weihenstephan, Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of Pieris AG, was formed on February 14, 2014 to conduct research and development in Australia.

On December 17, 2014, Pieris Pharmaceuticals, Inc., Pieris AG, and the former stockholders of Pieris AG entered into an acquisition agreement, or the Acquisition Agreement. Pursuant to the Acquisition Agreement, on December 17, 2014, the stockholders of Pieris AG contributed all of their equity interests in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares of Pieris Pharmaceuticals, Inc. common stock, which resulted in Pieris AG becoming a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the “Acquisition”). Upon the closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to be a “shell company” under applicable rules of the SEC. For more information on the acquisition, please refer to Note 3 Acquisition of the consolidated financial statements as of December 31, 2014 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

On December 17, 2014, Pieris Pharmaceuticals, Inc. entered into a securities purchase agreement, or the Securities Purchase Agreement, with certain accredited investors (the “Investors”) providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in a private placement offering conducted through a series of closings occurring on December 17, 18 and 23, 2014, at a purchase price per share of $2.00 and for aggregate gross proceeds of approximately $13.56 million (the “Private Placement”). Northland Securities, Inc. and Katalyst Securities, LLC served as co-exclusive placement agents (the “Placement Agents”) for the Private Placement. At the closings of the Private Placement we issued to the Placement Agents and their designees, warrants (the “Placement Warrants”), to acquire up to 542,360 shares of our common stock at an exercise price of $2.00 per share. Each of the Placement Warrants is exercisable at any time at the option of the holder until the five-year anniversary of its date of issuance.

Pieris Pharmaceuticals, Inc. and its consolidated subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of the Anticalin^® class of biotherapeutics for patients with diseases in which the Company believes there is high unmet medical need.

The Company´s core Anticalin^® technology and platform was developed in Germany, and the Company has partnership arrangements with major multi-national pharmaceutical companies headquartered in the U.S., Europe and Japan and with regional pharmaceutical companies headquartered in India.

2.	Basis of Presentation and Summary of Significant Accounting Policies

The following is a summary of the significant accounting policies consistently applied in the preparation of the accompanying condensed consolidated financial statements.

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements.

In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period.

Use of estimates

The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.

Segment Reporting

Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit.

Milestone Payments and Royalties

At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific,

regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount.

For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met.

Fair Value Measurement

ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.

Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair

value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents.

The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014.

Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09) which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements.

In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual items” (ASU 2015-01). The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”(ASU 2015-02). The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company is currently evaluating the impact of this new standard.

In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements” (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the “Codification”), correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

3.	Revenues

General

Pieris Pharmaceuticals, Inc. has not generated revenues from product sales. Pieris Pharmaceuticals, Inc. has generated revenues pursuant to (i) license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments, and (ii) government grants.

Collaborations and Other Agreements

Allergan, Inc.

In August 2009, pursuant to an agreement with Allergan, Inc. (“Allergan”), the Company granted Allergan a worldwide exclusive license to develop and commercialize certain drug candidates for the treatment and prevention of ocular diseases. Allergan is responsible for the research, development, manufacturing and commercialization of any products resulting from the license. The Company received a non-refundable upfront payment of $10 million upon execution of the contract in 2009 and is entitled to receive up to an aggregate of $13 million in milestone payments upon the achievement of certain commercial milestones or patents granted to the Company by the United States Patent and Trademark Office that cover a product licensed to Allergan.

At the inception of the agreement, the Company recognized revenues from the upfront license payment because, based on the stage of development of the licensed product delivered and the development capabilities of Allergan, the Company determined that the license had standalone value. Through June 30, 2015, none of the milestones had been achieved and, as such, the Company has not recognized milestone-related revenues.

Daiichi Sankyo Co., Ltd.

In May 2011, the Company entered into an agreement with Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”), under which Pieris AG will use its proprietary Anticalin^® scaffold technology to identify drug candidates against certain targets selected by Daiichi Sankyo, with further development and commercialization performed by Daiichi Sankyo. For any targets selected by Daiichi Sankyo, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. The Company has handed over further development responsibility for the two collaboration projects to Daiichi Sankyo, which handovers occurred in March 2013 and June 2014.

Upon execution of the agreement, Daiichi Sankyo paid the Company a non-refundable upfront payment in the amount of $10.1 million in consideration for the licenses, and for each licensed product, the Company is entitled to receive potential milestone payments of $91.1 million, plus royalties on the commercial sales of any commercial products. The total milestones are categorized as follows: research milestones - $2.6 million; development milestones - $37.4 million; commercial milestones - $50.2 million; additional diagnostic milestones of $0.9 million. At the inception of the agreement, these milestones were determined to be substantive as there was substantial uncertainty the milestones would be achieved, they would require substantial performance from the entity, and the consideration was reasonable relative to other deliverables. The agreement includes provisions for the Company to provide research services funded by Daiichi Sankyo at agreed upon full-time employee rates during the initial identification and research period.

In accordance with the guidance in ASC 605-25, the Company identified the licenses and research funding as deliverables at the inception of the arrangement. The Company has determined that the licenses and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin^® technology against Daiichi Sankyo’s selected targets were necessary before the licenses would have any standalone value. Therefore, the total arrangement consideration was recognized over the estimated period of substantial involvement, which was determined to be the period Company was required to provide research services to discover drug candidates against targets identified. The Company estimated this period would be approximately two years. The Company reassesses the estimated term at the end of each reporting period.

The Company has not recognized any milestone payments as revenue for the six months ended June 30, 2015. The Company recognized a milestone payment of $0.4 million as revenue for the six months ended June 30, 2014. The milestone payment was based on successful in vitro and in vivo studies. In general, milestones could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined these milestones to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestones would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Daiichi Sankyo Collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.4 and $1.1 million in revenues, respectively. $0.4 million of these revenues were related to the achievement of milestones during the three and six months ended June 30, 2014.

Sanofi-Aventis and Sanofi-Pasteur

In September 2010, the Company entered into an agreement with Sanofi-Aventis and Sanofi Pasteur (“Sanofi”), under which the Company agreed to apply its proprietary Anticalin^® technology to identify drug candidates against certain targets selected by Sanofi, with further development and commercialization performed by Sanofi. The agreement included the initial identification of two targets by Sanofi, with options to select up to four additional targets. For any targets selected by Sanofi, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. In addition to the two initial targets selected by Sanofi, Sanofi exercised one of the four options and received a license. The remaining three options expired unexercised.

Upon execution of the agreement, Sanofi paid the Company an upfront payment of $4.9 million in consideration for licenses on the first two targets and options to select an additional four licenses on other targets (with each option requiring an additional upfront payment upon exercise). Additionally, for each licensed product, the Company is entitled to receive milestone payments up to $51.6 million, plus royalties on the sales of any commercial products. The total milestones are categorized as follows: research milestones - $1.9 million; development milestones - $29.6 million; commercial milestones - $20.1 million. At the inception of the agreement, these milestones were determined to be substantive because (i) there was substantial uncertainty the

milestones would be achieved, (ii) they would require substantial performance from the entity, and (iii) the consideration was reasonable relative to other deliverables. The agreement included provisions for the Company to provide research services funded by Sanofi at agreed upon full-time employee equivalent rates during the initial identification and research period.

In accordance with the guidance in ASC 605-25, the Company identified the licenses, options to obtain additional licenses and research funding as deliverables at the inception of the arrangement. The options were considered to be substantive at the inception of the agreement. Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.

The Company has determined that, for each program selected by Sanofi, the license and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin technology against Sanofi’s selected targets were necessary before the licenses would have any standalone value.

The estimated selling prices for the licenses in the agreement are the Company’s best estimate of selling price and were determined based on market conditions and entity-specific factors such as considerations of preclinical and clinical testing results and the Company’s pricing practices and pricing objectives. The estimated selling price of research services are the Company’s best estimate of selling price and are determined based on market conditions and entity-specific factors such as internal cost considerations and the Company’s pricing practices and pricing objectives.

At inception, the total arrangement consideration of $8.1 million (which comprises the $4.9 million upfront payment and the expected fees for the research services to be provided under the remainder of the arrangement) was allocated to the deliverables based on the residual method as follows: $3.5 million to the licenses, $1.4 million to the four options to acquire additional licenses and $3.2 million to the estimated research services to be provided. As the license and research services were determined to be one unit of accounting, the consideration allocated to each license is recognized over the period of substantial involvement, which was determined to be the period the Company was required to provide research services to discover drug candidates against targets identified, approximately two years. The Company reassesses the estimated term at the end of each reporting period. At the end of 2012, the Company determined that the required research term for one of the initial terms would extend to a period of 40 months, and management updated the estimated required service period to amortize the remaining deferred upfront payment over the new term. Two of the four options expired un-exercised in 2011, and as a result the Company recognized $0.7 million of revenue upon expiration. The option term for the remaining two options was extended to February 2013, and Sanofi exercised one option to obtain an additional license. For the exercised option, the allocated consideration of $0.28 million for the option and the $1.1 million payment of the exercise price of the option were deferred and amortized over the expected required service period of approximately

two years. The program covered by the exercised option was terminated in December 2013, and accordingly, the Company recognized the remaining deferred revenue upon termination. The remaining option expired in February 2013 and the allocated consideration of $0.35 million was recognized into revenue at the time of expiration.

The Company has not recognized any milestone payments as revenue for the three and six months ended June 30, 2015. The Company recognized a milestone payment of $0.3 million as revenue for the six months ended June 30, 2014. The Company did not recognize a milestone payment for the three months ended June 30, 2014. The milestone payment was based on successful in vivo studies. The milestone could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined this milestone to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestone would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. Therefore, the payment was recognized in its entirety as revenue in the six months ended June 30, 2014 when the research milestone was reached.

For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Sanofi collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.2 million and $0.7 million in revenues respectively.

4.	Related-Party Transactions

Research and License Agreement with Technische Universität München (“TUM”)

On July 4, 2003, the Company entered into a research and licensing agreement with TUM, which was subsequently renewed and, on July 26, 2007, superseded and replaced. The agreement established a joint research effort led by Prof. Arne Skerra, Chair of Biological Chemistry of TUM, to optimize Anticalin® technologies for use in therapeutic, prophylactic and diagnostic applications and as research reagents, and to gain fundamental insights in lipocalin scaffolds. Prof. Dr. Skerra was a member of Pieris AG’s supervisory board when the parties entered into such agreement. The Company provided certain funding for TUM research efforts performed under the agreement.

As a result of research efforts to date under the agreement, the Company holds a worldwide exclusive license under its license agreement with TUM to multiple patents and patent applications, including an exclusive license to an issued U.S. patent, which patent will expire in 2027 (subject to a possible term adjustment period). Pieris AG also holds an exclusive license to an issued U.S. patent No. 8,420,051, which patent is expected to expire in 2029. The Company bears the costs of filing, prosecution and maintenance of patents assigned or licensed to the Company under the agreement.

As consideration for the assigned patents and licenses above, the Company is required to pay certain development milestones to TUM. The Company also is obliged to pay low-single-digit royalties, including annual minimum royalties, on sales of such products incorporating patented

technologies. If the Company grants licenses or sublicenses to those patents to third parties, the Company will be obliged to pay a percentage of the resulting revenue to TUM. The Company’s payment obligations are reduced by the Company’s proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the agreement. The Company can terminate the licenses to any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the agreement does not terminate the rights in patents assigned to the Company.

The Company has incurred the following expenses related to TUM (excluding value added taxes):


	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Transfer of licenses and protective rights	$	13,836	$	17,145	$	27,893	$	34,276

Total expenses incurred with TUM	$	13,836	$	17,145	$	27,893	$	34,276

The Company has accrued $302,273 and $370,999 as of June 30, 2015 and 2014, respectively, related to the amounts due under the research and license agreement (see Note 9 Commitments and Contingencies).

The part of the agreement requiring the Company to make payments for research conducted by TUM expired in February 2013 with no further obligations by Pieris AG.

Consulting Contract between Prof. Dr. Arne Skerra and Pieris AG

In 2001, the Company entered into a Consulting Agreement with Prof. Dr. Arne Skerra, pursuant to which Prof. Dr. Arne Skerra provides advice regarding the use of new proteins, in particular Anticalin^® proteins and antibodies, for the purpose of research and development. The Consulting Agreement has an unlimited term but can be terminated by the Company upon three months’ notice with effect from the end of a month and by Prof. Dr. Arne Skerra upon one year’s notice with effect from the end of a year. Under the Consulting Agreement, the Company incurred and paid to Prof. Dr. Skerra consulting fees of $11,157 and $13,711 for the six months ended June 30, 2015 and 2014, respectively. For the three months ended June 30, 2015 and 2014 the Company incurred and paid Prof. Dr. Skerra consulting fees of $5,534 and $6,858, respectively.

Debt

TBG Loan

As of April 3, 2014, the Company and tbg Technologie-Beteiligungs-Gesellschaft mbH (“TBG”), the subsidiary of KfW Bank, Frankfurt (“KfW”), signed a repayment agreement concerning the Company’s repayment of its liabilities to TBG outstanding at December 31, 2013 in a total amount of €1.2 million ($1.34 million). The principal amount bore interest at a rate of 10.53%. Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016. On December 11, 2014, the Company and TBG entered into an accelerated repayment agreement in respect of the claims of TBG against the Company. Pursuant to terms of the accelerated repayment agreement, conditioned upon closing of the Acquisition, the Company was obligated to pay €1,050,000 ($1.17 million), the outstanding amount under the repayment agreement, in two tranches as follows: €600,000 ($669,240) plus accrued interest on January 31, 2015 and €450,000 ($501,930) on March 31, 2015. The outstanding principal amount for the first and the second tranches, net of capital gain tax withheld, was repaid in full in the first quarter ending March 31, 2015 in the amount of €931,312 ($1,038,785). The capital gain tax withheld in the amount of €118,688 ($132,385) was paid on April 9, 2015 and with that the TBG loan was repaid in full.

6.	Accrued expenses

The Company has recorded the following accrued expenses as of June 30, 2015 and December 31, 2014, respectively:


	June 30, 2015		December 31, 2014
Accrued expenses
Accrued compensation expense	$	333,979	$	332,892
Accrued audit and tax expenses		148,500		403,450
Other accrued expenses		153,082		7,523

Total accrued expenses, current		635,561		743,865

Accrued expenses non-current
Reserve for litigation TUM		302,273		327,937
Accrued expenses restoration		5,577		6,051
Total accrued expenses, non-current		307,850		333,988

Total accrued expenses	$	943,411	$	1,077,853

7.	Stock-based compensation

In December 2014, the Board of Directors and stockholders of Pieris Pharmaceuticals, Inc. adopted the 2014 Employee, Director and Consultant Equity Incentive Plan (the “Pieris Plan”), which became effective upon closing of the Acquisition. The Pieris Plan is intended to encourage ownership of common stock by the Company’s employees and directors and certain of their consultants, including employees of Pieris AG, in order to attract and retain such people, to induce them to work for the benefit of the Company and to provide additional incentive for them to promote the Company’s success. The Pieris Plan reserves 3,200,000 shares of the Company´s common stock for issuance. In addition, the Pieris Plan provides for an “evergreen” provision whereby the number of shares of the Company´s common stock reserved for issuance under the Pieris Plan shall be automatically increased on January 1 of each of year commencing in fiscal 2016 by the lesser of (i) 1,000,000 shares, (ii) 4% of the number of shares of the Company´s common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company´s common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014. In addition, options to purchase 1,146,500 shares are outstanding under the Pieris Plan to other employees and consultants. 25,000 of these shares were granted during the first quarter of 2015, 32,000 of these shares were granted during the second quarter of 2015 and 1,089,500 were granted during the fourth quarter of 2014. As a result of such grants, 583,265 of the Company´s common stock remain available for future issuances under the Pieris Plan.

Stock options granted under the Pieris Plan may be either incentive stock options (“ISOs”), or nonqualified stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally three years) and the exercise prices. Options have a maximum term of ten years. The exercise price of stock options granted under the Pieris Plan must be at least

equal to the fair market value of the common stock on the date of grant. The Pieris Plan become effective in December 2014, therefore there was no stock-based compensation expense in the three and six months ended June 30, 2014.

Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three and six months ended June 30, 2015, was comprised of the following:


	Three months ended		Six months ended
	June 30, 2015		June 30, 2015
Research and Development	$	78,551	$	129,590
General and administrative		189,488		355,785

Total stock-option expense	$	268,039	$	485,375

The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three and six months ended June 30, 2015:


	Three months ended			Six months ended
	June 30, 2015			June 30, 2015
Forfeiture rate		6.0	%		6.0	%
Dividend yield		0.0	%		0.0	%
Expected volatility		73.7	%		74.1	%
Weighted average risk-free interest rate		1.73	%		1.71	%
Expected term		5.3 - 5.8 years			5.3 - 5.8 years

A summary of the Company’s stock option activity and related information is as follows:


	Number of shares		Weighted- Average Exercise Price		Weighted- Average Contractual Life
Outstanding at December 31, 2014		2,519,500	$	2.00		5.6 - 5.8 years
Options granted		25,000	$	2.85		5.8 years
Options exercised		—		—		—
Options cancelled or expired		—		—		—
Outstanding at March 31, 2015		2,544,500	$	2.01		5.6 - 5.8 years
Options granted		72,235	$	2.89		5.3 - 5.8 years
Options exercised		—	$	—		—
Options cancelled or expired		—	$	—		—
Outstanding at June 30, 2015		2,616,735	$	2.03		5.3 - 5.8 years
Vested at June 30, 2015		799,068	$	2.03		—
Expected to vest after June 30,2015		1,708,607	$	2.03		—
Exercisable at June 30, 2015		799,068	$	2.03		—

The weighted-average grant date fair value for awards granted during the three and six months ended June 30, 2015 was $130,456 and $176,898, respectively. There were no options exercised during the three and six months ended June 30, 2015 and 2014. 200,673 and 375,319 shares were vested in the three and six months ended June 30, 2015, respectively.

The unrecognized share-based compensation expense related to employee stock option awards at June 30, 2015, is $2,253,478, which will be recognized over a weighted-average service period of 2.5 years.

8.	Consulting Shares

On March 6, 2015, the Company entered into an independent consulting agreement (the “Consulting Agreement”) with the Del Mar Consulting Group, Inc. and Alex Partners, LLC (the “Consultants”), pursuant to which the Company issued 150,000 restricted shares of its common stock (par value $0.01 per share) to the Consultants (the “Consulting Shares”). The Company agreed to retain the Consultants to provide investor relations consulting to the Company for a period commencing on March 6, 2015 (the “Commencement Date”) and ending thirteen months after the Commencement Date (such period, the “Term”). The shares issued in connection with the Consulting Agreement were deemed to be exempt from registration in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving any public offering.

The terms of the Consulting Agreement state, that the Company has the right to terminate this agreement at any time during the Term of the Consulting Agreement, upon providing Consultants ten days’ written notice of Company’ intention to terminate or immediately upon notice in the event of a breach of this agreement by either consultant. If the Company delivers notice to terminate this agreement for any reason within one hundred eighty days (180) following the effective date (the “Return Date”), then each Consultant will promptly return and surrender to the Company forty percent (40%) of the number of Consulting Shares issued to it. Therefore 60,000 of these shares are subject to certain forfeiture provisions within 180 days following the date of entry into the Consulting Agreement.

The Company, using the Black-Scholes method, estimated the fair value of the 90,000 non-cancellable Consulting Shares to be $284,400 based on the closing price per share of $3.16 as quoted on the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the grant date, March 6, 2015. The Company estimated the fair value of the 60,000 cancellable Consulting Shares to be $192,000 based on the closing price per share of $3.20 as quoted on the OTCQB on the interim financial reporting date, March 31, 2015. Therefore, the Company estimated the total fair value of the Consulting Shares to be $476,400 and recognized the 90,000 vested non-cancellable Consulting Shares, or sixty percent (60%) of the Consulting Shares in an amount of $284,400, as general and administrative expense for the six months ended June 30, 2015. The remaining forty percent (40%), or 60,000 Consulting Shares in the amount of $192,000, will be recognized as general and administrative expenses with an offsetting credit to equity on a straight-line basis over 180 days. If the Company exercises the option to terminate the Consulting Agreement within the 180 days, resulting in the cancellation of forty percent (40%) of the Consulting Shares, expense for cancelled, unvested shares will be reversed.

On June 30, 2015 the Company revalued the fair value of the unvested and forfeitable 40% of the shares. As of June 30, 2015 the estimated fair value of the 60,000 unvested and forfeitable shares was $165,000. Therefore the Company recognized expenses in connection with the Consulting Shares of $79,666 in general and administrative expenses for the cancellable Consulting Shares during the three months ended June 30, 2015. For the six months ended June 30, 2015 the Company recognized $390,733 in general and administrative expenses, including $284,400 for the non-cancellable Consulting Shares and $106,333 for the cancellable shares.

9.	Warrants

In connection with the Private Placement in December 2014, the Company issued the Placement Warrants to acquire combined up to 542,360 shares of its common stock at an exercise price of two dollars per share ($2.00) to the Placement Agents and their designees during December 2014. The Placement Warrants are exercisable at any time at the option of the holder until the five year anniversary of its date of issuance. The number of shares of common stock issuable upon the exercise of each Placement Warrant is adjustable in the event of certain stock dividends, stock splits, combinations of shares and similar transactions. Upon exercise, the aggregate exercise price of the warrants issued are payable by the holders in cash.

The Company estimated the fair value of the Placement Warrants as of the grant date to be $664,064 and recognized the full amount in general and administrative expense for the year ended December 31, 2014.

10.

Commitments and Contingencies

Arbitration

On March 20, 2014, the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universität München, or Munich Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company to TUM under the Company´s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit.

On July 4, 2003, or the Effective Date, the Company and TUM entered into the TUM License Agreement, as superseded and replaced on July 26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become part of the Anticalin^® proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and sales, as well as an variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM.

this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding the proper amount of the Out-License Fee, but we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company’s calculation of the payments owed to TUM is accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet´s position other long-term liabilities in respect of such payment in the amount of €271,000 ($302,273). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company’s results of operations and financial condition.

In April 2014, TUM argued to the arbitrators that it is not the proper party to be sued under the action for a declaratory arbitration decision brought by the Company in relation to the Research and Licensing Agreement, and that instead, it is the Free State of Bavaria that is the proper respondent to the action. The Company has responded that TUM has capacity to be sued in relation to any disputes arising from and regarding contractual provisions of the Research and Licensing Agreement and is thus also the proper respondent in the action. In accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit, each party to the arbitration proceeding has appointed one arbitrator and the party-named arbitrators collectively selected the third arbitrator as the chairman of the arbitration panel.

On December 1, 2014, TUM filed its statement of defense, maintaining its earlier calculation of the Out-License Fee. On December 23, 2014, TUM filed a counterclaim in the amount of €2,529,400 ($3,060,827) to suspend the statute of limitations on its claims. On January 12, 2015, the Company filed a reply brief in response to TUM’s defense.

The arbitration panel held its first hearing in Munich, Germany on January 20, 2015, however the arbitration panel did not come to a conclusion on whether TUM is the proper respondent in the action or on the merits of the case. The panel had previously indicated that it will first decide the issue of whether TUM is the proper respondent in this action. The panel resolved that the value in dispute for both parties’ claims and counterclaims would be fixed at €3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On March 3, 2015, the Company submitted a reply brief responding to TUM’s statement of defense and counterclaim.

On March 31, 2015, TUM submitted a rebuttal brief. The panel requested that both the Company and TUM indicate to the panel by April 27, 2015 whether proceedings should be stayed as a result of settlement negotiations. On April 27, 2015, the Company submitted a reply brief requesting proceedings to continue without disruption and moving for leave to comment on TUM’s submission. Following an approved extension by the panel for TUM’s submission, TUM submitted its proposal on May 4, 2015, requesting that the panel conduct a mediation hearing and assist the parties in negotiating a settlement. On May 8, 2015, the arbitration tribunal set June 1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further settlement negotiations if both parties are in favor of holding a hearing. The Company submitted its brief on June 1, 2015. On June 8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the arbitration without another oral hearing. TUM did not file its brief by the June 1 deadline set by the panel, and instead filed another submission on June 23, 2015. In its procedural order issued on the same day, the tribunal panel reserved the right to reject TUM’s new submission based on the content of its brief. The tribunal’s subsequent procedural order of June 25, 2015 provided that the tribunal will close the proceedings on July 10, 2015. The order clarified that any further pleadings or submissions will not be admissible after this date. The Company submitted its final brief on July 10, 2015 to address TUM’s arguments raised in its latest submission and to provide the tribunal with an overview of its costs incurred in this arbitration proceeding. On the same day, TUM submitted its summary of its costs incurred in this arbitration proceeding and subsequently, on July 23, 2015, filed an additional brief to correct some of its earlier submissions on costs and comment on the Company’s cost overview of July 10. The Company replied to the TUM brief on August, 7. It is not possible to determine at this time when the arbitration tribunal will make its final decision.

11.

Subsequent Events

Public Offering

On July 6, 2015 the Company closed a public offering of an aggregate of 9,090,909 shares of the Company´s common stock at a purchase price of $2.75 per share. All shares of common stock were offered by the Company. On July 24, 2015 the underwriters exercised their over-allotment option to purchase 1,211,827 additional shares of the Company’s common stock at the public offering price of $2.75, which sale closed on July 28, 2015.

Gross proceeds raised by the Company in the offering, including the exercise of the over-allotment option, were $28.3 million and net proceeds are expected to be approximately $25.8 million. The Company intends to use the net proceeds from the offering to fund research and development, including preclinical and clinical research and development of its drug candidates, working capital and general corporate purposes.

Milestone payment

On July 8, 2015 the Company announced that it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed due to the confidential treatment of this agreement. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates. The Company expects to receive this milestone payment in the third quarter of 2015.

Cooperation Agreement

On July, 14 the Company entered into a Cooperation Agreement (the “Cooperation Agreement”) with the University of Cologne. The University of Cologne provides research services to the Company for which it will receive up to two milestone payments. For the research services under Milestone 1, the Company shall pay the University a net amount of $48,698 (€43.660) in two installments. Within thirty days following achievement of Milestone 1, the Company and University shall mutually agree whether to continue with the Cooperation Project. Having agreed on continuing with Milestone 2, the Company shall pay the University a net amount of $130,301 (€116,820) in two installments.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The interim financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2014, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 30, 2015. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2014.

As used in this Quarterly Report on Form 10-Q, unless the context indicates or otherwise requires, “our Company”, “the Company”, “Pieris”, “we”, “us”, and “our” refer to Pieris Pharmaceuticals, Inc., a Nevada corporation, and its consolidated subsidiary, and the term “Pieris Operating” refers to Pieris AG, a company organized under the laws of Germany that, through the Acquisition completed on December 17, 2014, has become our wholly owned subsidiary.

We have registered trademarks for Pieris^®, Anticalin^® and Pocket Binding^®. All other trademarks, trade names and service marks included in this Quarterly Report on Form 10-Q are the property of their respective owners. Use or display by us of other parties’ trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owner.

Acquisition and Private Placement

Overview of Our Business

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of our Anticalin® class of biotherapeutics for patients with diseases in which we believe there is high unmet medical need. Our current development plans focus mainly on our Anticalin drug candidates PRS-080, PRS-060, as well as our 300-Series “platform within a product” opportunity in immuno-oncology, as discussed in more detail below. Anticalin proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. PRS-080 is an Anticalin protein that binds to hepcidin, a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency, or FID, in anemic patients with chronic kidney disease, or CKD, particularly in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor, thereby inhibiting IL-4 and IL-13, two cytokines, small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. We completed dosing of healthy volunteers in a Phase I clinical trial with PRS-080 in June 2015, and we expect to report the data from this trial in the second half of 2015. In the trial, no dose-limiting toxicities were observed and a maximum tolerated dose was not reached. PRS-060 is currently in preclinical development, and we intend to begin a Phase I clinical trial with PRS-060 in 2017. Our 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link an antibody with one or more Anticalin proteins, thereby constituting a multispecific protein. We are conducting preclinical experiments on a number of 300-Series lead candidates and by the end of 2015 intend to choose a candidate for pre-clinical studies to support the IND for potential clinical trials in oncology.

We are also developing PRS-110 in oncology. PRS-110 is a monovalent antagonist, a polypeptide molecule with one target-binding domain,that is designed to block both ligand- dependent and ligand-independent activity of cMet. cMet is a receptor tyrosine kinase, a well-known high- affinity cell surface receptor that transmits signals into the cell when a corresponding ligand binds to it, which is essential for embryonic development and wound healing and has been associated with several different cancers, including renal, gastric and lung carcinomas, central nervous system tumors and sarcomas.

Our core Anticalin® technology and platform was developed in Germany, and we have partnership arrangements with major multi-national pharmaceutical companies headquartered in the U.S., Europe and Japan and with regional pharmaceutical companies headquartered in India. These include existing agreements with Daiichi Sankyo Company Limited, or Daiichi Sankyo, and Sanofi Group (formerly Sanofi-Aventis and Sanofi-Pasteur SA), or Sanofi, pursuant to which our Anticalin platform has consistently achieved its development milestones. We have discovery and preclinical collaboration and service agreements with both academic institutions and private firms in Australia. We also intend to establish a greater U.S. presence and take advantage of the U.S. capital markets, additional potential corporate partners, and the broad expertise found in the biotechnology industry in the United States.

Since inception, we have devoted nearly all of our efforts and resources to our research and development activities. We have incurred significant net losses since inception. For the six months ended June 30, 2015 and 2014 we reported net loss of $7.2 million and $3.7 million, respectively. For the three months ended June 30, 2015 and 2014 we reported net loss of $3.5 million and $2.9 million, respectively. As of June 30, 2015, we had an accumulated deficit of $73.0 million.

We expect to continue incurring substantial losses for the foreseeable future as we continue to develop our clinical and preclinical drug candidates and programs. Our operating expenses are comprised of research and development expenses and general and administrative expenses.

We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for at least the next several years. Our revenues for the three and six months ended June 30, 2015 and 2014 were primarily from license and collaboration agreements with our partners, and, to a lesser extent, from grants from government agencies.

The U.S. dollar is the reporting currency for all periods presented. The functional currency for Pieris Operating is euros. All assets and liabilities denominated in euros are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average rate during the period. Equity transactions are translated using historical exchange rates. Adjustments resulting from translating foreign currency financial statements into U.S. dollars are included in accumulated other comprehensive loss. Pieris is a holding company without operations and the sole stockholder of Pieris Operating. The corporate headquarters and research facility of Pieris Operating are located in Freising, Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of Pieris Operating, was formed on February 14, 2014 to conduct research and development in Australia.

Financial Operations Overview

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

Revenues

We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for at least the next several years. Our revenues for the last two years have been primarily from the license and collaboration agreements with Sanofi Group (formerly Sanofi-Aventis and Sanofi-Pasteur SA), or Sanofi, and Daiichi Sankyo Company Limited, or Daiichi Sankyo and, to a much lesser extent, grants from government agencies. The revenues from Sanofi and Daiichi Sankyo have been comprised primarily of upfront payments, research and development services and, to a lesser extent, milestone payments. We recognized revenues from upfront payments under these agreements on a straight-line basis over the required service period because we determined that the licenses to which the payments related did not have standalone value. Research service revenue is recognized when the costs are incurred and the services have been performed. Revenue from milestone payments is recognized when all of the following conditions are met: (1) the milestone payments are non-refundable, (2) the achievement of the milestone involves substantial risk and was not reasonably assured at the inception of the arrangement, (3) substantive effort on our part is involved in achieving the milestone, (4) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (5) a reasonable amount of time passes between the up-front license payment and the first milestone payment.

We expect our revenues for the next several years to consist of upfront payments, research funding and milestone payments from strategic collaborations we currently have or may establish in the future. We also may receive grants from government agencies and foundations funds in connection with our drug development efforts.

Expenses

The process of researching and developing drugs for human use is lengthy, unpredictable and subject to many risks. We expect to continue incurring substantial expenses for the next several years as we continue to develop our clinical and preclinical drug candidates and programs. We are unable with any certainty to estimate either the costs or the timelines in which those costs will be incurred. These programs consume a large proportion of our current, as well as projected, resources. We anticipate that our expenses will increase significantly compared to recent years as we advance PRS-080 through clinical trials, [including a Phase I clinical trial in healthy volunteers initiated in November 2014. On June 10, we announced the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for our PRS-080 program. engage in first-in-man-enabling preclinical studies for PRS-060 and, subsequently, clinical development activities for this program, and prepare drug supply for these and other product candidates. We also expect to incur expenses associated with:

•

further preclinical development activities for 300-Series programs in the area of immune-oncology;

•

establishing and managing relationships with third parties with respect to collaboration and out-licensing; and

•

validating and developing additional novel drug candidates.

Any failure or delay in the advancement of PRS-080, PRS-060 or our 300-Series Programs could require us to re-allocate resources from our other projects to the advancement of those drug candidates, which could have a material adverse impact on the advancement of other projects and on our operations.

Our operating expenses are comprised of research and development expenses and general and administrative expenses. Our research and development costs include costs that are directly attributable to the creation of certain of our Anticalin^® drug candidates and are comprised of:

•

internal recurring costs, such as labor and fringe benefits, materials and supplies, facilities and maintenance costs; and

•

fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing, and clinical trial activities.

General and administrative expenses consist primarily of salaries and benefits for employees in executive, finance, business development, legal, accounting, human resources and other support functions. Other significant general and administrative expenses include the costs associated with obtaining and maintaining our intellectual property portfolio, professional fees for accounting, auditing, consulting and legal services, travel and allocated expenses and stock based compensation expense.

Results of Operations

Comparison of the three and six months ended June 30, 2015 and June 30, 2014

The following table sets forth our revenues and operating expenses for the periods presented:


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
	(in thousands)

Revenue	$	160		$	698		$	378		$	2,071
Research and development		(1,726	)		(1,119	)		(3,250	)		(2,342	)
General and administrative		(1,969	)		(2,349	)		(4,363	)		(3,171	)
Other income (expense)		4			(112	)		1			(220	)

Net loss	$	(3,531	)	$	(2,882	)	$	(7,234	)	$	(3,662	)

Revenues

The following table provides a comparison of revenues for the periods presented:


	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
	(in thousands)

Upfront payments	$	—	$	31	$	—	$	473
Research and development services		—		225		—		877
Milestone payments		—		411		—		685
Grants		160		31		378		36

Total	$	160	$	698	$	378	$	2,071

The $0.2 million decrease in revenues from research and development services in the three months ended June 30, 2015 compared to the three months ended June 30, 2014 relates to the successful hand over of all collaboration projects in 2014. We have not received research funding from collaboration partners since July 2014. In the three months ended June 30, 2014, we received research funding from a collaboration partner for one collaboration project.

Pieris did not recognize any collaboration milestones in the three months ended June 30, 2015. In the three months ended June 30, 2014, we achieved one research milestones under a collaboration project. The increase in revenues from grants in the three months ended June 30, 2015 compared to the three months ended June 30, 2014 relates primarily to our significantly increased activities related to PRS-080’s development in 2015 compared to 2014, resulting in higher reimbursement from the European Commission for PRS-080’s development.

The $0.5 million decrease in revenues from upfront payments in the period ended June 30, 2015 compared to the period ended June 30, 2014 relates to the successful hand over to collaboration partners of collaboration projects in 2014. Recognition of upfront payments was spread over the expected time period in which we were performing research services for corresponding partner projects and until hand-over or termination of the projects. Thus, in the six months ended June 30, 2014 upfront payments for two projects were recognized. Accordingly, the $0.9 million decrease in revenues from research and development services in period ended June 30, 2015 compared to the period ended June 30, 2014 relates to the successful hand over of all collaboration projects in 2014. We have not received research funding from collaboration partners since July 2014. In the period ended June 30, 2014, we received research funding from collaboration partners for two collaboration projects.

Pieris did not recognize any collaboration milestones in the six months ended March 31, 2015. In the six months ended June 30, 2014, we achieved two research milestones under collaboration projects. The increase in revenues from grants in the six months ended June 30, 2015 compared to the six months ended June 30, 2014 relates primarily to our significantly increased activities related to PRS-080’s development in 2015 compared to 2014, resulting in higher reimbursement from the European Commission for PRS-080’s development.

Research and Development Expenses

Total research and development expenses for advancing our proprietary and co-development projects and improving and maintaining our Anticalin^® platform technology were $1.7 million for the three months ended June 30, 2015 as compared to $1.1 million for the three months ended June 30, 2014. The $0.6 million increase in total research and development expenses in the three months ended June 30, 2015 compared to the three months ended June 30, 2014 is primarily due to increased external clinical trial expenses associated with PRS-080 and increased salary expenses for our PRS-300 Series immuno-oncology programs, offset by reduced salary expense in lower priority programs as resources were shifted to PRS-300.

As of June 30, 2015, we employed 29 full-time and 5 part-time personnel in our research and development group compared to 26 full-time and 4 part-time personnel in our research and development group as of June 30, 2014. We incurred expenses of $0.6 million and $0.1 million during the three months ended June 30, 2015 and 2014, respectively, for amounts payable to external parties who performed research and development activities for our proprietary and co-development projects and platform technology.

Total research and development expenses were $3.3 million for the six months ended June 30, 2015 as compared to $2.3 million for the six months ended June 30, 2014. The $1.0 million increase in total research and development expenses in the six months ended June 30, 2015 compared to the six months ended June 30, 2014 is primarily due to increased external clinical expenses associated with PRS-080 and increased internal salary related expenses for the PRS-300 Series immune-oncology programs offset by reduce salary expense in lower priority programs as resources were shifted to PRS-300 and other programs. We incurred expenses of $1.2 million and $0.3 million during the six months ended June 30, 2015 and 2014, respectively, for amounts payable to external parties who performed research and development activities for our proprietary and co-development projects and platform technology.

The following table provides a comparison of the research and development expenses for our drug candidates and projects for the periods presented:


	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
	(in thousands)

PRS-060	$	—	$	31	$	22	$	39
PRS-080		641		151		1,254		348
PRS-110		1		23		5		73
PRS-300 Series		540		134		969		157

Total	$	1,182	$	339	$	2,250	$	617

Research and development expenses related to PRS-080 increased by $0.5 million in three months ended June 30, 2015 as compared to the three months period ended June 30, 2014. This increase was a result as Phase I clinical trial started in late 2014 in healthy volunteers. In contrast, no activities related to clinical trials were carried out during the three months period ended June 30, 2014. As PRS-300 project activities were only first initiated during three months ended June 30, 2014 the corresponding cost in three months ended June 30, 2015 for PRS-300 activities are significantly higher.

In addition to the amounts outlined above, we incurred $0.6 million and $0.8 million in connection with early stage research projects and platform technology development during the three months ended June 30, 2015 and 2014, respectively.

We incurred zero and $0.1 million of costs in relation to providing research and development services under the license and collaboration agreements with our collaboration partners for the three months ended June 30, 2015 and 2014, respectively.

Research and development expenses related to PRS-080 increased by $0.9 million in six months ended June 30, 2015 as compared to the six months period ended June 30, 2014. This increase was a result as Phase I clinical trial started in late 2014 in healthy volunteers. In contrast, no activities related to clinical trials were carried out during the six months period ended June 30, 2014. As PRS-300 project activities were only first initiated during six months ended June 30, 2014 the corresponding cost in six months ended June 30, 2015 for PRS-300 activities are significantly higher.

In addition to the amounts outlined above, we incurred $0.9 million and $1.6 million in connection with early stage research projects and platform technology development during the six months ended June 30, 2015 and 2014, respectively.

We incurred zero and $0.2 million of costs in relation to providing research and development services under the license and collaboration agreements with our collaboration partners for the six months ended June 30, 2015 and 2014, respectively.

General and Administrative Expenses

General and administrative expenses decreased from $2.3 million for the three months ended June 30, 2014 to $2.0 million in the three months ended June 30, 2015. This $0.3 million decrease resulted primarily from lower salary costs and favourable exchange rate effect offset by increased consulting costs and costs associated with being a public company, including $0.3 million in non-cash stock based compensation expense.

General and administrative expenses increased from $3.2 million for the six months ended June 30, 2014 to $4.4 million in the six months ended June 30, 2015. This $1.2 million increase resulted primarily from increased consulting costs and costs associated with being a public company including legal and investor relations costs and $0.7 million in non-cash stock based compensation expense, offset by a favourable exchange rate effect.

Other Income (Expense)

Other income (expense) decreased to nil in the three months ended June 30, 2015 from $0.1 million for the three months ended June 30, 2014. This decrease primarily relates to reduced interest expense on shareholder loans which were converted into shares of common stock in the fourth quarter of 2014.

Other income (expense) decreased to nil in the six months ended June 30, 2015 from $0.2 million for the six months ended June 30, 2014. This decrease primarily relates to reduced interest expense on shareholder loans which were converted into shares of common stock in the fourth quarter of 2014.

Liquidity and Capital Resources

Through June 30, 2015, we have funded our operations with $141.4 million of cash that has been obtained from the following main sources: $76.9 million from sales of equity; $6.5 million from loans; $14.2 million from grants from government agencies; and $43.8 million in total payments received under license and collaboration agreements, including $7.9 million for research and development services costs we received in 2012, 2013, 2014 and the first six months of 2015 from Daiichi Sankyo and Sanofi. We expect that reimbursements of our development costs by Daiichi Sankyo and Sanofi will decline going forward, and we do not expect such reimbursements to be a significant source of funding in the future.

As of June 30, 2015, we had a total of $10.0 million in cash and cash equivalents and $3.3 million of liabilities, including $3.0 million of current liabilities from operations.

Pieris has experienced operating losses since its inception and had a total accumulated deficit of $73.0 million as of June 30, 2015. Pieris expects to incur additional costs and require additional capital. We have incurred losses in nearly every year since inception and in the six months ended June 30, 2015. These losses have resulted in significant cash used in operations. During the six months ended June 30, 2015 and 2014, our cash used in operations was $6.7 million and $3.4 million, respectively. While we have several research and development programs underway, the PRS-080 and PRS-060 programs have advanced the furthest and will continue to consume, along with our 300-Series programs, increasing amounts of cash for conducting clinical trials and the testing and manufacturing of product material. As we continue to conduct these activities necessary to pursue FDA approval of PRS-080 and PRS-060 and our other product candidates, including our 300-Series, we expect the cash needed to fund operations to increase significantly over the next several years. We also expect to incur increased costs in connection with operating and growth as a public company.

On December 17, 2014 we entered into a the Securities Purchase Agreement, with the Investors, providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in the Private Placement for gross proceeds to us of $13.56 million. After deducting for placement agent and other fees and expenses, the aggregate net proceeds from the Private Placement were $12.04 million.

On July 6, 2015 the Company closed a public offering of an aggregate of 9,090,909 shares of the Company´s common stock at a purchase price of $2.75 per share. On July 28, 2015 the underwriters exercised their option to purchase an additional 1,211,827 shares of common stock at the public offering price of $2.75 per share. Gross proceeds from the offering, including the over-allotment option, were $28.3 million and net proceeds were approximately $25.8 million.

Even after giving effect to the public offering, we will need to obtain additional funding in order to continue our operations and pursue our business plans. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

We expect that our existing cash and cash equivalents at June 30, 2015 will enable us to fund our operations and capital expenditure requirements for at least the next twelve months. Our requirements for additional capital will depend on many factors, including the following:

•

the scope, rate of progress, results, timing and cost of our clinical studies, preclinical testing and other related activities;

•

the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates and any products that we may develop;

•

the number and characteristics of drug candidates that we pursue;

•

the cost, timing and outcomes of regulatory approvals;

•

the cost and timing of establishing sales, marketing and distribution capabilities;

•

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

•

the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products;

•

the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

•

the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain. In addition, any unfavorable development or delay in the progress for our PRS-080, PRS-060 or 300-Series programs could have a material adverse impact on our ability to raise additional capital.

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our drug candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we cannot raise adequate capital in the future, we will be required to delay and possibly eliminate the research and development work not only of our lead drug candidates PRS-080 and PRS-060, but also our other preclinical stage product candidates. In this case, we could be required to relinquish greater or all rights to our product candidates at an earlier stage of development and on less favorable terms than we would otherwise agree.

Our cash is maintained in current cash accounts at major financial institutions and, to a lesser extent, in money market accounts. Due to the current low interest rates available for these instruments, we are earning limited interest income. Our investment portfolio has not been adversely impacted by the problems in the credit markets that have existed over the last several years, but there can be no assurance that our investment portfolio will not be adversely affected in the future.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Refer to Part II, Item 7, “Critical Accounting Policies and Estimates” of our Annual Report on Form 10-K for the fiscal year ended on December 31, 2014 for a discussion of our critical accounting policies and estimates. There were no significant changes to our Critical Accounting Policies and Estimates in the six months ended June 30, 2015.

Recently Issued Accounting Pronouncements

We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. For the recently issued accounting standards that we believe may have an impact on our consolidated financial statements, see “Note 2—Recently Issued Accounting Pronouncements” in our consolidated financial statements.

Emerging Growth Company and Smaller Reporting Company Status

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, establishes a class of company called an “emerging growth company,” which generally is a company whose initial public offering was completed after December 8, 2011 and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. Additionally, Section 12b-2 of the Exchange Act establishes a class of company called a “smaller reporting company,” which generally is a company with a public float of less than $75 million as of the last business day of its most recently completed second fiscal quarter or, if such public float is $0, had annual revenues of less than $50 million during the most recently completed fiscal year for which audited financial statements are available. We currently qualify as both an emerging growth company and a smaller reporting company.

As an emerging growth company and a smaller reporting company, we are eligible to take advantage of certain exemptions from various reporting requirements that are not available to public reporting companies that do not qualify for those classifications, including without limitation the following:

•

An emerging growth company is exempt from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and financial statements, commonly known as an “auditor discussion and analysis.”

•

An emerging growth company is not required to hold a nonbinding advisory stockholder vote on executive compensation or any golden parachute payments not previously approved by stockholders.

•

Neither an emerging growth company nor a smaller reporting company is required to comply with the requirement of auditor attestation of management’s assessment of internal control over financial reporting, which is required for other public reporting companies by Section 404 of the Sarbanes-Oxley Act.

•

A company that is either an emerging growth company or a smaller reporting company is eligible for reduced disclosure obligations regarding executive compensation in its periodic and annual reports, including without limitation exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures.

•

A company that is either an emerging growth company or a smaller reporting company is eligible for reduced financial statement disclosure in registration statements, which must include two years of audited financial statements rather than the three years of audited financial statements that are required for other public reporting companies. Smaller reporting companies are also eligible to provide such reduced financial statement disclosure in annual reports on Form 10-K.

For as long as we continue to be an emerging growth company and/or a smaller reporting company, we expect that we will take advantage of the reduced disclosure obligations available to us as a result of those respective classifications. We will remain an emerging growth company until the earlier of (i) December 31, 2019, the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company on or before December 31, 2019. We will remain a smaller reporting company until we have a public float of $75 million or more as of the last business day of our most recently completed second fiscal quarter, and we could retain our smaller reporting company status indefinitely depending on the size of our public float.

Emerging growth companies may elect to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, due to a material weakness in internal control over financial reporting disclosed in our most recent Annual Report on Form 10-K.

Changes in Internal Controls

There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings

Arbitration Proceeding with Technische Universität München

On March 20, 2014, the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universität München, or Munich Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company to TUM under the Company’s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit.

On July 4, 2003, or the Effective Date, the Company and TUM entered into the TUM License Agreement, as superseded and replaced on July 26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become part of the Anticalin^® proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and sales, as well as a variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM.

As required by the TUM License Agreement, the Company provided to TUM its calculation of the Out-License Fee owed by the Company to TUM for the period beginning on the Effective Date and ending on December 31, 2012, the Dispute Period, in the amount of $0.4 million excluding value-added tax. TUM has asserted that, under the TUM License Agreement, the Out-License Fee due to TUM for the Dispute Period amounts to $3.4 million excluding value-added tax in the aggregate and has threatened to terminate the TUM License Agreement if the Out-License Fee is not paid. We believe that if TUM sought to terminate the license agreement for cause as a result of this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding the proper amount of the Out-License Fee, but we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company’s calculation of the payments owed to TUM is accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet´s position other long-term liabilities in respect of such payment in the amount of €271,000 ($327,937). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company’s results of operations and financial condition.

dispute for both parties’ claims and counterclaims would be fixed at €3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On March 3, 2015, the Company submitted a reply brief responding to TUM’s statement of defense and counterclaim. On March 31, 2015, TUM submitted a rebuttal brief.

The panel requested that both the Company and TUM indicate to the panel by April 27, 2015 whether proceedings should be stayed as a result of settlement negotiations. On April 27, 2015, the Company submitted a reply brief requesting proceedings to continue without disruption and moving for leave to comment on TUM’s latest submission in another brief to rebut TUM’s latest arguments. Following an approved extension by the panel for TUM’s submission, TUM submitted its proposal on May 4, 2015, requesting the panel to conduct a mediation hearing and assist the parties to negotiate a settlement. On May 8, 2015, the arbitration tribunal set June 1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further settlement negotiations if the parties are in favor of holding a hearing. The Company submitted its brief on June 1, 2015. On June 8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the arbitration without another oral hearing. TUM did not file its brief by the June 1 deadline set by the panel, and instead filed another submission on June 23, 2015. In its procedural order issued on the same day, the tribunal panel reserved the right to reject TUM’s new submission based on the content of its brief. The tribunal’s subsequent procedural order of June 25, 2015 provided that the tribunal will close the proceedings on July 10, 2015. The order clarified that any further pleadings or submissions will not be admissible after this date. The Company submitted its final brief on July 10, 2015 to address TUM’s arguments raised in its latest submission and to provide the tribunal with an overview its costs incurred in this arbitration proceeding. On the same day, TUM submitted its summary of its costs incurred in this arbitration proceeding and subsequently, on July 23, 2015, filed an additional brief to correct some of its earlier submissions on costs and comment on the Company’s cost overview of July 10. The Company replied to the TUM brief on August, 7. It is not possible to determine at this time when the arbitration tribunal will make its final decision.

As of the date of this Quarterly Report on Form 10-Q, other than the arbitration proceeding against TUM, we are not currently involved in any material legal proceedings. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A.

Risk Factors

No material changes from the risk factors previously disclosed in Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosure

Not Applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

EXHIBIT INDEX


31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Principal Executive Officer.

31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Principal Financial Officer.

32.1		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer.

32.2		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Financial Officer.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PIERIS PHARMACEUTICALS, INC.

Date: August 13, 2015	By:	/s/ Stephen S. Yoder
		Stephen S. Yoder
		President, Chief Executive Officer and Director

Date: August 13, 2015	By:	/s/ Darlene Deptula-Hicks
		Darlene Deptula-Hicks Acting Chief Financial Officer, Secretary and Treasurer

EX-31.1 2 d947317dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Stephen S. Yoder, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pieris Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d947317dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Darlene Deptula-Hicks, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pieris Pharmaceuticals, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d947317dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc. a Nevada corporation (the “Company”), does hereby certify, to his knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2015 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-32.2 5 d947317dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 pirs-20150630.xml XBRL INSTANCE DOCUMENT

1100000

280000

1170000

1050000

2.00

600000

669240

39732258

0.1053

1200000

1340000

150000

0.01

50200000

37400000

900000

2600000

91100000

2.75

20100000

29600000

1900000

51600000

3500000

3200000

1400000

8100000

1485006

370999

2.01

2544500

450000

501930

931312

1038785

3.16

3.20

29429522

799068

300000000

2.03

799068

2.03

0.001

2616735

304012

943411

3022477

24446

302273

29430

-1343694

-73041781

635561

11147196

307850

153082

14477523

85503241

307850

3330327

333979

2058458

5577

10027305

2253478

1811356

24446

14477523

16015

1866180

12641721

732221

1708607 148500

78403

13000000

302273

400000

3400000

271000

302273

1470235

1146500

583265

3689382

29279522

300000000

2.00

542360

2.00

0.001

2519500

242755

1270605

1077853

3543762

26522

327937

29280

-843097

-65807048

743865

18006418

333988

7523

21884168

84627283

333988

3877750

332892

1260015

6051

18474211

2052221

26522

21884168

14810

1207072

19805425

109332

403450

4800573

3200000

2529400

3060827

P5Y

6779510

13560000

542360

25800000

28300000

9090909

116820

130301

43660

48698

1211827

-3406942

11828974

-0.31

-13091

3027

136900

-3661560

-3441142

-3658515

2665

3027

2071106

4961

-3661542

41132

-68553

72570

240743

223083

2341666

49668

-2204376

-422410

-18

189463

1224560

-4961

5512248

181951

-17033

3170582

487595

1361460

1100000

300000

700000

13711

34276

400000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">3.</td> <td valign="top" align="left">Revenues</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> General <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pieris Pharmaceuticals, Inc. has not generated revenues from product sales. Pieris Pharmaceuticals, Inc. has generated revenues pursuant to (i) license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments, and (ii) government grants. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Collaborations and Other Agreements <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Allergan, Inc. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In August 2009, pursuant to an agreement with Allergan, Inc. (“Allergan”), the Company granted Allergan a worldwide exclusive license to develop and commercialize certain drug candidates for the treatment and prevention of ocular diseases. Allergan is responsible for the research, development, manufacturing and commercialization of any products resulting from the license. The Company received a non-refundable upfront payment of $10 million upon execution of the contract in 2009 and is entitled to receive up to an aggregate of $13 million in milestone payments upon the achievement of certain commercial milestones or patents granted to the Company by the United States Patent and Trademark Office that cover a product licensed to Allergan. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> At the inception of the agreement, the Company recognized revenues from the upfront license payment because, based on the stage of development of the licensed product delivered and the development capabilities of Allergan, the Company determined that the license had standalone value. Through June 30, 2015, none of the milestones had been achieved and, as such, the Company has not recognized milestone-related revenues. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Daiichi Sankyo Co., Ltd. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In May 2011, the Company entered into an agreement with Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”), under which Pieris AG will use its proprietary Anticalin® scaffold technology to identify drug candidates against certain targets selected by Daiichi Sankyo, with further development and commercialization performed by Daiichi Sankyo. For any targets selected by Daiichi Sankyo, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. The Company has handed over further development responsibility for the two collaboration projects to Daiichi Sankyo, which handovers occurred in March 2013 and June 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Upon execution of the agreement, Daiichi Sankyo paid the Company a non-refundable upfront payment in the amount of $10.1 million in consideration for the licenses, and for each licensed product, the Company is entitled to receive potential milestone payments of $91.1 million, plus royalties on the commercial sales of any commercial products. The total milestones are categorized as follows: research milestones - $2.6 million; development milestones - $37.4 million; commercial milestones - $50.2 million; additional diagnostic milestones of $0.9 million. At the inception of the agreement, these milestones were determined to be substantive as there was substantial uncertainty the milestones would be achieved, they would require substantial performance from the entity, and the consideration was reasonable relative to other deliverables. The agreement includes provisions for the Company to provide research services funded by Daiichi Sankyo at agreed upon full-time employee rates during the initial identification and research period. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with the guidance in ASC 605-25, the Company identified the licenses and research funding as deliverables at the inception of the arrangement. The Company has determined that the licenses and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin® technology against Daiichi Sankyo’s selected targets were necessary before the licenses would have any standalone value. Therefore, the total arrangement consideration was recognized over the estimated period of substantial involvement, which was determined to be the period Company was required to provide research services to discover drug candidates against targets identified. The Company estimated this period would be approximately two years. The Company reassesses the estimated term at the end of each reporting period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has not recognized any milestone payments as revenue for the six months ended June 30, 2015. The Company recognized a milestone payment of $0.4 million as revenue for the six months ended June 30, 2014. The milestone payment was based on successful in vitro and in vivo studies. In general, milestones could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined these milestones to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestones would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Daiichi Sankyo Collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.4 and $1.1 million in revenues, respectively. $0.4 million of these revenues were related to the achievement of milestones during the three and six months ended June 30, 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Sanofi-Aventis and Sanofi-Pasteur <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In September 2010, the Company entered into an agreement with Sanofi-Aventis and Sanofi Pasteur (“Sanofi”), under which the Company agreed to apply its proprietary Anticalin® technology to identify drug candidates against certain targets selected by Sanofi, with further development and commercialization performed by Sanofi. The agreement included the initial identification of two targets by Sanofi, with options to select up to four additional targets. For any targets selected by Sanofi, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. In addition to the two initial targets selected by Sanofi, Sanofi exercised one of the four options and received a license. The remaining three options expired unexercised. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Upon execution of the agreement, Sanofi paid the Company an upfront payment of $4.9 million in consideration for licenses on the first two targets and options to select an additional four licenses on other targets (with each option requiring an additional upfront payment upon exercise). Additionally, for each licensed product, the Company is entitled to receive milestone payments up to $51.6 million, plus royalties on the sales of any commercial products. The total milestones are categorized as follows: research milestones - $1.9 million; development milestones - $29.6 million; commercial milestones - $20.1 million. At the inception of the agreement, these milestones were determined to be substantive because (i) there was substantial uncertainty the milestones would be achieved, (ii) they would require substantial performance from the entity, and (iii) the consideration was reasonable relative to other deliverables. The agreement included provisions for the Company to provide research services funded by Sanofi at agreed upon full-time employee equivalent rates during the initial identification and research period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with the guidance in ASC 605-25, the Company identified the licenses, options to obtain additional licenses and research funding as deliverables at the inception of the arrangement. The options were considered to be substantive at the inception of the agreement. Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has determined that, for each program selected by Sanofi, the license and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin technology against Sanofi’s selected targets were necessary before the licenses would have any standalone value. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The estimated selling prices for the licenses in the agreement are the Company’s best estimate of selling price and were determined based on market conditions and entity-specific factors such as considerations of preclinical and clinical testing results and the Company’s pricing practices and pricing objectives. The estimated selling price of research services are the Company’s best estimate of selling price and are determined based on market conditions and entity-specific factors such as internal cost considerations and the Company’s pricing practices and pricing objectives. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> At inception, the total arrangement consideration of $8.1 million (which comprises the $4.9 million upfront payment and the expected fees for the research services to be provided under the remainder of the arrangement) was allocated to the deliverables based on the residual method as follows: $3.5 million to the licenses, $1.4 million to the four options to acquire additional licenses and $3.2 million to the estimated research services to be provided. As the license and research services were determined to be one unit of accounting, the consideration allocated to each license is recognized over the period of substantial involvement, which was determined to be the period the Company was required to provide research services to discover drug candidates against targets identified, approximately two years. The Company reassesses the estimated term at the end of each reporting period. At the end of 2012, the Company determined that the required research term for one of the initial terms would extend to a period of 40 months, and management updated the estimated required service period to amortize the remaining deferred upfront payment over the new term. Two of the four options expired un-exercised in 2011, and as a result the Company recognized $0.7 million of revenue upon expiration. The option term for the remaining two options was extended to February 2013, and Sanofi exercised one option to obtain an additional license. For the exercised option, the allocated consideration of $0.28 million for the option and the $1.1 million payment of the exercise price of the option were deferred and amortized over the expected required service period of approximately two years. The program covered by the exercised option was terminated in December 2013, and accordingly, the Company recognized the remaining deferred revenue upon termination. The remaining option expired in February 2013 and the allocated consideration of $0.35 million was recognized into revenue at the time of expiration. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has not recognized any milestone payments as revenue for the three and six months ended June 30, 2015. The Company recognized a milestone payment of $0.3 million as revenue for the six months ended June 30, 2014. The Company did not recognize a milestone payment for the three months ended June 30, 2014. The milestone payment was based on successful in vivo studies. The milestone could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined this milestone to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestone would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. Therefore, the payment was recognized in its entirety as revenue in the six months ended June 30, 2014 when the research milestone was reached. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Sanofi collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.2 million and $0.7 million in revenues respectively. </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">10.</td> <td valign="top" align="left">Commitments and Contingencies</td> </tr> </table> Arbitration On March 20, 2014, the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universität München, or Munich Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company to TUM under the Company’s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit. On July 4, 2003, or the Effective Date, the Company and TUM entered into the TUM License Agreement, as superseded and replaced on July 26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become part of the Anticalin® proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and sales, as well as an variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM. As required by the TUM License Agreement, the Company provided to TUM its calculation of the Out-License Fee owed by the Company to TUM for the period beginning on the Effective Date and ending on December 31, 2012, the Dispute Period, in the amount of $0.4 million excluding value-added tax. TUM has asserted that, under the TUM License Agreement, the Out-License Fee due to TUM for the Dispute Period amounts to $3.4 million excluding value-added tax in the aggregate and has threatened to terminate the TUM License Agreement if the Out-License Fee is not paid. We believe that if TUM sought to terminate the license agreement for cause as a result of this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding the proper amount of the Out-License Fee, but we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company’s calculation of the payments owed to TUM is accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet’s position other long-term liabilities in respect of such payment in the amount of €271,000 ($302,273). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company’s results of operations and financial condition. In April 2014, TUM argued to the arbitrators that it is not the proper party to be sued under the action for a declaratory arbitration decision brought by the Company in relation to the Research and Licensing Agreement, and that instead, it is the Free State of Bavaria that is the proper respondent to the action. The Company has responded that TUM has capacity to be sued in relation to any disputes arising from and regarding contractual provisions of the Research and Licensing Agreement and is thus also the proper respondent in the action. In accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit, each party to the arbitration proceeding has appointed one arbitrator and the party-named arbitrators collectively selected the third arbitrator as the chairman of the arbitration panel. On December 1, 2014, TUM filed its statement of defense, maintaining its earlier calculation of the Out-License Fee. On December 23, 2014, TUM filed a counterclaim in the amount of €2,529,400 ($3,060,827) to suspend the statute of limitations on its claims. On January 12, 2015, the Company filed a reply brief in response to TUM’s defense. The arbitration panel held its first hearing in Munich, Germany on January 20, 2015, however the arbitration panel did not come to a conclusion on whether TUM is the proper respondent in the action or on the merits of the case. The panel had previously indicated that it will first decide the issue of whether TUM is the proper respondent in this action. The panel resolved that the value in dispute for both parties’ claims and counterclaims would be fixed at €3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On March 3, 2015, the Company submitted a reply brief responding to TUM’s statement of defense and counterclaim. On March 31, 2015, TUM submitted a rebuttal brief. The panel requested that both the Company and TUM indicate to the panel by April 27, 2015 whether proceedings should be stayed as a result of settlement negotiations. On April 27, 2015, the Company submitted a reply brief requesting proceedings to continue without disruption and moving for leave to comment on TUM’s submission. Following an approved extension by the panel for TUM’s submission, TUM submitted its proposal on May 4, 2015, requesting that the panel conduct a mediation hearing and assist the parties in negotiating a settlement. On May 8, 2015, the arbitration tribunal set June 1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further settlement negotiations if both parties are in favor of holding a hearing. The Company submitted its brief on June 1, 2015. On June 8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the arbitration without another oral hearing. TUM did not file its brief by the June 1 deadline set by the panel, and instead filed another submission on June 23, 2015. In its procedural order issued on the same day, the tribunal panel reserved the right to reject TUM’s new submission based on the content of its brief. The tribunal’s subsequent procedural order of June 25, 2015 provided that the tribunal will close the proceedings on July 10, 2015. The order clarified that any further pleadings or submissions will not be admissible after this date. The Company submitted its final brief on July 10, 2015 to address TUM’s arguments raised in its latest submission to provide the tribunal with an overview its costs incurred in this arbitration proceeding. On the same day, TUM submitted its summary of its costs incurred in this arbitration proceeding and subsequently, on July 23, 2015, filed an additional brief to correct some of its earlier submissions on costs and comment on the Company’s cost overview of July 10, arguing that attorneys’ fees claimed by the Company are disproportionately high. The Company replied to the TUM’s on [August, 7], pointing out that the higher attorneys’ fees are justified and resulted from the Company’s submissions on TUM’s standing to be sued and translation costs are also reimbursable in this case. </div>

10-Q PIERIS PHARMACEUTICALS, INC. PIRS

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Basis of Presentation and Summary of Significant Accounting Policies</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following is a summary of the significant accounting policies consistently applied in the preparation of the accompanying condensed consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Basis of Consolidation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Use of estimates <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Segment Reporting <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Milestone Payments and Royalties <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Fair Value Measurement <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Income taxes <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Recent Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09) which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual items” (ASU 2015-01). The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”(ASU 2015-02). The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company is currently evaluating the impact of this new standard. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements” (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the “Codification”), correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption. </div>

<div> Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the Company’s stock option activity and related information is as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Contractual Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,519,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.6 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.85</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options cancelled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,544,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.01</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.6 - 5.8 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72,235</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.89</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options cancelled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,616,735</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Vested at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">799,068</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected to vest after June 30,2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,708,607</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">799,068</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   </div>

176898

Smaller Reporting Company

0.00

P2Y6M

-6676452

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">4.</td> <td valign="top" align="left">Related-Party Transactions</td> </tr> </table> Research and License Agreement with Technische Universität München (“TUM”) On July 4, 2003, the Company entered into a research and licensing agreement with TUM, which was subsequently renewed and, on July 26, 2007, superseded and replaced. The agreement established a joint research effort led by Prof. Arne Skerra, Chair of Biological Chemistry of TUM, to optimize Anticalin® technologies for use in therapeutic, prophylactic and diagnostic applications and as research reagents, and to gain fundamental insights in lipocalin scaffolds. Prof. Dr. Skerra was a member of Pieris AG’s supervisory board when the parties entered into such agreement. The Company provided certain funding for TUM research efforts performed under the agreement. As a result of research efforts to date under the agreement, the Company holds a worldwide exclusive license under its license agreement with TUM to multiple patents and patent applications, including an exclusive license to an issued U.S. patent, which patent will expire in 2027 (subject to a possible term adjustment period). Pieris AG also holds an exclusive license to an issued U.S. patent No. 8,420,051, which patent is expected to expire in 2029. The Company bears the costs of filing, prosecution and maintenance of patents assigned or licensed to the Company under the agreement. As consideration for the assigned patents and licenses above, the Company is required to pay certain development milestones to TUM. The Company also is obliged to pay low-single-digit royalties, including annual minimum royalties, on sales of such products incorporating patented technologies. If the Company grants licenses or sublicenses to those patents to third parties, the Company will be obliged to pay a percentage of the resulting revenue to TUM. The Company’s payment obligations are reduced by the Company’s proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the agreement. The Company can terminate the licenses to any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the agreement does not terminate the rights in patents assigned to the Company. The Company has incurred the following expenses related to TUM (excluding value added taxes):   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three months ended June 30, </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six months ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Transfer of licenses and protective rights </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,836</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,893</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,276</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total expenses incurred with TUM </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,836</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,893</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,276</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company has accrued $302,273 and $370,999 as of June 30, 2015 and 2014, respectively, related to the amounts due under the research and license agreement (see Note 9 Commitments and Contingencies). The part of the agreement requiring the Company to make payments for research conducted by TUM expired in February 2013 with no further obligations by Pieris AG. Consulting Contract between Prof. Dr. Arne Skerra and Pieris AG In 2001, the Company entered into a Consulting Agreement with Prof. Dr. Arne Skerra, pursuant to which Prof. Dr. Arne Skerra provides advice regarding the use of new proteins, in particular Anticalin® proteins and antibodies, for the purpose of research and development. The Consulting Agreement has an unlimited term but can be terminated by the Company upon three months’ notice with effect from the end of a month and by Prof. Dr. Arne Skerra upon one year’s notice with effect from the end of a year. Under the Consulting Agreement, the Company incurred and paid to Prof. Dr. Skerra consulting fees of $11,157 and $13,711 for the six months ended June 30, 2015 and 2014, respectively. For the three months ended June 30, 2015 and 2014 the Company incurred and paid Prof. Dr. Skerra consulting fees of $5,534 and $6,858, respectively. </div>

Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.

P10Y

0.000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has recorded the following accrued expenses as of June 30, 2015 and December 31, 2014, respectively: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accrued compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">333,979</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332,892</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accrued audit and tax expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">403,450</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">153,082</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,523</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses, current </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">635,561</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">743,865</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accrued expenses non-current </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Reserve for litigation TUM </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">302,273</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">327,937</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accrued expenses restoration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,577</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,051</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses, non-current </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">307,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">333,988</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">943,411</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,077,853</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"></td> </tr> </table> </div>

<div> The Company has incurred the following expenses related to TUM (excluding value added taxes):   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three months ended June 30, </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six months ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Transfer of licenses and protective rights </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,836</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,893</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,276</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total expenses incurred with TUM </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,836</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,893</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,276</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

375319

0.0171

<div> Use of estimates The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions. </div>

29361566

2015-06-30

<div> Milestone Payments and Royalties At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount. For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met. </div>

false --12-31 2015

P3Y

0001583648

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">7.</td> <td valign="top" align="left">Stock-based compensation</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In December 2014, the Board of Directors and stockholders of Pieris Pharmaceuticals, Inc. adopted the 2014 Employee, Director and Consultant Equity Incentive Plan (the “Pieris Plan”), which became effective upon closing of the Acquisition. The Pieris Plan is intended to encourage ownership of common stock by the Company’s employees and directors and certain of their consultants, including employees of Pieris AG, in order to attract and retain such people, to induce them to work for the benefit of the Company and to provide additional incentive for them to promote the Company’s success. The Pieris Plan reserves 3,200,000 shares of the Company´s common stock for issuance. In addition, the Pieris Plan provides for an “evergreen” provision whereby the number of shares of the Company´s common stock reserved for issuance under the Pieris Plan shall be automatically increased on January 1 of each of year commencing in fiscal 2016 by the lesser of (i) 1,000,000 shares, (ii) 4% of the number of shares of the Company´s common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company´s common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014. In addition, options to purchase 1,146,500 shares are outstanding under the Pieris Plan to other employees and consultants. 25,000 of these shares were granted during the first quarter of 2015, 32,000 of these shares were granted during the second quarter of 2015 and 1,089,500 were granted during the fourth quarter of 2014. As a result of such grants, 583,265 of the Company´s common stock remain available for future issuances under the Pieris Plan. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Stock options granted under the Pieris Plan may be either incentive stock options (“ISOs”), or nonqualified stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally three years) and the exercise prices. Options have a maximum term of ten years. The exercise price of stock options granted under the Pieris Plan must be at least equal to the fair market value of the common stock on the date of grant. The Pieris Plan become effective in December 2014, therefore there was no stock-based compensation expense in the three and six months ended June 30, 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three and six months ended June 30, 2015, was comprised of the following: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Three months ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Six months ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Research and Development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">78,551</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">129,590</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">189,488</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">355,785</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total stock-option expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">268,039</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">485,375</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three and six months ended June 30, 2015: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Three months ended</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center"> Six months ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Forfeiture rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Weighted average risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.73</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.71</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected term </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the Company’s stock option activity and related information is as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Contractual Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,519,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.6 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.85</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options cancelled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,544,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.01</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.6 - 5.8 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72,235</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.89</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options cancelled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,616,735</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3 - 5.8 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Vested at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">799,068</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected to vest after June 30,2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,708,607</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">799,068</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The weighted-average grant date fair value for awards granted during the three and six months ended June 30, 2015 was $130,456 and $176,898, respectively. There were no options exercised during the three and six months ended June 30, 2015 and 2014. 200,673 and 375,319 shares were vested in the three and six months ended June 30, 2015, respectively. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The unrecognized share-based compensation expense related to employee stock option awards at June 30, 2015, is $2,253,478, which will be recognized over a weighted-average service period of 2.5 years. </div>

-0.25

<div> Segment Reporting Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit. </div>

0.741

<div> Fair Value Measurement ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents. The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014. </div>

1206

-500597

1171170

-7234733

-7235763

-7735330

5253

-500597

377864

74286

-7234733

4224

628723

768905

485375

4223

3250222

-2365

-8446906

30481

390734

154555

-1171170

-72286

7613627

3500000

4235350

-524998

4363405

485374

897130

2.03 0.060 <div> Basis of Consolidation The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period. </div> 2.03 <div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">9.</td> <td align="left" valign="top">Warrants</td> </tr> </table> In connection with the Private Placement in December 2014, the Company issued the Placement Warrants to acquire combined up to 542,360 shares of its common stock at an exercise price of two dollars per share ($2.00) to the Placement Agents and their designees during December 2014. The Placement Warrants are exercisable at any time at the option of the holder until the five year anniversary of its date of issuance. The number of shares of common stock issuable upon the exercise of each Placement Warrant is adjustable in the event of certain stock dividends, stock splits, combinations of shares and similar transactions. Upon exercise, the aggregate exercise price of the warrants issued are payable by the holders in cash. The Company estimated the fair value of the Placement Warrants as of the grant date to be $664,064 and recognized the full amount in general and administrative expense for the year ended December 31, 2014. </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">8.</td> <td valign="top" align="left">Consulting Shares</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On March 6, 2015, the Company entered into an independent consulting agreement (the “Consulting Agreement”) with the Del Mar Consulting Group, Inc. and Alex Partners, LLC (the “Consultants”), pursuant to which the Company issued 150,000 restricted shares of its common stock (par value $0.01 per share) to the Consultants (the “Consulting Shares”). The Company agreed to retain the Consultants to provide investor relations consulting to the Company for a period commencing on March 6, 2015 (the “Commencement Date”) and ending thirteen months after the Commencement Date (such period, the “Term”). The shares issued in connection with the Consulting Agreement were deemed to be exempt from registration in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving any public offering. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The terms of the Consulting Agreement state, that the Company has the right to terminate this agreement at any time during the Term of the Consulting Agreement, upon providing Consultants ten days’ written notice of Company’ intention to terminate or immediately upon notice in the event of a breach of this agreement by either consultant. If the Company delivers notice to terminate this agreement for any reason within one hundred eighty days (180) following the effective date (the “Return Date”), then each Consultant will promptly return and surrender to the Company forty percent (40%) of the number of Consulting Shares issued to it. Therefore 60,000 of these shares are subject to certain forfeiture provisions within 180 days following the date of entry into the Consulting Agreement. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company, using the Black-Scholes method, estimated the fair value of the 90,000 non-cancellable Consulting Shares to be $284,400 based on the closing price per share of $3.16 as quoted on the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the grant date, March 6, 2015. The Company estimated the fair value of the 60,000 cancellable Consulting Shares to be $192,000 based on the closing price per share of $3.20 as quoted on the OTCQB on the interim financial reporting date, March 31, 2015. Therefore, the Company estimated the total fair value of the Consulting Shares to be $476,400 and recognized the 90,000 vested non-cancellable Consulting Shares, or sixty percent (60%) of the Consulting Shares in an amount of $284,400, as general and administrative expense for the six months ended June 30, 2015. The remaining forty percent (40%), or 60,000 Consulting Shares in the amount of $192,000, will be recognized as general and administrative expenses with an offsetting credit to equity on a straight-line basis over 180 days. If the Company exercises the option to terminate the Consulting Agreement within the 180 days, resulting in the cancellation of forty percent (40%) of the Consulting Shares, expense for cancelled, unvested shares will be reversed. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On June 30, 2015 the Company revalued the fair value of the unvested and forfeitable 40% of the shares. As of June 30, 2015 the estimated fair value of the 60,000 unvested and forfeitable shares was $165,000. Therefore the Company recognized expenses in connection with the Consulting Shares of $79,666 in general and administrative expenses for the cancellable Consulting Shares during the three months ended June 30, 2015. For the six months ended June 30, 2015 the Company recognized $390,733 in general and administrative expenses, including $284,400 for the non-cancellable Consulting Shares and $106,333 for the cancellable shares. </div>

P5Y9M18D

P5Y3M18D

P2Y

Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.

Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016.

118688

132385

355785

129590

11157

P180D 60000 165000 0.40 60000 476400 390733 0.60 0.40 0.40 284400 284400 192000 106333 2029

27893

2027

(i) 1,000,000 shares, (ii) 4% of the number of shares of the Company's common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company's common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014. P5Y

4900000

10100000

10000000

700000

664064

P5Y9M18D

P5Y7M6D

P40M

350000

P2Y

11828974

-0.24

6654

-2881637

-2769925

-2874983

2081

6654

698227

-2881637

113793

1118920

3468152

2349232

400000

200000

6858

17145

400000

25000

2.85

P5Y9M18D

P5Y7M6D

25000

90000 60000 284400 192000

130456

0.000

72235

200673

0.0173

29429522

2.89

-0.12

0.737

102135

-3529999

-3534430

-3427864

4484

102135

160244

-3529999

268039

1725592

3694674

1969082

0.060

P5Y9M18D

P5Y3M18D

40235

32000

189488

78551

5534

79666

13836

1089500

0001583648 pirs:PierisPlanMember pirs:EmployeesAndConsultantsMember 2014-10-01 2014-12-31 0001583648 pirs:TumMember 2015-04-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember pirs:CancellableSharesMember 2015-04-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember 2015-04-01 2015-06-30 0001583648 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001583648 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001583648 pirs:PierisPlanMember pirs:EmployeesAndConsultantsMember 2015-04-01 2015-06-30 0001583648 pirs:PierisPlanMember pirs:ExecutiveOfficersAndDirectorsMember 2015-04-01 2015-06-30 0001583648 pirs:SanofiMember us-gaap:CollaborativeArrangementMember 2015-04-01 2015-06-30 0001583648 pirs:DaiichiSankyoIncMember us-gaap:CollaborativeArrangementMember 2015-04-01 2015-06-30 0001583648 us-gaap:MinimumMember 2015-04-01 2015-06-30 0001583648 us-gaap:MaximumMember 2015-04-01 2015-06-30 0001583648 2015-04-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember 2015-01-01 2015-03-31 0001583648 pirs:PierisPlanMember pirs:EmployeesAndConsultantsMember 2015-01-01 2015-03-31 0001583648 us-gaap:MinimumMember 2015-01-01 2015-03-31 0001583648 us-gaap:MaximumMember 2015-01-01 2015-03-31 0001583648 2015-01-01 2015-03-31 0001583648 us-gaap:CollaborativeArrangementMember 2014-04-04 2014-06-30 0001583648 pirs:TumMember 2014-04-04 2014-06-30 0001583648 pirs:ConsultingAgreementMember 2014-04-04 2014-06-30 0001583648 pirs:SanofiMember us-gaap:CollaborativeArrangementMember 2014-04-04 2014-06-30 0001583648 pirs:DaiichiSankyoIncMember us-gaap:CollaborativeArrangementMember 2014-04-04 2014-06-30 0001583648 2014-04-04 2014-06-30 0001583648 pirs:SanofiMember pirs:ResearchAndDevelopmentServicesMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-12-31 0001583648 pirs:SanofiMember pirs:OptionsExercisedMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-12-31 0001583648 pirs:SanofiMember pirs:ResearchAndDevelopmentServicesMember pirs:ExtensionTermMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-12-31 0001583648 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001583648 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001583648 2014-01-01 2014-12-31 0001583648 pirs:SanofiMember pirs:ExpiredOptionAgreementMember us-gaap:CollaborativeArrangementMember 2011-01-01 2011-12-31 0001583648 pirs:AllerganIncMember us-gaap:UpFrontPaymentArrangementMember us-gaap:CollaborativeArrangementMember 2009-08-01 2009-08-31 0001583648 pirs:DaiichiSankyoIncMember us-gaap:UpFrontPaymentArrangementMember us-gaap:CollaborativeArrangementMember 2011-05-01 2011-05-31 0001583648 pirs:SanofiMember us-gaap:UpFrontPaymentArrangementMember us-gaap:CollaborativeArrangementMember 2010-09-01 2010-09-30 0001583648 2014-12-06 2014-12-31 0001583648 pirs:PierisPlanMember 2015-01-01 2015-06-30 0001583648 us-gaap:CollaborativeArrangementMember 2015-01-01 2015-06-30 0001583648 pirs:TumMember 2015-01-01 2015-06-30 0001583648 pirs:PatentOneMember 2015-01-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember pirs:CancellableSharesMember 2015-01-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember pirs:NonCancellableSharesMember 2015-01-01 2015-06-30 0001583648 pirs:ConsultingAgreementMember 2015-01-01 2015-06-30 0001583648 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001583648 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001583648 pirs:TbgMember 2015-01-01 2015-06-30 0001583648 pirs:AllerganIncMember us-gaap:CollaborativeArrangementMember 2015-01-01 2015-06-30 0001583648 pirs:SanofiMember us-gaap:CollaborativeArrangementMember 2015-01-01 2015-06-30 0001583648 pirs:DaiichiSankyoIncMember us-gaap:CollaborativeArrangementMember 2015-01-01 2015-06-30 0001583648 us-gaap:MinimumMember 2015-01-01 2015-06-30 0001583648 us-gaap:MaximumMember 2015-01-01 2015-06-30 0001583648 2015-01-01 2015-06-30 0001583648 us-gaap:CollaborativeArrangementMember 2014-01-01 2014-06-30 0001583648 pirs:TumMember 2014-01-01 2014-06-30 0001583648 pirs:ConsultingAgreementMember 2014-01-01 2014-06-30 0001583648 pirs:SanofiMember us-gaap:CollaborativeArrangementMember 2014-01-01 2014-06-30 0001583648 pirs:DaiichiSankyoIncMember us-gaap:CollaborativeArrangementMember 2014-01-01 2014-06-30 0001583648 2014-01-01 2014-06-30 0001583648 us-gaap:SubsequentEventMember us-gaap:IPOMember 2015-07-24 2015-07-24 0001583648 pirs:CooperationAgreementMember pirs:MilestoneOneMember us-gaap:SubsequentEventMember 2015-07-14 2015-07-14 0001583648 pirs:CooperationAgreementMember pirs:MilestoneTwoMember us-gaap:SubsequentEventMember 2015-07-14 2015-07-14 0001583648 us-gaap:SubsequentEventMember us-gaap:IPOMember 2015-07-06 2015-07-06 0001583648 us-gaap:SubsequentEventMember 2015-07-06 2015-07-06 0001583648 us-gaap:CommonStockMember 2014-12-23 2014-12-23 0001583648 us-gaap:PrivatePlacementMember 2014-12-23 2014-12-23 0001583648 2014-12-23 2014-12-23 0001583648 pirs:TbgMember 2014-12-11 2014-12-11 0001583648 pirs:PierisPlanMember 2014-12-31 0001583648 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001583648 2014-12-31 0001583648 2013-12-31 0001583648 pirs:PierisPlanMember 2015-06-30 0001583648 pirs:PierisPlanMember pirs:EmployeesAndConsultantsMember 2015-06-30 0001583648 pirs:PierisPlanMember pirs:ExecutiveOfficersAndDirectorsMember 2015-06-30 0001583648 pirs:TumMember pirs:OutLicenseFeeMember 2015-06-30 0001583648 pirs:OutLicenseFeeMember 2015-06-30 0001583648 pirs:TumMember pirs:LicenseAgreementMember 2015-06-30 0001583648 pirs:AllerganIncMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2015-06-30 0001583648 us-gaap:FairValueInputsLevel1Member 2015-06-30 0001583648 2015-06-30 0001583648 pirs:ConsultingAgreementMember pirs:CancellableSharesMember 2015-03-31 0001583648 pirs:ConsultingAgreementMember pirs:NonCancellableSharesMember 2015-03-31 0001583648 pirs:TbgMember 2015-03-31 0001583648 pirs:TbgMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2015-03-31 0001583648 2015-03-31 0001583648 pirs:TumMember pirs:LicenseAgreementMember 2014-06-30 0001583648 2014-06-30 0001583648 pirs:SanofiMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember pirs:LicenseOptionMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember pirs:ResearchAndDevelopmentServicesMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember pirs:LicensingMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember us-gaap:MaximumMember pirs:ResearchAndDevelopmentMilestonesMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember us-gaap:MaximumMember pirs:DevelopmentMilestonePaymentsMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 pirs:SanofiMember us-gaap:MaximumMember pirs:CommercialMilestonesMember us-gaap:CollaborativeArrangementMember 2010-09-30 0001583648 us-gaap:SubsequentEventMember us-gaap:IPOMember 2015-07-24 0001583648 us-gaap:SubsequentEventMember us-gaap:IPOMember 2015-07-06 0001583648 pirs:DaiichiSankyoIncMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2011-05-31 0001583648 pirs:DaiichiSankyoIncMember us-gaap:MaximumMember pirs:ResearchAndDevelopmentMilestonesMember us-gaap:CollaborativeArrangementMember 2011-05-31 0001583648 pirs:DaiichiSankyoIncMember us-gaap:MaximumMember pirs:AdditionalMilestonePaymentMember us-gaap:CollaborativeArrangementMember 2011-05-31 0001583648 pirs:DaiichiSankyoIncMember us-gaap:MaximumMember pirs:DevelopmentMilestonePaymentsMember us-gaap:CollaborativeArrangementMember 2011-05-31 0001583648 pirs:DaiichiSankyoIncMember us-gaap:MaximumMember pirs:CommercialMilestonesMember us-gaap:CollaborativeArrangementMember 2011-05-31 0001583648 pirs:ConsultingAgreementMember 2015-03-06 0001583648 pirs:TbgMember 2014-04-03 0001583648 2015-08-13 0001583648 pirs:TbgMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2015-01-31 0001583648 us-gaap:PrivatePlacementMember 2014-12-23 0001583648 2014-12-23 0001583648 pirs:TbgMember 2014-12-11 0001583648 pirs:SanofiMember pirs:OptionsExercisedMember us-gaap:CollaborativeArrangementMember 2013-02-28 0001583648 pirs:SanofiMember pirs:OptionsExercisedPriceOneMember us-gaap:CollaborativeArrangementMember 2013-02-28 iso4217:USD iso4217:EUR iso4217:USD shares shares pure pirs:Tranches pirs:Segment EX-101.SCH 7 pirs-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Corporate Information link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Revenues link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Related-Party Transactions link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Accrued expenses link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-based compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Consulting Shares link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Related-Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Accrued expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stock-based compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Corporate Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Revenues - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Related Party Transaction - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Related-Party Transactions - Related Party Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Consulting Shares - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 pirs-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pirs-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pirs-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued expenses Accounts Payable and Accrued Liabilities, Noncurrent [Abstract] Accrued expenses non-current Accounts Payable, Interest-bearing, Interest Rate Principal amount, interest rate Accounts Payable, Trade, Current Trade accounts payable Accrued Environmental Loss Contingencies, Noncurrent Accrued expenses restoration Accrued Liabilities, Current Accrued expenses Total accrued expenses, current Accrued Liabilities, Current [Abstract] Accrued expenses Accrued Liabilities Total accrued expenses Accrued Tax Audit And Legal Fees Accrued Tax Audit And Legal Fees Accrued audit and tax expenses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Milestone Payment [Member] Additional Milestone Payment [Member] Additional Diagnostic Milestones [Member] Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Agreement termination notice period. Agreement Termination Notice Period Agreement termination notice period Agreement Type [Axis] Agreement Type [Axis] Agreement Type [Axis] Agreement Type [Domain] Agreement Type [Domain] Agreement Type [Domain] Allergan Inc [Member] Allergan Inc [Member] Allergan Inc [Member] Allocated Share-based Compensation Expense Total stock-option expense Amendment Flag Amendment Flag Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Disclosure of accounting policy for basis of consolidation policy. Basis Of Consolidation Policy [Text Block] Basis of Consolidation Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Aggregate shares issued upon acquisition Cancellable Shares [Member] Cancellable Shares [Member] Cancellable Shares [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Outstanding Balance Amount of repayment to TBG outstanding Class of Stock [Domain] Class of Stock [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Class Of Warrants And Rights [Text Block] Class Of Warrants And Rights [Text Block] Warrants Collaborative Arrangement Disclosure [Text Block] Revenues Collaborative Arrangement [Member] Collaborative Arrangement [Member] Commercial milestones. Commercial Milestones [Member] Commercial Milestones [Member] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for issuance Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock par value of issued shares Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, outstanding Common Stock, Value, Issued Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014 Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Consulting Agreement [Member] Consulting Agreement [Member] Consulting Agreement [Member] Consulting Shares Disclosure [Text Block] Consulting Shares Disclosure [Text Block] Consulting Shares Contracts Receivable, Claims and Uncertain Amounts Collaboration agreement, milestone payments Contractual Obligation Out-License Fee amount Cooperation Agreement [Member] Cooperation Agreement [Member] Cooperation Agreement [Member] Costs and Expenses Costs and expenses Costs and Expenses [Abstract] Operating costs and expenses Costs and Expenses, Related Party Total expenses Counterparty Name [Axis] Counterparty Name [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Daiichi Sankyo Inc. Daiichi Sankyo Inc [Member] Daiichi Sankyo Inc [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Payment Terms Repayment agreement description Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Two [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Deferred Revenue Collaborative arrangement, consideration Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax asset Deferred Tax Liabilities, Net, Current Deferred tax liabilities Depreciation Depreciation Development milestone payments. Development Milestone Payments [Member] Development Milestones [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based compensation Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract] Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract] Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share, Basic and Diluted Net loss per share Basic and diluted Effective Income Tax Rate Reconciliation, Percent Effective tax rate Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Effect of exchange rate change on cash and cash equivalents Employee-related Liabilities, Current Accrued compensation expense Employees and consultants. Employees And Consultants [Member] Other Employees and Consultants [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Recognized weighted average service period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized share-based compensation expense Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity Method Investments And Cost Method Investments [Abstract] Equity Method Investments And Cost Method Investments [Abstract] Equity Method Investments And Cost Method Investments [Abstract] Estimated fair value of cancellable shares, value. Estimated Fair Value Of Cancellable Shares, Value Estimated fair value of cancellable shares, Value Estimated fair value of consulting shares, Net Estimated Fair Value Of Consulting Shares, Net Estimated fair value of consulting shares Estimated fair value of non cancellable shares, value. Estimated Fair Value Of Non Cancellable Shares, Value Estimated fair value of non-cancellable shares, Value Executive officers and directors. Executive Officers And Directors [Member] Executive Officers And Directors [Member] Expected patent expiration year. Expected Patent Expiration Year Expected patent expiration year Expired option agreement. Expired Option Agreement [Member] Expired Option Agreement [Member] Extension term. Extension Term [Member] Extension Term [Member] Extinguishment of Debt, Gain (Loss), Income Tax Capital gain tax withheld Fair Value Adjustment of Warrants Warrant expense recognized Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value Measurement Fair Value Of Unvested Stock Options Assumed Fair Value Of Unvested Stock Options Assumed Estimated fair value of unvested and forfeitable shares, Value Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative [Member] General and administrative expense recognized in consulting shares. General And Administrative Expense Recognized In Consulting Shares General and administrative expense recognized in consulting shares Gross Proceeds From Issuance Initial Public Offering Gross Proceeds From Issuance Initial Public Offering Gross proceeds from issuance initial public offering Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Taxes Paid, Net Cash received for income taxes Income Taxes Receivable, Current Income tax receivable Income Tax Expense (Benefit) Income tax benefit Income Tax, Policy [Policy Text Block] Income taxes Increase (Decrease) in Accounts Payable, Trade Trade accounts payable Increase (Decrease) in Accounts Receivable Trade accounts receivable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Increase (Decrease) in Income Taxes Income taxes Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Restricted Cash Restricted cash Interest Expense Interest expense Interest Paid Cash paid for interest IPO [Member] IPO [Member] Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: License Agreement [Member] License Agreement [Member] License Agreement [Member] License and Services Revenue Collaboration agreement, license revenue License Costs Transfer of licenses and protective rights License option. License Option [Member] Options to Acquire Additional Licenses [Member] Licensing. Licensing [Member] Licenses [Member] Estimated Litigation Liability, Noncurrent Reserve for litigation TUM Loans Payable to Bank, Current Bank loan Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year Repayment amount of debt Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Accrual Contingent accrual liability for research and licensing agreement Loss Contingency, Damages Awarded, Value Claims and counterclaims amount Loss Contingency, Damages Sought, Value Counterclaim amount filed Maximum [Member] Maximum [Member] Milestone Events [Axis] Milestone Events [Axis] Milestone Events [Axis] Milestone Events [Domain] Milestone Events [Domain] Milestone Events [Domain] Milestone One [Member] Milestone One [Member] Milestone One [Member] Milestone Two [Member] Milestone Two [Member] Milestone Two [Member] Minimum [Member] Minimum [Member] Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash (used in)/provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Net Income (Loss) Attributable to Parent Net loss Net loss New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Non Cancellable Shares [Member] Non Cancellable Shares [Member] Non Cancellable Shares [Member] Nonoperating Income (Expense) [Abstract] Other income (expense) Number Of Cancellable Shares Number Of Cancellable Shares Estimated fair value cancellable shares, Shares Number Of Non Cancellable Shares. Number Of Non Cancellable Shares Estimated fair value of non-cancellable shares, Shares Number of Operating Segments Number of Operating segment Number Of Tranches Number Of Tranches Number of tranches Number Of Unvested Shares Number Of Unvested Shares Number of unvested and forfeitable shares for revaluation Operating Income (Loss) Loss from operations Options exercised. Options Exercised [Member] Options Exercised [Member] Options exercised price one. Options Exercised Price One [Member] Options, Exercised Price [Member] Organization And Description Of Business [Line Items] Organization And Description Of Business [Line Items] Organization And Description Of Business [Line Items] Organization And Description Of Business [Table] Organization And Description Of Business [Table] Organization And Description Of Business [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Corporate Information Other Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Noncurrent Total accrued expenses, non-current Other Assets, Current Other current assets Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive loss, after tax EX-101.PRE 11 pirs-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`)V.#4?G?S$WN0$``)T7```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@`0_8))I8S6.+=M]_3UV"@BJ@EJ@ MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E M.9-38F(P.&>E:0.UH1]2CVQT\[`@YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;- M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^ MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=::W?]W=`[T;/N=$1(')1#@.0H0'*<@N0X`\EQ#I+C`B3')4B.*Y`QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C M-Z."N[_8_`)02P,$%`````@`G8X-1PQUTFF.`0``J18``!H```!X;"]?&?/ODKC;671NJN@^S]^;:ANWP M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28 MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T)VJ2# M-I`@RA49C-&;%;T9HSC-&;U;T9HS> MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ" MT5L4O06CMTST#I7U[O0VSL2_% MJF-GMH-@?_W.3J&A))3P,%XXG[_[]=U=DK&RO=',Z`*,$V#))I?*CE!Y$ZV< M*T9)8MD*$"S0\QQ8:83;IKT*4U<%S)Q1"1., ME6946JA0;\J`F>B\H&J;5*O(G6U`BJ7$2L^(O'?E2%K;1!EH5U)GW2 MYL6N`)P=)WME$.O8NBR^I(-A0*!TB$SVE:6OM!W4[34+X2387]F,&O>?J`@U M[8@8#*-:]3L7A"I.ILKA.)+OJ@J%S:M3LI`$):NEX#AFG-Q1214# M/%+6.FQ#IA4_CJFZWG M3K.7V(\2)PP)1.3)P;"E=#CO)#Q:FET^48,YN^9+;%(N7-4SSQ&Z]/Y`,=&6 M8;FT\*?T,SQ=0YO?DUVX_MJ1:/)I09=GD1J0N.^?.['[:G7^Y)&8W'(N4.Q> M?;]Y^W8S^.9:4?D6\Q1CY(BQRDE7EF/RT,R!G^F6O#QY)SLSW74F)G-\P/)2 M@F?FP_Y,ZOVI8G>U\?&ZVPRN+[#IG[>@AR2>7-&ULS9--3\,P#(;_"NJ]2[LQ0%77`R!.3$)B",0M)-X6UGPH\=3U MWY-Y7BQ[NM MKPDF!8,:-!@,+!_E+*E>S,;8QI1LT%=E=%SS@',KU5*!O&V'LM^IV!G!ZW"0 M@^S;T]\_/5"&)5WE+JB^JFF:43.ANCAPSM[FC\]T-JDR`;D1$%5!%=@ZF"7' MSJ^3N_O%0U*-LWR:9C=I/EGDU\5T7$POW_>3G?@;#.MNB'_K^&B0MHL*:SAS MMZ21M%SZ))"$(+QRJ*PY"T>8;V*"A>W')P@\']0)Z;)MH&VLEZ&B^S5$^Y<3 M5[:ROCVD?D0GKZKZ`E!+`P04````"`"=C@U'F5R<(Q`&``"<)P``$P```'AL M+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:( ME/)X8-DOV]:[MR_>X%#BV MR]*+41B1% MG\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMO MFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7` M\:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I M,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX M@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU M)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8 MD;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8 MS\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8# M*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]5 M6_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V M^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D M4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK> M`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K M$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T* M;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0` M```(`)V.#4>=+).<9@(``&X+```-````>&POE,\Q0-10EYGHE%Y(A MI:>R\*I28I159A.CWLCWQQY#A,,XY#6;,%6!5-1<1?!#!P&W_U9D.((/I^]^ MU$+=G``W#MX/!O[#V(&^?B%Y$]Q M;U!?[J#^\^OWEG3T*_],R)4A]MK,QV$N>'\!(^B`.*P>P1Q1[1\8]U10(8'2 M-ZP56(0CAIW'+:(DD<2`.6*$+AP\,H`MBM:/$2ZDC>TB;,89^GTD6201]-O? M\\,E/;L=S/$(I>O'TT`E/AP7'#N1UF^'=R'1(AA=K&RP M@XZ;")EAV44.X!**0XISI3=(4LS,J$1II`NE!--&1E`A.**&M;\IA%0#6$(PQU*1=!7Y*5$YQ8UJ M*]AK\FT*]SWR:VHZ?-9Z-;H$WSH]>P>WT%W-$BPG]F_QY9+.+W=?F?TZX8;, MMZV:/20<(#FF8QZMM/'Q2GN=FCJ(M*MCE79^_9_*O+9GK33&M;;8H2"I"56$ M+R4@\Y"Y,[+I6L?J6Z+FS)J^&]I5A1+]^%V+HLDRG*.:JF]D+I1=C&!O?S'R M@W'G->TH(MC;7W%&:G9M%?0O[/@O4$L#!!0````(`)V.#4>..JZHCP,``&`, M```/````>&PO=V]R:V)O;VLN>&ULE9;;4MLP$$!_1>.G]B%-+"^@FC\;>SXVY9T^ETFYB MI\G2^VK2[[M\":5P7TP%&I\MC"V%QTM[US>+A*E>83.#5M7)[54X6(T&"7]`%LO]=*RW!30PJZ7TMVN'B2L@(6H ME;_&8-?S3I.4#SD?MXSPVHV$1T>!X083N9/AF M35U)?8>LA"VD=7X6EMN\64HM2_DC&_"IF8)N,!`A^DDW.II/\[39IS!6$E_5=+:;;_Y8SI9G/6 M*69"%^Q<>Z2P"]TF#[%&F[511T:G0!VD'!\,P9)0O< ME8*=""5T#HR`.`'QCX(R`LH(*'LW:.;Q@$LFH"$!#:.@S>'>,;-`%2FN&-`;.Z+`4![1/0 M_B;H"AY`U^#(B`,RXB`V0H4U]RZ%1=.NK=`N?%:X'52U`75ML$DY@[FG[W?< MC,AYG.>VQIV&IRKL?V!4%U2S]J&?I/D51T=*H:=N\89^P7E(4-3"-*/A:A@:@P'VF-8H: MR",&;K-B!:,H*B>/5L[(Q\QZ[+C`GYTT%-4IG1%7=VXXI[634V5Y1-GUI_T2 MB!;J)4**H@+SB,"KW+&-W+5LBJ)>\XC7.S3HL:O.ME.S><3L4$.V+"ZDD:*H MYSSB^=JH\[51/3;#;JBH%81D4!3UG$<\IUZ=4J_:2"F*>LXCGN]`A>CHCY3: MGKUA^P8J2RF*VIY%;-^-XA1%;<_BG4*WJG;325&=5B%B^[K&OFU[1FW/HMW" MCM++>A1%;<\BMF\4W^T+I+9GXU7_]]+R8=$B."C;3J^"RLA^N*M)@_T9YT\L^%LA8+V637B/>,X+,V MM4T$XSB+6EQW85GHOE=6%O0FFKHCKRS@M[;%[,^>-'38A2!\=+S5UTJHCJ@L MHLEWKEO2\9IV`2.77?@"G@\@41*M^%F3@5OU0`W^2.F[:GP_[\)8C8$TY"14 M""R+.SF0IE&1)/GW&/23J8QV_1']JTY7#O^(.3G0YE=]%I4<;1P&9W+!MT:\ MT>$;&7-(5<`3;;C^!J<;%[1]6,*@Q1^FK#M=#N9/@D:;WP!'`YP,7[#`9<'H$/`>J]4&SU+.5!`9.9#)<-W4TV5Z[V5<1'<59J;8 M&P74"C`I(AG;"X!SP!Y:=N@#'&P%6@8@)P.D[4C;DV5[XM@3;4^T/?5.@*W( ME@&I`T@M>^X%V(K-,B!S`)EEWWH!M@+$RX3<(>2V'\P1G4$826J6.0;I,F3C M0#8VQ+M3]D:2&S`/LL0 M^:;M,&K,M*%MCB!,W7F+K$NV)>RJ'Q\>G.BM$^8VG7JG!^X%ZDOZ4UX6/;Z2 M'YA=ZXX'1RKD5:]O^0NE@LBAQ$_R9JCD$SPU&G(1JIK+.C./DFD(VC_>V.FA M+_\"4$L#!!0````(`)V.#4=>-.N/N@,``!40```8````>&PO=V]R:W-H965T M&ULC9A+;^,V%$;_BN#]C'@OGPH<`[6*HET4&,RB72LQ'0NC MARLI\?3?EWK80W*N:VVBA[]+'DKB$97MI>V^]2=KA^1[737]\^8T#.>G-.U? M3[8N^L_MV3;NEV/;U<7@#KNWM#]WMCA,1765(F,JK8NRV>RVT[DOW6[;O@]5 MV=@O7=*_UW71_;NW57MYWL#F>N)K^78:QA/I;IO>Z@YE;9N^;)NDL\?GS2_P ME*,:(U/BK])>>F\_&>%?VO;;>/#'X7G#1@9;V==A;*)PFP^;VZH:6W(]_[,T M^J//L=#?O[;^VS1*^&K^WE=[N,08X-OK95 M/_U-7M_[H:VO)9ND+K[/V[*9MI?Y%\.6,KH`EP*\%8#XWP*^%/"H()W)IG'] M6@S%;MNUEZ0_%^/=AB<7[\9&7,N)&TP_'4Z7:S[[L4.Q33_&=H+(?H[@'*$2 M>9"0MTCJ^BIQ/8_J^50OYGH=(C;S(.:(GB+`&&K.)!7,@Z`1 M6B#`8R(1$0F?R)!$#2='O5=^-XH!?;."E##`'K/HB$7[+.20]SJX`TJ`OG-M@F!F MF!1K9H.)B(Q/A"21"9X=`"X5">3GD,G@IM[ER2*>S.?A)$_F]R.$H&F"E'(T MCUF`Q;YB/HT@:9;,];$06DLDN?,@B6",`&564/UD4?`,QE?<1!T3RSSY\]]IEBKX'N5TUY=,G-7BDNIZ*D1Y+3@1JTABK4* MOE"+T]!RQ-,P*2-I%^\ M88[SS*Q10VQ/\/4I:'U"%O;$.+V*R<.@T+YGE(.N9Z970,4.1=^A@G8H^F[\Y-;*;LUC[ERK M(*JD<2M4L6*B8&Q2]$TJZ#4J!B8%$!HRVG!ATKAO5P%KJ&+IHB]=6A3[):,? MKS>"Y)WU1NI]P)V+-_MGT;V539^\M(/[%IP^`X]M.UC7'OOL1GERW^BW@\H> MAW%7N_UN_FJ=#X;V?/T(O_TG8/&PO=V]R:W-H965T&ULC93-CILP%(5?Q>(!8C`_ MZ40$J<.H:A>51K-HUTYR"6ALS-A.F+Y]_4,H(#)3%K&O.>?XNT%VW@OYJFH` MC=XY:]4^J+7N=ABK8PV&_D`5E(+];DZZ-K!A@$Y0T0O3+Z+_#D,+J0T\"J;<+SI>E!;\ M9@D0I^]^;%HW]OY-MAULZP8R&,AHB)(/#?%@B!<&[,E<7T]4TR*7HD>JH_9C M1SLCES;$)"/3C'*E^[O\ZK5(HQQ?;! M+[3H;O?:>+D6?P%02P,$%`````@`G8X-1P6KLC2P`P``1`\``!@```!X;"]W M;W)KR^E&?C&F"GWE6U"^+ M4]-GHO%:MFO M?:M6R_+:9.?"?*N"^IKG:?5K;;+R]K*`Q7WA^_EX:KJ%<+4,)[O].3=%?2Z+ MH#*'E\47>-Z"ZI">^.=L;K5U'G3)OY;EC^[BZ_YE$74YF,SLFLY%VA[>S,9D M6>>IC?S?Z/0]9F=HG]^]_]G+;=-_36NS*;-_S_OFU&8;+8*].:37K/E>WOXR MHP;1.=R56=W_#W;7NBGSN\DBR-.?P_%<],?;\(N"T8PVP-$`)X,I#FW`1@/V M;L`_->"C`9\;08P&PHL0#MK[RB5IDZZ657D+ZDO:[2=X;O&J<])Z#MIRU?UE M?T.&U;>54,OPK?/C(.L!P0&)*22Q$9B(L(U/)H%N$FNTS)$*L+$)H7D:/[;EGSWM[/MB#FV(Q5&)`U%!(&2'G%+:Q,:EC1$5A MB8TQI6))>MO:&$8*()*/Q0E/G+"+@X_MI6(PLC@#(GKD#U`HA$:R/"X( M$&N,R`(Y($,1(9(>MPZ(C(.4,VJD/(W*UDC>B[5R4M=21S&M47D9:60DF#@@ M9Y+Q2)`:'9"!BD0\XS[&GL;8UD@&6L=.(*FY5/0V=T$N8Q"T1@=4$IBDGXBM M`PH!B#Q^K%%[&K6M49(:M9.Z8)PS<@MN'!"5U!K)JB4.J)`)13\F6S?NLM8-^/K3U:5H?6J$XC^F-[E`8Q61S2!Q*(%VLK>M+6L_@Q\K\3@?,4J;(C;L> MF6F+HV[_:'4.B7$,DM$-RR7;3RFK,BZ;T=FB`4S MWA?@-T<0=A3R';8>&36CG@[Y:3T=\M-ZNM&[>LYZ:_AM'.P^KN@^/C)ZB!4] M`=WA?`S)9R?Y#:.[FX^Q&=^IX#=PL#LXW;368/=1U!RUH#\J-@[9?J5@K&F? MB>>3=;N=[#O;SWT.2D-K1,A-=>R'LSK8E=>B&5[XT^HT`'[!;L3PUM?PO`%B M/>D&QGXD>7>_6E[2H_D[K8[GH@Y>RZ8=;/J9YE"6C6E3CY[:HI_:D7:ZR,RA MZ4Y5=S>&(6^X:,K+?6:=!N?5_U!+`P04````"`"=C@U'1EP'R'L"``!2"``` M&````'AL+W=O3YA#LX;V9>>.1A_S,NW=1,B:# MCZ9NQ2PLI3Q,HTAL2M90\

0NIB>[ZZOV;4:NR7U/!%KS^76UEJ9*-PV#+=O18RS=^_LXN$I!VN.&U M,/_!YB@D;ZZ4,&CHAWU6K7F>[9OL2O,3P(4`>D+R-0%>"/!&2+\DI!="^F@$ M="&@483(:C>56U))B[SCYT`J7,)LS8%8ZZG`*(].VL\` M,K<08""(^"!+%Y+TB$C%]R8!ADG,@4,'O@`+%X$FWASN.EE]XN33-.&H5M#P MH:U5=I^?COBIX:>6/TJQM96P$&P@3Q"!B?KY@(L!$!"29!#[@,L!$`.88@A] MP-4P=)8E*`7W-:*11N36"-_G9R-^YM:(>&MD(<@V6PP2B+P57B8`P>$(9'PK`KS'NF<_R8,/R(,/R@,/S?PLA(&'&$D=@KC`Q: M*P689-ZL%V38U3B=$&^S+@=`C"&"T!MZ-0R=(8(2--(8.3=FP[J]F54BV/!C M*VTK]]9^'+X`?>..[/-DND@\]J4:GW;:W=P7^8'NV4_:[:M6!&LNU3UOKO@= MYY*IS.-G5>Y2#?A^4[.=U$NLS\'./+N1_'"=X/UG1/$/4$L#!!0````(`)V. M#4>"3&PO=V]R:W-H965T&ULG9C) MCMLX$(9?1?"](U9Q$QMN`Y$'@YE#@""'Y*RV:5N(%H\DMS-O'VJQF^30:&*` M1FOQ7ZR_N'R4M+ZVW<_^I/60_*JKIG]9G8;A_)RF_>ZDZZ+_U)YU8WXYM%U= M#.:R.Z;]N=/%?@JJJQ0)$6E=E,UJLY[N?>TVZ_8R5&6COW9)?ZGKHOLWUU5[ M?5G!ZG;C6WD\#>.-=+-.[W'[LM9-7[9-TNG#R^HS/&\ICI))\;W4U]XZ3T;S MKVW[<[SX>_^R(J,'7>G=,#91F,.;WNJJ&ELRF?]9&GW/.0;:Y[?6_YS*-?9? MBUYOV^I'N1].QBU9)7M]*"[5\*V]_J67&OC8X*ZM^NE_LKOT0UO?0E9)7?R: MCV4S':_S+QE9PL(!N`3@/>">)QQ`EP#Z'L"F2F=G4UU_%$.Q67?M->G/Q3C: M\&SDW=B(:3DQQ?33Y=1=\]VW30;K]&ULQY'DLP0GR;LB-8T',Z";(4(VQ71C^.%%R^LBC(6K&B6\'E4.>.IX2%='Q@'XBM!(I$DZ$5B*1<1XQD&R"!FW'PH M@4TE%9PA.4AG.*AX,&JVC"DA8A:K3R^P\:7"S(;,F=I""L:#?;EUE901H6+V M(?!A!\J"4,S(HX\Q)'9=X;FX:&[K@V$8WUM79WHZYG'$IR+:5%1A@".X:'AH M"/Z'(9^>B'8?1\P=]+&(-A95&/1('=`+8")BV:"/.[1Q!R3(C!P=C`%(\Q>F MBZ>D0I$85S[PD#NNPA1&'NW*5H(A#(_J*Q]Z*!Q78>JA@S..3%E3P#'E"(UU M&K$UH(\]E(ZG,/?0X5[&F!F6!PO`)2021J6(L.73#S/'5AA_:$,-,F9``>$] MPE%2L]_2F/<"].F'RG$5I'^.]M.>61$HZ8/=W56:YT]"(OJ*^D2E]H,A1#7A M,Y""4U@8@M2&V[C/!HMR50`THJ.ICT"*CI_@`L@7T?)N!?A@2GHRGZ>I]7Y< MZ^XX?3?HDUU[:8;Y)?1^]_YMXO/T:<*[G\/S=O["\-[,9GTNCOI+T1W+ID]> MV\&\O4\O[H>V';1Q1SX9M)QTL;]?5/HPC*?2G'?S=X;Y8FC/M\\F]V\WF]]0 M2P,$%`````@`G8X-1^(YO)"@`0``L0,``!@```!X;"]W;W)KP)%W);7=T-ZY8I^OM\N`B(!G`9,]BTGPOD=\#P0A"XPVX0I$F9&,*_^ M:8OBLL6V.*,7W],75PX7D;Y(W?/L>X'EE<`R"BR_'/$"DU\/R<[V5('IXM6Q MI,91N[1Y%4.O(._W'1"6[)'YT\V'FJ+Z,";R&Y6E/3^_/3;I2*7$XG![(_$JK_U!+`P04````"`"=C@U'"E`9'Z`!``"Q`P`` M&````'AL+W=OM MC-O2SOM^PYBK.M#"76$/)OQIT&KA0VI;YGH+HDXDK1C/LANFA32T+%+MR98% M#EY)`T^6N$%K8=]WH'#"\^R[7PLL+)@"Z^6&HR3:(B%9DMO\\UN'1$) M\%?"Z$YB$KWO$5]B\EAO:18M@(+*1P41E@/<@5)1*#1^G34_6T;B:7Q4OT_3 M!O=[X>`.U3]9^RZ8S2BIH1&#\L\X/L`\PG44K%"Y]"75X#SJ(X42+=ZF59JT MCM.?FU\S[6L"GPE\(?S,DO&I4;+Y6WA1%A9'XGH1SR[?!+B-(D&9!&\NI6GZ MJ7HH\YP7[!"%SC"["<,GS()@0?W+%OR\Q8Z?T/GW]-6%PU6BKV:'V?<"ZPN! M=1)8_W?$<\SJH@D[V5,-MDU7QY$*!^.GS5NJR^V\Y>E,/N%ET8L6_@C;2N/( M'GTXV72H#:*'8"*[NJ:D"^]G210T/H8_0FRG*S4E'OOC`UE>:?D!4$L#!!0` M```(`)V.#4&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\02K*<%H8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5 MVPB2B[B[FIF=Y:.:T;S8`<"15R6UW=/!N7''F&T&4-S>X0C:_^G0*.Y\:GIF M1P.\C20E69%E]TQQH6E=Q=J3J2N#\BOH3D9[NG6;``$AH7%+A? M3O`(4@8AW_COHOG6,A`OX[/Z]SBM=W_D%AY1_A&M&[S9C)(6.CY)]XSS#UA& MV`;!!J6-7]),UJ$Z4RA1_#6M0L=U3G^^9@OM?4*Q$(H;`DN-HLUOW/&Z,C@3 M._)P=OG.PTT0\[,QC=.GZJG.\[)BIR!TA3DD3)$P*X)Y]7=;%-)P^[E`>2-01H'RPQ&O,?:$N.Z/S)QD/M$!UX$]G=EI+!OY\UD="Y$'[QL4E7 M*B4.Q_,#65]I_1]02P,$%`````@`G8X-1_8YW,:@`0``L0,``!D```!X;"]W M;W)K&ULA5/+;MLP$/P5@A\02K+3N(8L($Y0M(<" M00[MF996$A&2JY"4E?Y]^9`5VPB2B[B[FIF=Y:.N6'+ MF*U[4-S>X`#:_VG1*.Y\:CIF!P.\B20E69%EWYCB0M.JC+4G4Y4X.BDT/!EB M1Z6X^;<'B=..YO14>!9=[T*!525;>(U0H*U`30RT.WJ?;_?K@(B`/P(F>Q:3 MX/V`^!*27\V.9L$"2*A=4.!^.<(#2!F$?./76?.]92">QR?U'W%:[_[`+3R@ M_"L:UWNS&24-M'R4[AFGGS"/T"AW7*?U9;6;: MQX1B)A0+89-%XZE1M/G(':]*@Q.Q`P]GEV\]W`01KTR\-QO3.'VJ'JL\ORO9 M,0A=8/8)4R3,@F!>_<,6Q66+?7%&+[ZFKZX M8KY?-6%G>ZK`=/'J6%+CJ%W:O*6ZW,[[(I[).[PJ!][!;VXZH2TYH/,G&P^U M173@360WMY3T_OTLB836A?#.QR9=J90X'$X/9'FEU7]02P,$%`````@`G8X- M1S4=IP&>`0``L0,``!D```!X;"]W;W)K&ULC5/+ M;MLP$/P5@A\0RK33%(8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`5VPC27L3= MUO&EEW([VW@];QES=@Q;N!@;%7BZ)4T\&2)&[46]L\>%$X[NJ*GPK/L>A\+K"K9PFND M!N,D&F*AW='[U7:_B8@$^"5A',I3=/GZK%:\:)DQRAT@=EG#,^8!<&"^HVI!MNEJ^-(C:/Q>?.6ZG([[WDZ MDW=X50ZB@Y_"=M(X?E!V9H0$``*\#```9````>&PO=V]R:W-H M965T83;(-BBM/%+VMDZ5!=*1A1_2:O0<5W2G[(\T]XGL#.! MK82O>32>&D6;W[CC36UP(7;BX>R*G8>;(.*5B?=F8QJG3]534][5]!1TWD`. M"<(BI%@1U(N_VX&][7!@&SK[G%Y>&2PCO4S=6?FY0'4E4$6!ZJ,)MY""55<] MZ&9'%9@A7AQ+6IRU2UNW5M>[><_BB;S"FWKB`_SB9A#:DB,Z?Z[Q2'M$!]Y$ M?G.;D=&_GC61T+L0WOG8I`N5$H?3Y7FL;[3Y#U!+`P04````"`"=C@U'3\FP MI:`!``"Q`P``&0```'AL+W=OP)%W);7=T]ZY8<>8K7M0W-[A`-K_:=$H[GQJ.F8'`[R))"59GF7W M3'&A:57&VK.I2AR=%!J>#;&C4MS\/8#$:4]7]%QX$5WO0H%5)5MXC5"@K4!- M#+1[^K#:'8J`B(#?`B9[$9/@_8CX&I*?S9YFP0)(J%U0X'XYP2-(&81\X[=9 M\Z-E(%[&9_6G.*UW?^06'E'^$8WKO=F,D@9:/DKW@M,/F$?8!,$:I8U?4H_6 MH3I3*%'\/:U"QW5*?[;%3/NWVGFX M"2)>F7AO-J9Q^E0]5:M\4[)3$+K"'!(F3Y@%P;SZIRWRZQ:'_(*>?TU?WSA< M1_IZ=GC_M4!Q(U!$@>*_(UYCMC=-V,6>*C!=O#J6U#AJES9OJ2ZW\R&/9_(! MK\J!=_"+FTYH2X[H_,G&0VT1'7@3V=V&DMZ_GR61T+H0;GULTI5*B)HO;%S(S/.7.&2SZ@?74M@"=O6AFWI:WWW88Q5[:@A;O! M#DSX4Z/5PH?4-LQU%D252%HQGF4_F!;2T")/M2=;Y-A[)0T\6>)ZK85]WX'" M84L7]%AXEDWK8X$5.9MYE=1@G$1#+-1;>K?8[%81D0`O$@9W$I/H?8_X&I._ MU99FT0(H*'U4$&$YP#TH%85"X_^3YF?+2#R-C^J_T[3!_5XXN$?U3U:^#68S M2BJH1:_\,PY_8!KA-@J6J%SZDK)W'O610HD6;^,J35J'Z<]ZHETG$G`9\(Z M2\;'1LGF@_"BR"T.Q'4BGMUB$^`VB@1E$KRYE*;IQ^JA6/!US@Y1Z`RS&S%\ MQ,P(%M2OMN#G+7;\A,Z_IR\O'"X3?3DY_/6]P.I"8)4$5E^.>(999A=-V,F> M:K!-NCJ.E-@;/V[>7)UOYQU/9_()+_).-/`H;".-(WOTX633H=:('H*)[.:6 MDC:\GSE14/L8_@RQ':_4F'CLC@]D?J7%!U!+`P04````"`"=C@U'.NA]7I\! M``"Q`P``&0```'AL+W=O%(0N(4P3MH4"00WNFI95$A.0J)&6E?U\^9,4V@K87<7;$#@"-O2FJ[IX-SXXXQVPR@N+W#$;3_TZ%1W/G4],R.!G@;24JR(LL^,<6% MIG45:T^FKG!R4FAX,L1.2G'S^P`2YSW-Z;GP+/K!A0*K*[;R6J%`6X&:&.CV M]#[?'38!$0$_!0,@CYQJ^+YGO+ M0+R,S^J/<5KO_L@M/*#$5HW>+,9)2UT?)+N&>=OL(RP#8(-2AN_I)FL0W6F M4*+X6UJ%CNN<_FR+A?8QH5@(Q4KXDD7CJ5&T^94[7E<&9V)''LXNWWFX"2)> MF7AO-J9Q^E0]U7F95^P4A*XPAX0I$F9%,*_^88OBNL6AN*`7_Z:7-P[+2"\7 MA_\AL+D1V$2!S5]'O,:4-TW8Q9XJ,'V\.I8T.&F7-F^MKK?S/AXB>X?7U&PO=V]R:W-H965T;0_@R)N2VNYH[]RP9*THRMZ M*KR(KG>AP*J2+;Q&*-!6H"8&VAV]7VWW14!$P!\!DSV+2?!^0'P-R:]F1[-@ M`234+BAPOQSA`:0,0K[QOUGSHV4@GL4/X5C>N]V8R2!EH^ M2O>"TQ/,(VR"8(W2QB^I1^M0G2B4*/Z65J'C.J4_FWRF?4[(9T*^$.ZR:#PU MBC9_KTN!$[,##V:VV'FZ"B%1OIX=;KX7**X$BBA0?#GB)>;VJ@D[VU,%IHM7 MQY(:1^W2YBW5Y7;>QT-D'_"J''@'O[GIA+;D@,Z?;#S4%M&!-Y'=;"CI_?M9 M$@FM"^$/'YMTI5+B<#@]D.655N]02P,$%`````@`G8X-1P"..@Z@`0``L0,` M`!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK33 M)(8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5VPB:B[B[FIF=Y:.^V'+F*M[T,+=X``F_&G1:N%#:COF!@NB222M&"^*+TP+:6A5IMJS MK4H)%=[V.!525;>(W48)Q$0RRT._JXVNXW M$9$`OR1,[BPFT?L!\34F/YH=+:(%4%#[J"#"%&5%B?B!A'/;K4-JQ6Z[N2':/0!6:?,3QC%@0+ZA^VX)4MUN9V//)W).[PJ!]'!3V$[ M:1PYH`\GFPZU1?003!0WMY3TX?TLB8+6Q_`NQ#9?J9QX'$X/9'FEU3]02P,$ M%`````@`G8X-1W"X]XWT`0``$@8``!D```!X;"]W;W)K&ULC57;;J,P$/T5BP^HS2TW$:2FJZK[L%+5A]UG!R8!U<:L[83NWZ]M M",4(*7G!GN%<9F0\9)V0GZH"T.B+LT;M@TKK=H>Q*BK@5#V)%AKSYB0DI]J$ M\HQ5*X&6CL09C@A984[K)L@SEWN7>28NFM4-O$ND+IQ3^>\`3'3[(`QNB8_Z M7&F;P'F&1UY9Z+BHK3@-TJ`./WJU[IQ:]>_V9"!MDR(!D(T(^#>R)7Y M@VJ:9U)T2+74'EZX,W!I18PR,K4I%[KN^^PU#Q.2X:L5\C"''A/UF!&!C?JB M1>1;'*()/;I/CV<5QHX>]^XAN2^0S`02)Y`,+8:++?J8!ZI,9R:I)Q`OFOB8 MY+[):F:R\@3211,?L[IOLIZ9K#V!]:*)C]G<-]G,3#:>P';1Q,.D#QS\=F:R MG0ALEX]DZWD\\'&'9'Z!B"<1+=\@'Q3/?/#DSG*09S>:%"K$I=']Y1RSX_A[ MCMR=_X;G64O/\(O*<]TH=!3:3`XW-$Y":#!5D"?S`59F0(\!@Y.VV[79RWYD M]8$6[6T"C[^!_#]02P,$%`````@`G8X-1S6^?2.C`0``L0,``!D```!X;"]W M;W)K&ULA5/;;J,P$/T5RQ]0`R'=*")(3:O5[L-* M51_:9P>&BVI[6-N$]N_K"Z%)%*DO>&8XY\P97XH)];OI`"SYD$*9'>VL';:, MF:H#RS\@OOOD;[VCB;<``BKK%;A;CO`(0G@AU_C_K/G=TA//XY/Z[S"M&P4;#YQR\M"XT3,P/W9I5L'UU[$*1/GS80T3!^KQS)=YP4[ M>J$+S#YBLHA9$,RIWVR17;;89V?T[&?ZZLKA*M!7L7NZ^5D@OQ+(@T`^C[B^ M.>(EYOZJ"3O;4PFZ#5?'D`I'9>/F+=7E=CYDX4R^X64Q\!;^<=WVRI`#6G>R MX5`;1`O.1'*WIJ1S[V=)!#36A[]&UL MA5/+;MLP$/P5@A\0RI*=I(8L($X1M(<"00[MF996$A&2JY*4E?Y]^9`5VS"0 MB[B[FIF=Y:.N6'+F*U[4-S>X0#:_VG1*.Y\:CIF!P.\ MB20E69YE]TQQH6E5QMJKJ4H!-=[T*!525; M>(U0H*U`30RT._JTVN[7`1$!OP5,]BPFP?L!\3TD/YL=S8(%D%"[H,#]81,$ M:Y0V?DD]6H?J1*%$\8^T"AW7*?TIBIEVFY#/A'PA/&;1>&H4;7[GCE>EP8G8 M@8>S6VT]W`01KTR\-QO3.'VJ'JO5YJ%DQR!T@=DG3)XP"X)Y]9LM\LL6^_R, MGG]-+ZX<%I%>I.YY\;7`^DI@'076\XB/-T>\Q'R[:L+.]E2!Z>+5L:3&4;NT M>4MUN9U/>3R33WA5#KR#7]QT0EMR0.=/-AYJB^C`F\CN-I3T_OTLB836A?#! MQR9=J90X'$X/9'FEU7]02P,$%`````@`G8X-1SE!U$RY`0``>P0``!D```!X M;"]W;W)K&ULC53;;J,P$/T5BP^H@23L*B)(3:NJ M?:A4]6'WV8$!K/I";1.Z?[^^$!H04OJ"/<.YS,#8^2#5AVX!#/KB3.A#U!K3 M[3'690N,,<$2\FT?Z*RUT;R"R5"G'R%E0J_#N'- M[WBDK1/2D9`N"#@8^3(?B2%%KN2`=$?YI=EM@NQ#8>H'MV&*R MVN(<\X,J=PN3W4Q@LVHRQVQOFV0+DVPFL%LUF6.6GPM?30<'U?A#H%$I>V'" M&$S9Z9S=IWZZON%%WI$&7HEJJ-#H)(V=43^>M90&;!'QG6VUM3?!%#"HC=O^ MLGL5#D<(C.PN1WVZ;XK_4$L#!!0````(`)V.#4=$0(``-T&```9```` M>&PO=V]R:W-H965TE$P[J`D_TJ_`:7:X@T MQ"!^-V00DWZ@PV\8>]6#G[M5&.D,A)*MU!)8-2>R)I1J)>7\-HK^]]3$:?^L M_F3*5?$W6)`UHW^:G:Q5VB@,=F2/CU2^L.$'&6M(M>"646%^@^U12-:>*6'0 MXG?;-IUI!_NEB$::GX!&`KH08/(I(1X)L4,`-IFIZSN6N"HY&P+18[W;<*G@ M7(LHY4`5(\S0+)>=/54PRTMPTD(SS*/%H!%3^##K*0:E%PA0$;PYD),#&7X\ M>BQN"\2.0&P$$BN01_.0G2W$8G(;TH=8^Q%70R1.B&06`GI7 MI0F*/Q0,)A=1CP_D%^:'IA/!ADEUIYGK;,^8)$HM>E#_UUJ]-9&ULE53;;J,P$/T5BP^H"9=`(H+49%5U M'U:J^K#[[)`AH-J8M9W0_?OUA5!`2$E?\(5SF?%H)NNX^)`5@$*?C#9RYU5* MM5N,95$!(_*)M]#H/R47C"A]%&(`'ESGM>;0\;@["` MWS5TKG"`2@U0MKX;Z_Y96F(X_U-_<5F MJZ,_$@D'3O_4)U7I8'T/G:`D%ZK>>?<*?0JQ$2PXE?:+BHM4G-TH'F+DTZUU M8]?._4G]GK9,"'I"\"@A[`GA0`A"=XAV1)3[-56PX41T)''R*>6<03BVCQK:>8^+[)>F:RG@BL M%TVFF.2^23(S228"Z7V!=":0?K=`]N27_`\:\D9?A%QKAN)CESIQK8] M77*N0`?B/^G:5WK>#@<*I3+;1.^%&T'NH'A[&ZC#5,__`U!+`P04````"`"= MC@U'!)3O$8`%``";(@``&0```'AL+W=O7F\F;#)QXU?N]=MT]X(Y[/P;+?9%=F^WI7[H,I>;B;?V?0QYJVD4_R] MRX[UX'O0=OZI+'^W%^O-S21J^Y#EV7/3NDA/'^_9,LOSUM.IY7^MT\\V6\/A M]P_O]UVXI^X_I76V+/-_=IMF>^IM-`DVV4OZEC>_RN,JLS&HUN%SF=?=_\'S M6]V4Q8?))"C2/_WG;M]]'ON_Q)$U:CA M+L7]4*$2YZ",.EF-.UG#WFJ7Y@?4&)?F$6IBPO@+-)U$YT%8#PG!@T0>9.=! M]@,2H0FY[P>MUYA.$Q':4*@-!=I@!`\:>=#><1KDP8`^<%><]V80IXS:?\[A MZ&4*#<=`L;KBZ.L>QZC',>BQ('A(D(?$>]18A/-5-#YN#U:$1^1*,Q=ID8%F M),4'QSZX?[B8)R;&P[VSHO[Q,A%]/5.L4KF55_J%*6404T7Q@2EDRG]\,(=, M@WYH5]2W5F3')Z)'C9EE$%I#\8$I8K%_U)@CEE!F13*6%N[')0_CDA60".K@ M%4Q,'J8F1=FLXC7#I#0/':82K\7GSPXJ,YY/$Z8:#=,,H M:R#'280;_YAQ$N'Q>,QK*^IC%HH:,TXV/!F?5(]6U+?%8V);`N<``7(`HRR[ M`M,FF/?X"@R2((#T*(8@,3)(XF+/#$&BK*4"@R3\01(8)*$(V<.*U&!2D8+& M)`E(DJ;XP"0)?Y($)DG$E*#CX;:)O($6&"4!4:+L'R1&1$;^1RR,B(1KC?.X MOD8B4D.8(TE9D*S(3BE.'5V).9*`(T[R<7'Z].=(8HZDHHPN$''*&51BAB1@ MB%-68(D9DOX,22E*#E<`>>D!^UNJC30$@H*Z/"D"C_ M4HW"D"A"L6:IAF48'I'W`PKCI`!.G+(T*@R)\B^U:`R)A@G*$F> MX!K3I`%-G+(T:@R)]B^X:`R)%N/)^P&)2`UADC0DR7WY*Y_"X"R17BH3C MKE9`0M_0:HRMAMA2ZLCZHL#JCZW&V&H"M@L]K(TF'E%C;#7$EM1CC*WVQ]9@ M;`VA0KHPH$A"SM`&8VL`MH+D`V-K_+$U&%M#J),NS+#Z*0QY'V\PNP:P*RB; M-X,A,?[53X,A,9H2M1YNO"+R_MI<_&(!O@Z>R:+/'MIVJ\M5E7_[D1_ MT92'CU=!SN^CS/\'4$L#!!0````(`)V.#4?E/G%>?`(``/$(```9````>&PO M=V]R:W-H965T2ZB!:YS)"=\*?DK[;Z3/H=0"AYHR=2O<[@P3JLK MQ74J_*&?1:V>G?X2@9YF)Z">@`;"X,=.\'N"?R,$7Q*"GA#,]1#VA-#PX.G< M5>6VF.,T:6GGL`;+?H(K`6^EB%!V1+F86JH-T=;W%/E!XKU+H0EFHS%(8<*E M#;(=0^"`\$0`UBC0-(H-&M&1S4$V1H2Q-8:[(KM/1#X-TS>*Y2M^T!2X,+XN)E^5]@<@0B![-&VG%X[0" M<%\``O.\@D=+"_\[\G`2!;26I`<-713-<(1,1VCB",V0,$\<]!].USQS,)A$ MX5M[J0?IS?4!0I$5ETUQ$8AC:V]N9^KMOM+3*7JC__.*M&:Z\(, MUF%:/R,Y#PS[!JXR:+%OY717\^,FGR8-/I.?N#T7-7/VE(LII`;0B5).1.#@ M250[%_>/85&2$Y>OD=P&/9'U@M/F>L$8;CGI/U!+`P04````"`"=C@U'`M#Y M?10"``!,!@``&0```'AL+W=O7$`+*%EZP/3GGS)D) MGN2M5!^Z!##H4_!:SZ/2F&:&L=Z6()A^D@W4]LE>*L&,/:H#UHT"MO,DP3&) MXVYC;ZK(Y='PJH8WA?11"*;^+H#+=AXET3GP7AU*XP*XR''/VU4" M:EW)&BG8SZ/79+:F#N$!ORIH]6"/G/>-E!_N\&,WCV)G`3ALC5-@=CG!$CAW M0C;QGT[SDM(1A_NS^C=?K76_81J6DO^N=J:T9N,([6#/CMR\R_8[="5XAUO) MM?]%VZ,V4IPI$1+L,ZQ5[=0Z=CD-40DO0(;`V,NB#7+A9D0"=C"99#!'T9]7!79/V%R)W]@N.W$-3],NW`PLCG/[OX#4OP#4$L#!!0````(`)V.#4<@ MI-?GTP(``(\+```9````>&PO=V]R:W-H965T3$3N(JFSHRT<>CN9,B*_,+8BN(SX*X MN"I(K"`Y"W)P58"L``T5I%:0?H8$KPJP%>"A@LP*LJ&"W`KRH8+""HJA`E5S M4SDP6'(N-NQ((M,ENL?F1)#)J&7'@.^)>O+@K>);Y2/-`]E97`]U[YJK[Y,8 M9:/H73DYS-0PL65R'S-SF<+'S!TF!3[FSF6@CUFX3.QC[ETF\3$/+H-\S*/+ MI#[FR66PCUFZS&>>(UDD?Z7B3J5B[9!8AWR`0])Q2+0#L@Z=&C6FUH;)-`-A M!N3/QST:#@(#@K0/?'(,$]3'+5W#&#A@_QI19XWH+!DF>^5>]R"]7720P@4,B*CH1%4Y$ M0[8`/:.S6X-O;P+POQT??KT-W%O(I`;C(D;>I_;!.A3"[N;&XR=Y`Q: M6'=[@\GWD]/=/B#Z.CEW%C+)20$L$F]R%I:SR4&I)SG1Q>MZ3[;T)VFW9<.# M5R;DNU^_]C>,"2KMP(W<"7;RZ_@\J.A&J--,GK?F>]$,!-N?/G_/W^"3?U!+ M`P04````"`"=C@U'Z_M?T%L"``#B!P``&0```'AL+W=O1PYVUI3WV4(@"+K63NDR]K.O8S+6IQ4UP[\94SDJ>_9^'O% M.W%9I#"]3KRV^X,R$]FRSFZ^;=OS0;9B2$:^6Z2?X',#K<0J?K3\(KU^8N#7 M0KR9P;?M(@6&@7=\HTP(IILS;WC7F4@Z\Z\IZ-^21F7\;/FOY:(+HR(DN1MJA M72XW>UZBHJJSLPD4:%9.@YPFIF@"!;E),@T0I4`S"F3]V/HQO>_',S^V_MSE MIR!D'%P53D-=#HPK6L5D32A#987NX^0SG#S`@5$CL/T?Q^@'(6H`SJ(=%Z2@\4`_2/LIM`AFCUR$FH9CA5@%-$<2HO M#R&41F%\40$(O(\"P?QN`0%,-,]J$ET7AY8D?A!"G3Z_9?D`TH?K#@9(91P) M>G=`E>,Z/[@ER`R6.UQ?U]JPO_P!02P,$%`````@`G8X-1RC6#$E\ M`P``S0\``!D```!X;"]W;W)K&ULE5==RY)#KFS M,VO>V@.EW/NHRKJ=^P?.C_=!T&X.M,K;.W:DM?AGQYHJY^*QV0?ML:'YMB=5 M90##,`JJO*C]Q:P?>VX6,W;B95'3Y\9K3U65-_^6M&3GN0_\R\!+L3_P;B!8 MS(*1MRTJ6K<%J[V&[N;^`[A_@J2#](C?!3VWRKW7B7]E[*U[^+F=^V&G@99T MP[L0N;B\TQ4MRRZ2R/Q7!OW,V1'5^TOTK"]7R'_-6[IBY9]BRP]";>A[6[K+ M3R5_8>7($<5:+C'>.>CZ2M4QX M7=@(@/L`6`8P1-;#*QTP9,!$((H1L>%6&HY@3,+0AEOK.)`Z<-FUO,X"B5$@ MT0I$U@*)DBB&T%$>T62'BFBGF,@0$VEBL'71Z)@)%<=&DE@+$%F3Z)CX=I+$ M2))H`1+K:QTP\;"348A)9)UF#19'29K#)`6`D\(8;HPP-_U<6#Z'-", M+K5:V!JH'H;$LICD8L"T,:!Y5&JW&`,TP6.`Z61`LZG4[C(21.29`L'(6GMV M#>>69/H>T(POG;)93*\"Z7&4LQ-4#S$`X,AUV+D*=(LR M;0!..>_`+S9@_1Q"]XE'-14-!L(D_:H\4#J)BC;[ODMLO0T[U7R8A'%T[$0? M8->)&.-+'DNYX=QN+^V;H-H<'SHZ7YGGLX!?_`5!+`P04````"`"=C@U'\;6- M!?`!``#9!0``&0```'AL+W=OQ$![\Z<1DA-MAO((U2`I.3@39S`. MPQ1RTO5!5;JY%UF5XJ19U],7"=2))U^[8:CL!JQ)>?8>. MTUYUH@>2-MO@4[2I"ZMP@A\='=6L#VSVG1!O=O#ML`U"&X$RNM>60$QSIC5E MS(+,PK\FYM\EK7'>O]"_N-V:]#NB:"W8S^Z@6Q,V#,"!-N3$]*L8O])I"]@" M]X(I]P7[D]*"7RP!X.3=MUWOVM'_R+:@&\VSU\23)E[3U/_2 M0)-A-4B\"!([`)H`Z#X`+0#(`9()D-RF[/U.O"9SFCC-0U2LR>JY+,DQRO#] M.,DB3G(3YP$`7@#P1PN2+@#I`P7Q&NPT68YQM%J/N2J*"UR$]]-DBS3939KT M/B!?`/*/UJ-8`(H'ZE',3C[*BR3/5PLRER&,3>46<>#L%@[D2+\3>>QZ!79" MFPOM[G(CA*8&%CZ9DV[-.WL=,-IHV\U,7_JGQP^T&"X/Z?4UK_X`4$L#!!0` M```(`)V.#4=!>3XF#@(``&P'```9````>&PO=V]R:W-H965TW<:U4OP%`'FK:$OG$>]KI)TE`F@NC;A9:4,9.DW_QK"OW[3F.\;U_3O]AR-?Z>2%IR]K.I5*UI81Q5 M]$C.3+WPX2N=:DA-X($S::_1X2P5;Z^6.&K)VWAO.GL?QB<9G&QA`YX,^&;` MZ7\-R61(/`,8R6Q=GXDB12[X$,F>F*^--EHN3(A.CG0QTG;M=(VCER*!JQQ< M3)"CV8T:/&EP2%/.:8!F"()@#P3;@&0*R-X/2+R`Q`8LIH!UL!)'@V"PDCG- M+,C"`UDX`2@(R-()2(,@ MKF89!'$U#\S(R@-9.0$/+++,"\@^NDK77L#:(0BO4D>#PZMT3C,+@J#_YT,G M`CT0\<_F@3XZ'9$(PRXVQ=[&UL MG9C;QS/U(2XO>A,IQ?M-;%EFRD@%^2X??MRD`E25H;T MQ@;YV]U_)7D7M+KRZE=]8DQ8?XJ\K!\7)R'.2]NN=R=6I/4#/[.R^>7`JR(5 MS6UUM.MSQ=)]9U3D-A#BVT6:E8OUJAO[5JU7_"+RK&3?*JN^%$5:_=VPG%\? M%W1Q&_B>'4^B';#7*WNPVV<%*^N,EU;%#H^+3W2YA;!%.N)'QJ[UZ-IJQ;]P M_JN]^;)_7)!6`\O93K0NTN;KE<4LSUM/3>3?TNE;S-9P?'WS_MREV\A_26L6 M\_QGMA>G1BU96'MV2"^Y^,ZOGYG,P6L=[GA>=Y_6[E(+7MQ,%E:1_NF_L[+[ MOO:_A$2:X08@#6`P&.+@!HXT<`8#N&_@2@/W+8)[U\"3!M[<"+XT\.=&"*1! MH$6P^]GMUN8I%>EZ5?&K59_3=L?298-7K9/&L]4L2-W==DO>C[ZN'7!6]FOK M2&$V/0,=XX48DHP1BA%;A8A@8.Q&)*H45*4;&#D`+$2L$"'!F*=;!4GWG2VCK8N3F?OR'5QIQVXF@.W<^!*!YXJLNRGM&<\*=)U/4(P+E8Y M&AFXY!YG%.YIPKV1<`@=5+@W"A0`.&AZL:?((7/$^)H87Q$3H6+\41A\_B:) MITDBF22><<*8:J"E&B@;QD=3#293Q0FCB%`3$2HB`E1$.%Y6G_J!8?G#>;L[ MF>EO&_[/[HZT!",EP1!-,!KO[B@B/HHE=S"C'$KT^D\40?@.EU`?B@8D]`FZ M-,E=T"SJ75.B8U$.NFP;"4U.TSW.+`ET2:!(HKBD'HKZ+?)`4"J65(`UF)MF M'#'+U=L'=12Y:)2-A"B5>O'Z%K_#9K0SJKBMA?J*$+Q#2VB8>X).7"RQ^QLOF>=L*['YFT_O)%1I)0[: M2A()86+,D?1V095^X1B*4O@?D?2Z397"[>"%6T+1W?E-S)3Y65@OVZ"4;0=] M!HU5".8\<^N5&)1*3&=43M`K)\!''V5!KV;@3&>;J!#,^$N"7J1`*5(N^@81 M:Q#ZMI.H$*">MD9/9L5Z-0.EFL$<%WH=`O_#ZZ/_X2&8LS[!AW>C_G>'<,[Z MA(8XBI@9T-8(]8KMT9MVP:IC=XI26SM^*44_G\/H<%+S"=HW=6U\0Y=/%!E/ MZ/*Y/X=Y<[]>G=,C^YI6QZRLK1&PO=V]R:W-H965T2?'SSGNWW;/PAFD^`2M\E+ M5C4YK[R:;:?^`QJO,.XA`O$[9Z=F<.WUQ;]P_MK?_-Q,_;"O@15LW?8ILN[C MC2U84?29.N:_*ND'9Q\XO#YG7XGA=N6_9`U;\.)/OFGW7;6A[VW8-CL6[3,_ M_6!J#*1/N.9%(_Y[ZV/3\O(I65G#6) M(9(DC2`E`#;@TA6XTH$0:\"KM1.C=J+5GEAKEYA$8,)1&")KX4ZHU774U9*I M43(=E`PXN9T@-A+$]S8\,1(DMQO^F`S:@TC8_=WF20V>]'9S'B4F/4^HPWRB MT/254.-)[:ZA@8C#:-`G_T):"F3GT4$.2QJ!R0-:"FQ=K@HD&T3=^H-,ZT!8 M8XIL3`L%DDRI(Y/I,4@S&4+L3!(4RY6=1)$3E6D)2/,$0NU4Y!O39RH948W) M*J2%`LE!H13R!7Y*2!J`N/Z0Y(LP=Z M14[IO7("TQY`4SZUOGM.S`-`C2#H%;9+A5(K3M* MW*A,AP#-(:A5MTL8.@1.PQAC!RK3(D"S".JPKX$I?2#W;HU@:AHT35.[IA5( M[EIXA%R(3$6#BZ(5B-SEB&`J&A*7)B;?H3)%#;JH'=YNL*E7'-[;1&Q*$2.' M)BK0N8D.DL>F$#$X]!`/=VK7#0!_>LMW$.)<@:3FXY12Z^:WU&`HI/B37H/! MR:YD]4X7@_X#]"=#X_D=5X M+[SMSIWBR+GEO&5=@>&HT_&>99O+3<&V;7\9=]>U/+3+FY8?SK]!7'X(F?T' M4$L#!!0````(`)V.#4<0C\UFY@$``*,%```9````>&PO=V]R:W-H965TI=\#W:EL@HK.!72P8YZ0/#?N3\S0Q^ M5+L@-`B$DI,R"5@W5W(@E)H@O?"?,?/_DL8X[=_2GVRUFOZ()3EP^KNM5*-A MPP!4I,87JE[Y\$S&$C(3>.)4VE]PNDC%VG"`%TI=B-*K'"1"SX`V6-S.J*ME@L3HI.!KE[:H=U? M-WLM$O28PZL)FFGV3A-;382^^32'J2;.?))R10(UI16?F!;!4G7>"D$YS(C[-WFHW;,R_PIXK2 MKUC%S!:8V0PS\IZ0N2;VGI`US2H(6H"@V=\7>6M%DUH12D.4+M:!D^O1XS/Y MB<6Y[20X>*Z+#P02,W^L6\#RBIE>EN=%^X1\0-%.]O3^+]72[^ M`5!+`P04````"`"=C@U':*Y6C3L"``"Y!P``&0```'AL+W=O!UZK4RGU`"AR<.,=JH:VHF)MP.EQ%7Z!CUMH(`;QHZ*]&+0#;7[' MV)ON?#NLPDA[H#7=2RU!U.-"U[2NM9*:^9<3_3NG)@[;5_6MB:OL[XB@:U;_ MK`ZR5&ZC,#C0(SG7\I7U7ZG+D&C!/:N%^0_V9R%9[;-JS;.W;U+L M:-,$Y`CH1D#POX38$>*Y!.P(>"XA<81D+B%UA-0C`%LL4^H-D:3(.>L#T1&] M`>&C@G,MHI0#55]ANF8%[>BEB#.4@XL6&F&>+`8Y3#R%68\Q>`JS&6(07DYA MGD>8))K";/^%`2KO9&CDA49&('9FD_L"L2<0&P'L!-*QR]96S6(RBXG2:(&R M*=S:XF#DXJ`ECF9$PIXC/'(T.=,&#QQA%">Q7U^+>\9#1PJD?_<=)9ZC9.1H M<5\@]032SZY2Y@ED(P?+R9I83&)K,C/IPIMG,9QG,4-@Z0DL/YO4K,WH,XYF M9'4@&S:>FQ9^.#+@*"^D.AS-N7AD3%(E%SVH75>J>_36J>E1ZF:FVMS>++8C67>]*&^W=?$'4$L# M!!0````(`)V.#4&PO=V]R:W-H965T+[R5FVTO+D234732KBR%Q8%/WS2&:TJX<0C_]&FYYA".#P_NC_*\&72R:%Q:0-0M(.F#ED`,/!VPY8.D0:P=HYMFH M^Z:81#+`13Q=)197B>>KQ(N;^+[6V*HU-FI%SEH5DTD&9BA)W-S"X"`D.7)7 M->0P2@!"3K^7(8=P#-,T]:@PL2I,C`JQAT-J.:0WKZC,PO^V77A]#<\TI&J. M29H3%S;7F,R30)@2Y)64W9#0[$CBXV&W)+R])Z'=E-#LRMS9*AI2&VP.Y-&PO$D_2JB/!H]P@RV9A#0[\@701(@`XZ#N:DHTXS?U)?HK>:/?,E(EC+"!(: MF)YBAKO;\NS9VY??UO4ZV2R+/V[RJW*S7/_UKXZ'HU\E7Q;S9?W7O[I?KU>_ M^>JK>GJ?+[)Z4*[R)3RY+:M%MH9_5G=?U:LJSV;U?9ZO%_.OQL/AZ5>+K%C^ MZG>_K8O?_7;]NU?E=+/(E^LD6\Z2U\MUL7Y*WBYYA*)<)D=)?9]5>?W;K]:_ M^^U7^`U_=YJ\*Y?K^QJ^F>6SYM._W2P'R628)N/AZ*3Y\')S-TA&D^Z'?CV7 MW>OYA\N;>EUET_5_[/WRT],J;SX<#8_^OK4.>'M&7[R99W?-I[?9O&X-X^?X MD%=%B0N<):^R=>L]W;_[=_]NZR;?%/4TFR?_(<^JY`W\V`)S\TV9M_/=OQ\W M?_E49;-B>9=W'Z^;OPG$/^9W!8(9)OXV6[2V]^'MZX]OKY,/ M?W/Y\=WEU>O/G]Y>77YSG29OO[T:](QX!9NH8`-O`5V^)'^7/S7?N]I451,D M?>`].AJ-CR:CGJG>%/.\2J[@N[NR:LUSO9-,ITMHZ665/7=NZG$ZK3=X/FQB^9K[FBR^SY??)O,R6 M6W>Z98`8P%M>Y"7-R^7=T3JO%KO'W/("W87[9KTW-U^;% M<#`@%N%GYX@;F[;M=E[-9@3P&-H^8?U0L MX2*M"@!&Q_EO%ILY7>R2SQIH2)7?`S84#SF`N6X!S7XSRV^+:=&#O/4>T&T= M$>UPGR_W(T\''S)$J/M\70`Q/@1R]2+YJD<2N%[#",2CREN@O4L8IT!.5=;% M#HX=XXA'CNVOM5!DK]<94;:_6CZ;J/NMU[CW]X#4)*1L(>^3O<6F%GH*P0W@ M[@?LQ_PA7[8!*0N$"S(MZS7C3!\)^YC7P(&GS$]F,-Z\)+K#'?K-OX M\8>\N+M'Q,L>`#YW>;+<$$4#Y)L**C.Z6V*X<]0M*'T5D379[`$"Y[`?QR." MT#E"/^:^WY.:OH&#*>Z6POFF3PD*J_6<=81L]MVF7B^Z)!\FG'TT.TVR6T`< M/,X.4K%C27O1"!+1WLS+QRTT@MZYI7?L94"^-H6+U2VX7(8])^L21;(2Z/`\ M1^1F/(-?\6^2#5=5^5```4INGO8;_E4.NP>ZCO!M87*Y/*)1BQVWCN2&HYL, M883`AW?XP'K>]P,#,5I7Q13!VX02"&[790RB8:%NJ&N>76N[9;%AQ]JJR&(/ MO[(WH6L5+:WP]C:?T@3YEREA70+PSQ/YNUSR!/MH8;B:63ZM_4\ M%'QO0'5?+G$3>(1D+GC6]SFB:-^7UYO5:D[4#+4./41@+/44:,RFZC@UFHPT M26"FGD1TOL5W*]T*!;I)L M@$$`<[D'HIS!UMYE5?%]Q@.]7P;]9'3&`J!.??EU M+W$_R>!1WKIW&_CU/I4YGU)"EJMYMJF3:T#T.2#'(2#:%'>1P5+* M^1R^>USF,U=O;NIB5F05#I1L`QY(_)NJWJ"-"5@3+,==3@$516LXF.7UM"IN M\&:"[/EX.$@^P8HK,DSEJ!F7MZ!$Y6$6UWU$N'3`'2+U83'$[KH"7VED!Y3L-WVWF0CK"`N"VE0MB35M0:/M-.$!0 M_O#G_V:@^<.?_SMC2C+-2:B#X[I!B@"3U/H M%4PCQ"\#_@$?@OB45)MY7NM4UZ^O!@Z$^F3!&E` M(2!$PO@%GRT*225@)YZ*`X"]U5_P3$1`Q[.XE8G0@D$F&K+T`+]&:-<;0!C_ M)0(SPVL&\]\AI8-_GZ9G:"L;>=L:_%9N*L$\OBB(O1E,"6(`?+2:`V1$B@+X M,F:;*]P\RBE`I:?E$5S\ M^8;4P@`Z4,Y1GM+#]=,"^<('=,9ZLK*VQ+\$;'MM[Z._):TWD\=<;:#,0Y/F M3$JY@<(!1P65.<<]/&85.G?J`!_]S/U!'N$24QR5;AX3TZW8 MA&>+Y#"OIH4_7'^D_I0'R>L,L)>W%@XFT06@<"6#$+V@84'1+Q:YRB_EBDD$ M#\'T/D&9;\[,"L[DZ`D=2=F2Y1LADP6,/I,+HO=JL%W20S#B9U.KVWOBBS=! MS_K*T[Q#E@^G\X*$K*-ZC3:;FZ)<15,XE>E`BBM8S)##1+FZA'4_-:UPNN7+ M)8T`]_=?_MFA?"23_\O_PI7"H=D7VLZ'NF#NB#($B/3,I/$R;!8+`=4UH$P! M@A9RXPZ)NCGF>)#L'-;M'I;V<@MLKGS$GPF,=5@4PJ8V(V1AA)6.@`>%HN)R M#52!V`Z+;_CM"GU;56:0AX8@T,$@^*V88?9`!?6H, M"GB9;9CX[QK>U9'-J!LO8[3LEL$1+1^!I\F&&0"XJ&I&K(2XDP4>$.]I`=RU M=G=LUT783:?Y:AV`!ZJ"MVL!U@/&?QY<#Y*O+R\_(,X[K^85"P,QP]*!O(%H M8,^/7A=0N1MV1;!H3F8]U,;1JGZ?`8V]R7,@+O,"A*$LK,I-+?!!EQ.6:R4) M9B;E>EGBPI?X.^X/MCS?S(CO=YWP5MCYG=/:'*T-Q+0U+JRAW5A)@6(M5%Q$ M)P00(<09%HE8);G;L#6S'M`%J5`8F#^1>`N4HH3UKW7I1I!US0WS9JN<:#A9 M.<*:\:00ZO-\C6+%A,`:%$[`#[QOP'KIVNYYI0MYR#KO`A88TU.'4,0>?E8(%1+Q5I&Z[S:S.X8_81"(%XL50YA`D+$!D4&#(2@H M1R[8N`S"=+?1.NU['WXC5Q]]X=2QIJ2Z$RO8$^0-=DI`(UY%5`,)SWI#.,[X M(FYVM,NA>+&9XT"H(SC<>E40.25[;H`0(6^`3A)!QQGH#$#(IB[1,:H MFQ,I`.D`R2-0"!G#BU)N'U$*1+(UFL+*>7E'YC!14VEAWO;A!3O8T?2^R&^- MKV&6@YB*2(?84"4'5^]?O3ND?]1.G]4)NSZ$F,EPO'SDWWF#TF]5YL/N874T M3Q+F@2'+I>(+`G(#/'O@WA5S5!3AR0>VD_/7'\NG;(Y8YECM0&J1>\DZ1R'= MZ[V,PT).:E2S>$0GEO=ZEXZ-'GY:]^-]3HX0'-_Y<5#40_%E#8P3B0A=H74" M`WZ/=^VF7*,QN2(N*G`D?N#"9<<-XTI!/-A4G@SY&9`$HF;!"\%-ZFXI:\4+7>)`=ZNA$U>6[FO0>N'$;/`I'Y"(O^(L1?Y%3$!FA#!P8L6:D+*16 M`0H]Y'3W_.+(K'`PUF_O\64C[TOPC+#Z&4A!#VQL@[M]4!\R*O%M)5M`4@.= M12%+KZT\)+L"W%.W]Q(#_%)W<-,%C2J?T[D"A44]'#Y?9?4Z&A)O_,&T!Y3H M!BF7;!G"H?#T<0U!M)']XBN,N.KMP8"FFJBUT#W2(._4F+CM&@5\O`4I$VTH M9%(1Z:(&30*@`P!,G4AD9?64\K%71%B#1P]Q5&C\`@0!Y'-(<-B+43H+3#@% M9("X17/T^&2.A(FNW2V`C:)R'=N*:*=>CFN<3M>`M#3!8!<=X7.`OPOJ;8CC M3T"0$,?@0&H7KM0N%5N-/(:NU&Q()IG$33FDDY3MXM!;OLW;*3R`)X:\.S,4 MKAZ>PPOF`,/S0:)!+]%'0$/63RM<*"E#!/19LED1SN._T4`FZ@8@#\I";@J" M/C)$1"0,]EJR^M"@I7QEZ#!EQ21'+HU:OZJ`,Z%4<@?#UTR>Y5)3<&!UEP.* MO^K9;[1T6FQ.*('F/N3VZ#F2WY%RR$K=2CW`:KD(H`;RM*(#Y7M";Q+1(GC@ M(I'=A+O"UCFX9/6`%)T6T'O@ZWB52_D>U:D(9Q`PXO[@U1-@0,C9D"#KS`&3 MK10U'3DC/0^Z:B1#85@$OE6C>H24!G@_RE&P,Z4&`C2=];:HZK4NMD[NYN6- MS%2SM(JZE/[;$&(ON[&QVPMO)#15/2%7YN(&+EO:`3E#S)JU.&A\^W40 MQP+\LLIO`0_P@NM^1;S$YQA(`HHZAF(B*:R0MN-9.T'UV\U MK'=AF2P$5[E#U<&H2=&:*Q]Q(4H"'($!YD+(-5P)YH"1CX`[)Y9ZN,A(]NB/(EQK`-SM`4F*/MHO>>)&I>[N5 M2F4L`\E15#,V.POF.+IV@H>=P$]9`R'",M?()_U:H$=<()`LF&J!5(7EPJ+%T'H$CR79=+,2+5#6'``1G6NB:>A9Q$26-]5^),RQ0AJ*V9XCWT3'G M@WN,5A:Y;.B"V+;GQ.S9M?;LWJ!R_GN2LMX!3P0!DHCJY?45H`DL)3D?#Y/P MDK,O?4.\>P2;6VT$6G_60KF^5,[E7W*Z/H(+XP M0?W#7;'(1BA)8+MAKS5)&7@IU3Z^"*LC%!_(&L<)X/8<#K'6%?*"S$)UA7I= M425TO/HTN:E*U')*]"EDF$R!H["V1,P`SCROEBQ&X)"XYKK<5#`V2\E&W@AD MF!T%9/%#J\]R^J3KG5B8;I;E#?I?Z&OY7>T(!$$+P"=4Z065[M$26B`A6:^1 MUA7H+0-I3O8N,3]/K<&<'ZP?KE?-2!I_63$<8[L+F.S4J,#<`^4"3)\7,,X, M+2_YDRX.*72@!#(_J49D3B*]P!$%#`8IHGYD\0&J*0/`Q],Y;$QX49T$I"7. M%T:#U8#4!^SHB2(]-G7.ID<<@EX`&8B^,:WU,Q'.V(QG=H<./XCBD( MDF2!,":.%V?GZ?%P0I^]2([3\^$P/3F;D)9[V[1)=07ZIT8^1L4:S@EN&QE( MPG95@6P!803[[;&[G0'AXBU5P[1:EES&OR4;TR;-]T M^"$2!4#"G/T@:XY8(8*'N@+9W/C93;Y^1`-O9.T+_J/.^Y1_*>HM`;*D<[+' MV*B5%.&>$>(2_GG+%\86J[,&5TX1#H[FQ9T]9M6L1@UE/[`H97.,5/DRXZA? ME.Q)GZ!\,](1O1$9%=75BFT.\!C!Y"1Z4%#]NPW0WUDA;B2<%PW.Q.>4-Y1( MW_(%AHA53\Z"&)=EY[KAPV/+"X;ZY,A.!/5R"0]=@MZ\>\>D&H@;")?J]P9J M+M,)&J4`]J2-Y?7+S72X_+Z M<_)M.:"G1\.+%.,W1-UPI&U<"85EFUARM8'C!O6C3C$.ZP`_ET\/!?TE"+IV M=R!X$)!NRTZ)F9&<4DO@7K,E'([4><>\6 MX_1@%8L"\?6N1,F!KE;U0`(IQCOJ+DB,7NKAX&1P5V[G^71==U@6X4LO_ODE M\76N^38[DJ;G8J&Q07Q,%5JK82`L\\=$P>70H.S/G10XM@`$D5WEH1">3:DF M+H1)G1`_.4V3X&-45Y]^[+DW[3D>&L-I*@UUF'K+'EZ=%:(G^J0QSMA=PF&! MQ"<\S2/70RG>]-OLH:PT_I_C`3-R)R#-1'-@YF,PPIXIFH9X0"G3";`+/KV' M<@ZG13Y"E\W*%5]XA*$B$W-<]BQ7!0`)P!>/S\Y+O>EH?6=1`3=--D850U8E MAGV0;`;OBK.-9F6?AD.[9)B8$)1\I4PHBZK?\?VWV9(B<1%V6V_FR=%P1#>S MF;;G?OCS?TY>?P&T)PJ6B4?J\W)3(\:@*1]CKW`R'_>[SVQCFBV*04D.2&=U MYZ/AX6\27^[`$[GXY_+F<(Z;6<:@WKF%%\R=K& M`=H?*<+-37FY6&,#;AMI*_8*`4KJ+2?5EKR]0.Q!K"S,Q@)(S:16=XY$"$*V MS-D0&"\X!(W`QN6@HNI<3.)H:T! M*]5K9N"?4?BM`$*]VZV=@9164.BMH[!>NDJ<)J0/1"0#[5=C=9B@^;`L#-)* M78AS7>8Y3LEGJ[Y7%C89T/YVQZ$3@6<5R]9"Q=D77FG2Z5NJ-N%(')3)^F@N M\@)^/9'7/2UWG#;8I.4GHM-V42SU/\+'Y')E0D7G@53;$,8=7I/[K+9F5#5V M36,40D`;`8.S?TJ)"O$2&&OWXL)$I#7AVA**?X.">5[7$@`MDIM@K_";AK2L MP0$ZQ/Z!<%'8`OR?"[Y-"091JMXJ.Z+VUU:67G4'3.E/&5^"F`(B4#XT`G-" M0KM)Y.Q/(YH$RZ^3U.C=QX&$/]<\NEX>X[PY!(@/E:TD?W5&H\`"D`K,/1F_.Q_2Q^+6[Q+HO M1QEYL[]-2.ARA%6S!E!A8L1#<^QK!'_4DBI8T60JM"1BEO8(!'6C4%7G+Z09- M)3.0JE%U'W@0L,^W7B'=P,NM@^GAI/9D4K<`J0?]XQL.=&NLT=\5W+K@:]T5 M:2#[9:JHL/))?QGZHHZ",ZJ)<\BL7H!(H*']Y/K(O^3332/:BVZFI,-=,$VO M@Y#/R=$XI42T-S,F7HPF?@XTA+?]-9N53TJ)'"]Z5)W>930DK[(U#:#XX84& M!@5['QL!MA_H&[H4E(J,!N'D/>>^$?TE4X3Q30J4:70][T%G:$_DEBK+C[$M*@]T/KRI]DJ,IZ$2VG7 M;DR3GD')1.X^FPECG2-Q(6,?XB-GM43FOA3QT0?;F(/$,2BJT@<#P'CH@9X3`T\_TI'Z_Q7"`_((_S[9ID M2P9TS0$I;CN>C]L"KR-6HF40+"Y\X;:3"L ML3TRB-O-9&X["?#1)JS[,T$8C/2Z.KI[5OM7NA9XD68442A&$_U29U>#PF(' MU0C:99M)(9J_N!B%)6&NVL8Z<^52-.(3)'7KR<8M*"5E]W$#%X[&0[&X;7,%T]R MLR*[6X+F44PC\G>+5:`N]`O-<6I1)!=3I#J*<:!D!GN_2<",0@LQ, M)"$L'F5?(L_KIT9X`O!F<2+HA28\>)+?)>8J&LQ&M7FRR%[95"F7BU'Q,>L- MLV*9W09:L:DCW&5OY"5%J([BM15=T?+"=KR0$^QEJEO.$0<.T[B#J*'B-!+1 M=+N9SX\HQ2I?K.;E4YX[MDC/F/?SB15L7)E)<%R0GCWB:9#VVW9`-0YA=3;T MK9\.3X[&)Q%E<#P6[KA0:7?SBLCKM?#*S4F?,>2G,$/`>D3"9.)$2:#"\]X M.ETOH6\"#A48P^'PYP[::,)6%'>;&08Q!VX)BC*!R]K#"WWQA,O,EK1G<^W9 MQ`'='A@OKAZ2C7H"%>>A6%2G#UF]SC<5WH9K MS*4B(P',.7P.+^\?/Y'QB:GS3X:9NV#_]GR6;[RWTC2XNGL>5Y=%M+GY4OFW MLX=T')A`TLFP@UJI?LVJ7KOU8RGQCN(!#PIGG:/UGR`62OC=8EZJ&%1P[4',/JG=0=NLA\#'_*CJC?IILT7%K6$EY<3(:G+H= M0H65))(N2<+M*4DD+4G"Q;Q_%,ZP3Y(@@>/"2!RN5Y(8&QGN%Y(+G,:PH`'D MN0*":PL(;(C8+B6XG5("!R.WG5:P-/<\62%IR0HS]SQ9(6G+"D)Q=LL()F`F ML>*"^[\O+J1MRY2]W):]NSVEB@[4;$H5.B?AI;'.=LBK?8)*J(;R1C(3S#@4 MQLS8+HS;15/:&>@'G\D"^":GRJ$S8JPCM]L#9?S"3]^)A;RY%CJ1AZ'%_FAT.[X+`0\=G,(O;D@W60+!;K M8"`5\&%DZ&)5(@?!6G[E`M2I5;X,%)_?&[2$L884:U@27/F[*EL(O[17/+5W MYGFBK@LNNA\EZNYC%MHEZKJ&]+V7J.N,J-MCT_!)@4^:@.%4O()O/!A5IJ"; M%M)]I7RHI4;"2=C_!PMMF:+H-#5=%@' M>@%E3`1Q-"JG"<'*G4$W-?3() MV8_U'VNI%:AIPEW)EAI"K&Y0#5+B7SVYJK="CY-EFQB4\0&Y9\(KB\0-]^/` MI2/W.C4WM@-4'*I9:U!)G M%M'')OW4%:L;T-WF!G?;9\!,T9.74"6ORK%5!:HP;>W]D/G+7`NS:9JO9=>6 MWB!S+V8882'QJ%;*?3$9G/CMR$A>@'`@[1XWGUKR;XOD&#-8Q"Y@AG%SC("H M/3!Q"A,0BNL]*'1;"L9R7-U4.>T0.R-H4EZNSE?44:9-*Z$F$J2+Y4,Y9Z]( MZD*=PI9X;D:PQ)L-93[/T?4+JA0+RVG=+3*O]%II*]S&Z^#N3:A3O9)M/#P?@\EE+#QM0(_<(X(ZR$:V<,#-(,("*!G"T= M@9R_(0`^TJ,/;;"BQ;;;IB*IQE.+(.=AX70UF.I$ET6+_OA@FW`,62,JV'4@ M20_N6ESQ$R&RD$@1/I#E*+X6<9#>Q/,^?VRNZ]@F@=L\9A%I)=.?+D9T0U*U M*6[?H_#/9X'MK_:RQ19KW9G]MMC)%ENLVSK;<4R*@:;'&^PT`,<[VC*VVVWG M32([+YMWWSP38K%YHK6'A!%38GU,*CA^Y55T$]7BU'7YC$4<]]Z#%\9[QQ** MI9[%,KC];>Y41Y@5K?OH0X:%PC^9:ET];R;M-[>$4QUC.)69P=GO7-2CXAL1 M52YC!SC'I6*#M%#C^%__Y]J]^]?_O9QB"#K:S#]]?D>ER]YCV"L0*2JS.YQL ML\Y'<4PB)Y&9HC']YW>IJ=6,8A+E]:PI(1\8HT0/8.X>33T^I;G/,!4;:&A- M09$L[E%UR5G#W.<`BT':+>I[NHO?E<4RU`36*A)SIJQ4%CHN"7UUC[E><%]? M%K[XS=5]OL!84@KSI@VLF1LN$&V]=OPO_^Q"T1P1\#>UAF%6V8JBTU)2K>^? MYJ2I2/$A]0\[6V='V;Q?/$A@=R'R"]:`(AW9YC!>%2TW(.%ALC?IP?-B5;+6 M7D\SV/8RZ]9HT>0/Q0U)AK=E!0;?B_)55IT M)K=%8EF!"Y8Z2[2\/J-106I41#@!5%WCD'SUE4@%"H.[R[BX2^OS-:>Q=WT< M4P&LDUG;D+2D'9+&@Z!?2"-GVHA-X<$8XX5Y'QK:Q!5".&3)'*ZMG$;%03MB MX"@LC0+,J>86CZ*!B#(F!:(P]V7Y<'R6',"M^HYJ:I'H6]8Q'CR`UEH;$B M5G-RWFTQ)^T,T*=6EQL+[A25359PM*:)22B`&$TDF%+E M*(&A38EATY"*8#BH$E;*-\64MV90@+=]HF1?+JF1A19(%TN%\A2L0K1DX?-# MQQQ>.$]4/!:!EW.AYD;O<',J#,6WI2'X]Q!34.S-#&L;ET%W](FK#LR-Y5B. M@`1Z4WUE]D`)6R"*%5,#1:!F6)LPFB/$-P9'6M,7";N=<\4`LG'#2$%W:+M/ M9F7.X8#Q/)5G8JUK'5_EMMP/6+SAQ,1[6S#7YXH;N1)YS@'1N)G/J_H[*Z;Q2`I?8RZ$?B_6#R[Y8Y4D?V+ZABQ4TEV^P);P)Y/3O&/ MLW1T?`)_C,_2\XL)_#$Y3L=GIXZ[-9FJAK)9SX'V&J0!,LVG?S$9CN$%J2LP M.1NF%Q<7DH7F=^WSOKOJ"#2$=DVQGFT,$W963@SV.X\2!S5`'.O7)Q=<"78= MJB->:3$[7Q(9Z4@;K4+D0L,)0LD[OEY.%'T?2KK#S4-0]JJT!.QEZ6XW%;D0 M[:T/Q2TNO\8@_*62*4U!]0GJ01(S\B?MT@^`WE_L8+)5[#9S-"3]GJ8G-JQ? MPEJ[EJ)FQAI)!)(&#`@G8P*M9L,%L="2)26YL`;3D@D[1=D[(QC[=UBFA0%4'A.O,.,\=7J=%MG7888'UU11XBT]([MH9'Q[`.J9RJU= M>VXX^Y42L+A9T!UL"?O3,`ZY(#`X=S1*1R=G?.>!=IR-1AWA87U52UR;"@3[ MW0Z[PXE3,A*=1WLGS6VX]C:2%R?IR>28=W&:GI^<-Q;5;M_6;H:%OR6O?"'8 M+5KX"=9ON%F[3R^_3KXIL3X=1]]3(O'$&!I,Z!>\+9KKEU;)!(0E!*]LS#/0=%Y5>`JX)>VZTEFV6`)EP_PP. M)@BAZ3_\IW\:&1O+P8O18.+]2(=J_J2\^?#=32GYE]1'C_+HI81`,AH.3B:_ MMO?$K]WU9'$0G0BQ?EXX1'/(;#//+7$43TTA.A:QCCI?%$`-.JO@*GJ ME$X>DAY'?9B`,,Q;?8&F^=QGJK6/C"Q0A-$^LV>>%0M"/!C/V8*(*AW9OD'B M&@G5_=NS6:AYCZT&.6UKA6,I$1H4A",&$1Z/'C1#[FF,!S_RIC7![@BE^.@W M[7.U&CR:53`$$M`?"QXZZ[^$^4Z'.MOIZ44Z/AX>I\JETR1V7V`; M#PG&./8K/@$N?#&!,4IL7X;,2=\5[XE9OL=AW8@O#4)QFVH1KS&*9>;73UU7 M*6F*6RRS<0=+9B"ON,_GLU3"X(@H%AQV%@I;8_U%:>*EA0\/3L_.=3"4_$RG"ZCG7."ISLZ3T_/SW&M+:!:4MRLMDDJXDMQR9"`O*)&"KNC$!!>5BIZ(N3OP!3'EV MEIRB>:EW@69>&!RTGI,A@^S\O.<;@.0%[.(8A!Y0F-+A&7XTV;=-:TN`"+)# MR8U^_1FJL9]Z/J?)-?;[D1%]Z?%^%#X#T:=G#:@C6,^?<)N79*R%5;PJL)A# M6;4;HH=>6:`#]L-Q0.VAL_U+5]\6*"*OI+==E M]M'@7>T(8`&G!KQ2NN.I#)IQ[5EO>`MC6%LZ,2LD,%P(8DVG+.5:M4PRQOR6 M*ZQOA\%Z2ZK'!%,M2$TKJ^\]%Y&VVERVI2%AABAFXU@O_&G($`MY<8%=XIKR MGSCZ+)#Y%"N^R34(N&/FK2[TO#*C<*LE`VJJZ:E-I0`W7*BYL6[,X75.+AF$ M2`/Z7X5,'U$F1'"C'Z+*194+3;]W+$CZ<]R5VV69?8 M1F:J/7*J7'VC*CZ,?.@+_)>*`W$Y_"E7^M!B&2@IJA8ZQX`:6CH&(H\0J@:R M$C]\_&O=T>Z=N@CT5BPI!96X;]QB494_+.#YWG7MCK!(; MYXD-Q6<9LY'X?TU\F&]U-TJ/SX;I>'*R)S91.SRSK6!8LL>&=VA=:Y8.16YC M@GC5N-L#X(PXMUPF6(XL@B+'-"O=I/J)T*:"%DTU=XE]$#Q,JZ'0FC-_HDT.3D'HG5ZL@.W'(>U)-E#5LPS M+0,AA5643M3=A&+@KOG&R?'IPKM/1MO^<&$93Z"%/ND8J,^_O7XOG0=+K$"S MQ$JM;+F/WF5#>`?7-[7X'N]+7WN.DJM\]@#>'NU1KF5^),P5,2VT/F.3#H4K M'9JP5HY-XL_IZ)X#2>DLD:T=]D!= M\;PS(0:7;7N)%!'ME8'<1.EU$ATAZHD=!5R M[=I81\;I"?=YULCJ68B,%(6LRR'3]L/$ZEEL(2).M+;QZ3GHUJBU'9^?I).S$V[F M&%5:EH_$GXI0"!&H(4'CY3R#":ZGV!L):X?.\KD4^/4J*Q?%U5[AY$MWCSEZ MF/+948:1X'=YU(-K4\M!@6@RI19[0F=U;:YY$9\1\;)R_"`KY]?M+Q7HA2_>'/_\7_3Y].D7W.YQR;(=ZU^,5XP0WS M%:SV^#BL=K1SM6=C$NUHM1>M4^E<<_)B[U7;5^-UQY@\3D]'I^F9+&0X:2WD M]X!D^:S]X=G%13H\/9?/:*+7)HSF@>SA5&9/OZ//1NG9\#P]'9[%'T9M@W=. MA#2E134(KAQ298@7:6K,2P3PS@AK^\:&DFGSQ0C^>7QR*LZHL]/T_*+IR$%R M5TD.Y]+'I+L0*_XC)O>.**S@.4Q/Q04.E#J=C"XB8?:!#TL$>C_!]NC=D\8> M"+R;I6&4AC%W2PB!D7O.VR`=?`3-PTV19+R`BW`R`3WKW*>?%*34MG)8LO:I MM^/7QX,3D=^:=BKCIR0+5ROF5>Q#_9:N\T'2&@2C4)D6G'8$$K>*1&""U`H/ M`>MCA;%,A(&8H[J\JM2DFHI+X$NO\CG.;)?T=55N5J8%]N4\_T(AO$N2D+`7 M>NA[[84BEN#;GO?(\Q!=#)(IP3*Q( M']JBMBJ;=6R=84S=W^/X,^\F$QM5X<-[!=>`#HGS"&><5%^`*@A:A=Q`IHHR9_PIQD;Z]'I6?*A6 M;[4@"'`U;P:WA%YR18XE%_#U&?BN.^PB#RVG.*4+Z!((6MK.ZDXD2`HH1V`5 M;'E">^>US'!\D!UBPT.1%4R3Y$LLZ8%*KND!C08:C@I#UAA$;R6*$):JGQ%&)O9ZF*C<$:K^>7Z"B#',ZFX,P;FDF^ M%_RF6I$<@W%3J26/F_;YG6$%7];;@];3"HR4M$L?[X&57OM`Q;;.)RF&I?5U M,6KD'K0S)&U$DY]H[\G!Z'QX:`7^^U;9<;TX'W,0F9=.KPRAN_3<,S9[X@5H M#5YQ##Y^PSR-7"EBM&[<8&QAQ4&9R<'Q\-<>7;V!TK5(C%XH,LT)'R==^70H M)JC(>.2D@Y@&,ONH\:`+F#!$`1K`)D$HN1@^JMG#R#/%@B3)8&W@<'[KB_'Y<7H,'T25`=05P@:2E1H9 M*>YE,AB=(E60ID,E^WC??[KZ^Y=P^5@YD%^0E5$+*^)AQ,*D:+%\D*HE)$AZ M:>/RN5:N#N630TJJW9QWY3N/ ME`T1(]HH)XRW.B5U8+SL[1@D63Q4UNJBS#O!#Q8KW4XTH?,"6=->OU.^?JZ! MT7KI;&\(A)M@&)7GO`L6#M>P<*C@N6=ALD968`>%H*4+1G0MLQ&;H`B1=LFJ M>RU=FGUDZ+2[Q9XT.!UWXR'[%HNB*#J[WB:)2D]:]%WU#3:P^,S61KQT;VRF ML!L=/G4AGET>*1IHW'0_S6WC71J=GE=@L?R9Z"^JTC!HJ6LA9E8-..'+ZF5V MTU4N?")F^XAYZ<*-ZW=B4R0QT[C[#2Z*<". M%Z-3,E58-A/OQ)?.LRWB.P2]#EQ%[#R[2$]/3Q%M[_JMA'YHO43==]O)N"W- M=5ORZ9M]TD:;QQ>2'2=`>,XF$\S"V6,#UL/M690FKN[F;:S.#T_3R632!0OQ M_+74R3]0>8MU2XLTW2VNI`D&3O&ZJLHJZK;1KV=>#!(='2,HN@[^0U4\X$7^ M@%F&&H+7#K5PL?[&G_I/=!);$@-TGAON$X>5[-S)\3B=G`ZW:7DD3'=EIS^6 M;H8IL55MN./!"S3F>?TO+.;RSNI"09?5]K,ZW9;68 MN'8=GJ<#D^/NT0:"DL41KX7??0D@1""O0'MKH)M6U.4&Y)$ MN2'/>GF_F._1<+`C'^6RNBE$O0\FJ['-.S=![G`$KF=3>1.-)&;1GBW6:*=*30C\J^2D\$A=V1SB>8U9S-0.6O! ML[J1]>%]1'2W0P.`F:UB9_)M!=8A"FR=?:8_NO_KI)K+*PYJ^]`@9G>K^L;5-U`;6YG MY`M$7GL3P"LQW31"S@%BD:6T`1)K@LGJOES[CJQ\6Q\?Q\-P6I\X3,U[.0$1 M5XKB!K990OJ4AZ2^M&E@4+J+"MP<:\IA>UK,RLPK<8Y]ORP?C^[+1S91X9SB MGC<)87'5WDN3E2L$LV?[=B4^:1T8-;Y.K#FZ!*P^;]9'.M(;#(QZ;"<:R0AQ M/V#3_DZ85GR0QLR)NGV3+$K])"!@JPV**F+6;'<%&`Z.M5ANTDAY//(ICP-_ M@%CIJ6)F@0430XS5%I`U83#S2;E>5(S7Z?,#L9SOQ)04ZUV@5Q,]LT3P<-=O MJBBI&:*1%M9Y\;'9==>JM4-@5LQ`1,1HRSD6N&4\*VX)`#7VQFB9/_..9$:? M!TM$3+*6G=@4L587@B.E'!,J6>5;*6`.;88DI"J7=UATQ93@<9+X<=_["Y8EMG;?5$0E8PZ#134PW1^V2G'45=SZ5P*[G*XH M-D@9MMK!.MF7`2-QEHSK!-":ZQ^T3-_\@`OO(V MOR$[XR99Z%SU$)GZH'S70#AZ4R95UH(MBZ9%#!VS'2?E"X0VHK+)U8-)O&19 M1.F%;9P>?`%Z,W=*F!DUPH)W,2L,JVV$;3JS345EV69/1>Z6B*?+>*Z(EW*A M28]!S<&-<$J<>K7":A0YE]@+V.G3S&B@HV6V,+H&%\\FR8J%M%"YEXQ/135S MX=TDDY(L6!IID9G6(695V3*?DW0:TA]3H]2@M)LEQ[$-#0'[.M7!A>W`MT(9B M-=U*Z8])=(DS,(@W",/KIA$B;PC1P[:(#/T%(/W:JV:H#DC^+^\KX\9]1;FI MYYCQ&R1.3[!GBC%K)!K[.(91P/&Q!.RI%B89O;X@M'>@'*33"43?CA,0:JI9.3 MX6'J+UNL:9--S829A4N`_T+!E>L%4=?4NBE3T!T17U<71H(4R?VP%2L3QDJ! M%LE[`2F[;G!KUX-@`E'W&M_)>"X0#M&91M.9(W`BI^D9$*@[5-I$44,I)1_@ MS9-DG([/-+Q,,,)86$#:T2X6L*.G/"ZIB@)-OE[/>:/+_*X$&5O,=^^]D'!F MH.EV0Y/VQ`[-L`ST;9,="3!,R_P#FE6;4+=TP&!Y?"*E1E;L8P])2*O'*?M-'!4!F6]WQ5@&S)8G")W6L-E5T4LR.:H5W%!"TH MZFN60C&N!Z%08;.T1%I.A[[SJ)`0''3N6+J/3XAQK5Q&6R<"0#^?.0(HG*W)"3X["P`D[`)0"_E,L@4S?H%/7D/X<3P M2"WF:H=JDF>5LY7V:_.KIM-".W>NO-J3(+7JC6QM6SETZ3^N0Y(`(X6/5D",9``+;O$K8UDO M3,R9T<_D)Y*XO()]/-NPF*ZE,[AL5F>MU`IG5-)8?:XR"N86^P5&S0)Q,4=@ MPA:C0_7!`@\8\`K'QEZX>FW*;'F1H5,>)](4HTV;@)I4@/TF,$X!MB68BJFI MA\W8\W6]!,YD`#,2@ M\$`\,\C6H$8L+&XV51WV.;4&@V2UOON`P>-OI>@4>]S..T(*B""0MPBCC2E($I`0MM(^B(=7@S3 MB^'%KCQM[_9V64B"]>[0%^/!V4GP=U/RK1DQRNBDB%QEZ;$1A34UNCS'9F-D MJ<'HTKRR:05K=)@3JA]A*7-N,![B?DRJ[G@T0NW1WK_.[T=64H4.ZQ(I%?(1#;*`S'=NL_IO:[-IQST M_&)\;LN;P\U9YFOGYT<\MS5@D2]$5?!?C#$AQK>\L[8DKNQ`!=6RO%C M>[^C!QB\B;6%>PO)V8WV]>'I_=A'*<3]-5(JTD!6*2Z<0P88=7YK954O(=8# M]ZY9<-W?L_..>Y8MER4VY&OHP)K*BX6ZN+)J?QUXR;K6#@/"(;5A"#LV[4:C M8NM1]VSIEC:`-CDRC2\=1GHM"XQFU/L=7S\FXI`E3T*)%'H9)&5Y>8 MJ'`(HD=GPT.I^H6%SN&.S<6Z\0<-J2S0:$IA\K:(4W2P?EENU/:2 MF\7P*A<;M"[/)1W&FQ$`A*JSVTC!<(P?JA+U@$'R-]F#SSXB0BW?(5^E+P.8 MQCU@:B*`!9.C4-G),)T,1P2GT>@4N(\'5!(!JLG^7W*DZRTLEQK6A4:4UT%, MO3;]`DWDW8<2F!1JJP?ZUV'O\!@2""_-.JLF=;_%U&`Z96!PH0\JN_ M:>PGE=_0^A]J)F"IO95)&H23Q'^1LX5K/%`A]:\O+S]0SP4J2M.*7#=9P"+P MF&.AUP543IQY$N=GVTJ0]^P&$Z5RM%_[SC%KZ<@W4 MF(I\P>]2"H?;JU*%&UUO,!)N@YW?.:W-T=I*T996C6`>DPE%T9Y?IA3[R4%9 M)(0[CJT1)Y%83VLJ_Q:UP0$244JN%"V=:B-(S$ASP[Q9&SD2UDS>?8#Z/"<_ M+U:%=-T8&P!RS![VQ9S@.;Q!H*(!'`7\8"N@[#D0EZAE_D->`ZDLDTKQG6[N&_I'D,W44 MN[BR!*OWCG.>)@G:'J3.@'1O0"J.LV0J/N4D]BGO+HO0+!Q(*:<`-V-KDN'/$B;V5T([+25+=CTP)$!#$DT*N0A[@A[<=6U M]D\WD0UIW_NA/Q$*RS9U`#_H1"*N-Z4!IOJNBU@;$1FD4^3*5O0B:_1FC?ZW M6IH3SPK4<9S&/V"4$&H_`4)# M:V9F";>L`!&1QX#+P!X]IVTJK1;25+=NBC)TH2!%S312Z6R0BB*?OYR8[:7Q M%(@]57)P]?[5NT/Z1^U#B>+VF$$LI,XPF/778"1;:R>&W:/[!N=)PCQ8172I M^,7ENXIUZT""8.@K1.)@'[67QW/?=UU]Y"DL/L2K27@($;LZ2/T^T#?=2F@3 MR@^B;:N@3+$,07LH3(?Y!^D"&<:,V[<>@'HP:6BE:^!7C6U7*^J,7P65,<%POKDOA[,.(O:F2Z[B+*I)(.8S,;YX@#K;<7]CK+$]\\5 M*F&ZHIB:\GLL,<`O=0G`/YD]-X!7WE:?:[ZRM2TO/D#47-9??>@L#/C8Z#+,T!$H+M4"=8OX=R8ME]93R ML5=$QXD$TY$CC@I+T9)C2*\([-@*U``SU/HP<*4GACBY/;/OV4:(>?'^2@VV\P-O":YMYR,)1&"A4MS0&&YP,?$!9]A(F!3RNIZBE`EXKG M5`"`+'J:!L2E4=V4K,-%EE`3WUO*Y2J635IJ:J_)BMF%8\+2I2M&8FNWA]8\ MW*EW8,N4]2^=%IM+?[:,U!(06F;R>TVQAK12MR([-1K*U>[I05UBY"(>J`1S MXIM$M`@>=QR?9>Z*!!;`(7-N3`OH/?!UO$H3F+"*<$:;4OG5KS7ZBL1L9PZ8 MS."HA_D.6WP>=-5(9$-C";>\$DN?A&GGJ:<&`C2=E0.+9+%UZE@;K5%FDR4'CV^^[V[!Z ML:QR:A!X,_?[%6F6FV#YU"TDA966Q7"FW2=+JMA0T?(J>['>A66RS%U1/RFK MQ$5KKG(UFH@*D]6AM91??IQ9ANIXTING36X37Z#(<"60!TK)]=]*G>ZC?MR. M3'\Q\,T.D)38H^VB-R$WJG.[OB,;RT!R%%2"WO2DI6O7L%_&[)H5'B(LR$J9 M5-=YQ$X$HPY0I^4H>80@.!,"UUGB*R2 MQOJOM/R1IPP:0,AGB/>1Z\SD<(_1!B27#8/JM^TY,7MVK3TW)>8W:$GX/0E= M[X!%@CR)J]OO+7=Y?06X!>M/SL?#I.>E;XCACP`BJXV`6.I5<*U4MHDQ9Y?B M'&3^(Y<&>J%$/Z7B^:8-2VB.KC%&+.=)+@S`6@+\233!FZS.Q458'0=AR!K' MR08K)/XI]Q4UI&QJ6*BN4.\X17CPZE,,5/^>`GS@&L%9532*M+KD7G1P%DN6 M/7!(7'-=;BH8FT5K(Z0$VLVN3S)BHB%K.7W2]4XL3#?+\@:]#^(]I]]-^T;L MJQ$`B/&DH?P65?;%S@1K))`%.JU!!)2]^WJ,S<%,"D4O7*^R^IZJ3`!_S+4P M*MWPT"2LFQ@1W:S)MH^A"I1$!^-@'.`R?]+%(5D/Y$/F)WTJ9/'@^E4UURG)X/A^D)ENW[.)]J+34,$:#,7'R2/>DL4XWJY5B^ ML'[>&4N0O`,:PF[#!"7,`N+)=WLC5XO1P*TF/1&[2KI7^6W.'2JS+TFW_;') MBWT#(;+@.OPPRHK#CA+8H93H'^H;9";D9]IO,#)0!@]9Y_7*OQ06U&[2%A+XOV( M(!7;\]@>!/`BV82YU$LKVGG[!&CV`$M2Q<(Y6KOTBOW;9(#UC@^&K*XD1MIV M'S8C;IM$N@66ZID7WY.5"?8MF77"9;M`1EV#\2T">X8RS*SM\^MN]Y0EWE"( M,G_YJ,8Q[@[<.9]8K"G(4V(5LCH^S";Q-47XL8Z+S_#6XT2Z\J>\*K6^4XN` M?,RI[)-UOUW*`G\NGA]H)7*)1W!V(,03CV[)3:)<* MG!A`"61!0N0JZ@W`GG76%*@/X-2TC0[4TH]*2CT0FK6TX*5PN`7%P=V5*(?0 MS?0Q,(G]KH-_6%ZL=>%J`] MQT,/DM=9-7^RSA>?+8_8C4Y[RC/@W)B1"6(CY'HH)=S`YS5P,@EG>&B35+1( M9KY2>J.P928]CF@Z`;:TI7PHYW!:Y$1UU+A*`@4?/3)))V-RO5?%'>5]Q.,W MX@YK%3QPTV3F5*'&I^E+PA7K!C-?],A1])F?F!"4G,E,9XNJ/S(@9.EIDD;/ MS3PYPL;`V"&$R>VUCN-^^/-_3EY_`;0G`IA5&MJTJ1%CT)N`Y7YQ,MO7>.=L MXU0K!_LXD>2`-&!W/AH>_B:YQ"(M+$>9`IOAY4N`^!/H'S(Y)R[LGG@T3+E& MKY:PL16^<&=O%V1$I)DM`<)/#S6LT"\-$-`\QPO$H03"99D44,[#DU^7,X3T M6DZUAG7,*`"'(8'O$GS"C]SD3&/N-TO?H\Q>(6PX(K><%&7R;P.OP&HI9F,! MI&92JXE'$@CGR3L;(Q12Y+U^80.74-6=LB65*FDTOFY4;J*X?W3&XW^)O!5( MMC`WVC&5)IWF MGE]4ZTPGZZ.YR`ND19B\[FFYX]29)BV7>JS3+HJE+E"IU2&$2B-C+6'6L7]I M&?O\EK%[H2)/S$.P?A[U7Q0,]3UEX>)S/UE^]W)+8Z\64O^EC]C_PWW$MN&0 M;P-U*7U<+DUDY&?M^75E>G[]7JV[VOGH:V[GTY@E^;*8_Z8&82+_ZU^M)`?Z M5[^+;:P<&4O+_TM'L___.IHEVQ#OK0F@_^A+-7%S3,8LC',EMUJ+;_^E45KQ MET9I_R\U2FO7&=8\3WL-CI++D`ML'QR\PM9*\T-XX_/UJ^3@Q2&,_95O0+2D M7"'@ER_P[T_WY:8&X+4D4\#7@2]\U7SXOKK+@(FJ!0:9%1)2OD;O;Y.7HFXE M__`-QM2\1>M0*TW\=:LD]6-/:78I'IW8\N"LZ#;?E!YBS9_;5=?_X1W=QM:B MKGW5[Q:/^MVUQF;9_.JTV4>D/;=-*>;(,NE&VU50&L;E-?2M\-(GO\T_T72\G8B77-6P/6!QW5!1XGY[\0XI8[R:KL,`2_U_>ZE;D.]0+G?>T>4 M9A'\8]*SOGHVB5>OI>.OC=]F31]=1.ZUEY=%^V+K!FSO]9^_B!\_$KST3MJ0_R*#?UX!T.$G2;WY:2#56%CQ9+:9 MV[*\+7X:)'OG;OAD_]2^35:`0#NI9%90[#6[N9%&&X)F(F?;-&@JQ4B]?;DQ M#KGK1,*D5&P;24P_^#2>XO!?_H?`AF.`RAO?N%)+49343\ZD5V91PP$L$R2B M"P?K/^GD3+/]!*C/:K2-3"/M<+4:28$.;:!SWD;*KXEI<\=$.!/[D]G/XDNQ M1.#`.OV&M=K<#M)FR9BP$E@9=>LQ[C-5>/+;U2Z8^;1Y6HU[[@T"\S06IF^$#2\,\\SS>* M1K\0@`"W+Z6/DA$F?JE9O9GO6@-%^B;P;T[[*&LP?W4K1.-NA>AG7SEAM98! MQ7ZLO7LZ'HI!ZV=:TRX._#,-:W=O-(%??E9K!_XWG=CD7OUR\_X8$2>N%_73 M!<"?.MX>2/@+3/%,A/QE5O!,Y/QE%O$\1/UEUF#8QJLBNUN"B`6RQ[_-%#5=X.DE?5(+G^'M3IK.7Y_/RN=_0/>RW8CA`$ MG_T6KU4,R+E,2H*F$W%NXA7F8.R#R9]N[OJO)EI;1K%!$A>,R1M/ MWTC1.[TC_6VVW#E2]$[O2!$D>M^Z7,&JAI.M!MSHG2WSP?&]]2DT6RG"I:_L MAYE/3UK1Y]/+KVUO@PZ/`(9^9]I4,HT=F1U]&D\F+6/G1S]AH!=;3,"??32# M66K6W2*.NK!P>3^J]:BO^^KQMI!9H](B!3_6^:(XDGANGTK+O5(Q7KNM`G.! M4BS[;7.-X"P@!]MBM_9@@-O"IOK>[8Z8:GG<.@.FNHEB;\34SI`V$[C4I8IV MQT_M'-6$3^V[X"T+Z?YD6ZA4%.?T$\2;B.IV.PX[`JOV\T/5TF-=+1);2%?_ M1W>=L36_NPZ!59Z.4(!5RO\A9W9(R6A^/NDV(:@03+$=ZM%4\UZ;?G8/T@HL M,4V!0^3/_A#PX02M^R,O<)?W-F4V<6$F#FVOB_PQ?/K8W(XDWVPWSB2G/181 M&_36+_>96M^^>P3E^TNGZVWH$.UO"^M"GR/UV:,(%(4Z.1R/?ZU6[XYFVHEE M:O^^49G\N$9\7QG,@:;T^O'9D")9.NNMASUIN?4J[JG4&\)(71):88RT]1#* M.$B.>7*?'RVK(">%AMI(GW5*(.1RW'_<@&#.9R$A_9>^JD77")JJ76(3#OMU M;Y?L4%_^`:@F>2T0Z6C`??"8#(:Z^_>Z>XHET6 M]EJRFZ&M?8=BXULOX_C6GWB./U\0:^^Y_0('HU.;:+?4;R71K?B8*G+#I`(] M8YH*)4/[^WJTV(,&V^@@&G[6$Q_K3]Z[[AJ"TI9'#6 M5N(P5K7UXSO`MVWVW"BRM?E0@M"2B4;NCLZI?'R?!-4WB8YSL6.*GNWWFF&F^WSA MXR+[KLI1'X5X+E!W#[A=&=G[^UY1?N\1]CGE9\%G^XGO'*H;`79^M@L?]AA@ M?_2X,D5SOBEN?\1Y=HS0K\LJB3M3$G?:2>&,9?Z:I=>?)1`UD+9N`M=EBMWK MFZ$TM=KU$AU)ZJO,9-+(AS+,/VXA\\'WP'H7PWE9 MKOL5V]'YL/,VX,^Q4L*+>4"06]6H*0DP? M<%[[V(DXR8B,3TP[2*]1,GNML/IYANL,:^T5$IQRI+5*V7ZDM1U-P?-QWBZ\=<:]4M M'R2CA"+>"`DC:`NV]W/U'2-HD1LM,;3OP>U<6"<:;$DS5"C%%:-VXL=6ERS@ M\[>H>!HL%43O5?KPL>1@;*-BNZ9]QI22CO*30L_#<4F[[?:_J@-:>O%O@[I M_%'+$KQ9>[(<#V[S3[W;&MU0"VE-JZI+.]I#)=@]VO'6P)I!_I+,F-/3L8\[Y4SV(L!^R4/]K"PK^IZ_;O_`U!+`0(4`Q0````( M`)V.#4?G?S$WN0$``)T7```3``````````````"``0````!;0V]N=&5N=%]4 M>7!E&UL4$L!`A0#%`````@`G8X-1TAU!>[%````*P(```L````````` M`````(`!Z@$``%]R96QS+RYR96QS4$L!`A0#%`````@`G8X-1PQUTFF.`0`` MJ18``!H``````````````(`!V`(``'AL+U]R96QS+W=O&PO=&AE M;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`)V.#4>=+).<9@(``&X+```-```` M``````````"``1@/``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`G8X-1XXZ MKJB/`P``8`P```\``````````````(`!J1$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`G8X-1TS<($'<`0``:`4``!@``````````````(`! MVQL``'AL+W=OT=``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MG8X-1X)-SJL-!```QQ$``!@``````````````(`!A"0``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`G8X-1R*!K]J=`0``L0,` M`!@``````````````(`!&UL4$L!`A0#%`````@`G8X-1S4=IP&> M`0``L0,``!D``````````````(`!'3```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`G8X-1X-TZ/B@`0``L0,``!D````` M`````````(`!H34``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`G8X-1P"..@Z@`0``L0,``!D``````````````(`!)#L` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MG8X-1^S.23FC`0``L0,``!D``````````````(`!`$$``'AL+W=O&PO=V]R:W-H965T$0(``-T&```9``````````````"``&UL4$L!`A0#%`````@`G8X-1Z"0O/3Y`0`` MX04``!D``````````````(`!$D<``'AL+W=O&PO=V]R:W-H965T?`(``/$(```9``````````````"``?E.``!X;"]W;W)K&UL4$L!`A0#%`````@`G8X-1P+0^7T4`@``3`8``!D````````` M`````(`!K%$``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`G8X-1RC6#$E\`P``S0\``!D``````````````(`!DUD``'AL M+W=O&PO=V]R:W-H965T3XF#@(``&P'```9``````````````"` M`6U?``!X;"]W;W)K&UL4$L!`A0#%`````@`G8X- M1^2*GLG#`P``[1(``!D``````````````(`!LF$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`G8X-1VBN5HT[`@``N0<` M`!D``````````````(`!E6L``'AL+W=O&PO=V]R:W-H965TQP`````` ` end XML 13 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consulting Shares - Additional Information (Detail)
3 Months Ended 6 Months Ended

Jun. 30, 2015

USD ($)

$ / shares

shares

Mar. 31, 2015

USD ($)

$ / shares

shares

Jun. 30, 2015

USD ($)

$ / shares

shares

Mar. 06, 2015

$ / shares

shares

Dec. 31, 2014

$ / shares

shares

Related Party Transaction [Line Items]

Common stock, shares issued | shares 29,429,522 29,429,522 29,279,522

Common stock par value of issued shares | $ / shares $ 0.001 $ 0.001 $ 0.001

Consulting Agreement [Member]

Related Party Transaction [Line Items]

Common stock, shares issued | shares 150,000

Common stock par value of issued shares | $ / shares $ 0.01

Agreement termination notice period 180 days

Termination agreement percentage of shares returned 40.00%

Shares subject to forfeiture | shares 60,000

Estimated fair value of non-cancellable shares, Shares | shares 90,000

Estimated fair value of non-cancellable shares, Value $ 284,400

Estimated fair value cancellable shares, Shares | shares 60,000

Estimated fair value of cancellable shares, Value $ 192,000

Estimated fair value of consulting shares $ 476,400

Percentage of consulting shares recognizable as general and administrative expense 60.00%

Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity 40.00%

Revalued unvested and forfeitable shares, percent 40.00%

Number of unvested and forfeitable shares for revaluation 60,000

Estimated fair value of unvested and forfeitable shares, Value $ 165,000

General and administrative expense recognized in consulting shares 390,733

Consulting Agreement [Member] | Non Cancellable Shares [Member]

Related Party Transaction [Line Items]

Share price | $ / shares $ 3.16

Estimated fair value of consulting shares 284,400

General and administrative expense recognized in consulting shares 284,400

Consulting Agreement [Member] | Cancellable Shares [Member]

Related Party Transaction [Line Items]

Share price | $ / shares $ 3.20

Estimated fair value of consulting shares 192,000

General and administrative expense recognized in consulting shares $ 79,666 $ 106,333

X

- Definition
Agreement termination notice period.
+ References
No definition available.
+ Details

Name: pirs_AgreementTerminationNoticePeriod

Namespace Prefix: pirs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Estimated fair value of cancellable shares, value.
+ References
No definition available.
+ Details

Name: pirs_EstimatedFairValueOfCancellableSharesValue

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Estimated fair value of consulting shares, Net
+ References
No definition available.
+ Details

Name: pirs_EstimatedFairValueOfConsultingSharesNet

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Estimated fair value of non cancellable shares, value.
+ References
No definition available.
+ Details

Name: pirs_EstimatedFairValueOfNonCancellableSharesValue

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair Value Of Unvested Stock Options Assumed
+ References
No definition available.
+ Details

Name: pirs_FairValueOfUnvestedStockOptionsAssumed

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
General and administrative expense recognized in consulting shares.
+ References
No definition available.
+ Details

Name: pirs_GeneralAndAdministrativeExpenseRecognizedInConsultingShares

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number Of Cancellable Shares
+ References
No definition available.
+ Details

Name: pirs_NumberOfCancellableShares

Namespace Prefix: pirs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number Of Non Cancellable Shares.
+ References
No definition available.
+ Details

Name: pirs_NumberOfNonCancellableShares

Namespace Prefix: pirs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number Of Unvested Shares
+ References
No definition available.
+ Details

Name: pirs_NumberOfUnvestedShares

Namespace Prefix: pirs_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of consulting shares recognizable as general and administrative expense.
+ References
No definition available.
+ Details

Name: pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpense

Namespace Prefix: pirs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity.
+ References
No definition available.
+ Details

Name: pirs_PercentageOfConsultingSharesRecognizableAsGeneralAndAdministrativeExpenseOffsettingCreditToEquity

Namespace Prefix: pirs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Revaluation of Unvested and Forfeitable Shares Percent
+ References
No definition available.
+ Details

Name: pirs_RevaluationOfUnvestedAndForfeitableSharesPercent

Namespace Prefix: pirs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares of common stock subject to forfeiture, pursuant to the terms of the agreement.
+ References
No definition available.
+ Details

Name: pirs_SharesSubjectToForfeiture

Namespace Prefix: pirs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The element represents the percentage of shares returned that were previously issued pursuant to agreement.
+ References
No definition available.
+ Details

Name: pirs_TerminationAgreementPercentageOfSharesReturned

Namespace Prefix: pirs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=pirs_NonCancellableSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=pirs_CancellableSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Related Party Transaction - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Patent No. 8,420,051 [Member]

Related Party Transaction [Line Items]

Expected patent expiration year 2029

Consulting Agreement [Member]

Related Party Transaction [Line Items]

Consulting agreement fees paid to Prof. Dr. Skerra $ 5,534 $ 6,858 $ 11,157 $ 13,711

TUM [Member]

Related Party Transaction [Line Items]

Patent expiration year 2027

TUM [Member] | License Agreement [Member]

Related Party Transaction [Line Items]

Contingent accrual liability for research and licensing agreement $ 302,273 $ 370,999 $ 302,273 $ 370,999

X

- Definition
Expected patent expiration year.
+ References
No definition available.
+ Details

Name: pirs_ExpectedPatentExpirationYear

Namespace Prefix: pirs_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Patent expiration year.
+ References
No definition available.
+ Details

Name: pirs_PatentExpirationYear

Namespace Prefix: pirs_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss contingency liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.
+ References
No definition available.
+ Details

Name: us-gaap_ProfessionalAndContractServicesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pirs_PatentOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=pirs_ConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_LicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 16 0001193125-15-290039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-290039-xbrl.zip M4$L#!!0````(`&^"#4?F").G#ZT```^F!0`1`!P`<&ER<]F70&VS$^$X5HXD9Y+]]5N4[42V1?D2^=(S M/OICCK_?]FX][?@YG./GI->[Z$LGSY=7/SVVV_G M>3Z3YY2>\UK33389#S_U:.U7_=PD)73O#6$> MT(2)0%@A0K\2^@GK3US_;[UW]O2:I_\_!O\)G;%`,(+U;LYOSFN$_7OO M-AL7T/OQ*1F_]OS1J'=C1Q6]&U.8_-D,SV+V:-%W9>"!/$R-NP29[#:KG& MS5KM0+XX<&C2YC'0T-#=O`P>FOO;EH8!Z?C9%&7SD&E;`S5ID7%*O#;8ICWF M`\9).BB:OZ1JLM]!%K]C;.Z!*X;.[]`7>38R%[-N;Z.`#R:/S8.&97Y1OC[! MF&R,H)?)T\';N/6#%@<\I?DBVSRET%Q4&\(R,I8,S_L6Z:"9=FAHH+PHGW)' M?VAI&#`IT'V2/+V-^9X4WZK)SQH:EAU:+%5%XYBJI6E0F;RL:N8=BWK74O5\F/T:>B:KLQWWO5)WY*\H%ES,WF68UX MR,WWG\\L0Z$YYYR_%,-YLUV-G\^*]/%I9/8)Q<64JAG/?`K-=P-2:7ACGLUX M8GJ#;%R:E_+&SM5DH[OK2!.FA$:("(+1_V#XWKO;K^$=OK,"`U.JX)^$2NUY MZ@6Z2D$)_.Q1[-$7&",$5_9GK3&T4X]Y7)[UAF:0/B8C8$PDSGHI[/]T>`=C M.5?>'1>AUU)NGX`,98'!+C45(45]__FN3P>>557IF% MT8O)!VEAKD&WF[?&8M9:D.V1I,P2_([`9T$C'(?>F_,F;^?/NR>1WQ4.2@X7_"SU?P'`7,A>1NDU&T.FVS`;_J`9< MF_S6?M=N8%BV@E[4RC?/([H3<"K&(EN#XZ+LE':C`,TQVXV83V&#O]E^=J=P M[TZ)_S`"\'"0,PNY@V\!T3M1`VB^D9GV&*5"_72Q&0&+ M_#4#JKA.7I-O(W,)M$'W,C!)#GWG/][8@,B60@YSS-IUYZI]HG"HE(Z`-QCS M0,2%'O)I/T0ZB@(2\H#Z'G#)LHA[FN3@>^!S4)OLG4%@&713$QPZW%%\-R"A8'(,!5`R*46"?. M*/<"/_05T@$EB&LJD?+\&`FP42(J?!S&;!6MN40CR]9O,RE.>J^3_"J_+6W\ MZR_):+*KF;9WVC$QTI;,O/B!676-A!ZZK5/]Q4CH+6FH0VE)<#G:07XM'CUC9K1 M4Q'M$XDT$PQQSL'JC9D`$X*0F.E`"!;?T1:7X.P7@5?$VQ:PG"Z@0A*F\5X` MK7PLY@(4ON;W":@FG.X'T,HO$RY`]>\43LHYV0NVC:!TAP;EAT*#NA3!A]'8X^;"6#/SQ@^ M9IUX6`4`&@\(^.T\ZB,5"`\!^`$+P:<7H6X-6`)PN+O-=DJ`[FJ=;``H;[5. MJ/XAQ/_V@.ZH3C<`M%V=DA_"/-D"S\[Q:],9X'^0[ACR8R>O[QBM8.*!!@&3 M@V(MV#Z.GW4KBS%QN./G]2`HH%[L`P0KZ5M4`5OV4X^)`@=O2,F]H$!:Y3=9 M=BZ/@T+75*O6X*#:*O^BGQ0/("KL7]$_)R!`1@8DA5_VDSQ_3B2V,-3@)RLP#RLM7Z'9R-:E]P,:VL'-EO5YGN:<5'E MD_KVV%S6X/6]RW7R:G_E_Y;DPZLGV[$>7/ZKL2?A9N@_FSRY-PL'YML' M5!E9Y+!5KT3R?J04)0@''#@LC`*D^[R/8AJ#7`:EJ_O1U*)V1%.63[EKX=,# MP;*WM?@R>?QF\H^CWF3G8*;C,/0%$GX?9)@?!L"XV$,,AR0.1-!7>IYZ8055 MTTDDA4\2"UD%79-^2N=(,USK9^.@.>1^TA&D^^R.'S17Z`\".;.0NPUZ3,!L M.!#DG[/Q_5>3/]I1?T[*V:@;\S3=+\75=Q`ZXT'ZE(QNS"-,8VCRJ^]Q6@R2 MT=]-LJ.X:,.T27QLRLC\KLDNJ!A9,\((K>N]CQ'^NX6161@]IWF%04\JL2\< M*X']`>V_?)QJ?Y;`&"]$2PG_6(=0#%QB(]D(/IPA3BFUIA8#"Y1I#!86X51. M`T0.9W/!/F#G1"[I*Y<*WQ_-I!.:Q:8V$3NGRSJZ@>:N\@=6G(HF`C6-(K"- MJ4VL``(#7P%M@J!`2/LAH>0_M^Q-Q5K@(SAV9\6AGN?_X_A?*Z`MJ/S63&;HY!FV?ED/[CS M.?MH&Z`^H4U.#[#)5RC?&["GR^1D$Q.J6R[?$)?]Y_YU*F(WP1&?XP^E^AT_ MSK2'K8YUDS$DB?28.%B+`_>AG#!#Z#H="7X.]B\'$T^+](^Q&+P8N- M^[8XMI)%SGBY!J>*U';.9M0L10=.:G6=OKVMG.6>5_/MUZSL_!3I:_)R6B0Z M3X&$RO8M)/'RFP>0Y>FSN1P/LD=CS\&^F/+J._#",0EV M+B^Q=OAYS.5LNAB#<([H> M)5V9>+NYM%\QO.GR.?F581#6V&TQN61PU>^@G+JYQG&:AT0PK);-PPT9MM8. MEM1)L2]S%]UQL)<$98TF4R,92Z)H.$RM0DY&UTDZO!SWDZ>T3$;'W*I.TTD) M@1GE=5'4//N-&/E4K">G9&KC;DQ ME4H]-6'D-!"!0NW5$IW6TM%:NOXU3X;F!.P$=U42%HH+M6`HN`AHM(>B\7.: M9V,;O4A&BUEA)[1?G8I6B+KGNB5-^\]_[%1&NP_G,7A\N!:[VB'Y<;Y/;L%% M3`>F.?H%T#U/SZELH*OXF@&^]?9^5I1?LO+O!F8YR.[']ARG4H:SF-@^T/,5 M)A+^AT(O"A"/9!_Y_4`CUH^9#XHKXN&Z(GI*!>.>6A4:>P5C$?_K/'LR>?EZ M/4JJH))=MR?+P>#''9'IW!DA"K:NJ%GP;00XXT=^49C2NJHG8<^[[W!SQH\: M"%@2LU6'(Q+E=L)6K-CI7!?G/PTH`*6F5E=R1'*4E$2MF*3U:3=QW/$I^9;6AE]@0<6-!0 MG\U],HK-?ERUS6U;MUU7U;3,@&J9_B9F;)RD>67UA6DQ&&7%9-?3ZZH4$K.J MBHDRS-M1B/J215X_1/V06A3B$*D^"1!F?AQ[0BHO#M<89Y[B]5R`C0K%?(XY'162>_TA0E;S;?: MM49T'\51[\@=H#BJA<56CLRV+XZ:`PO]KKZ-9@=N'X5#@J+4"XF\#76"C(8L M%'&$6$3ZX/_X/O(C$2,5^%X,_$@E\]84A[DNWED@YF#TMBW_KO2W[Q.V`P"S M>-)U`BY/:)ZR(BT_'/S;!HD&C;,A$,T:IZJ6H!Y9P*&=R-\+(+2EA'Q),FP# MR(GD3MU5][@HJY=`*TDK7176DL\PY6OU4!^`(UHCR2-[]1QH[Z`O,/("R9F0 M?18SL5H;\6;M<3"I#YA6=7*@Z*HE`91VUDJAC(ILKB=82Z:PDZJZ$ MI6-"_Q@E+`V@[9C=O_'ULTNO!!REA,4NUXUYFN2#A\3VR.[SY'%)!+^MX]=3%/7,F"9/R/$R#1?>!(/2SQPIT(CND?H#!F(Y(W M/9.@+84Q!'O0DZWDW!RV,J;3%7:74@C./%F_/>2`E3&=DNBNC)$+9OM1*F,Z MYEWW3 M=3OX&&4Q'7-R6]W(ZK8]1%E,IU+)39[R/*]>]G.PLIBN_3;W`E*E:X;^T/ATRF(ZE=%N6XI[\!/YT#ECAV49 M71+M=(HH%LMIR$[+";`&VV?S MLHSNR@0ZUO5./<XJ8S#VYZ6#X+$=O+ MUN-)"<-LULXN+T6_X;.7)#7>F!VP\@;0UE36=L@\B13]XV&9;D!D`9%^7 MF)/EZZKG3^H=S2T)T32]DZ&1"#AA21Y*BO M8@G5LOYR M+?X^XTO7E!K"V--\P7"2`ZG33M/-^\7\5C7ML"/I[/'Z^4.?GF>#)>T[2ZBJ?OA.Z;:!T4R@0_P`2;F<5A/BB MB%Y/VR(6P:1(QZ:8OA525*'(:;=+```@+&=YIE=Y]6EO5Q#/L\&V3:!=QDN" M\?)2/:)BTXPZ8!VZ_*";*]>M&\K7<]8E3"1-1M>3;Z-T3:C MK`I%S9RQ[5$AS>]5:R45MX\%3]\=%501B5_L19KP86OJ&R*M/2\(4"3[,>(B MIDB+B".*0ZXHM$9:ND/ME3EF*]/H0A%="\V_4WA:!!%AF&'R(\`#]HG>`SS4 MY<=.7UYC4OX0S+,_=%HD-5=2JYW0:956]6N9YBG?VYI"`!EMAFPO0IHVEUN" M;[W@%6U/]B)L7TQI(RB@#9_3H1D&K[\6]AFZJR>3)];5\@=E^CP]-ZQ\KPG\ M;M:XU7U?1)%NWXMMR]Q%#+Y'\UI4\&-D+D*V5(6R8&LNO,M7I`/+N.EH4F[% M;5M`Y>L`P/(QBGWA(4X#"L911!'O<]V7/O&8$'=\$:KW*E)%E?9J-T_O1MG2 M`?HL*VU>/+`'&%;KES:%P1'M7ZB/0/B#2)F5#Y`G9!@%1? M@P<6Q&`U*R%12"F-52"Y\(E%I($O-O79-Y`NE^-!;I+"A&;Z]Z7-Q"WSU-[H M8_?C4>6'.^<23!A-%LZT6JEPGMS91*&MSI'W0&5;+F+CL=ULT@UG=FOR;:^S MO"J'*0&:;Y-R6B5QG6QW<+0-`KA/8R]D"OD*Z`;3@2-@<1^!GPA61L"I`%7* MW4=\#-O9*,1#)U'<(ZJ'9T[!(&M;MVHY7VR%PB6 M-MS<,GG_QJ-BU&9K<4+JME;#U%>.X)8WV?:%"'L0%,XS9N`#H40]W:R%A`;! M"0N>+8*RO=?6_9*VI-W(YQ@]>JT>NDT$E2L?#ZJ=1 MM7O^5#V(711^GA;P376;XR0XI.T>H0U428+N[8/3^YPZ_8(P3+ MNIJ93G)^KN"L87E<.\@I\4"#U7.(ZC->Y]#,$X]WR=+;`XUN6T8J42_KW822=;0O MYEH==U,LET'W2[#P0Y]GCK@J^2TKQQ3\%8 M<2=$_W][?]K<-I(EC,+?*T+_`>&IGL>.(%38EZKNBN!:XQDO>BR[^_9]XPT' M1((2NDB`#8"R-;_^GG,R$TB``$5*I$3*[*FI$DD@EY,GS[X8IN:9JW=WKR;T MW>^OO0&(:>F.XSS()KYZY))>LB_+TZ:(VRIM`QMUO'5X*VUBDYA')CC5AWE> M3M2N:AB&AD4)[HMS;-[4!LRJEM$%(Q,9*)2V!Z5R[8.PM9IMX!(9EKZ6I&^W MSQ;[';]2O3`.I]MDA^]#$FOE;FJC%:^Z]'H:"*@EXVC+@KY[..$U'1%\RY%( MNKSBC;Q7HR@.XO%A>Z_::C6AC\^P*D:GQ^UR(XB]I58WAPVQ]J1SM:IY/6Z/ M=5M5EB/QX#?J>16R5JYAVX@TGFR?JBZ[KFEC`O/_1/%DO_;7#0^V/;?#TWV[ MHE+7UUWS/4ZGX3C_.!U^']]@2:Y/01Y^C)L9Z,&AM]'.\'17,R5Z^-AM5H'V M!S")-)C!J]W)/(JC+,?';@_"1-GNN@&0V'*)V7MVL:D6+Z_'I:KJE70T4U'MYR6\-;U?BO>G@UQ'W]F2:3>!_-@)HFR17`0A8<$N MO^N6:6F>O9[(N'W;L.#JJ,;0P:`7?Z#V^I:E]LV190T!E*;9OP<0NNGJU>SZ M#7:W7F24>TH\!@Z;-\:PM8&I&0`'ISL`ZC+H>ZJO.8XZ&'F`*Z8][+L<(=:T M3#$J1H@U>ZJ7@AE3XBV^<&B[;2<2U=W*>WA.RKESAK)YBZ#'DLF:#()RV8I- MIDS1_0P`ZLV2\9];0ZOHU5;/&NF"B-&W1JKKF'W@',,A<`Y'4]V^9R)V##S7 M)7C\_I^S_+=)=/N?U_EOL`/\1'$]2I;?S<*_O1I]_/!9O7S[_PY_571MD?^F MT!>C[ONW[_[YJ_)_/D=S4`H_A-^43\D\B/_/;TKOXZ?!\)/:__CN7??B$EX; M)[-9L,C"WY3/P__GL_KY4_?#Y>CCI_>_*C%`\S?E'_"">GG1[;_]\,>OBK;X M#E^]'7S\QR7,^)OR;OCY,PQ7_!XG*2`!'^OMA\'PPV?^DOHMO/HSRE6$GPKR M;_)GJ'Z+)OD-_?Y*&8>S6;8(T&)`UP@_+X+)1'RF9__V"F[*7UXI5TDZ"5/\ M7@9,*G^8**!C1-?QWU[ER:)XW8*7^=>S<)K3Z_CX%?[AG..?OUR)+W_))VM& M;!V&HY(2$>PXE/E!Q^F`+&)M\PP2NH05J!1Y,IO/_?RSC\ MSV"^^.T_OG>UWTRMH^!E5()XHH`B$F+@L/2S3C];'9@FPWZ.H)C-[GZE`UD\ M]V$86QV&MH_#*"&U`I(?FQ:Y3DE-@"7G8;HA99+>OY?67"5YGLQE`M;VRJZ^ M?[:IJ\0P3QL0R[L?KUZMW0S-7$7H>[9?>V/]NWS%'+,%A2COM:+#?!8.T""!M@XB8D M#LC!-6PJ`7KP'_W^<#@:M2`G"A1-G&9KDLJ9P;OA")E'.*]1/Q6^$A,UBBF+ M"A!VB!=-[S[7
]YEVAWE,BFKD1HHVEKB0"ZYXB./QCRDFG-%KIFEV M?-??Z.4X^98&B[^]8O]]/,H]QVZ-CN<;^]WMRZ"QFZ%^@-702/W(@^_/2'&W M>F,5+W3+Z]B:=FRWX+';MC2S8]E[WO;+H_L4T;2BHQ\?TMMF1_/V3`P/;]MN MQS;,9T=YP,D-]+DG`&?]XG`%AZPN%>WF.]=N&LY@6ZS?]YQ[5@5/4/QAY)S/ M"7;*J)/ZCL*+7Q\=S7=,NV,[^@]'\RVSXSD;F9%.5/^ETJL3%`^)ZC\EC=_. M7H@^&?79"/QS/7?0:_X11`U>(UR9)JDR*UIH*I^_O#\Z*)'X`!M MRN:SRB./9@5NQ]NWB?D`MXUN-<][]CMQ4CA/"N>10_'E"3PXT17^W4SP:=-7 MQ<4\@B`"WS([EGYT5L4'[E;O:"XRM5WH-S\"33>!,DR2Y=4L?$)R]/!)#Y:J MOS`X'F*&@'<*2C_8H/0])K(CG-U5PI+M MN]CB[#K$1.Q]YG;9MM?U+-U0K1'UF3!\U1M:IMKMCSQ]9)I#<]`[Y78]=6Z7 MN9O<+E$;=-U@ATBQ#R"GJX`A+X:Q1G[_44%T$85IE"D7-P&,,PZ7>30.9EE' M>1N/SRD/+DYRY9K`A\TJ4E%7=YHFE/RV1E+.Z8HUG%)5Y-8":[3D,@J#/[M)AK?P#!1/)XM)Z&R7,#B M8#11`8/[;<;,A`U_)ZQ%`TZ77.5!%,/+XO=.];64UQ:D)4S*ZH)*QA/>\0=X M?2YR@8O7._3*ZTC>SW5R&Z8QO7^-O2^S\V/$0]W;ZUWMRP=-\.5AG=WBS$_W MN!U\W=DL3*^#F%VZ$Z16(/4V5KK+ZV66*X:F^9T*]0DDR@(\/K]1JN"$UU_S MZPSB6+\`=OG=X+/`V#G-:/;R^( MS!+)3*9*,E[.@E291!G61#*12@0BN$$`>S(U*^#%"^(E]-@ MG%,I]I65!F)*!`%G$C3!0!,]PTN6"<#K%YUBS'Q M!:OF\*;QQ>D?)Q\R]D$>NCF!&82)<"$C4$$7JM<[+>N:2!(-HC<])K!57&Z. M)\I5.`Z66=A1K@(\"HXS61Y86^XKC54VQS7A+ MT0/RBX9\V;)PE-%P5V$8B^M!2^]@$85LB40FKU5A`.D3!I"`7(P%-&%6$22/ M$X?W*TL-@@ADXTBY#.(_[Q*`['E'>9=/3F)!HUCP/KA#_-6K:$CIX(!G4=PH M('`0PPAU(%=%A>I1U`0&8&Y`HTF1X3H44J(_8(;93`$ZH43`%^#:+](HS(/T M3NG&I%I%%(:3+1N=8SIN_N_#3Y_?]KOOU.Z[MW]\^%417C5Q:X<,`V"(JE4X M&P?3:3(#FA".;^)DEEP#^TE0RYH@PYS>D0@B"R#!-?`W+)S*.1VL\QJ;`63A M+,3&<,#`X/4J&#H,AM-E2A*^3/0:)0KDDF$*LLF^6@ MFL6T("Y%LDXIJ14$G,M%1)0:)*-V0:@&KA*2$5N>M)CSE6(T-_`>L@GDY!Q8 M-1Y1R&Y([^]*:?!;4M.<`8O^%:(P1J>YQ$?OC1*GY+P4"/)V&BC@H@!#+)>Y,6SH$'G:*WFXN^Y M7MY=+J.2200%WPPPC9^^P(O2W(%'B=^&P)%71(P.E]'%XD!):!*7%PE*H169 MMI2(29SYV=?/=2$\@\X%%TQ)D[M@QF23F,OHA6Q,]B2N/Z`D4_XBE`EV27+R MTTL"1I#".'#!KI.4Y(6`Q#$JWY3]6IISI#=4Y6?CW!%K^ZURJ\K'8!1XT'3/ MK?+)9ED>'K.U.6^30F&`JAP* M%$D:YALPJHH\EX"P!9+5%4IPZ(]@X$#R$2K?2.CB/\$6EC&GW#DC1O*XR7*& M6**4P?9,;UFCYG M+JX>OY9U:0B>7.##S-8#G`7K=1)K8.Y:7/9Z=;JF%K>HTYV*O:MU63"`1$I: MI>%E)F@`?[J4^/W?,N8Y>3II7A+BA9A>%XG4.O`B" MIM(%&R,%`.&GRJ4CA!GY46\C@">BR2:8J@SWI'"$+^`2\'Y`,IKZ/08D6>7@2HM"SJC*VB1D%8$ M^!8PDE3E96%6,VBNBMC1*K.&VPM4$CDJ'F7)M@H&+FR9,%IY!GR%Y\IE.3J\ M+\OIX?%"V("F.VO%%.S2<$3^3A MY+='&*;A]1*`EP!3(B()G(;9@8C!W(#$3@/6K^!96\7>FG$\FE0OOL*N9F'I METX.WULQN%:"%KBJ75D9WJJ-R(/5ZGA`*L!!^K.D9C.(LY56"PV?5PD'.^", M&;5X?`?Q^]KF:BXM"7E*E8<4PS:@MQ&?HV0Z^[7<`P(ETTCMDO>6W0G^U44` M5WZ9GDSX36K2)=`_*MF*B*5M8\AG@G`SS!4.\ZI%G_W69,DG*HL29\6PQZP' M.#>P@[NZ21\-_D^H!M1UEV:Y=8TMGX.F:L&O&:6;C>$5"SX;I=64,UEG1D&Z M!9*P6!SY%RJKD@*]V,JY8W^:P%F69CDQ`O$-(J3-'@0Q]KU^`U*%6CP'[7Z# MBIVSW7.PSF_P%D4PL3%!MA%&`H+KML7^2S$IN`8F]!7LGV`F`,H4^")$0P[A M("8RY\R9L0+Q5OA]00H5,`$QPW&2_N?Q''!:M.HQB(6'H`Q$(>7`*BW*S9Z` M,BB2BV:A0[) M0ZWN1,3S$,*\.5>ZQ<.SN\ZC71<-*ARC$3_;^KG#9/UU/@O94='HIN":Y`:. MBE4W15754%&Z\^]S5)`_PY<<&E7W2>U!K107]^9T@/>%*E&)[MW6#5$8F&1' M1"W"=KU3HG0?M[LE8+S:@*LF*:)QVW@I&A@;,P%NX:5H\%$4_.Y^[X02%BTP M*VX*?DOVXZAXX11['V;YSFITNDP>91.Z%(-PC_V^\4K7[?=B7KK/`N6;G8CM M3@&!YB!*@4:?I)D\$L:M59Z`MAK*@0#H[SS/Q31/#C_&B&!;X` M7_Z+Z;HK"Z-C2I:YX"B,`]V5"ZE3%#X9DBFZ[>6QD$V[)"+\"LE^#O8@MUJL M3EJ9LD9TB&IG%)0L>!_;H0`7DLWH.J:[2O$?)1$J3.MH+:K%#M3E`B(\P.XK MOAE9UNMPR\+KZ%9:H;21) M$@*V)/-H#+0F+ODLUQ%.A*?--%USMTE2$3`1T%#FM2`L69&1%> MN8?YY,XV"G&]SR>'HL5=G7'>[Y,K/3U5KU>C3TY9=9X5('P*I]D)[66T+UU: M`.T9.:Y2)A35(IN***F"\H/$7=4)JJ=WA5W?Q?"(D)4)Z'[@>1+B%M>MP&T, MNP^I530C?8R0,L%21J%=\6'++04%H@BTM:O8`!P^.VB[0!+(.*UH`7 M^4&@%(`D:01&0YY#C+,&V$U`12+Y/<`ZW48I4:*0_UK<^37-"64/KU0X88S7 MS$R*;7K2B/NMJ_))77X1YX@E>9#6HIY->"D;%0:_8HFJF8N7;5 M7_:&B7R@D8]E'TA%NI8Y&Y/&H\D2E6QJ"%M1Z7\VS^UB4WRL0N:'=T&UMU8B M.,6#%=L;&I#'3+6M1!96)#B8SJA/5U[P%B`)E72"X0G=;`/Q8%7W)V6_123H M**O:=`7`*+*4.V$I::NQ'T7$1VN\1V%_OR?BHR(YU&(^2F!L$/718#M'5K,2 M]='9-I"#,ZP'!'((:TY(BB(\!K3.N#_SIX!`L6F:<4J&<%1+U7TY&O@\"Y."P\EF.,^_S>4KC#N>L); MLJ\J/`)M8B"4N%KB=P#W)KMV::%62R,X90QB5@BQK8PBM!D/7N.0=67OJH@U M0-L,V==A%D)_6?,N`%W;&>*(I/71^SESIP*D1^%5ND3A$N/R.[+/JF;%YW,D MA?.\9G@M;/C"=RZ]7])X/(#BQJY2=^W<\*JJ9;F],N:WXJ26%%-YUE+XD(8H MY"]^UG0@'!_DX##.&UH1B=2/M3=1Z$UTQ4OUIX!)82\@LL&N$<$$X"JZ1DI' MPLQ$<)IHLJ[(33+:M&"TC#W%5(@\7'`K7^%+$E@,:ZF@1\$\BR,\J\?;L4,T M2U95"\`CWZE84&$'(DLC4J(2L4]RTA[BR+:-K*A&E)U5$BG;(\K*).?5B++- MHU6J'&TECJ8EIJVZTTVFX1!>'[IV7^#:_4%HU3G(]'CVT]:Q9W+D67D<&\:> M@3A4KD`(;!M'GC7%G57CE]9'GK7$G17^@_LBSYKCSICDP(3&^P+/UH6=G?VT M4>#9/6%G?#.M@6?WA)TQ5)0#G&52N&M->+$SU(6 M&E,*9;%4"@YD\FP9'5A!%/9/<\&\+6K=U8OD%9Z`;CSI)T26PGC<7&!O9W7R M--L:=(=F3[6\KJ-:QG"H]K2!I7;-GN/;GMGK>:,=U,FK8?>:*GD'4:=.UW93 MJ$XZ5$Y,*P>[K_IU6YY%+0IQM7Y2>A7E4HN+!X18[F9%'WG&=7GGC<9`8#0V M1/F2V'&Y=F:^&( M6K_ERGO^8=3_+8;'8AKS_3)&.PM[&XW4Q:MW'`>0(093$&-P[@X9!R83(#>9 M$F49(Y+7`>E&S#H4S+!($1W!+I5&O)=OJDRP`O"-5%V?L M5FLYT`I1PY\3R96A!F.\XV:I;NGDOI!J1Q'Y)FL(EUMP8>^*0BK=:OT8Z:C0 MSE6>%67:$U0[RA\A1JH(2++J<4P99;\HL^!;ITGLJ\^0+EF4$IDB_/=R=E?>`PNO M@686QS.<3KFW?P#LMGH[\+S9\57"?VOG(Y\.Q2,M`(?#"3CPR!>S1*7\#@-)MCPO-`N?"!<"7&%(S+@JG+7-U5E"-,JF" M(^!'^%E@TBAD\;\W+)X%D*'V*P_]`U2,F$PA2'!UVS+I8Q!ZGMO7E:SBW`K6 M+KZ7(F&U/1$CH+ MHCFC)[)C:1+,@VN,)YBNL-4\C:Z6,3F?I$.5Y"L%3:L9X\F\-B[7_3$N"L8. MQQ0`6@I!_$@8?9=0KXG,*%=+V".RD+CP5<7D(P')*N6)A;)PE4=STM8K4B4S M$*'^VP+ILY\D";/QWJZ60$A9T\@)N8MFO(#\'5(J//ZK8$;GD]V$85X+1D@R M9A%DL<0SP%45$54:)F+A+=*BB=&TU0I'A+Q-LAD6!!D!O/MHQ?07#AD#S(17=`Y4>AUR9(P>(!]243NU01985AX=HGA M'UDB;98;ROAVQ37CVVV)!E]1P\JE/%0-ZXA`B0*WZA-)ZB1)(8M%$E&:&IK< M2\P]*T/(:"@U#N:2&8&%;Y/6P528,L"13)51.I%0%;&88<;X)HA(/4U662;@ M0CA[-CUR50+4.](-GT:8'83T.4/,%SXQ],0"M6=5CP&.W`5`)OP@!7$FW4"R M/8?Y&V50PUQ=0J"0KR9,22:YEZ!W;,/O6(RD=S1'ZWB&^X:RM9;`(?@)XY:6 M[#K/0`[(&=5E.BT)YR3^G).Z'<3H-):@9#0EQXNUHGZ,1.L*%*^I8$P)KV6- M79(KY)]#\WEPX',3.BHWX6S"I;(4I)<;.-462PQ1HQ7P&(5[`+3P4(0AK,XC MW`6HG'.JAO2*;`2(.''A)..233.=+:1-SD"PI0'#D#D0BKPP0*%I@8).@$!C/#9B0WF?\1.J-L0=(K@+6$ZS)ECR MZUZSX)I-UPB4#;B.>7F5^$7B`.5*0<--:B)2*X!Y-EI;W[HN]D[Z7F7/H,=@ MY"AM6\(68K>D4`B$(:QH,.\5F"R8(<,V2G8@,4ZZJRY;1X'+DIDPJ3>,&!I0)3U2?D9*ZC#`@?F<*_I?HXH2E4DXY([.^3A M?$SPO).`RD(!5Y&Q&*]^PJ+009+!&2=49EFVY9[]Q*$D[;^@#FQ*U`6PX#GH M&P`4=D<%D6:V<;2?9GDAR7`%J3@A?$XZNG.&G](RO'(9K4H^O%]SPG*4YB2$ M].9@`MH3(V%,Q:>SY6G4H!OQC#H4^R9+-/[%3,U+4K+K2JQG'DU4G*ZT>K$( M$:;N+42X9UEYH04UT7`A4U,R/\+XT^`6&<>4U'&"4#E_59VM'B5#5C*$-\"" MT[WJ;U[G/M@2AYFP+@5C@`R#!KD[Q=WF1HP[QJ/X#6F6L_DE(?&V!*^T.W$99G(8EMTT!@,$`I!J""**WX878YX M*U`'56J18XLITBBT\EKC"Z"3?"SYG#(V*^L[@$%)$_J![/3DQ61&1F`UZ^X( M7?U"(FY=K.P-73D@-#GB%<1@,6`QA<;>1G3B M).HG&8:EQV5M;R:N-6J01"SKZ+=*X;/E?(Y.%XXQ]T]1\5`STUV!0A@FN^IJ M*Z0G<D65>LEDJ,@RV1LR0#$P_'2(,ZX5,Y/*N6"=QI&\ZMEFI$/3>`7J3RK M#7`;(I>V"4"J!B\-PJN]=O/T!EVM!P^K@Z$]5*W!P%5[O8&I]DS7Z@\M71L: M_JF;YU-'2=F["9)"Y#EU\GQX7;S/O3^4=TGPX-BL%PRC+FOR5%5"S::0,3+Z M7J%9X7,9KJ'VPCR,`&^7(!2I?X28L@MJ"D@]ROSJOZJE[^`45EO><2$P`@V- MR0'_,_V'T@OB/SO*",CXGRAY58>!!VK#L"@8KG,7.9^%;1Z-96$JJH>TN9>D M=(:(_$RRWPP-*8!#LF4'F&!K:(!)X55%.8W2(2N;EO1S8S5W\_7/^KE9^.'? MB+PB$(FBA3S654+Z&`8G81`(:KDBE%W7SFWS+^?*%REGM>Q[U]*1C`S^9:W! MPBM8J)Q2P\,SD2@I3'_SX$_4<.:1RJ-1RJI8P"+)&^:T6K)UO0W9$.*U\HMD MO@0Z7K2#73WM5;\L-_7!)QB10,#K:Y?SU8+RY("\QOFJ@"R\CB&OI(1"XZA]LD5W!\1\HVQ314LZ6BV,$#JYWH1BEW[!6&SK[;\BU).<W3(8G3"0Y5A<9A)L=<.:+"LLV*P MB-!Z>,T*57XGI05S(M862SA3&%&[G_#-E&KXV%"+:N60F4:[[\/ M#YJZ@>?:T4ROXWHVO^_UQ7$+'G,XU,.+*LBB>QW'\W!(T^B`&,GRT6DG!.`: MG?>E\^$V$2[;X]V;`GD#@GH/30H7 M#&V[WX)TH. M'-6W>IKJ#GM:K^OT76MDMTG41R!-["]O<1I$*:]S1;$:I(>QUM6$3F7.MEQ; MIS<+QG^J@`L)1AW/DTDX8[=A6MB9F9XR";-Q&ET5_0J^A6BU"B=J@"46KD,* M9.*H@6WP)CSZBWMJN!0@UG=6%A,355D?DE;##<&_'H9<:3Q_]YDU#7E^;'73 M=4J%<4SBS8;*)W_?@??O52>ODCQ/YL6<=OLKN_K^V::NZKYYVA2@?C]>O5J[ MF6IZ[R;;K[VQU;N(T8!($51QY2"R@)EDI0'(DU2G3VD40]8Y5[>N'\WE]'W M)]C+"\`3OF).`04G*>F_HB_0?CV+)J^V/(7FQ-5G0Z%CW.@&^+4)@P-F<`U; M2(`;_$>_/QR.1BTH)Q)LZG+&U@R5BP+OAB,4'<)YC?>I$64`CT-(PI9085X MU62^1ZKX`,K#/Y)7D]YWSK6-7HR3;VFP^-LK]E]Z]2_[7NTA[V]7N'TXF#R( MT.\)HOU=!%KUT2&R]L(1>5_[^Q&(]%`4LKI-4-_%!)*CPV_7/'=?-(*[UKE^ MT!A^./C\#V[?481])XVR/]4IVF8*^_-12B/ZN6N^:"2'#1XVDA\%&4=OU-'A M-CXWQ8J:'%(U2V=QS/:Y64ZEEG_:YU[Y@4HLTCIP2#'\0[#JZ4#RPP/QGIB4 M55_1;MU`S,4T":-?!\F80B(_WRW"G3F'S)&KZ6Y74UU_I*F6T?75[M!TU)'9 M\P8#7^N:O0%S#N&H?_VEOI!R>4,J4?XIO(XR]%+F'S!@JP.%B@ MKUK=K@/+U`S5&VF6XYGPE.O`,O57OU^\'7YZ>ZE<_%?WTWO`KR]4S..RH[S] MT#]GRV]::+F-SRD%QE[>S:^2V5.O7\/U?[IDZZRLI.II!)R*LH_3"]:#@B%0 M/+DL.Z)TBW*'%\DLPL"^W?L51[K1'_2&ONJ;NJE:`]=5>W9WJ';UGCWPNO#8 ML'N*U'OJ2#UC-Y%ZA&'H]I1QC!589J'.9Y3(*Z&<4N*<(I!NW5).L7[MCN?" M4XQ!XW)P.86"2#"7RIHN.,S/>%7C+*=0(ZKI'0;(]H;I,NHIRSA8 M3B)>6WTM"L+;)1(2E6+E92Y`X)H'XW!)M;XRY6T\/F<)2ABR<9-@$9SD&^NX M4D1K1J*5`[L:[*JLE!*6+AJ+V6+%#*[#F)JNW5%\W2(O+]J7F+9"522R:N3G ME_/+<^6/;O>B$O]YQDI=DRT@FDOW+8JI:2/+)N[.9A4*0(^/BS@\7EJ%MWS! M_`&6AIRQFB5781@K(6;`%P7;<]YN34+6$&<(4)3ZU9U"H,7H;C95H4+`;5%)S=D[L2:Y"?Z=,$LJ!XQM0J'6>*!=7WSC;M%P+K%PYA>7`"J%G&P(I5C95GI1[2Y9=UJB<#JX%8]<6LNS62B4[1":K8>0%N,]^D@&^,9`%42B;8E/5 MHUK-H_L#U,[J6:/"TTV94'A[Q=8C(D4L5[;L?%E66Z*(T'F`?>C*%AE;G9BM M%/W11;F#(^X)NU\AZ`O+U!81DG5%X,B`M3?QIT$8WX[DK.6HG%ME233IM;Y0E MXEF:(UY'N6EA(VVAW@5%!':F2&5@)!&2V#3R>JJ`):@.E1]8YEAX)N,5W"81 MEB,X^ZFHX8;E$3&1LX15E2*6`*N"BVU?`.Q$"U9IP65(T%(^B29=)V*P`JQU MG)ES3*J3C-8`%&$Q(>2:-TGA58S.?BJZ]/'F;'+2I+XFU6ZT8ADPL[ZVQ[>DD\(C1*\1A.O=UBV#8JR M:D?ZF,I]83@!U1"0R]WP.T?:S=E/DI#!4O[SHAHN^Z&8`P5WF(8OAK5,87LB M&J&P%HV"J!2-ZH-J'_=:?S4L44!E)C*J6'O&TL&4,&(OZ[676=/;*@6"NT^* M.8H[U`OTAM=3#F4(46WRU\;*>#?XGMQPK\CN$16,J+\I%?4(YZ^S-W*996KG MJ10M>+E`P7\4]3C/>,O*K98N+1S>?WVU%HBLK4XFNFU1JF665T9G8LGK\7V' M@9TVDYA<,:S<*"N=53&$5%J^4EM@GHC)>U_"V8E4OK(%SOE]-+Q$\EHG8Z:2 MCR/6,W3<(=U1-)OJ,/1)238DH8X0!Q&?BZIS4(^I!>LM&<5"WC53`G79ZT=& M%_QEAHR2;O04()ES*$;Q;P:K#XQ2UW5"YN/7D7355EN1 MP:"O(_D122:3R18[7GA4?E9"^?+!\Z*2;^U][$Q^M\"=D$F:]Y2C9&[JA$9% M@KEQE[<%Q*VD$6E!"G4,GE++/7B@QMJDAEY\`ZQVT9G470.K&N4AJJ524=U!H4:?R(CE79ZA4`BM_197.YUV6!.("GM@ MN#7!2S=9D?.JC$0,@V=&]M`X#:=P09!7B./G9A?\76J/Q[HO\FZ=Y`T3+4*Y M064693>RI"33GO?E4IF!B!H3L]J^A4VZLO*TZ,#)K:Z`E:*[A;P)NMMETW/$ M6@S2P4@RE>H/,C/]:C=T)`"E!`32:T)EZNZ1M6\J'=+/J+US_2"D?2#5E0^Z MB31+@G[SMLO>/22W\V-))ZS>:MD>E6@3OZ2-!]%AAB>BP2BQ,5FHL;UJ2=]3 M+),,!)AI>7?5M5::=-(0?+<5_9WUT2`[7GT00/M8O-Q8#E[PDNPW7GJE)*&B MX#,[4219_&(`FH*X&`LZEV"_BW5[EW=>X6U\[T=)NO9K"ABAM^COI`N]!U$4 M%$(R@)X,`"L&@,L^D!9`6<4SM&K4:%0%)#Q%",O2$&%@,MR\W`PO`+J.LI[]Q...V*4N`YJDS0)E M2Y%-@EK':`%L.D'O_O\6)3&B>+',>?$+]%RP-V<#% M]/\MJ^-RE:E80-FR&E:):1B%*D@+$-Y#]`_?!M&,]2TC;V49A\%MK^724*XM M87:<5&L]RT7 M-Q-%?PKK+[?#\*Y><&C\+G"K`$H\K?A].K#J@1G*$I/P\'+RXV*G(YV:."XA M%/)"PNPP.]C!YT^J1HWEI&?P%X[#'`^DC8$L$:8QLW[@H'B`6;),QV1T)"%" M,I24.A`GEDC1,+(C'M^=#J]V>*9\VY9Q1$(4#*5@',S+S*4U MZNL8H>R.U=91>\%XB(Y`!=Y0_FYEN#.Y"]CIQMUW:/T@NU'0V@B^LM,_5C8F'JOPDC8)2$.[\1)H998:B#\*,B-4.%@I(&5\4>D?5%, M#W8F94.D5)@PR[AY()/H.^?`33P?F[12'T.*Q,-!Z`%12JO"$*30*J8=K&]3 M3[MJC.(YH^)6EBA.EZ9W9;%!HB0_NU['TDS6+UZQ.IZF=6S7)*_B=$TL4MN$ M/-!+[B_?P7,E)E85%Z2V-96C/]V*2L1,HUN:J7]RP"R,PL+BR?9! M@\B;(0OJ=UYBK[BN_,U'7 MZC:THI8K18LBGL.KE9ZS04[-*E@V'+I5*"J-_2:T\DI$W)F4^-#(P<+O$6LB MU+9$UEC@)HQ2V6^)*R.EF44EEQ$^LR03Q(U63XV[2:M.6;0Q9K1FYQN#1T@: M:.#,F(864"@N:]"'KA<<@07X%'&ZZ`M=+)BW&WY&OW/R MH?!!*DS[ASKG,^B/RED`Q"! MM\KEJE`3#F%%>K.:QU'K,"E>"4D3N,+=&\DT$GL`\RW'SG-R( M1;UN>&7F(*OC>%VL*;:,'_G5$#2%UW*'(?XW3!/$YO'1&L/VRWX_A0B92A)M MFL3P-PM8.K'DQJRA]\&=5'1_U+WLB:YAW,6J+P*/<6:>"@F44$Y"/GUBSL/Y31[4Y-L]2KA-4 MFHF+I;=DK<-&46)WW#7`+SQ.1TQIBNV.,Q$O*`4LP;N%.:A8%N.=&6.=\#Y9 M7F<\CD3DZ3'JB6QX944,*C&@DH`?PD>[TVAE!TE[R-Z MMJKIG097I4P&N>YW*8".@"Y^-G]3AM^!J)#4$?"L@B_Q,L.;B'&RF4P=FSR= M@F#B4GAK")`PXHF4Q20]4>8G,Z)<)C1Q4H3!UPRAPLJZ:"WGRN7R*B<7K6'8 M*C:GKN].4<]^6K.EMSA,1XKV9,T3A2\I8RE;(=TK;LRYZXAG`!!8 M&&EDHF4H$5X6MU,EO0BXZ@M;4'?>9&7<1+!$-'O1JX%3*@)3E%5HXXGLR&1G M%%ZEV],=XSZZ4RF1H;RFR`J8T-.U-[\JW8)$"+VD^G@7V-5=%K50'Z0YS-Z/ M"UFA.E6:8_"VP#GS*^34V!RC-\EH@R&K(9EO&;^LU$JHBGNS\!IY*-ZR*"R" MVLG[-:>,<@RMB$'FNHD6@-?BV](W!@(@FB>X4Y11BHQ7/>`1#&@@'>>4!/F: M"A_E6(&"S`=D0N5MF&@$"B>M/$+-<.1'>`?M-+\.KD/U*AC_B=88-N5=C4Z] MV>JBG_U4O[AKA3*)*M1H`HKGTKBMHW84/II;)P((AQ8R<"("&\L>V(][&P*@ M4S^92NL\3#TD&TR?M:DMC'5OV85CNFZ3MH7#O3GG;J"6BZQKR.L8*^7V-J;J M4"?DNV+9*)^7BO8E/^T,%C4IV=UK?+I*KT3EJ*'%!1L5*2^(SU'N10I,(Z63JRY.HU>)?'+*P< M*%J^^CYV?8ZI.!Y=:^KZB]%7^%]!VJAKMV@_W*%FPV=%>IET.G6Z2OM>V1\0 M5FQ/3&$YU/2-+B#A1?$3MP!?W17R(=/?BF)76/RJ0\HSJN*4#1Z&."WO@SV6 M"1X#>:&[5`MER$I\%*\L=T,B"*.LRCM;23LHX*TGFYM).]S9O"-"]WU_A&[Q M?3LZ]_U)^ST=`>W?2PNL>T/HI:A_$8D]KI(==BTEW%>/V)-3KFDDY_XY"=^07[BQUQ4H[P5 M)Y?LT;ED5QE7&[NYOPLNP@-8+.U=+G_>Y8;*/76^]?L#TW&LOFH;74.UC)&K M=CW34K61WQLZHY[?MXU3Y]MZBE.]WG!CR&6&IRAZXA;V9I:_.0M$X<"RAB:K MK2B:_8VH-;4^YH\5N_^_,#]WM^ M?%M]NI9;SJ&WW#J.WH_F>F+"ZRE?8\.I\/CZ]!IV1SN^2_1@>N%MU$G]D+;Z MV`-NN>\'?\6?5X+8[-*'7&)]VFM_S]D\8(15K"DM&"@([6NI3W:13B`[@>S' MDD?&Z(&8S9CK*OR^P(#G$Y4Z7;D3R(X/9"]#I-K**/,>BV.L6&3LXU.O.K9E M_5@6&?W8MOKR+3(_D-QSK'88U^@8YM$9)QYNA_&/;:M/1R7,EVNW/1EU?FA! M=O\@VXP@G2#U`I'KYQ%R3U_#[.-HY([U MY&(H)6UB2U=>6D'0CJ,D'7K'U;R.H[G'=*-.Q.-$/)Y;LEBOHO`4$];GZ\6H M*"?(X_T*&>O8TOJ`Z%R%?C^6GTXR#(0VR/^7?J7O/@%/]).(X`V!DE M"]?R_0=>US8MK:=Z?=]7K=ZHJ_8\VU$'AF&,O)YCV5T8#$=9QA&;.\H2R]#= MKU\N!U\78?J5I5N^^EUW'<_W)'@_+7S8X4S"Z-@BO+I=1^T.-4/U1IKE>"8\Y3I?]:_6J]\O`>38L>]344F65P7X MZR\MBZRBUU"4H"AJ2'R"YS!1,8J7,-S'!2\NGNT",]Y^&*WL5>]Y[FC0MU3? M^[MMZS1L8(7FNISK)% M<8R5&D6MI3$V+DZA:]I?-BQ'(:LQXG6IM,4LG):VY2O\@_`1&)LU#IB@[RK$,'JR>;@3"D M?(F!*J=9E'-I:FC]AC6OWO./H_YO\1A[9+PN1>#^;Y^_O"\_#GY[4P/-$]>. M^X@U=F=WI3AHH:JIF=6B4E06@&J`8;DSK)=5@.D,"TTCH,BY5@/5E_>BT39V M"%T"F*$,N,-3=-D>JYTTSA4+O\,0:3J*/T; MUNHPF2J]*)DEUZQF\$TXQ[JT5)J(]@,0P!I$<^R$TF7MH2-1F[<[1)CFB"$T M`FLWB,W$>=$TT%VHF&6'6F_7-W+,RJVD(0AP MU$V2-^.X#K"IQS*>8!7%9#:N6.9/(8X MM"#L(4_%R<61GMF[(+P8ITK2\92BE@.K6'!'=XBH"CEAB<%HWU+TMD$"#E6 M`1S/EAF659MQXL2&P.#:_2K"7E$-1]8@)&,E+J<1W+)KNMQ8SIY5*B,:.0^H)#55W\/& M.^(,,JR"S>*G^"8F93EN-@\=\=E/!X+%F>Q*RJ.N"RJ,F/*5S((L%[=9E$AERVSC.V.@&.4\B%B=4\+Z`,9#@.9Q,99Z":A'GRVBSQ3Y*&I[$,];=K M7O&1`Q@&>$W,8%)T:\9&`:Q2:9B]V;+XH[PGJG=9J\EXCPUUG;*X6G5N#[JB M;SRRD*&W?2%#\_FJ"9ZFWLO4#ZJA6,/F%@?K@SV,C_)V%?7NG*9Z=UL2A@TN ML]QCVV< M8I-0IL^\&31J)Z4)@+56R'E7`*:./):5/%5@CVYV/-/9Z-T#">UYS&;=CF[] M,#DE;L?SCRIHZQ&;-:V.X>X9C3<@;EK5\=8"GB<`8YTD\IX;<;L?'IA,3UJ3&D8N/?%(%5&G8+PZ]P7=+6 MF\,C#I3-GJ3%E[K9D[1XDA;7$G\3B/\D65[-PJ=B-P^?\3#Y]0F")PB>(+@O MJ?')@FO7^?:#\3C%P+&?3K5#0.LEBFV3*(*3:3!4:NAPX,QL-V,PQ^PI"G-+P.J#$Q:WF? M401:##LCZW\49QT6A)3FT7@Y"S"PL2&*NGB:!3_#`U?)A"+@1,0A+'619+RM M<.5:2]&#(M*K`2)$B6(@#K,(;C=KU(PAJ%?+G$+"KL(R@JH((2M",A?45QK& M4BH.9(I\.RO"OPCJO"'W-$WFO#OVA#7=IC=IQ2(@?^%'''36"I8-;93Z4ZSH*%(R*P[:'CXW+(:4B1DS#&S[K>T6V7 MD7E0CEU=+TXQB[YS""KD>6])?.>W<)7PGRLCT:%;.HVU8\$X@HE4SG1UJZW[ MA"%6=ZK\;'=LTV+;=#J>[=66NLK+5U)LM\B):NN`O5$67'<&0]!?'Z?U/#?, M@,MVGWKE=3VW;VE=U33[(]6R>EW5LX>^.NKK5M^P>X[KFZ?&V+4L;68X4JGZ+M'0**)," ME9T`PQ_G24K!TB%'*4:,.>93+'-:X$YQH]D]Q`?+NXUCK+F1'4HYP9VE6-U8 MR#%%V.>I=_>\J!GA^Q_*.KN3=8[=MVG;'W7*3]K%G$\KU_ZH M4'P90LU6X5_,PI4L9*L6@>*H`K\,Q^MHYM'UCWO@;BW/[ICNPRG^CT#=GRZ2 M8">3'BQ]?V%PO"!V.JHA7,LH[R-AZ?*\'U M-3J><^!(4L$8\H@SA\28U0C%FE3*Z^A-Z3$N'^_`#_!+2_$95$W@=WA@G,SG M6*P;^);TP+GLQ=L4C`T%<:_N+_AZ52_X.BRJHK`SWMGIZ%BNM>\YZJ"KC51K M!/_J>?V^"E_W1B.C:SN6P6MQZMH_:Z5K=[&3'54,+HK<=K-L.6?E<45SAD&$ M\0OQY).H4O/(0ISF:D73GNY;`\=53=_IJ9;O6*IG&D/5Z5E=S[:SS^[]ZE/SK:MG&VS2D&7%^]Q:R3< MJT!XQG(6AV:N6N^?Z-:8YY-;I)[MN8->\S$ZPM;;106B-87Y'8L9U#3-#LCO M/X@9U#2-CN<;^]WMRZ"QFZ%^L)Q$.:ML'GQ_1HK[6#^PY75L;<^1`(>W;4LS M.Y9]"H#8$OD_4O9474<_/J2WS8[F[9D8'MZVW8YM[+DLP`MTCKTHI_T)BJ?0 MA\U(/8MXJ)/ZCD+99\\0UOE8XN>8=L=VCB[`\]$TWS([GG,*>/NAZ=4)BH=$ M]9^2QF]G+T2?C/IL!/ZYGCOH-?\(H@:FCJ2W(>7FHM^>5>8HJNH=DY3!:\7\ M:%*&:;@=WW2?74Y0D++#HZU`?QVMTS!AS>IAWLSG<<:'_( M'*!-V7Q6>>31K,#M>/LV,1_@MM&MMN_$LI/">=BJT@F*/ZK"N54^5:,CZ:JX MF$<01.!;9L?2C\ZJ^-"T\8[F(E-[N'[S(U#R%Y8%=(+C/JCY=B5N]Q6*[IU" MT0\V%%W7M+]L&'PNLW0IM%L0\%DXS3[+N6G+U6DK(;FG MC!W7T%W/-ARU;WN>:HVZINJY_9YJF4/<==^#8#\K8.366WNKJGAI+/_S[ MT]1/.O71=[YMS<4X-98^-9:^%^2GQM+WO'MJ3GQJ+'TZN_W<_%-CZ?U87DZM M`C?8[*E5X`O=[*E5X.8FT9?7F/8$OQ/\3O`[7OB=&DN?I,4#W.Q)6GRAFSU) MB]L3_Y?4DO8$P1,$3Q`\=@@^HH;Q9B$*.ZJ-^Y&5._U[F,&4'Y98%>WCE![- M=E'M]>V'T4I,Q,#KVJ:E]52OCU5,>Z.NVO-L1QT8AC'R>HYE=V&XKX94[Y4Z M-F:O?C==V]3]'1327;/M/=;4_11E?X[2,'Q++8FS?%GX2)@J6&B\RAV0$>MD34[19V; M8H*F41S$5/<[R^$+T3P]BC'>.DDG\"/OPOSE_/)<^:/;O>`MV+$L>1`'#*&* M!NP%$+#)ZK^6D^NBQ[P2E#@%*PIR)6!]G7%UL-XDQ?6()O=4QA?>"/G+LS)F MK-/V!GQ'1<\7>390[/$=HO9S@4;`H;@",04IAK=L?:9)>PXAR(-[HN`58%%]N^`-@F MC9:KU[!Z1?\1HJH23KJW80K+J!#/C\L#:+;,PT?47"_) MW.J][OJ]@:=U-H/7MHJ%;?\OM.5W=-V_YJ?M7M!EYB^*:CVXY3 M[OIA.V/0F831KX-DO$2@L]KL0WCB4?2]ME=SY`)IAKVZ_DB#O79]M3LT'75D M]KS!P->Z9@_&`+;Y.PZB:HYJ:G_]I75=U4,5>_VX"/&NQ]>7(<>?/0D!0\T< MV7X?Z/"@/U`M>P!_&5U3M31K`"QJ:'@]1I'+@^-+>O6[Q)Y:UWU?YX91DG9G M<*UB:J/&?[](D^LTF&<70-/&=SL[N5'?''C]T1!XCHVAGXZF]OH]3QU87L\? M&L""G(?U]MXU]RG[5W!.SNC2I^0NF"&Y?%YNU&7T/0(VLA#L*`RP\^,UR!2, M=2`O@`=FRXG7O`-=92UC3)"#&(ET>/;34A%YW`&I,$%:.#=;'F%Q(`\ MZL2.<@6&_!,Y%R@@-S!9BN!2$L8L0/J,D!.6[!,Q%=<+V`><0OQ0S'$.G!>F MX8O!K8H](2F/B9EE&>T87A4K?1V\*342/E$634+.O*.,M>:(@3G!#F$DXL5A MQ%[6:R_#X%%^5V4P<,FF&'Z.C!Q[J8]O(K@XG,D5J^\H"8QGK(QW@^^)1>-7 M+&"8?8`!)N$,`(HVZ`@XZNOL#=;@#SB'Q,<"!6OJ1]-H+%@E_Q'9*G)&&&3[ MI4L+A_=?7ZT%(HM_SM#3$`([AI$609971F<,]_7XOL-(PR!+8HI7IE$1F7B# M^CI(\"$>RL'06`'*-<_H`+E`$I02^3E'<7C_/B2?!M3%'A`:KU%&(V7C"`$( M4$9XI.'U$A:7I'<=N;,+B2N$.(CX7`B;+P$45W"BL&0ZG3PAX:<$==D50487 M_&6&;67H1D\!DCF'8A3?PD.T8RXI3NJGUS0D+8]?"XX3<[DUSZ8'[K:NBUU/$^#^J,Q"\+_4&>AU)6-W:(ZA\1&H6)%,(J5U0 M^:R$75+;H**_;^U]H)KYW0)W`M>0X\-$62[HCN)G@/\X3/,`C@.P>PPG@%M) M(Q*E$=1DASX!JA#2(P\*";HP3L45(6ZS35,D3'6Q,D3Y3^D MUR'^7S9J`[BX( MV]B%IB>)&A-<<*&PD)(X]Q@QT* M\L7!)V:>1BD<#%]RIES/DBL^%PR9$BN-E^4W$H,I=,'GN;$@G)8***E\J=SE MNK$%ER3A1-,ZT6/'.$'\GJQ(+U7R*(9!\,`[<1*GX11P$2F@@#17D_'WM.B? M1FPW1:Z(V`:O\VLW79#,@! MT(5[),@;(BW('?A]189>.PAI'TC@Y(-NHH*2^-J\[50(Z$P:Y<="78ZHXQ%- M`*,0&>#WH?$@.LQ00.0.Y1#&X8OWTU)_DD@I3#='6L?4A+OJ6B701S$-P7=+ M)EDA(><1S8EVE_H@@/:Q>+EN1R+6*\AV]AO<_PC0LZ1642:?*%('?C$`34$( MB@5)2<;C9;IN[_+.*VR$[WT#D\J#5-#2MM"%+4YPFZ-9]3P/"0 MF1,J2RE7V&?U$,HFL]Q4;3:U-57-&A_3ZP#N M%DFR_<(4B_;Y>'*!+"/.>9O+D;!77A;FRD%AJ=Q]VJL_M'N6-W3401\V:PT, M3>TZNJM:EFF9/<,:N,-6>_LI^WH/V==DM-'/:P:<-B\JC=@Z3#])%U@L+@2& M1]RQ*!O7,O(A5B`X@,Z$:\6("(7^FV1&F=7<>X!6(`%[SA'?!W?8JXH5.A[K).A>4ZNG\HKP/ECQ#%G6)&QE&_!2BSXQ2D M+AF:IJ,8#KQJ>@X##-+SB._[V,,B;6O)Z$&;#W*]CI%0C9W]Z< MDQ<,-*8HRTD(3:93D#++>5K-+$*V+LY,N0F#R;^700H#95PP+93;*9"&&8.& M="(H8%"S8@;Y41K"0N-K]1]A!-(,K`B4KACM-!QLY\6[2Q1R9R"C7,"8[_() M[+P*MBK09#SH\`-/YTQ"&X57*:SZ3L(>BV$/PA"]@4S/*_925U)@Y<5ZMM2H M#N/^LW($NR8`:R_F>C6C(YT6!SBKV`!GAM%\P,R1>"">5?")LNH(E]#"Q63J M$OD+69J,!CB@?#6ZXE=`LO(.<8FZ\<$.8L^Z+;+[U[YL_"]S"C(;_=H743^#3=&2.YP\,B.T M(,GE(H!:)4R?6'/Q[J,BKQ&ZI2V[_YL$Z?+KP6]`J+XL$N%Q1LF.:U2UT[E' M?1V'I)?1N5XAI96GSFY`:!&\09Z8U8"K"*^1#`TD+%$U,*MTN33$*1#J ME=Y[6FY[3U_A@YF4?OU^'1+H:>@RH](G"BH@\@E[!8*C_@]A&HL>0*%>N0-Z MB;$%Q%?;)SY1S%U03$'ZB%(@\5.R$+1^"@-!F6!,9M55"GA9/G7!GT*1H7R. M+!'"<(F5!<-)Q(C!+555SN@*X\E)-^FM^+%RA=%R>1N1R"=0)SP.DVR#.$U#L,))]QDB?Y.,2M`:W_6S7/;0=O6 MC`2[.AV]8)M&PBNV7:.G'^`"W\QP[A())-GN?X(\F-UE:-B7?W_WKJ]077DR MOHT3E2HD96BS+.$;7!/-:<",8C&`8_A,%4$$6O#%ETL_Y^[QRI%,FY]5OC&\ M8BX.>J0V:2E2`*\%B1@TP1#W]HT<77SASN+(GNKV9JHN8%K%( MHY))%S(2N1U7K\D*Z\7;04JS<(O!:N"6*5=14G5,,<\3:;?`=Z.Q/#KXK(]1,T<<@L M)3!$5609SX*,+@.L'&W0P8(6+KQF"Q";B'80WX$%HZA$CFAN_98JNH$&RUQ? M.`Y%KMQ$UZB@+>-YF"MSVOY,@;L].2'K=SGJM8I>/>LW1$\`X=Y//T<#23)+ MKAD*`L?(459&C9RB$0@CF0Q:L93(QXXN*`Q!BH$^W40+.3HA$V$_\^!?*(UC M\(P:DR2.+MNJ!Y==$[R`DN%"J#DX(<;Q=I3A,H4ET2K^.UB@'!+S-%*TFC0, M7-S`IJ&!)DSJ5H*S-24A=VT#WU'X/_T+TPN`$[.X2WUGUG4=/2%]SU$'78QF M'\&_>EZ_K\+7O='(Z-J.93#K^H7YSQV$\C?LI08E(-:@DNP3TT9O<%@^ICK/SW.!(=0V8J3>N+:LWW=E,&EL>!%EZ M2-KRE'@H"Y`24Y^O;M>PI/V2Y>X;!32@<"`4+:'\H32L!K-9PJ(PN8:$<:]B MR7K'T/6.9[BX$R`_7)98!P=N*:M!@L5J$+1)G^?PKH)$V%S)%,+/*%G9H(=& M<=SB2:PML/Z/BL5$20,ZY2JRB'A6`?P.-WJR:-90P@]QL(WXT6$(^;/AG9N% M`0:EPCA$?"_6@#8>S*P:F$*2)?7RAC3A28L'^M; MDE)(\#A81#D-@6]>AR"BDZ`M/(1PJQ:`TPU)6L>`M]Y>&=O[>HSBB;7=S]J\ M!M86Q'&RC,=$XS%?)@=A;X9AQ.,0K901:8GY391.5N-""PMD%J)I&&\;QJLA MX2#$EPTHI<)*;Y+@?,7;##(%<1!$0,PCY3*(_[Q+F":;82!<7LVY$9/CT.@' M+*,=2(,M5E&9XISK\BQ<%:^F&`;=VQA:RI,U`1"392AL0+"M:33!8%:ZIWD: M!GEI`D(34^D'I019:=`\C:ZO)29\]E,]W!)N=X3A?@VN+`#A;72;-+FQ8']H M'46^3]E/:&L,.(AI[V&620FZ991ZE1!)-GSL"]E@)Y7&@4PDITQ3X3`&@+-ZHEQAL*PB>OYN,SC9<[[)7+])%F( MW)3"R70B=&V$KJ-@$(J,FY4`!Z41G,WVY":X5ZS+1C/EM=Q?$]Y70"GV__-,L\=1Y.2>?#:?TO( MUYJ!O#-C2U3^(1+6HA2&G@1WF=1DI$8IWTOA[[7E(IN0ELA6/U]B0CWFJ.#Q M%5F1!%Z67 M];QAN+;QZG<84;?A&\MCL<^-ZZI:'$O#[<>I;,WDM7/Z299G*\;,/=@EN[[G M=0VGJ_:&`U.UK)ZM=KNFK_I]W?']ON=IO=[)+OG4=DEW1V9)-$RH+%%E+"'9 MR3JY-;M^6\:$E*%_2B\)T@E%747`XBB2A32`QGC`]CC;2;+(>S MY`X3`\6X7%1&_Q#H"QBX.&0!A#!`R/+)+F9!4Y`(=US#C]5H!N0'Q*-Y2')( M!6@8DT;&T1I_QZ2$` MJ$DC0U>$*HE82L8>.5PRV0!2CB('9>(3"EU;BNC(@4B/\S.1:"<2;F^419@L M,&4P1PXV68[)0C/'CV@,*?3(JS`.IU'.)*DZDT<[(Y.<9--B5!P:'V3.'YRS M.,%6@R//2)2/@!T`"DPI.LK-CJ'!W=$TC#_9RI*+2RDB/P"O)&LH0W9YOD(< MI*"FN()R(`*E*(!4$([I>;<1:7G?T)O/#78ZGDKE9.K)YM9?Q.8W!PI?4'&*25GF!W=$B,R2/ALRUNG7 MA!<9X!)RF?HIFU8%YZ#)HCP/"_NI(($P0D$$SY4N+7FE_Q%IS1UN9,UJ5GC+ MU3J&:6^-N!1H)VV[P``I;@=Q`.]Q3B%4XR5=/I8(D=9HS+EBT3J*"PV+XPLB MH_`U!F.1Q27E5F5A2JI;!]#E@0(SB?%-0XA:7$`L03*OOFZMW,%FJ.F6T[&U M(@:M!@P*E6FZ$#`(6U>5TDJ$]%PQ;$37+>#`\M5K8.@HIL'1GAWH0^')>2#< M(\^G+;@)0!LWWS>BR$_S0`W$40X#N&8V^(=33.G")F;X-H1I(PTJ'I MD@KB"'*4-8/_.`U'>_'J7#*RQ7%;G&8STLX##`D3%7\*+EIP!#'*:YD=O;W\ M6`_DA',":`%^S%BIA,K;PNK:(-L5M!$K-215TP9_6Z2$W+)H$YZZ#4MBPA9> M3^XTP>H[6*"$^`K6"N)!4,)!11P3;1_G"B_VJ=P$6#<`P/`]FB_G5,&%T#6, MV2!,+J@/0)B^#91Y%1QR[6(B0X[9*L#DN'UY&D0IK"'],\PK%9!JC$CD&(BH M4IIT57*A'!-9_(SJDC:C/FDXQ?@U%@C([-]LI@;]1E0[+!,=&*1)-H^^*ZQW M'\];:&12IYP%*9R0&BWEJ/^(RXNR0.[#N9>_*KK;\L/Y:JSBWW\:L#?QVB]:L MG^1X,:DFX(H$<*`]B5RO8]OZ1N\>?P,FW?`[MJ_M=[>[POK#P?$_>#`CE:"; M@)H?8<4/BG5Z:BS?DO>N8H#G=RS/.S9\?^RV3=ONN-Z>F\J]E-9C%:;Z1+TN M=S'GT\JU/RH47X90LU4K46;AX@DBW*I%H&@.7#Q0YF\X7D79 M'=,]4?QMZ<;3=:K;R:0'2_-?&!R//_AK?Q45R.U5^+LXFV#.8W(=B.95$V69 ME>EFO5D`3.5R?)-@.;%Y,@EGS`=6A@TSH[DHVYCQ%[_Q7DYJP)HY55J&+3/N M[!@'LS%6PA>N;[$^&*#N[%OG&VGSC)RQ),23[^/D^SA`WX?]?*Z/O4_]`NS8 MQ^OYV,EN3OZ.%VSS?]`;Q[C1EV$'6&_X'27I-(PH;@]SV)]]U5LN5\SHO)M^"$\ZY%>"./DA3B0J4^&[37VW@_+:G.:9(I37J7*+WP% M+,'Z262`YX*!4*#4VM:[3)^J?3OD2;'E+;/K:J`YZ\#&:U7]Y% MTYT`ZD?0;SY*A2B"?$U3M*/3?8R.K5/=A6?64IXLD/+\^+;Z=*J9<^BJV7'8 M"-<'*'^LAG`='\F@`C+'=HD>3"_VG7ER>`?<+Q\B\P/)/<-E_,X)T@M0+1*Z7*].<;#DOX\J= MB-,/BUPO0X#:RH2S)N'YF!0SH^/H3L?]@70S[<&Y02?=[(AUL\.1>_X>9I1U MQVB(@GXG$B'H="/`Y'1>$I)I2`]W)4E).<<2U9VTHI1J^U+B:-27D;GUX7VHBNVW' M2!N+`,,0/^OPA64[].K/NNMT/-_#YHC9@C6XG-U1`6#L8HG_BA-1J1=>+MR# MCUK)&>MESIK>8CMPQS7I&].U.Z;N5]KOWC)]F+__K+,U.L@6/PZ MB++Q+,F6:?AQ*G`Z?PNG?7H7)[.O%T-=-S_955;=U3?V_ MFJ:97R\_#[[JGOX50:0YIO95>Z5,PG$$!YQ1]FPT^=NK:/+598EEZ.[7+Y># MKP"ZK^R6O?I=U8V-V>.4B36+X_IKCKP!T/5&CI#M>OT^JJN.W;/Z1NN;O6_ZO#B[X@"'`.. MZ,9[>ZG+,>,-13Z%F(:ME$>G5,^.KLU58;X],G+I[`-V;V/E?7#'.CX3*QIU M+WO41QWN>/?RB_(A.2_)'3ZF:GY'DDS[`/7;,%YB\?QIFLR+A'9@=%%^H_27 M0$CGV%BX?&?PF_(:Q^;#O>&T?\B;<\3A:S+`K/.P,2'=`Y#^([XH6XHPD%Q-\NPEC)<+^V["# M.)O"JG%1#P.[++M\D?L4QMA5/PT625IJE7X7741R3JP^M;?#N:AX]LCJ`L]/! M/O"S)3D&J7!>-"_&P7,GP88#H3K/N0*D>':G!(L%T-"BX%"AIL$M;"R9XFDM$NH#$2AP'XEWHH`)'+`HD51" M@X13:@"?\+GY443L=&^3&9QF`(NX0^%N`L(`C8`0%KB'E9+XP`DH;U$,H*W. M0*=R]I,HS82;'2_3%`X7H9!E828:5R@+V!"<.0P1P;-C-AO-BU`BB0!`FY63 M$R)3?WK6^!WD["DL`1"?.BO![$3X3N*A3/#^.X`+D-YQP6T3HF>KFMZI*GZ1 MI$@3&7P;`^Z$RJ4`>D5_-W]3AM^!J"0IW!B<&['N2[S,\"9&\$(F4T*](02SJ(YS(3*%Q+E+^>7Y\H?W>Z%($7C$,Z" M$"JLK(O6HO#H(KR[R5&-G'Z&S.* M=@<$:Q%@E4VZ5^,97()H>M>!VQMF\$2'AIHP:3:L+1!)=9YQ78G(-!8T`]IZ M#LR>7I_==6@J?!"IH_00WCV<9#EGK@6BLO!L90]L!T69-'ZY2S+&][",9W!S M$8!4_!EXU7@6$F7+E@M\%G@"_#_?G:!T049KD[>$AP?@PC.%Y16<;X5N3P$@ ML#!2!QB(..%%9E;X=>XB6"%J,<7G6]P[8Q2$9B0CDNT\41V M9+(S"J_2[>F.<1_=`7F+RA0Q_'K]&:\M3.CIVIM?E6Y!(A#=68%`^?$NL*N[ M+&JA/DASSG[B-,58H3I5FF,HH%412I+5`J8#S`")#G$$>.AU2/[_-&3\S*+BB^M0H`,+] MHY'914&K2@@H#`/^+YL0SFDYQM8#F?*:BNWEV(.6U/-)>`78?#6+KOD(2**J MC\P2I!G2(W0;YW#GKT&15Z^"\9]H=V!3WM7HU)NM+CJ\7+NX:X4RB2K4:`** MY]*XK:-V%#Z:6R<""(<6,G`B`AO+'NC!WH8`Z-0.3+[PG\/Q31SA2?83.`Z& M573R;]F%8[IND[:%P[TYYT:REHNL:\CK&"M5F,[!5)T9",+3NV+9*)^7BO8E M/^T,%C4IV=UK?+I*K,]H.V'4%&9"T!L$MR]IG;04)H*0Z3?GFA8C4R0^!V1Y!740GX>-LQN)4C7'>1`(BLTN4+]% M4QVV@@.*EJ^^7^UD#3O++Z.DH&`A:,PN4-Z73J=)7V MO;(_(*P1W&,R8B[AT90N(.%%\1.!\TZYNBOD0Z:_D6Z:P0QC6%:'E&=4Q?'' M.`QQ6G;Z?"XA?A#("]V%H4Q0JBHEA8M7EKLA$8115N6=K:0=%/#6D\W-I!U2 MO79&Z$XNLL.E_7MQD5W`!01\N;@)8)QQN,R1@&>D5YT#!7V&W3-!?B)"* M-P75X^88F4A>`:5%"0CM"L4@RSA83B+N#9B@+V4B"7;8_++!%D$J$-F%LN6, M;M)T24V@A)VC>H_8/\T.CVW-]%4C_V5XC8]^$HK=?BW[9E\;#`H^D//4`>Z.=![1F]H&:,'6?;7Q];4L'[5'+]B1.=@40JX/-1J_HB%.>6Z MUEZ<9('VU)#AE()F-*S"S3<`=P*9#7F8N4"`-@5TOS%%?Q+>AK-D00\#&EY% M28ZB53)+KDF\DF2/C#MW6TNLCV^B<,K7@QP1O5P9]>>DXR%AH)K-&LP8"!4[@$'JB,XES03ZEVQ9,<@ M,2'*-W$L;G13:I>K\#/*GLANFJ(\B8/U[E9G6KYCJ9YI#%6G9W4]VW+Z/:W_U?AJ M2![(!5"O5[]KYZZE2S#;/P`8Q"=A].L@&2]Q@!')0!Z9@_&^&J]^OW_&G_]9>V:JHA2;/?C="2X MQ=L8]7.)CN]L&];0=[6!YZI=2W?@=`U=]2VKKSINS[%\JV_VS.%!4&$$BT)P M4=Z#^`X8AN!X7E+PK9%Y2/$-3"F/4FJ72[W#=IBAKR&%`9,]A6@/J422` M?$N6LPF/E0A!#2"Y(PMG,W*L95E(UESX?1%$/%A#N.F`7);F'^:)H_8#(,'+ MUM^K,/\6ADB3TS]#--"C)2D:1POJ)LYEH'FY!^Z^6<>"D"\@FV`-Q*7VXM)F M@36D6/L("+AP=$8)&:.*MN-1O%CFO,$X:GAL#?(@H/LD/$YHAGR+$7ED'V(, MY'77,"XW<17*D;0`9;G@K`96B6'U-!0R/UH`G4E`\E]P&T0S%E-+$5"E9LM9 M:;DT>$N"V9;FGL?<&Z-$S7>T#UW`$07@?R_).T@(QMRS3+EDAY^1DHF&>SI- M/$;$,'*G"E1BA\K18L7^CT([*>H<[0@A05H'H;H5E9X1-H:R1,Z!*,$_A/H;Q>-MHMIW"R91Q:!DG5^AN<.NG9-6`'_(90"^:PDT""L"A7KB7ZL.1G5O@U$'A43_(;A1TZ,&M M)T4.`RA2U#RO[M:+Z=R\Q(Q;-]'U#=#E600CH=$\!H65`V6ZC">,KB'P^:XI M:;!";="-AI,O4PK6!!H8L=`'M`*Q(=*P<+R%Y*(O"02GEDWT&1C$.``:7&K1 M]`"Z!'&B"D7!(?C1"7/4VC!5W%5C6P+F8+&X$2I(TSLRRE,@"=V/GUVO8VDL ME/1GQ>IXFM:Q,;0T8V:V;2?DP3YR^&@'SY6H8)6T"V/DN';TSX.`G]N4+V8P M*8T-42D_\C"5D-PZ=$&+G\C?3+($#P1%,D8C%29?8@D=88/)2&*X0V)`WZ6( M&N)=@G?U=9F/<*0NW=T5O#1D;MV$F0P[\!<803Z:+*SL]EN`*A\V^0.)2^!M MH?DN8[+5P&$B]H((`'R!BRI`N8R=4V0P(5FGR/9H';-7\9O`W'X7] MFRB]&RDF-:470X;?TE8'%$C.M![2\S+Z\:/0YT3`^0YTV+_8AS'>QWP:M;N!I?ZJEVP/5\W704`<#P^SJ7M?M6:#5&7YS MV/"KWW5#<\IMKRZ[=LQ`!#,>]?@'QN#M:&--!SFR7:MO#VRUW^N!WNUHANJ; M>A^(IV%W!_VN9ND&*:PM.Y-/LV'9U8U]1/*%%#8-;X"H`6M@H'B79/CPQRG` MY`*EX"3NYGD:72TI*>ASG"DEH<&&=OIJGZO;VA: MSS+LOO?5_-H2$O[J=]76--MW2S@\(EW/^/"QZ_FO5"(-VA=%,JL6`4_O4AB8F=@$H, MK[X5W97W`J`-$P=:"8#J&J;EFF:=".P%!+5+)VS&Y8S/"B-['8QLUY%@U+#T MZMX:;IFX8<]*+*SV/0(43%.Z*&NVT$`\X<"3*E"&/,GH.8_4:]NN;=AFC3"V M[F`S5C&"*Q%=QWT2%,=WGTOK6S>>T*<9W9X_@BA&?.F"U@@SR>+%06"(\6AV MLD-(U%D.L?#GI1*M`H?IN@!3F=&PU5;W4"2?)=TQA0A?I(AU^=W%+(AS`-`0 MOF6>N>=DJ+K;MDW7,CQ)9-Q\/_5$L_Q`R+[>*CNL\L;*JNN2`^-Q*#@_KRS4 M2O0LP[!D/E\N>$4(0GME"&HD_?=M?,'L!7LEZ9MB9NL%=`P/#JPBR*S=QGV; M9O2-*?Y=9B-_UHVWXJGK>+YFK]OXZE:JF^_.9@E%##0[;_=Z[GW?T_LC;:#V M^KJM6O;`5+N]D:^:6E^W3,WHV5ZWYG>N8K5GFZZT^\WVTGQY#T%F::6\<'W- MU>O;N)]/81:B^0S3?,M8CT/87>LQFH:M&88A\\\U>[CO[DK*R;X,%)M>VW:1 MVS"=M;=6VD1-NP@R!`O^9UC:IIGH5!_F>7E1^^8]RW)\V?BTS:;N._XNLU&_ M*^W0,#(1P4)SDWY[7K+>:K\Q-N6H]7MRW;ENZ_O.(561EOQ07+$I_T[KX`3WL; M<^-\?-UE+E4XXR9KS?,2@'9U7`.1Q&## M<,("M_:S3;TW,OL#2[6=WE"U!OVAVC,&KNH[7=MWL.1HUVKQ70R_?`*"9VOX MOW*;]V_DB#9NM-M0+,.T8?,/W_B0XO@_3H>\:`1&BWZ,FT6+@[OYQAI7CF'Y MOB<5]7GD/JM0^R.,,<437NU6LK<.06%HA8EE.J8EJ[WW[&*3,.UG/?Y6_P-I MN)+\T[SV#61BBN6X8($.VR+BM=)MS_%Q3)MY?*8([5'WJ>H:M:SP)@#H8]U>];?75D MC$S/-;V>WQ]^]32MW4!4*0Z&!4?_^LOS`6D7AS1*TFD88>K4LV=#R)Q,9$-H MCO98"%=W*,$,B[=E6.1.*B*PK\0MHX_BUFB@FKIFJ5:W[ZF^V?=5&*OO>DYO MY';M@T@9(*!@6%@%+,^;,D!YYF.>6HO16YNG#&)"=9DT"-MJ#C%E$::4'8SQ M;S?);':G)-]B2OO*EE=9-(F"-!)U-RGD+V55HP)*K:+T8XI=JV1X\^)A5(R, M<52LUC3&NCEEWIP#$4:X"F:X:!Z6)Y668*GL5YCB4-3_F90AKY6:&^=*/TSS`'Z4IJ81 MITF2QPENB"6]SNY$$.6$13@W9'6NA6M9?`C7AQO`%2:LU)<"]");2HD%E[Q2 M!]^?$.TP\G,>99C+ALFCRQG_/0VOE\R1FM62Y2B(=Y)0*JN(`H7=\,!)VDIU MXVS31`*SD$J&Q2Q:]MYDU^<)E'W+L#-9@/C'ZB;`XP&CM9U: MYJY`Q>(Z;K(M"=&*@^>))5E`50PH*%L1*1+;9PE+X=68T8^QU7@OUP4T4X@M M9@M-_K7,8,A\F2>^U8G9+-D!\UUY`CBO#[@F-G=3YK]#&9@U+CH6V;?%I+`O MV7ZE-\L>6=ZPJZM>'V17R],]U;-,$F7- MKN>ZJ#RW26\4]BG(=>_CI\'PD]K_^.Y=]^)R^*OXXS<%6X*ITV`.5^;7%1)- M/V;1_X:_(D%_I5Q17B*IB]C_R97[*0"3?1R\9+8/Y7584$_*"%&)'?%)X-A_3V&PXPP?#4(Y1+2XA3XB9FZJR1-*7;Q>J:[>9Z2>E8"GI:6)Y.U[#<2ML5F*_ MK1S7NX_C;L:X2T12&";M@O4>;AVNO=2[_XCU[M/Q37GG'='!0Z[`$U)8V815 M70A0`9N$"Z0;Q$S&Y4$$0,D986LH=5@\U15/58Q!))+PG-M!.,.%*=)+?Z3) M"U3SO*NW=]FO/LIZ99@UH)R#>=BJ&EK#U?E7%@,*`M'2`W MJ.OQ\))UTLMK4/XYJ?]9.]=T%%207^(;;^2:LWQ-:\'$L5I>]GF-T1"\J49& M&A++KH^/I=Q9)``<&D8`D)9)+5Z$9U-,5ZR.#4VZONB^@IL,*=Y"(0;>C#1- MNZ'W&$H,@*%53YRJ,9*F1.<>I3G5(V$J.JM3R)=4'45Y365PV>*$>%HM"IK. MJX!C'1+8R7$Y(FH4B$G074559B^=X`=1`0ZDE3E<8:HH#@(,9[-85CMF,([( MZ$>2V26;I029]3IX\]IX(UB^9.;KCG-1%*Y2K>6.;AXN/>5&O-MD1O4F\;@6 MRRO0^6&X:8BB[:G,;*4#$LN_YK!N/%XR-'7*`B?B&MP4M7FH%QW=$LHG)^D, MBUZ6-$]6"Z3668B,I7#7-'N'(4E99K1RA4-$ITEPE\E6-.5;B@;C&%&!R\H- MQ0!8H5318J-8.*XF52*X59.(ZLZS^?E0=74@4*Y2TB1XF4\T4Q5[QN*IK+;B MN%CSN?)V6@'B!.X":CQB!E:MJ`V,K"O''2^/(FH!8+6VFV4\03Y$9I4[#A7E MM>YI;\J;518=*FLX%NTM5BC4IS!?I@C@%>I$="5F.E1Y'JS'!+9!66!%U)1> M%U6U*99^PFK+UFAI?H?DBFI8OK:TOTCKY7A1*'M5`G19(5E81CSGG=LPW5)Q M&'VH58 M/;[S\7/___:`KC%C!/\&A0`JD$22&0EFO'PJ?Z'#IT2=M-!H.RVRP_D]"G0= M&ASQ-X"$\K/N&_@P\\-L"@E#JT"";X1!@@^PZKU&)SC.+OLO$RZD1+XXB#21+ M;@&%,.7HV$&X2D8*)%;KS10;]H`4PG$:SH'44=6Y5;I+6^+(T[1FOAUIV1Q[ M.DW-"S?<"6_^A77XIM,LS&G*,7"RB(@SNEBQM4K,ZJ;#R\C?U%D$+(]Y#JE) MHB#/*^Q5F,U$Z3MNBZR)*BV"CU1J1TS0*7QJK!XZ+WK$$$68.3?@:4UHVJF< M+A\T!`*XC'D34-$7E$&;EH*R0WAJG5#1VUL\ES)>I"$OV-5HA3S[J80Y"W0@ MT8`H`9RF(+3L.,Z5+LG/*[.>_53.6]*N59,GOW+RC,RI7L69]KN.541N*P2&:;&<^Z4-UF%8 MSS95"_L^]GJ#@=JW/1?&@+&-_E<+[=(7]C_]][HWJ,7Y[F6[.P(K=X:WN\$_ M"?XL>F,N@QDNP-@;O`?>P.YJ@Y%JVJZ'L>2FZAM]6_5[0\\Q/$"#N`H+/DHG@\2QT1L`.3.PXB-R8F->2(V MCX7WIABN0>@1,',-S36^ MZZ9N6RXFW+B^KWD(0].U'#GV3K57.[+W>IX^<$:JUAT-5:MGN6K7US1*!`"" MTM/\[NBKCE.W%B:IE-UKWZ"$E*+H0Q]]Z%>\EV&AP5X(%]6>X%$/H1L!"@UZ MMNJ:UDBU3-M1N_JHJ[JN9MJ#@66[/8(`A15<&/_DZ+3)'AH+6TDP>A_-T(,7 MA^_):#@"O$G2!V,$)$*JYU[BOS:#9#;9@4LV])N5:F\2_3OHEJ]+6KH4 MWL;:^TV*-GUHG"R,G^@DCEC\.,W'`4F>ID6"AE=`Y3B91V,%Z&DP(V\G^D;I MN?.5(FGW8OZ6]Z7ZP/\^O-SP_3=G?9$8T_8M9JM/3ND!"^I;JNSX04=VQ M=-O7_>Y`PXNT)B=:VP):*_M^2B[S,`@--=/7O7Y?-?P>R*S#05_M859P#[YT M3-MR!J:_#83N8S//BD.N9L&BMX10WQZ.',]QU-X`&;$.`GW7!B'?Z(WLKN4. MG;YK"6*\?QS"FKEE-7`N#7WF1<\?"1]'UWUW59'TM('G^4-'-4W3!;4&]MX% MQJSZPV%/'U@]H^NRTE*_?V$N6:!BZ)_A!#(H?>\U=[\45!,4]#0;WX23)7`# M.6R(QPU%W"E,C4BSL%W-(8MH^P&'V#U MB465S*(8U.[`O"Z'VS:=D>'UNVI_9`/2]>V>VNV#`&3ZON/KCJ-;HQX,KC4G MZ%,5"UWW'$^N6;#)[HX;("0.MU8OT4T#EO4H@.RW4!]"!-G2=]2V=-/<0>$^ MHMRM"H)I@[;VR-I]3P@2H-^[J&6XEIGIAF_[VN-`]'B%L@J(NCVN9_E.WS!45[=ZJC4R M>ZJG`0GI#?!WSQPY/;]4('7@6@,9VFZL;-+-+%@GW.2EK:!P>`&2\$-FI\G5HW8JTW:%PP4OH M4_>H/J(_RW978F3J9E_71RH,AE<"@-!S?>!^H+UI`Q,`8CCL2K16>;1QO6!#HUJM`J05`A3I#`_8L,2V.2;57],#(&VL6ZVIR)A MVUZRS3'-;Z`R16F>G>U['[#\6(2.]2ER[',R9'%C!P=CO:D`DK5S(+*,R[HA-S!>U#UBN5C#8_-*O!>2VFWL^-H&?D8Y_UWW'@3]V MP#9(7VJMBFYXUI&SC>U`MA%&&2S`91.0[8:-/"^6Z3O`,A-!UEIZ5_<-[45A MV3T@VPC+S+7RG`[KV+&P(L)*+H*SQ MAGIOA)8;[869Y3W5:A4S/R6]<&B[;35)U78K[T$6"'>,I]4M/@1/#6YL`CQUA9!V M+WX^K:MLUR$J:TYQ!VZQQP40B<*V;V-A`&,TK[N$*5.<91!FXS1:/*8X,0#5 MTWP'.(%C.)9OK8!1[P^[7=WW5<<:ZJKEZSVUU[TY&/32-TJ/HE"*#$?X93_/`@`K%*M((&FK9*++G[?_4,NF3,HP-8P0HWYOE5+$X!1R= MOF1-IGF^CMSMF1>&J55RGE.=Q2)`I)<`P/'#($I#"BH0F0X4>*^(>/M.$8^! M&?7+='R#753TCN5J'<.TI4TU[DD4-\+L,FECR\(S*8KGS8*8)7EF&`TR7O)@ MEBF0DI0%;2B38W\MM4&^:QX7);8;MTO7BQF6%9EFE;NSUI$<#@#5-OJ!WCCS!` M%DBE[KM8*FT(--1R/%4;]KK]WG`P-&PJSTZ!@QP(;6MJY&W`!X5W8NMH"[C! ML'1-\S<)MJ"K;EH&?09YYA[ZZ;FNYO5\N/,];`EI#?L8.0PLP_1ZYF#H#.V! M?T]D@>776Q6T;7GWD"$BIVLV'NI]P7U;0\8;&GW=47T3(ZDM:Z#V@`JJ7=0C M3+]GV^;H'LCH>&K/"1H-ME\%37/\R5K0K,8&ZE;/'UJ>K]I.%UCM"(LR@D:) ME98\;V"-!I;AW0L:[6&@V4T`D^G8A#F,'%!HL>L".&S'`$UIFX"F!LRQ[('; M!SA@@RL$3Q?NU,!%$477/)BS[_9'3'-J;[%9`\[F04UE+'Y1X+6LU;4U@`IZ MN593'/0&CN$/4&XP5$L'G.@.08SP0:`8N8;M^H:_KD\[6CSDMJEKMW!$J015 M&.XF688[4@\I;^G(S^+AN01"XX>S<-\[AW`4>PB@-QT2G(PZI00EV3?U)DJ) MMA3X';1-W[X_P'X36DF*N`.`MK3WCXBPWPWC:`:'95B.;F[%.%:UL(V`01%W M[2UP6>.H9\ZZ6('2$R")A9/;C\O"J-VVBHXB74JLPCW&IJ31;)EO8^KP/")" M.^N-!*S`;H@CT'7/\'RY7]##-E:+Q`Q2I#SH8!+*W8ZAL.H\VQ0*+2VB*K6_ M5>U<;GY]SW9JO`TU^K=4EDEN4L^#-*1('5'U>Q?@:/++#KRN;5I:3_7Z/L;2 MC;IJS[,==6`8QLCK.9;=U;]6;;1B_Q)1V'X[57"P9M+`V]+P!MA;=!N6/=$_ MA""M?0Z^7V!M'+AO>9Y&5TMR4'Y.+H)T*\?K%A=&ZQLC=V!Z:M=#3=;#=CV@ MGP#+[@/)[%F&W8?!VIN).3!.":%'[G"E$Q=_=90F\WY#,[8>E;V0NOT.OP-[ MIWX>07KW-@_GV8-S@JC5`:L:KN/[AA3XW+#RNH]H!1L%)C[GA5K3W-IS+=^K>(1:=]!`7^"X MDRI,MHXSVOV!MKJ'#4WNU+Q^`YL1TQ'I;/>)RE!8[:$IUH/MZ?N,?&@!TG[SS/<;#/$D6/0@K\RF6>;K0GX>C$6[ M3L=;`>[3TL&6^W\6XK4-A]`-B:S%7=U2W[Z<+=GF2S[?[:ZF97 MH]V>A5[NFHE8[8+1*@=Y'(&\-X0FN[?W-J\#W%)UZH'-&7V-Q8V9]_M]-^K- M2`6W-C'/:C7_V9/!9LMSV:H2V!_I5II9*_`;$V]-?S08=&W5[O81CP<]M3?2 M7-74!OJH9_?ZGN_R>F>(NDT)AX9=P>D]['VWP"VS(#FEY0&KQW`'6C22!]^! M?8+JB4_M^2_(/>Z2?0-@QZQA;37"7=^)!_;LM>I)T.TM>^7R($\(FZ?S`.X) MJ\W].`&/H71H#:(/B>ZA.`OC194E?HI`JPKD=Q/S1JF,YBGF;6='\?"0-X/1 ME0,*>3L\N1T54]/T`-(`5L]V5Y-OUA/XC7)Q5M)[GUJDK]3L^9#$_;()Q+99 MJRO0VT>A@FK\L8"6WU"`J&DS#7L^_`TW\?^FBDOK=MN4Z-P$(/II#Q!X>)T9 M?4VBZGT%`UIW>%^^^S&`I;TXX;T9[FM@$> M?QKFJINZI_O6P`'-TW=Z(*=@_(]I#%6G9W4]VW+Z/:W_M;G2VVY$E$UW?TB" M8AMX'ZSINX6!UVE@]ZYAF-M83W9BX'V$&O!W*FM4S0W>$W0W)":-9G,`MFON M3OEIVO4>*<2G*/MSE(:A"%W:$858S6?9D$*8311"7P'P/K?_M&D@6["\C6*! M].8T$,.W#%#YI4"@7:2!'(L/9Q_R7DOT[\F'LY4/9S\\T#OYY>4FU/&C1M MPX?_'5O2X.Y!U)XT:,)%MDSI5CY-TN#NKU1[TJ!I&:XG5X-Y\J3!W1]H:](@ M#%)/@3O&I,'=XT=[?M*&)/>`T@9WCT_M4=J.9EC62I#R;M(&]V"U:$\;7&$& M:](&=]W^:8N-;M8`JQV=#<<##?=QK9X>G#6Y^P-MS9JTGSAC^$5K1)V=$&=^0G6J>-8U28_D!`WANIZ(PTQ\6^HUX/RX%JNJ7V>H.!BG5C M80P8VNA31O\NPQ3OW>T10;4QZ'`CJ.H3>,?<2I:O7NR,+PZJE/4-< MQH'!?;_1T69C=+1I/&W"XUY5T_WT:EX3-ZM[<%6\QVFK3P>1G;5J7D,$`8-M M_7$`V75IB%6`[+PTQ!J`V+8I:8I;]VE^DBY9:R&TGR99:W1/%^?958^LW=;7 M6`'4[DM.K*,VP"6<=JO#KNMK/,EFVRVWU+7W_YY=NW M;^=9.#Z_3FY_Z;_]'Q#!`:5LP!L+>'+Y6CE4%E[/A5^9?_7]*IU-HE_#[XM9 M-([R]R$U:II$)/'?7A6D>Q;$'X)YV/T>`;19FS!J6X0_L-?^^DOC:`^: M[G.4S\*/T[?Q!`.WET`#RWF'\\4LN0LI\(J3/3RJS1;QUU^J4/CK+Q6`_W51 M!F\QF.5`4#!6_W<\2Q4.6`,&7WY;/!C&$^DQ0S5U''HB/01$78H,^X7CT;9( MM98L'3@2R31:P?&+5>WKG*FN^!GROS MY1:M>RKG@?7I_4-1:ZXP\<-3J8S?I,%V@C%E#L9>`K'1"LV=%LVJDTH&CU2<\ MJ^IIO@?A>?ZCVL^JP7M'>'C!]Q_T\/9^6$<'G;5%P`X=M0_77J=O=J[FWCPY M6Q6)//!S/B1U[#EU_$-#JI,0\Q(.[R3$'-GA'9P0\]S06=^JY\!1^W#59HO$ M4^O^@)3]B:?K^U`=^,D>:$#*(1[K2>MXF>=ZLM2?>,&>D>MDJ3^AV=[0[+!$ M[0.`CNDX"!ZCC#NODWC7-4&M-#VXCO8+NI7[(OD7:3)9CO./*<]3DJ9LCD@3 M^4P_$EDP-M,QC3V&QJ\@ON.[+B"V95B.;IYDG>VQK12=$?&D&>NU'4^8?A"8 M;IJV;^HGDO^B2'[K)1Q^S]G#6*3D=`.?^`;:U>2^DZ-E"Q%YD]/;9Q)=^^F= M/"W'=GH'I_\="'CTNG!@.X:E>2'M&N(8#PW]"GC&^QTS&PV7%^F;XKN\3 MWS%Z3`,4KID[7,W2W3IZ4UR-:1GTV=*/&=V[LUF87@?Q7NR/M:I=$E*55T`\ M^V4Q2N&P1`V%;?'O15P$S5B"W`8_NZ#12/`S=N$T?G"[H-^Y*"3G=@RSN@J4CM[[T#]-B>7$&&<\"* M$IIQG.=4E'2OEC3RHT5%2:[.%2KL,\VE-8X8L\5]_` MHQS?._C"5J,HCO+P'5S(R=LXAQL97KZQ_[!)L=ND=\HGMUX)ZL2P]!L5-(S`F[]H9=IS2X M$Y[M%<].,<@OXO1.,XM M)U0\MD?,TILQR_<C^'Z9ABN/R^&:[YMGC!\9QC^ M^5MRPO"GQ7#-.4D'+TTZN#^'JGCLB3'KQ\2D%W&BEFX8)CM1Q])T/%'-,HR# M/U$1(#?\]Q+6UT_F"V`T!?\I->GY/(GIVCZ)\JP;JF%NE.F(CSW!F0IZ[[KZ MP4HP6U#;BS2Z!8A=S(+QTUE$#NI0#\T>7?'G?\'H MF!=Q]PZS(JI,I7CH;;Q8YAD]H;^8TWMVAO&4>S8/;\_FOO=\JFKQ@-M7A$3M M_U1.W1Z/L-OCLZ**X5N>8YY0Y>&H\CT<+]%Y_G$ZC<9ABB@SB-)PG"?IRT(8 MP_,=CB#Z*4+O8:MHRIB5HBZ`UN0I+.US\K"/``\.WR\.IWHIB=JVZ[OF2?*\=QXQI%LSP&KSX-JE7274Y;O M`Y'MD6DX6XE6AQ2>^%PX>S)X'>GI'9+QYPGV+%K(G^JOO9CZ:U4$,O=L/=P$ M@8Y5(CPT!'JZHFK/A$,G[^M!'HMFL3`0V_*<'_&8MIEO$%[E;^%(TB4N^5,X M">?4]>>"CJ4J2:U_=N.XUR/`H@.3JO:[9^MD)CF92?)*)M>>4>V0KM?>][QA MJY9#OUX_>H*RA#)%:Y-G0!G6\-BR?9W)-B<46N^F;6]XS*DK:W)X0MZG0]Y3 MM^['(^^3=^L^87,;-ALL?_*$S8\EQ5&\!_WVA+BM'LF3&'IR1AXCNG(CA6]8 MUDLJQ/,2T'>7UH_FL8HT^Y.0\YR7S]%-_^CJ7YXNW\:7K^G&\;:WIXOWC!?/ MTEA9*>+5Z]A,Y^'Z3@*9B=.MQ?_WJF4W-$7BZDZ1UF%N#TBS*FZT$M# M&"PQLR^$T36[2"-O9.FG"K('S
1&F=,%?,8+^-*,H:<+>#*+'M<5?'%FT=,5 M/!E(G^7JV9HI[%VG/EF//2U*W=BGL2R6JL$_YCXOD:OU_#OXK_DCHN8V\^TN_V[CSBJ/(VCZOLMXGHIY[[#DJK''&W\H M-;J?>,^GTML/.Q9]GY5P-&(UV3# M[ZA]9>'DQU&Z0(8'JN(](?J:GF,;^@E]]XB^P(_'^^E&]X+0>!E'#(>C++$, MW?WZY7)08-T\#+)E&O[.?_L5?OOK+^)+-AB^WS+2\,NGUI'@MRU&@GF_PA:^ M9E1@IAB4*N5*'1[PO0\@.0/@D\K!WKL/!J7F]VG801@G\RAN&Y@MK&W,U9?_ M^HNT]L:MU[:Z;J+&]Q?PZ\K;^.4&[^(5`Z*R.CL3)_BO&PQTR1"Y>1S^8\LP M9S^Q>P)__G]02P,$%`````@`;X(-1\!9,?:9#```=J@``!4`'`!P:7)S+3(P M,34P-C,P7V-A;"YX;6Q55`D``]+[S%72^\Q5=7@+``$$)0X```0Y`0``[5U; M;^,V%GXOT/^@=8%%%UC'N%X.L6^%+1$VT1ETB5E)^ZO MWT-*MB1;U"663"F8ETXC\_)]AX?D.3R\?/SU9>Y:*\P%8?2Z=79RVK(PM9E# MZ/2Z]>6I??/4[?5:O_[R_75":]4CHGV,D\+\M^5_'@D^_WPX?K?.3,\N:>=[BJM-Y?GX^X=S9 M%'EBLWG':KO6^? M_MP^.Q^=G5^=7EZ]N_Q?-#5;K#F9SCSK1_M?D/CT?1MR7%C#D^%)A.,_K2=& M!:2>+Q!=6S>N:PUE+F$-L\+XM`/57'0V M"5O??V?YB:]>!(EE>+[8)#_K_/[?QR=[AN>H3:CP$+5C&65A25G/+B\O.^I7 M/[4@5T*5\LAL):4<`"UM"OE7>Y.L+3^!F-L79RG,O\/=\Q>SC$%JLX]]8BW[M$) MXW.%NF7)S'X"X(Y$4IYO$`3.S)=)[6HSJ%`AY#SCR8"K+"AR+5EE@Z]BX2LP>7/8L>=0C'MO=ZT/M%'8SVC@C; M96+)<9?Q!9,S5*3?WSB.4D#D'C"NO**&$FG=(D%$?S+@,`7!X*;JI,[3JFEP@=# M2@V/WGK$$17(+E]_"U52/3D1_7[_LH!A#(NRR2574B*Y.SSVRFTF?8DEPH8N MRI?8V4A$6IW.TL7]R MR(8HQT MCB&>0K,"*)7'AW0#0_8*/+?*A)6W_E+-4BJ6KI2^TNB2#91\I9=(YROB4FU* MII%>:JFM,9\33WHC`FQ7D)X4':;E&\N%*RJS%R['`O^UA+KO5[CTMLI7>CEN MZ&?F83%BVP6%K2\I^GR**/E;528[`?@9SL8EB7HHD=6(,'-(9H1?O%L7!H"" MXC@BL*HEJ7'KTKRY\J5V$(@Z2VCSH1:2VH*I6F)=YKIH+-=*R`K?R+%]JGZH MLN,5J;-J_CIGM$K^1>JL$?\1&KLE=H_B-5<9>X6ILCNZ[*^'>'[GU)\81TF+JR"5/_ZNLJX0M''[% MG9V:JX23&@@`@0#ZQBEVY^X;Q>&,']:HM-A,DQFJ?S5*TIP@M.J`$[SK8 M]<3FBU2+=^W3LV"[S0_!YS]V9GT`'U?S2'*T/;8VE,H)1;=>1`SHW:JXF1D,LPC]VB?GL<$ M"W\X!CQ8#+&-0:G'KDY]DM.:0!T1G@9K-(5AA'(96W:Y&7,=S(4<.F0H.`MV MJ,PI6O!IV0QP6&( M/40H=NX1IV#XB8C'`U,\L8F.28Z,)OCDGI_29J3(8L4-CT-'W-X4"/^[MU(1 M/Y@3I.@(N0-;EM8F'IYO\D\XF^_Y.YO*F,[5L!@'R.IPV/O3TY;UK':7J;_A MKP4GC`.7Z]9YRUH*`,<6OKM75W;IG2@D^^$MD,WR&$*Z/S6-[LZ@'66=TU,- MR9^](?))1E#(]/P-,=5,XB'9BS=$5N-MAF3?-8=L@@\:I9ID$6]YGC6H43-X MIAG1(=]FMFNJYZYI["CK!ID:KV&=E&I+'A`TD7S*X)4:G`J'L)_?(&]=2"MD M??G66&N7-<+N_>8T/&7A+&3=(#,S'^N,A?R0>8/,SGP#^'[8*"3;(,\Q'UEM MQ#?DW"#W,2?GHO'\4!8-FL;RR2+/FEU(_S7S60TW\<3O)3&*,KC'PTAT7*@- M;N'9[\2US;UD)E9B/V&*.7+EOF9G3B@1GG_P(P"E@9Z5RUQD60XO#]!;_7;C%$\9Q9$W@_@5P,WEZ%?%U#Q1'>9.0$W0)\$U[U,,<"]WB M>I4U&HW-!\UX"ZT\T886=*G-(/?%EJZUNZE,((6I+U0;#C!1S\ M;-2,TTW3<2,NM3D:&2+(PSO3+&ADO.`()D)L22=I%&UD8/C(@MN;SC4!YO8W MJ>VN(*9,@8T,6R?:2_LAOHJ$W,A5]IPB2[#S-]F*<9J?"K?V"2-W,*0 MD^7^Y*X)=N=M5%/+-]J+6,*[ZG>=Q,EYZ M?NC(7W9,\_(.*-6PL9ZI>M'NO]/.C1SI"E(^6&D.R;O:QJ" MFO1ILFB33&0-KX.+-;2*'5.:'DW:2*-?U,Z3N5Z\\ARDR\Y:&TX[FW]`U=00 MOS6`LP_C'5QL/601<5ES$XWFJ0<+?W[V=[>DGB7/E;4>G.*;J'/SV0FLDA^T(7Z8<\A;ZS=G7GLM4N^+^0ZB3L5 M+Y0D5ZF1&_#*%XW.VF[D$?_RQ:-SHAJY"[%\\62OAC9SY^$Q))44?=)L,?PF MK;V(@69GX3=))<:+FKDQ\9B],![;;N2=`4<25Z'P=*\AT.3WV4T"U3^_;A)5[N?4S;WE<4]7 MA#.J'G!QY>)0[*&;(R%^.U__21_+*I2]YCNH2. M"#4\XBER'_#>AK+,Y$9VM*1[SKVU'QF;T/-:IE8%#"[;S4R(I%+"-F#8R,##X44(*LS M-S*^4&QF+GSI9(-"":^71([1L9$GR7./^O&+=E,F[48&45XEAL*>R6$O`ACR M#56(;+P;2ZR?#YN,,W1E1\R3CY!"HKW`:.#>!K/^B(7ATYMGQ!WQ!;#QT0P/ M%`KYVD.MF7Y5>@7@5YBC*;X1T`.4*@FYY/G`>'<#,'B_H#_I^[]_DD_O;AX= MK2F[B+X-P321%U9,51Z?0[",NS;*8??EYOKUENTSR[5#EO(<$ M^L>7^WR**/E;52C5E+G$V2R@1]?3(Q>:)KW1'K[97"=RFKA`6CC@[1'9?*@5 MH2YS731F_GUI-W+LF:H?ZJY1NL#"&\(]DB'R>FF+C)+47<([>PSDI8![_L,; MY5!'C=FB[$^B=F/0#]0%4*%9/PAV7]>S50[D4L/6V;6'Z]XOU-7MX$AMC&3J M#*5+55-]2;&8ZR[H7?LY!\J/'5F[=!#AC_\#4$L#!!0````(`&^"#4=">GW[ MQ!X``*[[`0`5`!P`<&ER&UL550)``/2^\Q5TOO, M575X"P`!!"4.```$.0$``.T]:V_C.)+?%]C_X,L"BSO@\NSNV>W&]"Z<5U^` M=!PX[IG9_3*0)=K6CBQY1"D=SZ\_DI(MR28I4J9,XJQ'X6?C\Y/SHYZ*'0CSP^GGX^^/1WWGZ[N[H[^^8\__^G'_SH^[@V' MO>LH#%$0H&7O%Q<%*'82U!LY+U$8S9>]:S3Q0S\A@_7N_?"WL8/1__;HGUZ/ M_/3+Y?"^=W%RWNO-DF3QZ?3T^_?O)W'LK48\<:/Y:>_X>#7;3QEA]ZEV4?KJ*D<,F]@A$Y-/9^8?CL[\?GU^,SB\^G7W\]/[CO\NM MH\4R]J>SI/??[O^0QFT]1B$GK^<()E[U^$/2&M!?N M#1%&\3/R3O)!@QS='B%HB#\?E3!\&UOC3"_8K M';Z_6S4_/_WEZ_V3.T-SY]@/<>*$;J4C'8S7]?SCQX^G[&NY-8'#2];-RV!] M.,T^9JVQ_PFS.>\CE]%4`9V>L`7]W_&JV3']B2S*\;OSDQ?L'?V#3OAC'`5H MB"8]!O&G9+E`GX^P/U\$Z"C_;1:CR>>CA1]CNDX?SGYX=T;[_^4ZO[Z ME)"]2><83&[]D"RF[P2/$68'YBIP,/8G/O(TX58<=)\8/#HQTB6_QLC)#"6^ MZP3F<;HCO&^.FD.>]S<.UX"@'%,N%*,9"K'_C':%5#BB<=BO'#R[#:+O^"[T M_!BY27.@MX?:&=IK'[M!A-,8747Q(J+76>G<]SV/;4`GV(&O-)C!(%J7#O;Q M8/(8DPN+,#49B:1ED^JE'P`[*O*'M,EJ/8";'CFM^_6I.TCQPN_W[SLB!L#&'3 MR/$G,8C<-1HG9I=)/*)!L,D1C5/DK2A"950O#=!@LO&A,1;*$QA$ZBF)7":F M>O1F),.W<`GHS-$Z:@551U'B!*S1Y6:CG-+Y01A%3S.',7/D];\[L8>_A1Z* M1S/TR)!_#!S3Q&D+RCV2]V=$U48""]&UG2GJ8YS.%XR_?"-];J/XR@G6%9>R*3IS`=8_1[2N:^>4;&UTIM=#-JZ$.4(#R*U@:%M2Z)!_'4"?T_V&3T M$!`]PUNI)&4-I62-*#H7R(S02W(9$`:@28X]`M8V)05JG4R;,T^UG8"PF4*K M'ZR@U!J8MBEV%06!,Z:V$O\9]2EOG[(/;1X\G3G;QE^DC+:)O\Z<%N$_.A/W/;M*#J?)OK+AJ_;;QR/H,?G24E)&%"N69_[SMC/R`R`6IUOS>=WU*Z M&#X'NT'1^IE8SSR8E#6U_/1>13C!A0&`X,!ZM7!V=H3#/L'B& M'#BVN^\'UFCN^&%C4+/>;4+*9CB>H_D8Q9I@5KJV"..,#!&[ MZ1@=KRFC!REO@!Q>;QUB1R/L*C"30X9"C_H*LE_I4`9BG[)Y3ZL3MPB,8D"3 MG6!5`Y0`80`A$(88`<*T'4&T;V":A`,Q<`A`Y`:M0!'0^,PHYG(IQELF M#AXS!I/BXZGC+`B[.G]_BH($KWZA@L/[X[/S/"#S+_G/OUZFV`\1)GK@[ZF? M;?(;\B_*&1)$)-4$WV%,U,%!3/^FDOE#2MGJ8)))LMG7%62!,T;!YR/#@Y\" MT*4JPPYB)L'>O!!N[6/T&/LN*@3<_"L^%Y"AV5@@6!,!-@J9I_-K?O'R,=IJ M!P%MMI`+#!`'N#F=D/FL*;=8;8%X01/)-+XC%P7':)20^@H#$,W)&+ MD(=OXVC.V'A(^%G\Y-`XBFS_"G&H[0B!3P8`XVT/SIP&(Q7N`>EA5>AX8/AH M[X3+TN;1K8RPO9&;KM<*,Q%17HS9:3B76[" MMFM("C6G'U=A]G9T>] M!4$E)H-]/KHXZJ68P!(Z%,OR4W`N,3G(XRF]!\09)-LB]T(J,MZB@UT#K.!VJ>$ M\!HL<+\X4-Q5A,Z""N\.E`JFC#<%I=X?**4:FG,*PGPX,,+4R!<%XC_`(,YU MK31"OV(.J-XD4E&\(,'9X9)`+._FZ%^`H:\@8*JKMM6[@V]H*1;\;T`8;SN2 MN5BKJ)!EA`5R./@&WW9&MX?NKQ=V(2Q=X#HM5"`%"L^`38C+5MHLWDV6',1! M:#YA'L)UY.`9#7HB?]$#^$R6AYS16\>/639A@:W(I:3<'\1I,YD@FO27N[9' MSLN0<*4LPBLERS%8T`I)-(!!99`KHN5_IT? M]W#ZE)GJ1$=+W!X"^KS,R1"YT32[#[_Z`<()D;.^HF06>>O_"M#1&,"(`5WM M#MU2D,MV==TA]@BWT-&MTQU6U-6[=\KRGR;'Z(@(O"=ZV*$-U2OXC:X%+E5X M]S^X=8_O8VK(M-96/2WF<:A^IAV(J'!76^]<,H"^SF5OO,Y(\%92KGZOU,2)]]X,` M4:\*V=D24+8:06ADI?H5-.7P@9"F^*5=:UAJ!HF,5E>3$0:1.YOPL:O`L>?TXWP+711G)`[LS]G MY1"$--88`@;'E(9^+&A9$^H6D5AMN4V-[))KQ_?=F?_DA+\M(RD3%;2$H-PU MFJ`X1EY^\0F(MMG*`DA+1_UR.2*3\\Q">GWMPDIDGM/I:1=&E-*2DZG0T3Y\ MI*9YI:X'B).I5*UKJCU$"W:=;PB^DOM7H9<1Z&Y>R%_(RVNC3F,D%E;JVQN" M*,FTO!&*YS)`MIM![,)[WZ4UC:G3'\7/Y#]8?@N)VQNA7CY\MCYBZO&:&9R? MJ-QUF(B"5JV`D460TM-@ZK0;/0` M2EWT4C<9Q/DQDMS)W*:`,./2X9=>4^+VG88>2#,?TCM>LDV*[V#02?E1N87U M$$*M<>'Q&$S4U$)I%Q@<%FGLSAPB)*SDJTU]7WKNU/O#8(<1M:JS>/>UC%N2 MP%=VFE'TB&)JMKZ-8E:F!F=JKNP$&QF[8U2I57;,C&U$\N"#HF*/5.S9(I2K M.TP7QHU^1B$LV8U+VI@XT5BIGY71:;=D?T:Q^.`K=K<2MVJ#/X0EF1H,!%7B M8:74?HDB#S^@1(`1MZF9*#PGC":^^*Q6OD-02;62AQV%2!I#"R0'EN"HD1EX M+4$@)A,,)J5;608SMRT$U-\6MS&1'G++I*J[LZX77-!B0T]UM2"&W`&\#B$Y MMSJ:5>:-K(::*6LKX%&KM:%$C=QTU<7G4>T5("Y@7^"9R.UCKN(JS,GP[H#) M4+*NY=B^/V!L^=;G'/$/!XRX(?--3JD?#IA27!$TQ_MO8'AOI2TTB.%0XWX5 M\AQ@JL*.A.-KR38G)^R(L,11;G,*PHY8ZP4NVIQ\L",AFEC!P',/S)-#PWP+ MGN+6YF:0N>G`"U@!GH*UG1N^HE%K1)`L.%#!4,6,9_6H4'4%T1KCB)I9J#T2 M="6O62?LM$R#6E-I81B$DOW43H$L\HJC(_/BA>#766FS[XQI5_9T;6C76G39 MBN\L=JV],IHN>AOALP6*4->32135HAO6.%]`J61JS&@KJ&_+)KE=,<)JGJ.* M4%=8"R=JL(S11B!V<=3LM01HQ^>MCQXG.;E8PH\'B'`U"J-87'M5FN:XBC(G M"TYJ-]\Q&9=IR&-@EWZDLGD,1G'67-C;09/%\;+7>-@.A512[`KJV&M4:HYJ@:.]DE4]CJ*, MP6)SVLOL];';S$0LL(3:IVI:J"3<5!`28(]8HR0=-D70#BU5<1%E$;AE++6# M1&VB@&R16R)`9XKY#U'@).Q]^&190J.].FI$J0TZV![OUGY-V%"=F._CA`?8Q10C34K\Y_HIB] M)"4KAJ\Q@F48%M#5YH?JCO)J,#55\645Z51_I`4M0>J81!AG%4"G*'27?=>- M4R?H)U>$M2_)CZPDIH#.:GV-T%:5.QG@2E((I.4R-IL`56N8((S9M45+W^8Z M\LK/0[DWV7F"!57L#)--6=S1-6G/6PVAX2W+%+(L=G$/BS!0)KX=&8P"B.YK M"M35=K,(%R*DE+_H;S'>`!VKAO!6(Z(S-2(,99N[,^2E]#TYM4TMJ[#9;"PC M4L5(4(QLXR/PBR_Z&E:ER+JN4-\1N\E^R6*'24WA_9=F*MS:-KPE9WKT(H''MDNS/=3E8A/=??6SA@IP.71-X%\(1!Y9(*.ZGL"I(F]W2";Q@(\IBLU=&!&CYM;ZRN M%?,Q1@\M"X=N^1^;0CUP^?=<6,%ZH1ZF'H/"++9F!4,9+H'U4MH%\&D,!I?( MUJ-Y4AV:-4Y,IX`URK]4B M8XU^8T1Q!A'GK]$X,1"F;>BYX^S=!UYMU'($]!S&7+01+'N MNKWMPVST/=H!LZ(W/&;RA\.W6T)`?/-"O>*ICV<4#EKX_0 MR'D1X*#6%R9Q)IS2.X-"]-5)<@%DB!9Y`8K!Y)%(;:Z_<((AHF>'DWL+':F4N!&8\D#T,5'V'#F M0WSB!NAQ'RN"DB5O&TA5FFJE6LZM>L#64@W2&%?[NV!GU:"/CMD'WMAJ%'69 MY@WN;S&+JJ(0"Q_?:`1K@1`(G[A@=$UW%^'A.),:$DZK+^Z0>4@SE^68X/680V%EWSCPQ$2MS&RH&B-R4 M/F`^F$P(J#$]*-=^C-CC9))SI=#-3!$NQG(?`R<4`[/5!J0,%YF^)O*CT@02 M1JD+8:-11^`$\J?SCW;E<=RBR>I%,'K>V1\_D?/OA].,:8IXM=$IP&BT+1)M M(3#>1*#()%^]E"DFD)'QC7"LQNMU%[HQ(C_>A2L[7"93]=-D1H1QPOZO$79C MG[%_'A_.PFZ=?Q85FQUWU!TD=(E;V-V]%JBY?8\ MG;I)9OE1E4YFY7ZD.M+646VZ?RL58TZ5%N'CA>K7-0?86A8=: M:\AEG\9KD3%;N;+>N7[#0[1S]`>"P'?D)]1R>$?.]+/OT*4*FZM*$9@SME%-]7UD*K M*^Y5OIFBJ`"W9;H"?T)Y*W!.YT8M'ON4W70'&$*G2Z0=G"TV1\HUVRM[LH;8 M'&?7=/^TH!S9'*,'12:N?J<4U[VU(J:IEEV?,Z$K8;!,`9<9?*9YU5DCPY59\`;@E`G3% M=-?0NEQZ\D`A;*Y@;_8IV\8((8_(+4B@IAA:%+-=1)>S*X[/(/.(\[R8VB@J MKLSL=OQ&,\A&,U38@D'JE`5L<.3Q;W3Y$Z&*G:V-\I):^.H]87`*DO#?4K([F2IG_D* M2#RYLAX682#U:%T551H+WH*FIN`IW8QG]&A8.K],IJ;4FD>Z**JMT^=:_%K1Q MR]D="0]F-_X4T=LQ(#?_OO?CQLR=I^C0Q[_=QFA=67)?].3. M"YL4302O"?)ID#2'"$:'[M2NJ?-9&!C8W+KO$+94"F'>$-!7\5Z/,5%WF$:W M*K%4R/RX/\;LW5OAOK$`--A'MC:%WHJAH"QS=L$4PA&2R_ALZ"%=,''48535 M_[IHN#"D+&SM6TNBKX1^!G.LG^]:V)FN!^Q.,$M[JVZ3[66S:@7LHA5O#4T( MJ?`^HNZMP!X-)?;G=KVRY=FT'-B?3O9*%HAOB+`_E\WRY6G)0AFA+$R2*4,F_Z;D)X>;)\\[:]>=O>O&UOWK9#MZO:468OO_;H>K9:9F][ MGHY32R8^M$]#Z>RP?IW!A@03T03ENFJ.>YG2;KIH;"A`0+IX:@LC#LUE*TI4 MK"LPM'1>Z^<]2&H"<,;=8.KB*G2I='-+G%1:125[Y(]PLZLH9"I[Z@14F6Z# MDS8#I(N[[A4693:#!0!/M/Y&;\6,)SIN%Z;#_W:`I(M[.:LRE%VN&G+]WJ>W MXF;*H`64[?4`L'(_"FU/&U7!6A4[S0+123I+A9N]$%D#@E=;7O\MPO`MPO`M MPO`MPO`MPK!;$88M*N8VAZK93JU+\[+[LVGX*RP.4K+;N*J M6S%LKKC==K![FUY?FRMXV[UW.9$:-A?YMIN8RK8YFXN!`Y/8I.4(O%YX=\FL M:0CM0NEB.WG&CH$/X$_$=5.BT/2E%%1^+;(Q9%1:06W['O>QFYDH1Y(6)'Y3 M1-H/#BJH_2K5DWV'9*S)?6%Q?<'\\0.:K<1,7D5F6"FC22]K21!WT)_&B-&: MDL!LR(P$VAD3:%\,U>!0[&@PDS4DIK MEG,:=@Q>H,+J5\5+N(]./(A9(5&/I3.2_<3K:.>/U>X#9Q&[_:@W>#C#XA;/4JU M:VMP/D3A;H05#V`$YM),W_('X\I>();%O'5>='H:@;*F(G11)/DNW%Q='NB[ M#&<$']ZBBIF!I+49:/+G)K>Q`>TQ8*M*7$7TPHLR!E3V,Q&0 MR97H"CZ7UD#QK2AC$X'%S=>&M9O.M\=/Z?@_R"470.%L$N:'4 MK1*2^T+BF(7-5GGJ22`7C*#&0+P?-9=R$G0QMZ@MZH+R01P]!%[N+J0&J!--WT+?Q<"]1O?)ILNZ0+9 M`Y(*52-4NI`LH(W\3H$OX`']#:J`F'9H*5@=+2D08AFQ)'Z@G%07-MBD99;X M6E=6Q<3$<4V`[PDUX_N.>#:QMX/$[O_LQ"P11!*S#Y13,)_[R>K@T<0(PH11 MZ/I&T@M,!4*OTS4&X\"?9H#P7;K\MA#.Z/L(XPH]MV[*#=`E':R`7Q9L(6@, M#_?RVID3506S#*'<[*Z$`[>C/?@\1>ETENBC4^YG),AAD";WODL%NEO$?\]& MV`PZ".P:+2+L$[B<,7T9SM^*C%7L!(Z':B2>)4&$FO#:%2Z(+Y?E+_K1J+P! M8/##B,AJ,W+M7Z-G%$0+EDE9B-JKJW04/:*8"@"W43Q(9B@F&(P(=%+438S= M,:I0N&NVMHFQWZC"&5N;1XA"]@2OVFU\W'BZ!%(H%!T M(0)%#]$Z::<+82>[['VNM-R%H!,32%=5'O`H$V4;H5SQ5#"*'@;:)ZW@=!E.J(5T,_?%=R,T_>H'""=1 MB/*#+#AAO&9MS"_>Y?R&%L!@ZJRM!Q^$$@\1IY79V4??(X79BU809Z0I#]#O M;X\9F5_<1:T/2):YPYXFHD$H#\Z<_%.U*(9"1V!\6!I#3;D\87/KWKQ[0-_9 M)W'ZOU)GZ_#:UUM^^\2W*G9O63LWL1(UMP!VJ8S#;VL!U-)**KRF-L`L=T*+ M6EL"N?RJ$+;O-/1`H1P4'M_SG7A9NKQJ=@Z_/8SE4&XOX.1;=\>:UQPUVRUL M=8:.4G4-L2D"/K]086=*-.TUD@)-%'X!ZW=G8_0ZL4.E)H)M_$HJO,W)OTU0 M*]D'NI#8JJZ&EIT;)2,<>+*Z^%GA&FV@DNO#E6,/.-1)BSB*ZG$7(I^T\!:: M-+H0\61LA6O?Q+4W`$J%!HU<)^!Q4(8W0"/4[4VQUD&]QIP,'@2DGA4KL<7( M[KK-"*X.!+?IH"I0V<'#U8PA*U)^6<-(2R@5 M[^/F^_\JP@G>>G372F:_(R;6K2FE=EBCTAO2M9"MWBJ1&D=U$ MWDPFJ(?QQU,Z.7W:FOSG_P%02P,$%`````@`;X(-1R]$LDM[5P``,O,$`!4` M'`!P:7)S+3(P,34P-C,P7VQA8BYX;6Q55`D``]+[S%72^\Q5=7@+``$$)0X` M``0Y`0``Y7UK<^0XLMUW1_@_P&.'[TQ$J:?(>D_`/A^``18()(UCMB=[I;(1)YDGL0KD?C7__'ML$>O M.`A=W_O3=]:[\7<(>VM_XWJ[/WWWR^/5]>/-[>UW_^/?_O-_^M?_!TZ$T9/SS??\PQOZ[#SC?8@^N][OSTZ(1XC^=X-\#_W' M^X?/R'YG(?021<>??OSQZ]>O[X)@DTI[M_8//Z*KJ[2EO\0Z_83F[VS[W;3P MFP?_Y&U^0G;A1S'9%WIB@AW&WYV#_S@]V/Y)F)C^F#W[WG_\3BA_^Z5OHEE[X M.DD?MW[\CY\_/ZY?\,&YCOA/WX7N MX;C'WR4_>PGPMEF+?1#\2-__T<,[\BTWM(45;<&:TQ;^:_)CYF??(?KD+P^W M7$"KDJSXI1^-*?GD1\Z^DZ:%-Q-U]_0?E%8EA?&W"'L;O$E5IC($7YE/*)>F5V,K\8G_ MFOSXM^OUFA`W(H'EYL7Q=CB\]C8?@\`/;OP@P&OJF.'UH__1= M)Q$_9ABID!+*`(?^*5AC);/%W_%LO7[;/U,QAST10F,L]JY^>?P.N9L_?>=N M?EO.9]/I)1(A\YW@:Q%E"A"?1KVLC__==87[TF MB$A(QI]![&!KM,-U4/9Y)UBG>,A?6PR1//'CVB?1^!A=E=QB&_B'CMZ::N2? M8TPH3GX2G,A@Q76>W;T;$24_N.%Z[X>G`#^1#O\]T>9W M\5=7EF:>>:HJRGKM?#F?E[O-$"5-LE00/).QEPJ!'@"['@B73Z7B37NZH*&QC_ZQJJN/=4C?XC ME#5B!UZ(."S034.<$PY@#!PZQ%?P6'T'CL!&:^D_WQP M(BSG.B(!<'07:"4]+IW,K54SQ40_P31-@9!:FTV8$2^)S+6[M'9 M(^=`6QDA-T4<JQOX MWH&HXNP_^V%XX[-).O;6I3Z:_Z&5I)CEF8IJTGXYLZUQQCTVCBLU@6@;J-1( M<90+QL?^;-$\IJ4=A!^P/2]@IG9Q\PI[E8T'R.C"$+NU/^0\;YZE=26D?7`R M'5ME/I8FF-#]H`YTTDM&YR,J;)OVB6C.^G7:&.W72[A&:!A383&7&@($QR:# M"@7M2U@M[PTA-"COIBQGTU5[B!C"`I1.P$-<:);S2BER#6'5B*.9MY$=.+>] M/`BZ%362#O/V6,"Y@?5=9R`4=&3#I%J3;\KQK68D-=(=W2"D5)J-YY,Q(Q+] M2=K>D_/M^K1Q:2N?\<[9?\(XK'S&UL:`H)>;!88-FY_JQ=@J9MU&#BZVQ41J)"10)9< ME/M2!@'J8D^'TYZF9=Y%+SB@^<`!?B%&=5_QK;?V#YC.Q+_@Z&Y+%.?'?24I M9CM=%=7D^Z;5?)%1+VT!L290J0T4-X*^I\W\,$*D)>1O*5'!QL#]&<2N&L1G M!EF7#+(GXH&[[BX^7^G#E8VHIS/?D,A!>DMG_[.[IPN`'KYWWF@G^C,^/..@ M,1"WO6.\6V]12+9[6%E3>YST[9E(E,E$B5#T:RRVGTDGOX/7BM*"1=G2U6N% M:E>@?G"=G>>'D;O.48="N&:Z?DDJYOV_C)5`!@&98O>.N[GU;IRC2^9;O`Z$ M\[3)3KU9!?D5TN5L5F,4%85<#R7"@'IG'+S_O[)OW'"E_O`?W4W>//^[9<0$\7OCO0< MH>OMKM>1^\IF_&VKQ'TT992?^O576)K-DB1S-5#DHTP1-@8O#"_;U,ZLZ MF2(_P0:G_AA>CFP]?3D]4XQ=@#%5[@D'!]=CH_@O/AE]X7L%C'K)^('_^"X[41('@,E8ZR# M[+K23,=8T&0A.P"I9&2?4)1(&47/(VT%.`Q3\PR-YJI64"NAYS[/0YV MCD?&\X)E^=I#QHE9U4#VVR_&4VN1T#*10>?34`OMY\&PS,)H(>1Y6&PE+&;( MR.-"3L5&S"!+?'LF'&\>7YP`OZ?5O>C.'O9"QJ&/<;8!;SU&[F63RW!2&BF< M1@-MY'EH8^>O?K_PC`XKY0(VM6RFY;6DE M2MY0W?D8XO6[G?_ZXP:[,17)7ZH,)#_Z[9IT5AO:87W:.[O*EZW_W@"/:HW* M5YU:AP1=I5BLC=14TW:UV83:YEPI=`"2_$C;5P5&D'%5H"F34:L8>NU MAK%^J!L%2AU2![."L#T,<51=_*S\TB0W68O2`YI%OA3!7@0Z+=!!Z>)I`*[J MQOR]Y`0E-\ZAP7EG6Y)!^2'CWJJ\YSR9SY=%KX7?@3\#1QSB'Q\_/CW"N[!P ML[H.$LZE6\Y;EYXQ[M"JYW272\LN^G//1ZGEPG$G$(6HG-8:&TIT%ITJK@$& M=VRID`UY8KA)`?E9YN^$;GBW MO2%C=G_O;MBZ$BM0^\:K]RK]FNG]$@F=)'UF.K%G=I)75"C0ZF_3(DPT*^[( M1*.M']"+)MR0_GI=;#MYPG#6D78KL(C`I**[+2K)C2LROP%6KNT'LIU#]BN0 MP39J%(B:;=W(&@:B8TUTNR?ND)+ZVML\NCO/W;IKA\2Z6L'LM@K49XDTV$V? MHZ?\U063=#LH<^1B@VS)JM`D:JRS#EZ1VIRI[!93G0X')WBCOVNQ&N2H0@>I MBH./L\T/$EE.H>OA,+Q>_^/DANR0RD?RM^@MK=L9WH;A"6_N`OHG+4CXY417 M*^^V;)LM^2W/(?4(-QEMM&BLL$(^2U(;TX91H>41BMO.2^/&XA$91:7-CU"L M`.,:4P$H]@`8+DG8V@7L+B84,D'(C6UT.M)@E&L#&FFTDJP4<_297 M?;;?TX;B!O@Y8[Q'3<^$.'I(NN)J/I]/D]E/05+"1:`L,BV0+`A(XKF+%EQV M!UQ&)BTMW,DF*B(K0`PAZ.DN,M"A?]#8\^KLV8YG=.,$P1L9[/S%V9]XB69R M[QH<`$@II)!M-;=3(H4O;&S,_E(0/4).A%+IB(GOA5GQ.:"/WJ:)73VBGY;0 MLX.3.!=-P6/R\E883BC\Y;L#TRI=GE7R@Z7WPD-R@E'SZQ7(R;PW+M($X'A?N M'1L2-<^V@"UM@>%15>#3[73E66XXE(W/NMYZZP`[(?Z`XS^5W(,C`IRXS7I) M>^[<7HU;N1NW@=)&T/=I,S_`Y"/T9PF6KD!K@&R2UQ$KCG,Q7:[8T=NI++`A M")MQ$#FN]]EWO'A-)J"U+EBRYQ8'7_QT#1AO/OG!=?@!/T>/>'T*6/V+NU-$ M+X_?D&'$>V?/;I'GN)/F5DS&!+VJR^?V9"NMB0:(J8!2'2AM4BUHC0B4Z<$V MK9T04550KLL(%;1!B3I`PP-(FR8G*ZA\.H,)\#&IX1?YZ.G]GY&?RP>-/OT0 MLQ2@>O@,(#%L[X3AW?:1G@QK/(TO>-!D)*FU+KU[L!BG9V69$+9W0L4`G\,X M%Y&MB,@8][@.5:)/,WI`!OR5G=>([H('=_<2??R&@[4;XOO`7>/LEV'RV]`2 M?U1%6>9YI*:@_$;=-+T`+7/,1!C=Q6321BAM#;'F"L^$V4-`VYH&C,-8FUG@ MF%K@:R)U`,3MQH,&;G,[E6T:23K>W)ZL5LE% M$C$K[PJ,HY5W5'YB@LG._,5Q+:$2Q4))KM_>;7D;Z]?K-+U]:)T5!!?6%,?0.9D;T9@ M1'S`K]@[P28[=O#?4@>N:*`A4518I*#EI0$04?'0_60Q;>4>3`I/'T#M[D"A MF<,-5S+M`>H_LUC]V8>8Q'NG)!2BG^=K0TSL4@5IBL2N=(N#O/Y3TNY M`S491J<="HI)#\[ML;VJQH.X\E>IA=(J`'#=A!X-86LTA+EI2P>G+\]B5.TY M6&ZW+^TI"1D:NSNL;2W',U5Z#V"1KS];M#-\\%QN6?]3MAT4FWV/I1`D5^S% M)Z0><(B#5Y9X\^D4$579:4A!@IVR',.<5E)._B:T^:(PBO>].(=DE%XCF9Z4 M2QMBF7%Q4RAM"X[:/9K$+IB$%!XRM M[5^/^R8,-WCJJ,3H65.W1033_+%8='*4BPB/NS%P#NF!7>^:C@3U*\/J;]-B M&&%_E4%>BAXELK$6_NQ`?J`,C3&64#@X9R7%#""84DJMH$F$G"&DS5QV`8HU9?QL[J MKY=9PJ0,IG/I@*F!$_]M_&X\M@H3NR.9Q+*N9H0FX_%H'/^_/F1CNQ#V:C0E M_Y_9=OI/>Q'_,YD+$OVODX>)Z!&BF47L@0]XS58^T,1B/YT.A)W\ M0CU-7P&(A<<`OV`O=%_QK;?V#_@+CNZV3\XWO@-QWS#+39X:TBX]F4SSSBR7 MAF)QZ/O/?AC^,$*T@(6_143R"%U'4>`^GR)6FR_RZ2H.V#TBVDPPKYM@3Z`# MDZC-+RM\$II"4]JB%Y[V=&\QN]-:E)#,>]A\XB%'$^E*^M/Q.VQ M#,+P@@EPRI&X;&[H#9/[2N[9R%:E2%A`21S'5RS&Y7[ MM@;40_#YUM.3G,]I,(9T MJ<(SGW(H`EYX2`NVC"7#X8.P8I`(-!0C;CU"2S88^^QZ^#;"!]XB`.]IPXQH M4$'A8&]:S(%?J7"$),&R(BSL=E=L)EDBL#=JDSA&0.>*?=Q[M,3#B3) M4GH!C"]%+53<:MY(&5I+)+[5D`D<`FFZ`TSNI$CO:\P0=FU/BN6L'2L\2+8(1JTD;![Y8VAUBYW.S:9LB%:MV@ MFSHI1=`PO!.Y+9]_7(,-CX?"JTVE7AT,%Q4O"YTL+5XWU^28H'>BZ@##LSE51ZCN:I6Z.?$OG`E2%[P2_-TS;\ MP^!JS:WEZ5HVX/`8^_35/X.Q^=N#86RFDD+VVU*A2R7R!\W8COBE&=N&?QB, MK;FU/&/+!H1G[!,][B7E"O&38$QDS2N,Y^SD+./C^@5O3GM6\_2S[^VN"`,. MJ.*+])9?*G\0G.N`U-:#%(9=)1?D,RDW"PQKMC@(\":YL97[(*;H;M)3OG`,J#1G7S?$`#R_ M<.OH^[-?L"#V_(2HDDE^5W6 M&BP+=5B@3,&(6,"A(H=`-[%_-G%-8!!@HGUVG6=W[T8N#F]D>=;P#@S-ZHK( MWT$QG2P;6%:0R*@V0C<#(=2Y6.M\VN<2!\(JOC-R2,4Q"@RGC@%>NZ)*GJ5' MC#(F;U<^"*_&&4'RUZ%HT!6`+0/`G*?77:3LV!68>NH$D''>WC^R`H!II=_D M^$`HJ!G0_I;Q^@&M*DGZQFQN359)/?J"T(9"R*;K"FA&:%419E+3]2S-)5?BUBE5R06EA[(Y*_89%83CC6:7)]XQ=HMD!QZ><:@ MO>S>[65LO*"%9*41QOG?8=#1YGU1[=9J$&=*'6*\:595OD[)B4U!D;S!HDJ%C:7P_5M-J>NO3K#A MC$GZ:,'XA$FK^K(7QHUG=.(]J021NVT<*!"37PXH12W0^[?2@VD]`J9*W^,8 M_L0,T)+5<'P1EFR9^`&:LSH\-&%.,Q/,7L)A/AG5_\WT]`))%*25F+W(C=YN MO:T?'&*-1+%=YCWC$5M"*>F+.\=D/I3$X40LNJ;5Q)E@5)`,%U:UP[4&`+E4E;BF;WP`\A/Y634+5ORLH?K27`6D)S:K M^6)1X5-2B#DYWK*Z]+:6]2:\M.D7563-\$'M''YW`<[U=2!B3+DFX:S*;^.#N M3Q'><'8/VMXRN/?3HHK"1L4\&<6D$FGDB]>T1HA)9;>-)7)A=FVT@F4LH?G2 M>S\,T9&`#=,%O`3KAH_5U`Z-I'\6=V!DC`1"M>T6KVF9BEMO[1_PD_/M@?1. M])YIUSL1A>_2&VEYYT85!)@DH+16\C=]V78RKLJ$HU@ZRT*F\M$#IM[C[N-\ M0%93:@V6B-R7#>RR#6A:<@`T!NONQ25NJAD*CJ9WVX_?UB]TP9XJ>.?=..$+ MB2'TCX__.+FOSIZNXRN3]PRQQBG=75?I).3E=&(5B4Z3*=)&8YK['J(-LNZ( M_:70]`CEC:.\=<@08,IF=MEF.+49C0XH^3LQW3HU'?L+SC6`CR#G$ZP>5\ZT M/DBT.1SW_AO&27J(]'FC]O=,QHLV910*>XV3`IJIS*L@R:-4R('9[VD2,\N2%^P?2.ME`; MV7W.Y6(Y6\1;V9F\..KG$@T?U="(RRKCHANX!8F0!S0T@F0QX"YZ(9/P\B>4 MA6IDBUJ*;-G>=+MY(#O<1QR\NFO,R=79,PW(W^ZV=**Y\]Q_XDV\JLPR.#^W M5%O3W0I`9ZY)=?EJ[_-T&[&8,LU+.*.U!AM2J^-\LU'Y-:K0`*J_@1K6!C.L MZ9&*9F(WC6MT?L'!QL`OOO>*0S)\8U\^?/(C9U_\/<7RQ8_^AJ,JRD]^D/R( M/F>=0P=]2@PM@FI#IK"B.+/*HRF4:(AX@8'53(G5C`-`V!0!B)KH#4C(0!(V&V]N7ZS\J*L^)OR`PF9SMS0@LE41F&_2B+\ZA*8^]\3&C_EUN6R$S M?%$>)N5R$!4$Y>'GP+'5X)CS\68W*CMY`W"0U99_G(@R+;77*@^97+\HM2SO M'F,K*544"P"O<78.#EL:A[&Y>:/3E";1=;QPWDTGYKY')B3"&U&:GS7NZQ4% M5-;3ER67SP0!WWFB`9:M#,LL$S@.5B=$DQ7T)((Q\3_CZ,7?W+*EJ;@XG\L_%]0^Z2K*>/)8-STE/6^RG$]M*TDKBSTO%HD*,I-TK#!J^AU4W10C=K$& M:Y>6I#43QK'[,HZ9-+?S0DF>`'>&J?7$Q#!R#S0#]Y/C!O1*%%J3D-Z%0N], MWL<+^R'[>:.GR+]M//))JR;IMZOY?&XG9?DRX6A+I*-7*H8>LECG#<3[1N$H M_J7IW-J>P%ME\%0ZNT>'%8$K-)`L)H[B7T*$L)X,8*M^?:X!S(0I97;GD4G- M@OT%HS@MV/5V<9-?O.-9P;-9;H/GB>^<-?/@"AA!TN-JI>.)" M''H\=IYTN$,@3380!J(O[#CRL$="FNP@C$K$%ZXN8T#42GQAG!+;4D^T^H;7 M)UH1X6Z[==?D:[-*)0%>$P&B8XP2KQF/3.TZR:YZKJ;+^22)1ZE4XGBQV*0V M32+8=.C1#=(J@TS%LD623##H,4?=B.VS$9L))_+,S(.(I*TTA8XC$4PKB$>$ MEN1?;ES-@%9Z;/Z0@N?-!PN^,O(]U6PZ2Z-$+`X=F3R:OYL(1&]$HO$@H0N< M50(7RT.Y0%:,%"0FZ`)H2WP]P!#0SK`"]UMLHHOT))YLXBSJZUV`V:E-T4!! M\#P`Z;G*2%]F:$_3"U02<<'`0$;W^F'E^UW20W3B`S1E,N)`CN;D8.D87VCBYTG-WRA_+G;?L#/T9\=U_OL MAV%6"I&7/B3UKLDT+1F%Y"\BGXZG&6D*]Z\_=3G'UQ MM_VK0XN@1+R#T>)W#+)/J(B*XR6;;H45[EPB)5\J$X9G&F$R?B6OI@=[47X( M&))@4IY8)%:[64`)]?XM^^O_='%`+/'R]IG>TW[]S6UEEOAE"(H)-5+(89\L MJUP;H4P@^I5*`\I-[@.JW06J<<9)N6HC]=I-!QP!%B(I$%-`W3CK/&+Q6H1L=X)LG(LJCMS(3FG+@?+U M;OO)]1QO[=+R&V$4L$7+\-[?N^OJB7VU=R'X*5)(>AXTGDWL&B_)'"\3C0JR M1RB6CGY-_GS"WR+TGGRYWZ&9J\\85<86/'L05)7QX4:*MII(RZ9$H;E?DD)0 MQ>I.UV%(VJU>'Z;RINFM"SFUI/>Z)O8BR5\J9Q"FLLL5VE`BWNQ61Q^0JS$& M!K)X2Z0/W,)TR5-J`9JXMO6#+7:C`>5-JG$YVU]1,"/(:,#UW`A_=E_QYI;P MWMNYQ.)$*1R%[]]^=O[N!S=[)PQ%"U,*$DR.#.35DA[$+B:3)/4YEG[%Q*-< M/HH;H-7!61.(M0&[=-67'6R==C`V<%!W]]+P0=&8`V-TKB&M)2.>D2M*&0:S MFU136#5:K&38/2KY-&T(>L;>IT$D:*YHD`%P740$2;YS+0O!^3]C#P?._MK; M7&\.1&=Z1)[F5W^,M_$X?M/VED%.MZBB<.W?,NFA$XEL,%F6B3[RJQ9W![F* M07IXQR[S,H9U6@7KE(1"$E#2*XN$D['-``DFW$"2>WTL]`+=;@`]ADTG)>178J#N%MZ6YO$+ZK5<]&MVT@'&..-/K:F?HJG!@-4T= MYG<7#8D_R/7JY^L-IQL;,T\ICEWSXUCA+II;KUYY`6"YSIB):A&OFP>!K>-I MB#+9XMZY1M<3-@,_#.\#?XWQ)OQ$@-Z&X8F>Q[ZE5_0X^_O3\]Y=WVVW.*@7 MMN\BP7AP5%)/-F_?FLQG:3RD#:"T!42;0&D;*&D$Q:V@M!G#`;!'$UB#,D%+ ME.O1#G9NAV-J!QHWD)O:P4WL<(SMX`OL8":4=6)^'KW4C0DQ]XHSX6E./-6Q MZ5[Z]WCK!SC+F,?AQV\D$/O!QO6L3-<,BK8]UG MBP;G>3W"D%ZDL!>K)*4B.9(2GU")B96KA'*=T#-3JG"$A>[]E12+[U%E5WX5 M=$.I:H#(Q=EKWQ\$+A8^DK$2 MR\%IJ]IX#*JI(+\',5W,2_$C$P5>JU\+-+L#-+-\Y3I;G6O-MA@`3SXG M=TT+TAA$;\#QI:B&M&--K=F*PYE4'FA*@C:,S>21P`C$H"8W%+"H9I@!,4F8 M/"!^!YY-JKGK2WO:RB?0#`"-.-LX-8"-?2F7E.`5\*9]8=QY[[B;>E5GP8/& M.51L77HZ8BVG5HDX3`JB8GJH32R_`W\VI&E&`&I7F_[1^O\"P,(7(%Y+,V9I;=P(E=9R%;EIAR',L91#T:/:S1H(TV`"4(O'Q+7H.CQW#:_N$U<M=[U>^R=Z\M%Y MH]W<4^!L!`,OF9?-LDA"(^G8O!I/)QFGF$#T?2KZ!YK$DDI'B?@18@V`<4L[ M>,8T]AYR4JS'6!HPYQ3=K58K(A2TXRQTF3\-BZAM'BYFK="$`Z$P[:N3W:WX%+V\ M@]1?A:5M31_Y.=YJ*1X"QT/=1'A28V$XL]NSD;/9;8S1X6(#9"'725OXUVR7 M83#O/L!'Q]V(ZT&TO@;*N+(N"CZW$`]%$[G052$T`V8D2Z$E1S('1K1FGQ23 MK,$FPR#8`R:]K4LOMJ-I0=+?N/(:*,'*NBAD1-DS(<%RN8@*'@[!S@+,"%:` MMN9`@^-7LTN*^=5@$AA^Q>=LVOJK\E-&V5-J6GZ]8#K/CK/$$N#[G7.03$M0 M,!^*.1HT>D[9Z^N((9V<)E^V?!SV"(![TW85]J[L2<6WZ?M02PQ=$=A9;B\; M.\5YO?R#I:8=N^@M35Z=`09QZ?L[82FL_/H6MR*,4WUA!YUK(O*?WZ@'BGO!LW6RXL M$?_`=R#[0OR)7[L99U:/9\95.C8.L$I=&7K M9-=S>..^BC]Q:%'$/PP"R/='U1=`":%>3FER1K_!*8KZV5W3Q=WK78!9S8?&92G1DZ:+G#:K(7N]UFRQ6B8WJ26" M4":IWP6L)E9K`V0!`!(7(-6!RE9'9:2KQ8'3(>Q<$K^4?X M@%^Q=^+M&O*?-]K?<910*/4XF9;Y0:=7J324B(/JZ[2@B[LZ?T^D^W'%1N2D M3C?4X9.Y2Q71-7J@.[FD4TDM7U=FU$S1^!(6G6ONSM M`?9X-2O-O8@$$&YVU-PJ:0Y/R8XPBK.JP1"NYN\5LI6QP@S^(G?'*/&`0S(@ MQ;3B>\7YOV8;B/F^223PEY%/B%]FF M%)65UD>BHR(J#KBDI29\C#GT;;0G`D&)TN9E)9H(T<.0Q-L]X>#P`3]'/SO1 M*6!;`0_XZ+S1\5EXM[T/7&_M'IW]`Z8EFC+-4JY M\W25SZ<;9R,\TN05XEOYZ^%..$AI,"Q-,PC"^VV>'B7XX_.QZF%W=PW4B M[@M&`P!/"VDG'2]6RY3:88A*TM"O5%Y\3Q;4AK&-5 MR)S]=73C!,$;^>%?G#U_LUGJ73#VD.)Y"%020O*9#,ZD1G1 MPIQ49I:"]<864P@:,AA:OR25AM(UU6S;>C@$;/%C/A]%UAP`/3\X!V>'P^NO M3K#!&P5N-KT(1\P&;>0OX1AS!H9O(Y3(18G@$6*B!\'2LR''%-T[[B'>(F<% M9G&P3G["YF\#(J#`4P7LXUEI.-1[]$^[ETB=><7WP(E74$:^)$)V`)[/NUCN M`&G7&7#2,>942U=*MNX>-Y[^A^5;@WNVTZUJ'0BV_>Q\W#R/?PQU>Z<-AP MY2[W,=,)'PTZR'[TU7*^G,9)'YD4%(OI\VY=;@;(V5`LTU#$J2!GX[$5\1A) M"A%P(TL,X2'O@YR-M_@*'@0FJ-)]MI.Y-;/F/(KV>5VO+$F[P.'0%.3V85V8 M.%0%O&FXG2L\NG:^4[B-L'<>YF=.-CP%1M5,!=E#4?/5S%I5>4JD`)U;.Q>( M91B()#T[HK'5T)@E9HT3=5:68>NEY--77X*2^5-@E,Q4D/[V>4IS_NV)%&A* M=@1B&08B2-$G9)EV"`K*:[7OI)2>L;D2DJQ8>DUB,5LE0T. MO2&LI'1'8I$%6T!RE M3:+G-_0];16YW@\H:QCE+8]0WC;*&X>IVF/28//48+1,.OK^E!CIQV/!=-O, M8$[6,B3M]?"I&"_M MWO\:(LKVQJ`#6DI)+]GT11_PTGX<]6^]5S*MT#R\D14*'W4D-97OK6H`YKL'E>=`QI9H?!11U)3^:*I M67)+2[3)KTF^K/6:7@PV;QS0^$(+``<41=Y(!!(5RUY>`.DVC%$5?C$!IVC]@FCG/=ZO",V9C0MZP M?/F'Z6*14SL6@+ZG(GY`UU$4N,^G**UO<^_`%;8Y`UVV8K$GKX*-9[IJ/V_3 MWF!4J#M_A=P5D#`<_7J]9L?A2.P@@<8C?UVS`ZGAO;]WUV_Q?Y_PM^@]4>-W M[A=3%&.4Z6JZR9^KMV?9!.(KRMM`Y49&*&X`_9K\25M"K"FPOKQ/BR35<=;T M+#37*+#4[.;S9?9V,*&6),,OOG?CD+9H\?,]?GPAO4S(3S84/&TZZ9"OBJ1_ MK>;S^70<)Q\28:@@#<7B@+(0=2&SH)")TQ)UP;,[PC.2I]A.JRQ?L<4>(-TX M"4#IK"`>521WF+?-Y5O?,]E1MRDCW0]-)W,K8U,^84S'ZXG8'^`GU7H1QW7' MHQ=,+R:/H>($*FA_*^NM03Y>[=MD;JQF#(?=AX?\K31"$JV\DQ MN%@6NMLVQ&;#?:D>5!8(JI9^5`\TNUR5>NNX`7JE]0?0NH`R9))'`K1FNM4V M;N6]JM`Z6HG>U(&+/ECC\U!T;U)&Q8%F5<8WC\@,WU.@#YTE@PZ0_>,?F^[RQ'?=YDT-JGA+2`\OY>&R7 M.$5\+-^W2L4!#9_UH+-YZ,)8'.C8N7^NY2G"U$N\7 MEL.&-^VCULJ34"0LJR%[H-FVILMEE8JI*-")Z3EX+/-XY.AY#J@*24\I*%IH M<^L'6^Q&A9%H4@R7CE>9ZX!SN9E0-48W6`AB%'I77A,39%8T/6EPY-G0O'Q9 M9$XE22X747'4"L(I!,$N2.I0Y4MCHJ M(_V6F"M9OR4P02^4O0_YL/.%P'+FO[ M;OO^%+H>#KG7;G408#Q&J&@G.VN:S5?39-NU*!^1!E"A!3I!3-OH_](N?BSI MSP36L$S0$FOZLX.MU0YFPE$7WN?12=F6QH)5TPUGBB\/,4BI7!@V79#A[T0U M0/5X/]I9L:D#IS](_E)G(;>DOFI1[;)!44="BML#-OC>B!@AS/SEMD2=['M M^"[DI'64-P^>:`I@O%H8Z`MQVP$Q[ M,Y<2N1ITEZ\%,Y_9&H-8K@KI]:'/L,$:-;G:+#CZ`9&);KVM'QS`]C/[YJ*V M:,6S.TC@HN/,YN:J5GJ0_!?38-L_KQ"^9#"I"3>3W)6=IK8KXW$@B M$15$DG@1"P4BND:@A0,R3@(T.2`#NP4KY8HE%K8;94"<^D),T(56A??@F94K M(U^1()]$\,F5RP7*:M`+E^4X/-%&:Q0;Q6XL2D9B4071,W?$4.J/$@Y##I,%3H\F7ZERH00=S_AO_ M<`SP"XDR[BN.$Y0^^0%V=UZLWOJ-)N2&M&`4&ZBR?^W9./7/CNO19*;KP`U= M;_?A%-""#CAP_Q"J-2DMJE5,!1RA1$*4: MHH**;');4!)1+;."3;&F*%85Q;J2#AE'=`I,]`6,*T/Z$"Q0I59>IU:."E9U M-G\_A1%X81>#L:`6#0U\L"&%5ZIOJMR]'S!0A?IG3WY<_4S1Q66E#B`L2JHJ MS33;MN5#7AZB:'&I(-ZD&U#Y.:-&L_,9AQ^/IDJFHX7@1LC9$J51U!S3H>.3 M(IED8H^*I2\PKK1M;FJ2?CEQ1GF/;F4O%SW$&_B=3@@[%J=RM>!SP1%'N&VI MT=!@$4AMX7\`*_YGK(!;"VM:9/S`EOC/1=:PG++/18*34&%=?V@+^LHK^<-8 MPC]O,7LRFRRY;.E[S5Z5,%WQ%3BS][W=%6GX,%362*S.#W!9GEO&3O1E^2^9 MYA!7$X45I+%5Y)&P(",@FS0AK95@'"$/PV]VM;IAC4MB>^C)QS]%G]TUE?D) MB\X--CQF/,>^KH.D7\SM^725GA`\12@1@X@6S6`S]_HD<]$8$&3[!?CX6JX`EEX.H M((`NZGP\-O_;@/50(GID7107ND:&"NM.5!^!X:5J68*I-5\MK1(E>Z^VT$+' MCA`LDQ!D:-@11Y&!7_QW:#F:VN/1>&;!#Q4Y+*AP\)SZ#[J&B&]T#R"\]C8L MD]+9MQU3%+UA=-#(54/^2L/I=):2(9;&LI-2>>`[9]HPVETQFAM8MKIA>80I M-@P0DUBZU9-_O?['R0WP?4"7:Z*W>_*%(J+I1_+3XX&_4*\@P"S/)+52N!9P M,LUH%Q]DBWR4B$>I_!%B+8R8NV:-Z"7B*L;OX1VMV]Y"Q7[,,&5V(!J_."$K M%W],!#/<6(3;(#D5/;O"517+Z1F#XH!>=N?L\-V6'HD[[5GM;58H]`&O_9WG M_I,&D.OPS]C#@;.G@61S<#V7!I'(?>7L"6@6;GS=O4R==9 MZVD1VJ#0/G)"M(LU8"QP2CJD"R&F)\`PQK,JQJ-7Y^3&2^YJ*[:/KD.4:,#* MA)1U0!_YJTA]#_5A#&CWXWUP,PO=L2V?DVC]0,,*Y'?;;8@C^O)-@#=N].33 M;B=ZZ]51N8U>;.#G(5*AY+2O#H'(2;5#:Z8>'5=BIN"E=A9Z#-Y3)X)R[5"L M'GKR4:S@)7
HS>4\ M70`,XM\!/CKN)AG-B<\,-3]KTMN;%)".@BMKF3I]+">=B`&?%M*`RBZB&D(% M,*%;E6C`!0_#!O?5B3#AYIH5^&N<<;0\;)0/31K(5WY<6&E>62P(99*`!N\Z M@=GJP,RQ0^1F97IP#0'##W^-\2;\1.#!.9K61MI1UW, MYPLA4?T`4<%T]1EB8;XOR'8=R&@W3NBY MVW[`S_R9EN`5(*I5]9"?H=CC21/)OL\E$L?[`5&A\/0Z#V:96(1.>]^!O0Y7 MQOMX1&JT!1"%-J=U1`B-@U=W+5Q=;GK4+&5J[2M,7"8Y5:B8.-TX$17"KCR? M#4$SN5-3BA>JN<^;9TA="?GZ../Q5$@3V*5L/?A$ M;!G""G>;ZS60AF,2(.9L<1BZOL=R&VY\CYU_2+43%S61?-DLIR0T4CA(OV3^#)93A9LI&S"W"\>+C%!"];9*<%`DG3[]"'X!UZ_!T' M@0/,1@5WKE!3UH!`/&T^[O`%"R9/_%?,($VR1N4/9<[L9);$W@6= M%774WI;1WI1OU]RBZ,AE@&!>*]R)+3YAVG,5MR97T[%=\EW0J4IG!+8<`J,> MS-]%K<($\>(XJSJ^2O`#WI(1(]X\X%?LG7C3#.$K)OU]B3!ORDJ$TV@1BA(!:9G5S`&U#>2#AEB4AM5M*2\?^` M=Z<]??HMOI*)4U)#_*SI$P`\122=9[)9W069D1,#;1S*3@X(#0'34>YI.8E[A\R>/N"C'[I1H0XR-WP+7S+: M68HTD>]*IFEF0B(0,8DH$5DLWPW58>K#F=`HQ,$K`9K6ZP8YCZ?FA>6^L=4@ MX'02[0TU/`A%&\4S`-/9K(DJP%.K,P'9:H!`>,'=[^&`A_;_XHUU@E4PP1M` MC*BH(>U)4_*W)FH4;Y0$73W3A;&!+7(8(7C#<4,>@9H,,R`F27B.N2$KP:9A_UV?7P;80/BAU5_AH\OS)=5,)Y MXVBNY'I4+&)RAT6SCG#;F-8"%YAM-3>5(%S94`/B7%O]WM;7X#FG7.5V,;?' MRQ;.P9?SU8M63#GH)3Q5)Y5@W+`6]HJ*O7\K_D9]8M8D8``LK&NEL``PL1I7 M-(8W53L;9M,ZQU!G:P)7E6$@QU1#XN('-USO_?`4X"?\+7I/-/A=T1^:)`R` MC0UJ2?NIO5RU=X]Y`^A7V@1B;0R,K&=;H MA#PQV/GXG#U;K5*2%8X%]G`J4+YL_9E@IB4T%,R&`\8<1]H/``[FT!]1)"GL M?YWFS]SX)WHGVI&2M+4JE_S[9ODAIY3"=,9*,@J+@H90TZLGK+8Z5H/\4G/9 M"O$4S`7#R!`3:[Q<>YL/^!7O?9;1?AT$-+\RUC<^/?+DW^-@ZP>'3W[`;M\E M8]\GHIUP#YIW'RV,?.9BS<:"5F.1;J^SH7%*:I[RZA"A^S+B%.YP@H[A_.I_C@% M/(PQ;D#MD6H08R.-I-04JRK?9SBQ2GS^7/P.>&Q1/70]F[?&#-`SYAI1UHF] M*:`47(YD9KE#W]>QQ&OH=#_@4TDF^:/Y0FHY:D MJ\U6]G1JI4?4.%W8(9-M^,ZP/J"60\EUA56Y;,BK;OK`78XFDC@-'6M386CA MD)NTD7H,)&E-'=4P4GEO&$&DK)3TL0;1&C1*M0.RK:!['+C^1O01A>]!!0V14K*>-5DM M%M6@42ZPD`E&L628R*$/JP6-52YLZ`-<#AMK7O4,TEV[!Y:!=>1B-QI.9+A: M"R>M9@-:4(@"=TUL^T@KP+U=K)WQ!!9SQY;G`BP$"9ZO,_WF&@&%)Y+@>WGQT`L_U=N'U MFO2#)Y8Y^`%OW;7+S\EK?=$H>]JTD2_@,+:SB7(L%*52T?<%N2@1_`,4H?0B M9N0JPMO$4F!9)>N<989)64;3$/?5V9^D-'U)S_88C>B-T[' M=U`G]U,W#SX499@?^JHI*'LO^F*UM);I,#AK@J:5IHVPJ72AF?1N^J0ATZ/B M/LU@#T?X5)[^_#_Q=X!S">W_OKGEW<'63971,T4%!A"DVEI211VM@(QV'5% MX>DYC!R/NOVPN"UV8<)(.S?W9UF%S`D%B<_5,^[WXUMY1XG/UDH$SN M:()R7TSZX&(*+_%3O/,#TAL34F=T'S1[:PZNQ-^R$0?)X/(#_\35G;7%@87J"O.1@(\3$T)\$G$EGP,OXPTK'K/W#@8R^PACF MD<$\$I@A#R8`GQK=C\.BNF&@N!,F/>2??7\3\F_B;'S4,&>J[2L,YL<%OH3I M_&6$F"3`"S?/1U4<@X6(^B9A![NA&854.#0W>.Y5Y46C%;0D*CPZGK]U^8GZ MI=^;3C`H-BY[L,.:S:9)\D#\NN'L^NXZ6[G.D*GRW0'8D@",;+XW.7:VL5[# M"-*_K%_PYD0[O>OU.CCA3>$6G2>ZM]]6F5)!@,F^2%HKA=KARV0A(!5.1SV) M^.(-4>A7U@+\KG=?1K!Y1DCR16%[-&6'+O5S:B:#96QAV?,5%RIPA-?>Y@NQ M%.?7Q7J;#%.K^VAK""0"Z-)>FB2+Y71>CQ0E-8I59>(<$98ZSGND4BV=J0,> M5&#L6@L^1NQJ/GKI)G=SE-/Z#6&CX^_89P<&&33]O=.B#4RYALD\6&@&S^,)`.BSK9`8J)&``II8CH-)3J"6;@6($U:V'R<[('VS:%2]P?]0T1+Z,+IWB8HANB>Z_*%"J=S\NH]/"QM2Y2ZBD1M@JL@""84*"BJP M;CFNASG^+3`C]/Q6^?5`!G^]6:<6DW19QWRTZ4"7YDBB:NQA1@G%Q79),8.* M#5W7G.?3AGFCZ#;!P8UC^K!(PU5NPUI_5_-T-6X/;BV>,WXIK*B]?\N?24X' MLB&AW(#@7/D@@>!,I14.<"T:%MQYTZ'R&C'I)(L/)DK$H_6A#">,VK$VQ.C7 MCN;CDB:J-@-A&'I@>\(Y2BAW6+9LN,-N1`),\TE0@D M:?VAA)YB8"RJ_I>T%,EU&)X.QRXS)RV-`(>D[IK+%[J?SVQQ>"IU\;7XE*F" M"KH,.EB9,FHML7O]2L.G!TN6>P7:FI:<>7&V:]IH3`:U*A*[-5$ M1?1G,KZ(FL]X0L:U\VG<%N/._&@@\0[OJ,H/^.@']&O&!5+B_[:&,:EW348G M&87DCV7-9DD!@T0NR@0/KZA0#]#M1NB@K%9QUA)9I:T#PL'&01+O0S<_;))E MC1I('T-9+F9IZC)G>@'$(`VP8LJP/=D8UKJX1"&XX\L8@X2N5J(,WQS#X4AA M*8.WDL'^\Q=:/9S0GNW56DH.T+$)<#YVTUL^_74U;6%Q*;55M"`W2M;E$DU` M:MO#V]*NVC(I$H*VX$%))]]J$4F;Q2]J$/7)<0.VS%-8P*#[^_1RA@_NJ[O!WN;!B;@[Q[VW M>PG#+5DP*H1<:0MK5+MD*:^@'PMW3$.4JHBHCA7^:( M3)7=6H9I2I_DHL9N(F1/I,<4SC_[:?`21G>M*!3(.1F;BXM4MPL;`FHV-8N# MF3TBCCT&/P:4YJV60:'<-_C#C!+_XM/=PKT;O9D>)U9:OO218AF.PHX._=-4 M3,R5_*.-%L\Q?SE.OF:2P*.E&;+W/FQL^#87'S\?W/#W3P'&MQ[Q=QQ&IJ)G M8[N7&CN;P,B?;UB,^Y]E4PT151&E.OY1`N?YMF=A,TU+0DZ2EA00N5=;:C$W MM5C`L=A%QE(1\7N+I-R/I:>R8F=5X]O=3@%N"']:11NOYZA';TE"32<6F;$E MI2"I6/1>',S>)\$L>:Y\CB)7H;]8U=1%P!G.NAS#M52TA+`>B^,%[%#ANH]8 ME-?1U&A9V*![ZZT#3'YXZWTYT:J@2:)K>'V*7OR`ECXH7%"FU6SZ^';"!]X5T%I$'P)*R69M@HGAE:V MIJ40]"MM'K'VH8Y, <+4[U8[C!KW;4Z*=E.:/\42XJ'E6"[*OC[NGA,#(C M8"?I=+MO6W.7$+M:,,A?'60M]"WN)L,V/Q^VI7JQ,Y-,LPL+=5KMG%R/F=_, MA)R2@78\`PT^I$DR6$N@D_DD%Q7^[M)=/!RLW9!BB2'J]F5N.Y<0\'C*JV3J M3+5%NKM\QS_3)XU_%Q;A]!B6A;8\_H>,FR7S7&1<:Z.FEH`F_`(7'LG2;RLYUB8[5>G93123>,[-R\^2.K[#J7M_:MF M<_T1(ZE,:.@IOK9^/-B=I[MR6M>33T]SWIVB,'(\6D:K<7AHI,F+V6N2PR-) MU,ERO)C;NC:9TBI!>0*]SXY^HX)Z?0XE]6\N]6%L3;M*T,;N:3>I#XMSA_#I MN0:?G;Z_O$TDM7!Z_NZ1PL<9=C^C,'@'5.0/TR=I&%).9G,RJC314Z''-'I" MC/3-]V'Z/H[)GFU0L[!+^4"R$[(_>K\H.T$#_JZ7N$*6)SN&UUZA/D9X*U'O MIM=V+VA5K!6,0@&JF:Z\CL)Z6$$_=OEM04/D#J!XSG!,SYEZI%W3N;Z*%FH!^@^Z ME6'PN\F-I_^_#?:F]T'.__*7V$FPW*`,XI\#/]2>_2QHZ8(">H/Z"E?A+7O8 M5XXU*D9DIM5EQMVSS=LR5F8YA)<=,054U1D'>5_B\J-;)8"S7WYP(IR=>#?B MV^U:7&Q4;(4F?WG61&-E7D'$K(UAV2.(*EVHR?%'"*F:OTUS\0T69=&&6F]+ MK??*L]YEQESI`-)?/);[C(/8/Q4J_H`/CNNYWN[&]Z+`64?MT<-^F MW^U3`Q^H>;FG:+O/[A8/8L8"'_ZU[9]V_["7.-]I2X;MKYT+FK-TS0>DIQ67 M^BXWRF8E!7UZ/2L5WPWTT=OT.>DXT[A3SBI.(7?'B1".__;L[.FB>(_&>HR< M(!JPN692YGK&.]?S^K98[_/9,VW5LD#HY](O><(JS-_M]TM<>(<)L!L.E,IK MJ'/5LE-*1L\]['"7NER(?6S3?;&^;S&5V[4N]$!_R-Y:GT%GR@:5[=(OL,\R MO>G?7T*M:%'UN5WAY_,4OO8VUYN-2U]Q]A_<<+WW0Y;9\!RRB2YW#64`JH$L MO,+CEBYN.)E.IH6E6"U=HE*/.&)983D85$"#?DWQ]%.]3;Q$>VE?4?/`YF*^ MHL1B[J5]2CU5_(Q_2G-+R?`?M'EQ&5ZOR[O*L!4_;V7=%HW,#6MR"9G MDHO<]Z+V8/<.+^;[2&\>#F@5$R:P:+F$\HDKH?1X*8'',M\5RNL8;_Z" MUD)E,:F4B]9W66,6JF,UTY,^V>%M^F-SFY.][Q[U\S$XFTIQ8^`1V&`XT+DH MI_2I+G'<'`,L%^SM:632V-0%C7R;]%OY!F8Q,%VV M>!U&Y.N)G#H'EUS##R)Y.]8.L.B5F@*7EJRMA$Z2CK.)O9IJN\4Q)70R.H2N MGM1;:G:/7T)S2O9`OD2_B=@]?@ZY\_9P0W>XN*TMVUK]ZPURJ224*YF,>ZVD MHE>)(2V;:$4F/U]?C"WYR4"H6-T=_P%*HP!^%[5:*#CY.?P\PW@445IGT?]! M+S)<"\\`&8G5"AI<4J"6AZ50]TZEHI5TE)8X^?^'"-%]?1&U^'P)Q5;T!PVM MH5GQ0X+%Y=:P"1/55.^;F97NZX:.`!VTS]//T)&GO5'NB:G11U9U^'AZ_CM> M1T]^7LJ-NT31^##(*F*3)I+??C6?S^WD`I:G%XR\RD8D_=NZ>*]F&#=%MW>W M66,C=#P%X8E6;B$_CX@)C><6):PJ0;HWPE?G[S=X)P[OM(V7.]3>7NT/+?=YD MI\=30C[-;#I.!MY,!-O69#'C5RH&ZBIV/;!L)5C&NLDV1ROUFD)+@/+DXS]. M;O1&Q[F^1T>V,EQI?`>"+TV*J#A7,FZ,Q:!>FO_0`_%T2XXP"_8"]U7G/Q4FIY2 M4F"8*J.:BO'T9(8+K(^H\UF&` M21Q$).B`K24*](BM2P#H`+"%_'R`@+POT:N%\[E)8`;Y1*<7?[\A'S->9>,. M%&L/&AVJ5UN77L>93"=6@26)D']!R0KI=10%[O,IHE^!;L7=.P&)2?T0QH^< MO7@P?A[*.=M5IJW$F\<95LR$P8ZN>7Y6'D`W&F`8Q&B=Z')?`"6*\M1M/K4F MRH09P$16#W"[#GR([!%/0X6F`&/3;1B>\.;#*7"]79PD%Z<2?,%?V:_X6Y!2 M+YMF6:M&\F=R%Y-5<2`72T:QZ"S]]3&I5$#DQT]`'5_N`7QAD.!LDW;6 M&O/D3#,X%K)?5DX9;+JX0+.@H;"S43N%34%;>PG(Q@-)`Z2V!LNU%/0?QB&A MSB21C@1\2X)%A0=\)-[TXM`,=7\7.(=RE8/K4_3B!^X_:6&7]SA_6!@@.LLT M'2NZ*JK0Q\V*AV.'L+?HO>DO=\EOV?^/"!C,B6DO6HY'G/Z%.)55!QB\@9"FH[XFEDS M)*K4O$W$E;(5!D"6IO07X:-P%%')F&!#$YLWXH)(!=$'BC/>@DO_D'$M`2F` MTSXJRI#V1&<`.4\#LB)102$?>;'D$(/*@CW[IP-;,S]:L$%QI.)N(IH4C3$0 MIGSPZ4T2\A\S>1Z6+;$2*B=)%T*^Q/*&PY@N^$2<$>`#9$W9]5IX4S`)%'/< MC>L$;X_.'DM49>`^;Y@YC4HH1.-E.@0C$@92E$$/*EL%E4F6"-VLRA*^(?0D MW)\.!R*?R'9WGKMUUXX77:_7_LF+Z#:POW?7+@YY&R6=1!A/S%?33[;F\VQ. M+)DDZ\Y M8F2"7N`Z'OP!OU\"O*?@M!;_)KWS^"79RH^3&Y:F.O,VTC!N>GG>-R2R57YKN\[.6 MI2^'MU:+95*A]7G7;Z8*MZ_NJ+5E1&MQ']M1=5M&=2-]8\V1LYZO#$T/:W!P M<+V8DFG9WGM,/@AQZ1U.$S\?<'0*O%JZ=1<)QOFGI)Y*.5TK+Z.,XTB'`GPD MPE@R`"V$?,S:*518#I*FR!-.A+YB5G\;O[K^*=R_)<>/2O65HG]R(KL[> M>AOWU=V_>J7K__>`,MJCZ*PI@\2]2>TYD_U%M7'Y\PFKM(YY009T-W`>&EL%C;'HSG.C4OQN M!`[L]2UIL4U/PGB^:LKH?+7(%@L+W@*>"7LVI!H!!I(`*W`J#@O.2'SEK32> M#H+U^>R7QM<'TY;EEXOGI"N/E_Y^^1EJ?;Z;UI81K5O6T[JI;LNH;F8-K.K( M^?)6"1I([T$:N-L6:@")^H_&9TWV($T**(PXQFD?0H.LORV5/G*\#?KB>U=. MX6>%\`9[VY(&X'8/P(WU1B(G+?5'7#M!<.N7XZ?`]Z+TZMU<*V$-A;:W#/*M M117YM=6IE1P;_^5XM:4B\])B!:^#K;&@%:P=@^V&U12M)/VS2#`9(X%0+22\ M_QA&[L&)N'4Y*P^9)%*I9?G*4LMQ4F>3"*!Q.Q,QBC/SWM"OR9_@)\G/@6@7 M(.)4!"@S&MVI1(0Z7"V3GK^R;CA*JNS1E,2X$%_3P)C[K.DI$4\1V934V8QZ M`9LA):)005:?%2:Y\R4]D"P`2.+)E!Y<=A$7+N`Z;>`G-`-&! M_16[NY<(;ZY?<>#L<*F,WMTI"B,R3'>]W7LG=-?7WN:#NS]%W&J6'849[!"[ M::C0J]C)YFG:$$I:JI>M+#0W0JQ!-B5*FH3I3$V8QRZ9QTG,X]5*6,96\O-6 M"T;:$UDJJL^CSC%+OT,H\?,2YM]OUCRP``$Y``P`5`!P`<&ER&UL550) M``/2^\Q5TOO,575X"P`!!"4.```$.0$``.U=69/CMK5^3U7^@^ZDZE92E=EZ MQKZQRTY*OO_FW:L1B/PX@-'BQU=?'EZ/'RYN;E[]X^]_ M_,,/__7Z]6@Z'5W&403"$*Q'__)!"!(O!:.9]Q)'\7(]ND\``E'JI7BXT2V, M?GWT$/CKB/PS&.$__>M\>CLZ>_-^-'I*T]7W;]]^_?KU39($FS'?^/'R[>CU MZ\WW?LHI^W[T[9NSLS[Q831],WU3F>1_CQ[B M".'6RY47K4?C,!Q-22\TFN*I)L\@>%,,&A;3'6%((_3CJ\H,7QZ3\$V<+-[B MSWQXNVGXZH]_&.6-OW]!L-;AZX=-\_=O__7Y]L%_`DOO-8Q0ZD5^K2,9C-7U M_7????>6_IJW1O![1$>YC7V*D@*!(VX+\G^O-\U>DS]AF%]_>/_F!06O_DX^ M^$,2AV`*YB-*P_?I>@5^?(7@RLXYR\/>+<#\HW)_!I&>'F@%]['"))/7(0>0G`.0:!)M^*@^YS!O9<`7?@U M1DZ?0`I]+S0_IQM\GRU!>\J+_L;IFN`I)^1>2<`3B!!\!ETIY8YHG/8+#SU= MA_%7=!,%,`%^VI[HW:$Z4WL)D1_&*$O`19RL8O)$5<[].`CH!O3"#O=*BR\8 MG-:YAR":S*NO[3@*'K+ETDO6D_D#7$3X9/E>E(Y]'S^4*7[.[^,0^A`@L],W M3XE!F*;@&429Z2F+1S5*?HCW%;D>T_4L\2+D^>;WK]9'^I\*/:)!L?$23#`0;1`C7&60AF,P;/[2>A?('#$[J(8U] MRJ8&Y&7$P_?P".A\H_>IE:C.XM0+::/S9J,"Z>(@S.*')X]>YB`8?_62`'V) M`I#,GL`]G?Q]Z)D&IR\J]PCOSX`(@I@6+#]["S!&*%NNZ/WR!?>YCI,++_0S M3#I^\W[RP@QWF>2_?$W4:HM%.R3LCW"6#D<4[#`RXJ)HGURDL;XRG[&DEMO M8*E^WRA;&J$L).C3'6V805$;W>!T?O82LFT,3T,\JM'56"YA2J01A'E7C!Z! M#D3FF67M#YD\A=DC`K]E^-M7S\#X6JF-;D8,O8M3@&;Q5J&PE271)%EX$?R= M?HP<`BQG!!N1I"JA5+019>=R,C/PDIZ'^`+0A&./A/6-)$>L$TESYE'K1,20 M$=K\81!(;8GI&[&+.`R]1Z(K@<]@3.[V!?VASX.G\\V^Y\\31ON^E_N&PLBSO>Y[KSQ^YY7<<^@>V]-@,274"'9WT+O$8:8)P"][O>V MWQ\H+H;/03C\3VR]/YE5)K3B]%S%*4:D`P'.@O7HX.QWI&#A.AO>4&6KZ MYSWJ(G&_/(?\6[W/EQA7)_.M"!T%N=-"#[.5?JG_M>5*U?TNL]9G^T:A*8&; MGS#_"\7<5A7Q@_C^U":)&X,H(#K/_*_D8P9\..B7\;HO-<%BF M`.&/KW9_?]L[/1=90KPEKO$6\\)_`R^YBH)+O$0,TKA-]:CA\0ZPB=6U&E?E%_#$"07>&OD8APRRZK]OZ:F^^..D3IN7^)N!\'_N//=U?]*BQ=L5=05\ M[3_!<,LIS)-XJ?-V;*B(&:=[%"IQ.?;$SY\KJ*$Z7].,`E8[A*GOYUP$BL72JB^.T'% ME36V*&'F\H22HBQ9@M8W2_[#VZ:*LE?%I6ID6/$UF)*!WQ,VZ=WH]6C;N_;? M\7RT'6NT&>ROH\IPK67%N8<>*;H9>KWPO%4N,((P19N_-"7'XL^_-.R*Y-$& MQ572D"55>K27=CO-H&$'E=+/:6^)^FR947L;+P3L-D;H#N"=./->^'/2&L7* M3+=^A?<>#&ZB"V\%4Z^IL9"UMD(Y0B!MJFT;/]JCBZ.PYS2R1Z?D5-;:6*=2 M"=1F6QM4DQ!,8L/$_[KZ+8//7DBMFNF%ER3K38@`9Q9J?:W,JN0ZA!-H-K-! MZV7!\^![-=\6^):]BR-?N-TEG2S/0_DM%?>Q,8O\LU'@+E4@Y! MT,$&_?<)6&%!K(CJ%>/.;FN'ZG@%DG1-PHNI\@M?T"NBC,'L%I=X01<;@>K:Y>(B2#R"$@P9%. MJH`HZN)*HYE;GB+:>+&DCQ(BC0_W M7+5Q`AG^):VKTZM")=)!N>K69P(WD4[#57<_P_NMJ\.?VP=3U-I5!T##&XQC MK.GF$WA0NT[EK10Y06VA.G/+,;`U5#QOJQ(H-W4J>D!Q314E3&ZJ5O1@$MC/ M2J#Y#0`#6YJSBWIV5/]R+C>Y8^X:WQ M>[F*_)GL]!C$#&X0RM2I+UH/@G)^GARE+DY[4QT0IZYT2W3R`'H&R6,\_.>N M,WR[5Y+KCD'&0-O<@J[["1D#C!U8WGOF&7N,UJ9D9#%P$4-^)HLAS[N-_HS_ M'68$K=&G!`L^H\]>LH#17^RP98AF4BV+C'$>ST8S.X]^G0C)(\EM;H/VC?"V M><5([0@?$W<)PRSELERR7C9F\@E$(/%"DL8\6,*(IL`A=1X*F#DSD?6R%W!( M5`_7^%[,;>D[@GOB& MP/0M;B)\@P'$VY)]?M$>@ML[3G(@>:VM!IL6&_`<[\\Y-QZ#U]H.Y?F"B\]; MLY4-2N]`6FYX#IWU-E:HQ$]\?OS(82*D%)A)=K.\GY5@M3I)`N19+:V%UW'! MY!$O[F0GV`L!S'L3-_)+\`S"F(9DB*WKA'HYN?CU/Z1ZH==]_#1 MP*JM'-C-!6CX$"IKLNH75T.=V,Y^=T@75BN<9&JJ_46;VC-[\KPWFX;0CW_[ M*#:$UL8HS**6G-*:!G37F/.$BR@/]/"K5<+QO4W_+Z3; M^9,'(T+\&&]1?/0NLP3_,Z_A(EFO?7QY2(A6':GOXX1.*$T3^)BE>9Q6[@BJ MB9;JJ`>(A,3*8VITRPZ&.=&T8N[.5-1]#95&L?FR&]X+.^]_WU>8Z[G-6NY( M%1'2?:?&MH@9.Q1'Y`]I"6MWZ_89Q%C(M'<3PPXCS(=DJ;L.XZ_H)@I@`BHH M%?+7-R0_@5#^PB.,Z!!6"A<%_\E02JO;S^(I\./(AR&H7>RSF)!XG\3/$*-U MOOZ"0'`3;4TC8_S`/N?QO))J'WU\ZE0LY&!F]MZ/L?7XV1^]>(_>=$"3/$=.(G8T+)L8SRW M[*[#6BZO0J+5^6G4&0TMT5O;Y#<1*]<3?PXJG85"[NRO.L!`YD=%MR)!D:ALH%+7 M83Z-;L.8RQ3@[0+]%-`75GDNC6XV(S;(:RH)UZ!-+-F16&)0$1=: M%8,T^*2.@QX>#K*0$3.##PB7F^@9[UK#^T-UT,/#H=W^T!U\0+@PU"C=]X?J MH(>'0[O]H3OXR4^!6W2,IG'[)XP"22`OHZ$=>M>%;G/L_Y;!!'!+`W'GH3R` MI2)P/@`!]5V>8IXT)W8ROP2/@B)P_"YV(NJ4Z!X(K1MFF6;WD`8OLAI;\70H M7&8!M25A,D1:24YCRQX:6Z..NCO&;A9PL/95,5HJ] MK19NZ=%>5<\37=6HN^X+LB]466^ZZUXC^\*6=^^Z[BFR+WQY[['K7B+ZVN=& M+)9$=]C.2^208AQ,(\BR4;6+;#YF%)OZ^'9AS\>,(,M*TRXX^IA19%O2CR!L MVC2*6C9NUXLGF,:W9C=WO:2"6<-3HURX0(GF>JV%_G`58=D^#`[E> M^+V_]=#AN+N5D3]FE+OZMG0K0SQ\UD3%BFD.3U:Q1C=%0D.X:K,NKIE5D75R[1V>Y7CI9%U&]N,,C*JO<`;V=:-1.5997="TP94EZA.#]&Z*2IK.9*Q$AGF430F4F]).)Z!V`X&W<'W0$5': MZ?7VG#CC$B(_C%&6@(LX6<68=P!5H+8EO"M_M)$4XSQ#,`((41UL7H,O+UV\ MV==%6<))0OY-K+:UO*?BTJV&!K>22H&4,)[,?\;/B(?OTV1*O8#$APC< M)]`'VQ]1\2MZSX&AW5B6Z]M^!F0E>#/::65^S MV^I1O8()(K1\\^[;#^\H)>0OOTR2A1?!W[TB^=HE0'X"Z=TSF6].`+Y8`,UI MWB"OQ0![HWG&2`F@V=E*8L8*=5A\0W$(@PVI]Y6[OE)]=,LWR;S@S8QM)Z0% M\\8IN`\]GU(C/-Z@C$>';,GG`;#X6X.F95@C(X72T$K9`":`WYYVW MQ/]9R=PHO,`4.EJ>#WW)RG+9LEG4FUL-@VD\#FC\`GG!@N(^=F:!P_ZMID91/(&NAE890I'[DK@:-F4&-Q4.R=7` M*#,(FM*!N!H>90;EEAJ5_14X.210)2R)J\4?V^DNZF^UD.??`/?NS3NW@B4, M(,?GQS>HO3^A5CN@FL=[N_F]=<>S"A?C7E;'EV0N7^]M*T;ZMYS+P7X@JH MG9!=:0`;\]OB?+[>_N?_XIV+#_[3^A8\@U"@3E7L;'5>-]$J2Q$EYKW0H"7J M874&GX%'MO^R=BRV,`L-0GIC6$F^6&A)MA[V#V!!J>3,B-_>B`9_"A992%JO M\PP.'%NON*V=]'C/(,H`"7S"CP:Y3S[#$*`4\R"?0?H4!]O_Y0"K,8`1I-5> M.:%/A.X0>Z2;ZQ>AT]TF.Z?W+E1Y.\U[RW6^N-4USL23]9(YK?F47<9;X5[K M3+JZX;KMC1)P:AR$@ MIAE\-0E(V6ED0\0>$TOZHK`S1<$=AJ;\2T6!C81J)MU1[(1XA)AJ$H^$'XT* MP9)X#V$G([N%N!T21X;*GF2C+6MM!]6(BB^51+47H0>79!M\B7R0I%@"'"]I M]DLNQAI#V)EC1ORA\!.2KHEE1Z`\9C8ULDLN/0CQZ_7@1;^N8^'%PFEIIV9M M_JX5CP$'M&:K`5!:.>KGZQG^.$OWI==W6+/BZ2!U>@YK1@1IP4!)G)^YFY28E0$],$BTTF4/#N*O0R0MW5"_X7"":4C1\O$L!G M4N3M#5&$I0&$1Y^!9"DB9+>9C=UW"WV2[)WX'(#D&?\/$K\^_/9&T"N&S]>' MCQZKF<'O8T%4]NVRB8U5^^R]P&7&WE[L-F;"@2G>:..-'?!!XK3LA8K<*9SH M5U6I:?2P%+`:9'XZ28IC)'B+F4TMTHPJAU_XY/+;6S&/D_=>`'/YNS7JA.>Y MVL*.>\'6I$$RBJN(*L(NEJH=9HG_Y.$';//V-V50X8Y6[V^I/B(@BFCJW+SE MORJ<[D9W,(OO04+4B]=Q0BM"H%ST$IT.(V,?&"I2H<+,V(;GW'"/_B*W0^UUA8.^LITQDOSC7K;!1U9\!4K%T;],Y.Z#6ON%(_ MM@'IPPFD!DALM>T&KX\GO';>32,JJ0W`WYP`;CX2+.EA`]>W)[B4GXC;8TJP MH>'ITHS9WU4_N!H2TA$L@67=U<"/CHCI>4>Z&O+1$<0V*E%7(SY:0JEA!W`U M^++S)A39BEU-.]?WR=T::EQ/N-020,%&Y==RL=-D>K+H;5;FIW!3IVN/$"^4MKV='+R63WMR&;'+')"`:]1N7L!Z[ M;MKE?>"F=KL?=%6"54MDW=0^]H.L*.U&>1.[J?'H!U%Y0IX25S?E66'1`7XP M=7F`W;2YJ,`BBGHO\7&3Y9;CPXM3+@^4FX^J/C+-V.D2(>?/EHA%MEJ+PA(R MHJ".*C;:40='4,5C"D(OQ:>)B+(5"/K+YD?8,9AN>`^(T8_\-5X-#B'")/:M MQS*4SRU"64@^JY"^A=_85#89X-,IXRV1TE>6+MF_,?O'(D?8WDK!"!C!%-S" M9Q#+>!C"/+,V>?KS]Y_XH265Q35\]`886`S+*F3QO'KCF(RMXW"-N>T MM)(?*$:H>BWX?I)YX3B]P)?^&O^19L#EH*S6UPBVJB?6P$D54B!,0]-L8BF' MRQP@1!\EDEN[D%PWMB]RH^&=QUE0Q` M9J`,_C"BKSD4W4H2/DJ[#6@N^.&N_J*_Q5@#'%@FEU-^FX/);V,H4X;_!(*, ME)A4V]2BC+7MQC+"5C@#G[7>8C)C>$B"N#ER:&C_7PV_;0*>J7',]WE9?$<%[,H_G MG3PY>QXH_@(7+Y[%Q_7XW4[*%P7NF7F1.)](SB"J1I,R.7LI]+V-CR0CG3$8 MM31ASN>PZWMWWAY="58VBM6_%QP\.E8?+C.VF8L84=?!#9I5(CDF&&$7BW6S M*%T\]Y=J$]OVX`/VB3C9X@=HBS_95T_V53?XJ+;FK9/:D_T6GDP0NPB).9XC MM4*FBS;#4DM`E!Z#KP$LTV; M_YWB=>-PH1H#6!&:\_3'MS'>;F/_MXP$`-]$=/?AC747IP7](+B.DS$B:_,` M_`SO'`C0)$M1ZD4!GLBY%WJ1SP/!]%?LJ!?X-7UVU`J,IG:*P#^F-Q'FW3-F MEM,&V;S6]BDO,AB0<'TUXFL=[-,_!0%8TNLUS_`LV#L*'8._LF>L:O]R9HGR(@&-3:LD9UZEY%S M.ID31@L+*VF!K8Z M$K?K*DX-V$0"D^O6!0V8%+D8UUVI%1#CH9)')&MZX7U6.D:K?P):XUB<::5);A0 MF1.C_:"HEV]%2;]AS8:F7E;:;++.1E3MQ;=FWLLX"R#YPBU8>.$U8%LS1,VM M&,V6JS!>@TT4D/+>E_>S$YV2P@5]GDBL9_(,I%M%U,/&#&BXJ>Y%).DTH'E( MUT/>STKVV/R91IMWV@MY5G.5'C8YT6Y<3-W[77#67%?"FH-1F[UR725K#EJ% M.ZB;3!63M3H2,%49LFY*VX-`5(W-KAGUY%R6ZP9V+=SDG+7KAO56VTS&/+IN M9F\%FA)>;8SLP[_+%-A:M2=@V\EUBY,^8JV>W[*4G;-!5`]I[/_ZZ"$07,1+ MHM7-EW$H854D`#V.*)$7W@KBH_SPA'<'*F0=XC9WG:5X'C<(9:+`(NUQS+B` M%PQ';J*AV66]2BW87;V4N(--S52119+"=M[<+_CP$*L3",9?O21`,W+G5G\G MYJF[./TW2*?`CQ<1_!T$N6$3`U_\B;1[+U%S[8D(IW"FF[XHO+AO>&O?-E0C M#?A9"I_!9#['I";DH%S"!/AX`-&Y4NAFI@X3O7+O0R\2%&)JMK&B2\.?EX0G MUIK8I%'HT]]H9"4;#?/`5#(:GJ_+)H7++3U%]!\_X5,%HT5^%?%N0*.?L(;1 M+J.Q,X''Y@3*I-DY^2*`C(QOY!YHO5XWD9\`_,>;:.-3FW,JXRQ]PCPDOE0O M`?(32"]5UNVRIR\?U#EK3.C9@R$1!/"[_PGWY1D/>OO<06%7/-^4YWS+T5;9ZN7;(:Z[LIM$[KK!.UQU:N+S4`PL#CH9!V4!Q+,?>?J+14?PM, M,R^B3YG9FT2"VSDRMYP,(4I=>J2+%>_4'LC'?&4R)_^@-O@F>84`*NO#%3G;;05#],TR?J/&0(/H$5[/X*DJA M)+VM[BA6%>L,K4"MQ$Q#(G?=8YRM@2BK8.UH>TJ3@5L!H8/B!IK+('P,7-VB M.L]S/0Q+VZ3BJE.$+H1[U>RXZEK1=M_V("2ZZHAA"V*FCLC5%`E[!UFJQ'35 MVW?O2#/-,JXZ_'9"UXQ!Q]6"=,.XAQ4TSZZF>&B]`"W4,Z[ZW.W]?A"J3_?G MDG<8*._);:B$_;@E0%M><27^1R,,UH#MIN/B7?U?*F=TLG90Q$L4M]"5_?.I"!A6R427HH MG\&^Z(K$/47\XRPN^9:<1?E"4D_.GD!IU[*2XB>D@X.`S585D^!86Q4[#];% MOZ`?_Q>I$U5G"VD=-Y[O15]?L8'4)Q"!!+],Q!"XA!$D=C]R<1:K)ZQ*H=;7 MQJSRO,$/^&J@\N]ML0("5PA1CP'-0.C^(.YCIXH``OC!>B+/+W@&8;PBA*GL M+96>=LOAFCG]:N5R37[KY$BY9T=*"ZQ?3^]?+=)7D75PU?*K\=1489/X?9^+/FK@YR4*P0RV;9 MSY[9W_LY6*548Z7&"&5Y?GOT!5&?TPLO]#.B!8P6U"EA,J\Z,V#B3`@();V% M15GD9(&X[D$"/M_P%VP(DY^]%[C,ED)!N-[&"I68@9!266MC1=5`EEJ@X"E_ MMT:=6.%1:6%7L='^,*DI,[J.?U!QLUO7K\H]3+AP'U^TE\0N@]\#0:WZ_K][ M4/&>HEF1NE_"G![]?-"9W?A33'B"$/,\^]Z/C2\?/*)3B'Z]3@"H5\;L'T_F M=^WF6,'LYAQ`$N/$`,'HT`>U:V2610,#G]3\[JKY>Y2PV#)Z9Y;0=;WVCO11 MTV%7F?^C0*(NZ52Q:`B3KFON96C4%0#'HX\W)&/NG+*CT[CW`*0)KL9=Q;IY MWJ\>[SX`EL;AU1L6SJSU-R%EN>IS,=35VZ.6T.T8_R-;VJ;*S>VT`D>RN&SM MG]LY#0:^M#V9&HZ@/K7,V:!2M&0*%A@VO(25>.:QG^+7*UW;B&TY&==/QO63 M<=UIX_K@S"C#2-)=/)ID/7M-TKW[G0-'2\1\](^A\.MVS;B3!O\3DY0QLESP M>_GDL''1V%`6"3G$4UNJO$AX>IGH;)N+JZ?S*O^NDVA:N!F[T72(JW!(A5]Z MNDF%^?2F@,0[X=N,E(HG`G_FA404[^,F;4?((>ZZ0RGI$-< MYH`.`EGM77MR1#RFPDW\N?.>V#/3'OX=*#G$6R//]9HSU!JR_-X_/PAN-*?6 MHCRO1\`@]R-7W]S(Z]RKJ&F6B(/$62C0[`5D#0J.ME#EL.0,<)5[^.>EZ)3C1NW7(&'O>D5 MK,JN.O(.>V%8YI!N_K?Y\W`5!:?EZ%.+Z&J]L[[#`/OTTG*U?MJPSPS#*]/5 M$FO#7@AE?7ZG4FPG\6-_^FI7:[8-?(DT33>NUUL:YFW7T;6S7+23Q#^X)ZHF M!+4IPW640I`-UX!RE4Y:`]MBD.I*N54A?=@7GG(05KD\)WW"G@Y22Y_\0GB7 M$UNGL(0EHZ$5>N/E,HXH%?=>,DEH9:>`IH/!JTGAY$U`H:?E&>6[(;='RV=1 M:VUF#V_/\?;,"'8QM[&5NL*_9?AJY$2#P*I7!)=M(V+=%DOG/`Z=]9 M(&KT[H_:QNU]!YC1-*I=>Z/S+HZZ`V<:YV> M1JB4%"`L2WC=1,W599'>93@C\V$M*O_2$K0V0PVU'S+.,),8;F.CM+#F+"*' MV=XH1=M-+J6ET=((%?BU]PD[O&!<8)O]2F8^1I+-S2+R-(5M1&6TFW^L1M'C:,5\3F[S5'L*D[Y^N#ME8+$JQ5T6D.FRYZZ'BFJ#:!`4G(]UE,;*[%. MV?4(3&VX-,U8^RM;,GS\6(H3UT,66Q]'X5ET4Q(WJ!:ZU>[Z0;1*6#,1:!4/:I]Y,1>MQG(S"L(,G64) MY^`_&4K)X2HAY)`M[F,M+_D4K++$?_+(3H@7B;?<5;%AM;5!]&R-40W-'/]0@7=!A$/2+P@(XC>W3O;[TEMX"'UF2 M`J)P^%*:`[/C<.;S$&?X$=>?3K6?$?9TDJ6WF+^($+@&@!_IR6IF.USI$JQB M!#%=WB,,\86^$_NHV,GZ/%0CQH87)H;.U]5?]*/W6`/8F1\"F/]ZPD_H)7@& M8;RBB6=*_=[F89K%F,DD3,-UG$S2)\P*G:]GF#KAU$V,?6"H$+HE&]O$V&9" MDLKR3KLW7_FCU4B9-IQB52#@L0.NAS#(V;BZFSF3575=0Z$'DNP-=ETMH8>6 M`O_GNKK"!&!U`ABZXJPIWPUY!TMT>>J5S;7Q2<-=O+0_:( MP&\9_L;5,S#CQR+-8,O6P7`:&5$;U(9EZCJXS0SE%XU7(*F'JHH2C');F\F$ M2"JGWB>Q#T"`KO'A(N'L)"#H)L)K[X7W&1:H_(8M M;.S.MJ=/O_]PE-'LY)%J?:QXN7DT#3[QF+KSEO@_55,'*G2T/!_JJ"1)&\YM M;LWCD%>O^@Y\I3_QTZ0I=1[AA`+UE7'BX) M\NSVULH"<25D1I:H(U#XR"3W2C8[OG3M:D(+F="Y!80Q;6"IR-&N)S=1%_6J"ON*BLGU!$TROGTGQDA!5G/=54<+,ZYL[KJ+CK&= MQ9&67??84<&OE=;?=<<=G8W7"C8W<]GHP";1`[ON6R%3O=2N-J:JPU4N747! M(T)GQZO+66\E'80XZ@_G/=]D&/&4*QM@SHX:&*8280/-AV.%1O[\I*5%E M2RYHUS5-RFIS`4Z[Z@-',\_)E/,<69BKC'$VL]1=G`(TBZ]AA&4,+%YL%[ M@(L(SJ'O1>GNFIRNA0[T=\*;/<-.0Q[.<>^&W.EH:P&V^<-Q'7&.NW`!9.V- MH5]:\XZFKB24K#^--A`'+Z+;)2>1`K=;7BA-_A,\&F'DOXI61-K=!^QWX M6MG#"3[=6>2#"J)J<](>QH[#-Y9FLTUZ=7(FKN-D'.(K-J+9EXO?BW23XMW8 M;BPK+F=@0=9A"E9QLKVH%)=5K:^-67TA54$V96]XWG.-1L-G.-3O?-?=$O08 MM.9N<-T=00\=Q1O`=1\$/=!:/A:N^R/H@:C([[GNC:`'&I^==-T500\G?=9U M?P:,P4CBO.HC`U&UZY#'YO%T1C@X9;Q$^V!F;)LGWB@Z]<1[&AOK"#5TO(PZ M`[D7>.1)#H2TVY!2W:K?<3HC##%-DYC/UD#G=%!%^%#W("MZ.:UFYC4<> MQ5FJ.M,=YM`.KCY.1WAZ+\'C4%CM.BF2D\EI;.,\\B!4(7P8ITN,?/5,<>=Z MA$>GD.W1O;>F1<*C`/\ER?"E);+_GI)*MB98^=[6E76V%B=Z'69%^E`QS0J=6!Y0@/:GD(B?EY M20(@Z<<+!O\B1BFB8+5=AO`;@`23/T`?EJE5G,@XI+=1D M4_A._(YG0C-@T.FI,QZFOV<7/3;YU70@8S^%S_A0:_)GK0<>"A[%-J<%>:ID M$\>1?(T1RI:K-JI7(Q]QZQ'K\3R[[I/8YV*8.0ZN^SWN9P5T+^C].4X.AJTC MOAI92!RO\K16G16QW)(4\N_4'P'E;C:>OZO?,KR\$B:QT6/36TEIJK`Z M1RCT7(0>0I/YSQ[Q.Z(%5J=P\6194U+Z2EX\$6\H0M95DL3)18R70\E>KS6$ MF9(T4B19IU_::1A.KNKK4)XX.1['>-Y4BAE;]G-M46YYQ]-59PP;SYOF.G28 MYC".'9;J8GM'J,'2I3(5?$<=O;SM'4,EOE@![)']X28HF0BO_G M_P%02P,$%`````@`;X(-1T@0/J#R#@``@)P``!$`'`!P:7)S+3(P,34P-C,P M+GAS9%54"0`#TOO,5=+[S%5U>`L``00E#@``!#D!``#M75MOX[82?B_0_\#C MAX,M4,=QLKOM!IL6N6R*`-E-X'BW/>>EH"7:YJE$NB25C?OK#TE=3(L4+=E. MH@7T$LCBS'"&W_`R0XIY_^MC'($'Q#BFY+0W/#CL`40"&F(R.^U]ON^?W5]< M7_=^_>7[[][_J]\'HQ&XI(2@*$)+\$>`(L2@0&`,'RFA\1+C&W!T,`1@+L3B9##X^O7K`6-A+N0@H/$`]/MY!5]254[`VX.CHX/7 M1LF()B0\`4?&JPN&H)#4()1*R*+#X9O^X<_]X=%X>'1R^.[D];O_FM1TL61X M-A?@5?"#)#Y\TY<$2^IX`I(W2^_X[D-*>/$Y8A-0!,A@B3#YR\.ABE6;FY58+)E:PW?OW@UTJ4&=\/X,PD5!/X5\HJFS`EG- M\'7_<-@_'JYSB>4"<2>;+G'S+3!;;[$%1@QS[0P*Q<.WQX<&.9'@)+';_%"P M@:II((GZDDK*"4S6S7P6CZ()1<%FMO2;05IH4`?2+P5;KI-S%!S,Z,,@*U1& M'5NM$"2,R)0&L$"5F1_**DO(>$4*''*OU;O5DL,)G2[*=\ MH3KD":,1&DNO!.KA\^BZ2D>1#;@#13>XI$&BM(0D_$`$%LMK*9G%NKX>P.%I MSTM1Z)!K$:(I)EAK.SP<@C[(VR-\9,+J7RFI7NIU>82)'=PRC.\JU M)A<1Y#SS*(762#+\69/!#]ZQ1*P0!-0<2$)$U-PLGSB-L)HY0W`.(S7?@/LY M0H)W&.Z$X1V4X[:8(X%ETS0&5'-O0/7U-JB"5VN*_="AO!GE:[D4CI$;PZS, MC]2;>D@5)!S0*;A=J%6U%-#UQ!H8W4J/9FJUSM!<-BU^0#[4*JG].+ZU<:Q" M;TTX2*6#5S>4\Z[+U8#S`O+Y542_\FL28H8"X<;1)O,#^-,V'5%5`G0M'7(5 MR'VB`O$Q+2:T50/>LADD^!]MRZJ-Y8\S$MX9=AJSX8KY$O,@HCQA:(P>Q7E$ M@[\,/WC&2OU>];-:$!=1Y/61X6/:0$7I`).E0W@+E$8K4 MS"UC&[$<2TPX#/32>5N4F\CSHSRT4=:B^UHV,(5WN#?&_1)-MN[)5;Q^/(_* M>"HQ'7*-D$-AA,<25W1UKUW6]E^Y(_+R&="`7I< MJ""BZ[];]-^B/64P)T-FV8[:KFR0O*!<\/LY9.A<;25*/#57PWZ^8QU^KWA= M]HI[(9GZZ=9G8%37><<6:S?"DTBM@#4^6X\'=>3X47YCAWBY2)#*[.!M#J]* M=]].?X=J%2U';1*F6^P-P=THQ0_MVS*TN:0.T2TZ;!QCD<[!1(ZL.GI%)-AA M+F\HTH_U3W8W+J3K4'Q-?N<`C1W@/IEP]')4_=5LZ3YJQ&:L@KIXO-9?J=9PC1XZN*GL# M7J42.V=XMF1``\?8K0:_DU@IOG)BH'.-%\L0-'"1_=3D=Q4K>UB5+>A<9N-Q MQZ(9B^U68[?U+`RU3C"R3T%NP>A'U`U'6)!,3=8:P:6%U?#NVEMOXB?TN8"47NA@KPN[VHROU;.K"?V`6JE&):CKL7N`+@N:/L6OVV":L7\&,KM6>&XJ;PKG<_ M&>2KSCJF0N5B)-%YF2CK8=GD.*:K',S95\A"_IF$B(WGZ$YK<1?!FD[S5)7[ MWGQO_ MCM39`^D<#XC!&3KC/(D7>GGW6?)<47:1MQJ9?8%1(EENT_+?U)F#_-//YZS0 M[Z[>A*7'77.]^IEBP-`,*-6`'$:!H1S0VJ4?OJ54F8*=>^[//8W):X1F^!'(-.E]JDE5?/S17 M,Z->A\GO!U9&U#IKUZW(]H!O<6"N#JY^8C^>5GHS%];!N)=N6GD^KF:/;L(])OW1JKEX<78O)C[65W+2.W77XRM?JCUK$C-`4Z`NW3M2- M4Z<]CN-%A'K9.\@"Q>^_JFNP8'2!F#JL,LC%Y@(L[O6[P;33E-HOTRJ7,&=H M>MI3MW+U\]N/_I0RU?A[&&X9+!8?AE M(>8;L3N"$Q35-%G2.DR^41*^$6O+W;R&T9+%8?3:WKO#]O<#\^8N^6O]9J_W MTG3*!"#.6\8JKOD#Z4V"-S30@CPLZE<_Y^NK5_WA4?]X>/#(PTS%)AJL6KJ9 M!CE?4PV\UP-6Z:#K=]Y'.$"1X(6L_DI6\^9P7B-8JU5,SD\IHVJ6=ZI9AF]W MT60[+;93P7G)85VOR!E4I6\:.T+Y>LD=_$"]:>H&F^YK]*KCXLM_]%="ME#$ MNLZS7NTYDWZJJ#^[X%,K<-K+ M]G;'\/$LD=&+C(MOT`Q&5RC??59+B#^]5.D22%_Q>Q)3(H,=MKP6*%;Q00_` M"1<,!N*T-X617N)H0KGTP30<:]9T>A=YT22]Q>^T%S`D*^L!@M4])&JM(J06 MLBED["47+XEJB-\8319Y[5C66F%F$9I]Q)'T3:EF=JKY(XHGB)FV;B1-#4[O MZ#T):0PQ<=F;*FN;&R8LBU/W8=B,(?U[C%B,B1;\B0H:DH)K,G!244)R&.U:5W:1O5L.%2NTJ5%7EIJ[PK MBI"Z8.R:!'8_LLT\D;]_N0YRH8;)5$JZ M66!A5$G1)J1J?AN?&K29MG4HT5@&*.K[FV(^<0#E(6H55D6*>Y7<7BH4*LZ1 MGF7JE4S=3L0SC_#^=LCWZ8HQW(%I)4V[(*UY\TC)*`]U^[H@S6\8]L%53=0F MO"XAQL$ZC4NK;'MPK$/<*N.,KRM7A^C6#G&N M+E/DYTOK2TM]A,TQ=.Y;<(L&U/R_+)PY_E^#JR5JD;?(O@_Q(J)+&2^G.\]J M#(4N7]]`UR8W__!W(AO^(Q)S&E[KC,]J:YT+^[V-XM82V@2L9(C5PN4*8I8= M.[26W?J]:7@#IIW3*RMS2_F5$$WVE%YQVE-:*7Q"8E,+N#B>SOP]II=%U(Y-:$*=:#D M45JAA?\'P76[?&0FCC/UZN66QEHU%&:G5RL7QWZR=@$DTJ2K&FC#&!"N=U.!0?)D2T!G! M_R"Y*"C/%4:+["3EFYAN)!GG=XP&"(7\BM'X6J*L:KE6!W9@=)=,(AS((16I MI9'9-`T9OP6GN9'SAH2U>NRJ(FA3M\]T3#MME07KI>U37[I,A>I&29O4+K() MV<'0]3TF9VDK=YE*FEK[3!7EK83BEB#+B5R%K51^_)56*V\4MDEY5[QA&>$C M:I4QB=+)$4R;ME33K/5N_>[E5N:YFJZF=UCC)FNC06IS)Y@[C5@5F8IC(M`, MO6"0E*M7++"K0"@3M,J*+"*0(3<+,$>AU+&%[OO6$5MZCPC-%/?[E&V/..RF5U[D-4D+9HN1XC+L3.8ZVG//@QA MQVMU&=H%EDOG>\0>Y+Q8U\0R>1L--/ZOIK&98IW7KD=N>NG+G]D>H0<8)3!= ME.71D$3HBK(IPF(5FF8#Z)JY35E;-$+>0T*GV/+1]==M\L6-QX>J3@]E<*B[ M0^6RR;1U7Q+;!.NV-EV3@"'Y\IKDJ8'LDIA$S"E3FT]&^+*/1FQ88;VYK>6- M7(3XZ5[[F'Z18X:,H]371.IBI+0E]M&Z=6O:,=U6?`C5YE8M7<.6)UAT?N4Y MVMI?_]K@H2OX=AU;WPK'KTDZU9?L'B$U?ZBX@1)M50(C=:AACQ!L67^[5B3: M0OL65:L1)A6-4-/S='R7?SBX.J?KBCA:HU&+`IQ=7?6+7BT^_RC5L-[6C4[J M_Q#^3XZS8[I:A96;QTW3IITE]WVVKHSY1LHV]0FGKN6LN)>JE7GP>O]@QHE> M4\XVH5E+=PO=)ERM1'L\L0\%&>_:%!,;W\6;:98BT9NG=^4`2-;.8#9E;%&$ M.T[L0[+&NS;!DWWTFTVI2IB5,JLF>=%%Z?M!>GN'?/P_4$L!`AX#%`````@` M;X(-1^8(DZ&UL550%``/2^\Q5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`;X(- M1\!9,?:9#```=J@``!4`&````````0```*2!6JT``'!I`Q0````(`&^" M#4=">GW[Q!X``*[[`0`5`!@```````$```"D@4*Z``!P:7)S+3(P,34P-C,P M7V1E9BYX;6Q55`4``]+[S%5U>`L``00E#@``!#D!``!02P$"'@,4````"`!O M@@U'+T2R2WM7```R\P0`%0`8```````!````I(%5V0``<&ER&UL550%``/2^\Q5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M;X(-1[FWV_6/+```3D`#`!4`&````````0```*2!'S$!`'!I`Q0````( M`&^"#4=($#Z@\@X``("<```1`!@```````$```"D@?U=`0!P:7)S+3(P,34P M-C,P+GAS9%54!0`#TOO,575X"P`!!"4.```$.0$``%!+!08`````!@`&`!H" (```Z;0$````` ` end XML 17 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Revenues
6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Revenues

3. Revenues

General

Pieris Pharmaceuticals, Inc. has not generated revenues from product sales. Pieris Pharmaceuticals, Inc. has generated revenues pursuant to (i) license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments, and (ii) government grants.

Collaborations and Other Agreements

Allergan, Inc.

In August 2009, pursuant to an agreement with Allergan, Inc. (“Allergan”), the Company granted Allergan a worldwide exclusive license to develop and commercialize certain drug candidates for the treatment and prevention of ocular diseases. Allergan is responsible for the research, development, manufacturing and commercialization of any products resulting from the license. The Company received a non-refundable upfront payment of $10 million upon execution of the contract in 2009 and is entitled to receive up to an aggregate of $13 million in milestone payments upon the achievement of certain commercial milestones or patents granted to the Company by the United States Patent and Trademark Office that cover a product licensed to Allergan.

At the inception of the agreement, the Company recognized revenues from the upfront license payment because, based on the stage of development of the licensed product delivered and the development capabilities of Allergan, the Company determined that the license had standalone value. Through June 30, 2015, none of the milestones had been achieved and, as such, the Company has not recognized milestone-related revenues.

Daiichi Sankyo Co., Ltd.

In May 2011, the Company entered into an agreement with Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”), under which Pieris AG will use its proprietary Anticalin^® scaffold technology to identify drug candidates against certain targets selected by Daiichi Sankyo, with further development and commercialization performed by Daiichi Sankyo. For any targets selected by Daiichi Sankyo, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. The Company has handed over further development responsibility for the two collaboration projects to Daiichi Sankyo, which handovers occurred in March 2013 and June 2014.

Upon execution of the agreement, Daiichi Sankyo paid the Company a non-refundable upfront payment in the amount of $10.1 million in consideration for the licenses, and for each licensed product, the Company is entitled to receive potential milestone payments of $91.1 million, plus royalties on the commercial sales of any commercial products. The total milestones are categorized as follows: research milestones - $2.6 million; development milestones - $37.4 million; commercial milestones - $50.2 million; additional diagnostic milestones of $0.9 million. At the inception of the agreement, these milestones were determined to be substantive as there was substantial uncertainty the milestones would be achieved, they would require substantial performance from the entity, and the consideration was reasonable relative to other deliverables. The agreement includes provisions for the Company to provide research services funded by Daiichi Sankyo at agreed upon full-time employee rates during the initial identification and research period.

In accordance with the guidance in ASC 605-25, the Company identified the licenses and research funding as deliverables at the inception of the arrangement. The Company has determined that the licenses and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin^® technology against Daiichi Sankyo’s selected targets were necessary before the licenses would have any standalone value. Therefore, the total arrangement consideration was recognized over the estimated period of substantial involvement, which was determined to be the period Company was required to provide research services to discover drug candidates against targets identified. The Company estimated this period would be approximately two years. The Company reassesses the estimated term at the end of each reporting period.

The Company has not recognized any milestone payments as revenue for the six months ended June 30, 2015. The Company recognized a milestone payment of $0.4 million as revenue for the six months ended June 30, 2014. The milestone payment was based on successful in vitro and in vivo studies. In general, milestones could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined these milestones to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestones would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Daiichi Sankyo Collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.4 and $1.1 million in revenues, respectively. $0.4 million of these revenues were related to the achievement of milestones during the three and six months ended June 30, 2014.

Sanofi-Aventis and Sanofi-Pasteur

In September 2010, the Company entered into an agreement with Sanofi-Aventis and Sanofi Pasteur (“Sanofi”), under which the Company agreed to apply its proprietary Anticalin^® technology to identify drug candidates against certain targets selected by Sanofi, with further development and commercialization performed by Sanofi. The agreement included the initial identification of two targets by Sanofi, with options to select up to four additional targets. For any targets selected by Sanofi, the Company granted an exclusive, worldwide license for the research, development and commercialization of drug candidates identified by the Company. In addition to the two initial targets selected by Sanofi, Sanofi exercised one of the four options and received a license. The remaining three options expired unexercised.

Upon execution of the agreement, Sanofi paid the Company an upfront payment of $4.9 million in consideration for licenses on the first two targets and options to select an additional four licenses on other targets (with each option requiring an additional upfront payment upon exercise). Additionally, for each licensed product, the Company is entitled to receive milestone payments up to $51.6 million, plus royalties on the sales of any commercial products. The total milestones are categorized as follows: research milestones - $1.9 million; development milestones - $29.6 million; commercial milestones - $20.1 million. At the inception of the agreement, these milestones were determined to be substantive because (i) there was substantial uncertainty the milestones would be achieved, (ii) they would require substantial performance from the entity, and (iii) the consideration was reasonable relative to other deliverables. The agreement included provisions for the Company to provide research services funded by Sanofi at agreed upon full-time employee equivalent rates during the initial identification and research period.

In accordance with the guidance in ASC 605-25, the Company identified the licenses, options to obtain additional licenses and research funding as deliverables at the inception of the arrangement. The options were considered to be substantive at the inception of the agreement. Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.

The Company has determined that, for each program selected by Sanofi, the license and research services provided by the Company represent one unit of accounting because, based on the stage of development of the licensed product, the research services provided by the Company to identify drug candidates using the Company’s proprietary Anticalin technology against Sanofi’s selected targets were necessary before the licenses would have any standalone value.

The estimated selling prices for the licenses in the agreement are the Company’s best estimate of selling price and were determined based on market conditions and entity-specific factors such as considerations of preclinical and clinical testing results and the Company’s pricing practices and pricing objectives. The estimated selling price of research services are the Company’s best estimate of selling price and are determined based on market conditions and entity-specific factors such as internal cost considerations and the Company’s pricing practices and pricing objectives.

At inception, the total arrangement consideration of $8.1 million (which comprises the $4.9 million upfront payment and the expected fees for the research services to be provided under the remainder of the arrangement) was allocated to the deliverables based on the residual method as follows: $3.5 million to the licenses, $1.4 million to the four options to acquire additional licenses and $3.2 million to the estimated research services to be provided. As the license and research services were determined to be one unit of accounting, the consideration allocated to each license is recognized over the period of substantial involvement, which was determined to be the period the Company was required to provide research services to discover drug candidates against targets identified, approximately two years. The Company reassesses the estimated term at the end of each reporting period. At the end of 2012, the Company determined that the required research term for one of the initial terms would extend to a period of 40 months, and management updated the estimated required service period to amortize the remaining deferred upfront payment over the new term. Two of the four options expired un-exercised in 2011, and as a result the Company recognized $0.7 million of revenue upon expiration. The option term for the remaining two options was extended to February 2013, and Sanofi exercised one option to obtain an additional license. For the exercised option, the allocated consideration of $0.28 million for the option and the $1.1 million payment of the exercise price of the option were deferred and amortized over the expected required service period of approximately two years. The program covered by the exercised option was terminated in December 2013, and accordingly, the Company recognized the remaining deferred revenue upon termination. The remaining option expired in February 2013 and the allocated consideration of $0.35 million was recognized into revenue at the time of expiration.

The Company has not recognized any milestone payments as revenue for the three and six months ended June 30, 2015. The Company recognized a milestone payment of $0.3 million as revenue for the six months ended June 30, 2014. The Company did not recognize a milestone payment for the three months ended June 30, 2014. The milestone payment was based on successful in vivo studies. The milestone could not be achieved solely upon the passage of time. For revenue recognition purposes, management determined this milestone to be substantive in accordance with applicable accounting guidance related to milestone revenue. Substantive uncertainty existed at the inception of the arrangement as to whether the milestone would be achieved because of the numerous variables, such as the high rate of failure inherent in research and development activities and the uncertainty involved with obtaining regulatory approval. Therefore, the payment was recognized in its entirety as revenue in the six months ended June 30, 2014 when the research milestone was reached.

For the three and six months ended June 30, 2015, the Company did not recognize any revenues related to the Sanofi collaboration and for the three and six months ended June 30, 2014, the Company recognized $0.2 million and $0.7 million in revenues respectively.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based Compensation - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Stock Based Compensation [Line Items]

Number of shares, Options outstanding 2,616,735 2,544,500 2,519,500 2,616,735

Number of shares, Options granted 72,235 25,000

Share-based payment award, award vesting period 3 years

Maximum term of stock options 10 years

Weighted average grant date fair value $ 130,456 $ 176,898

Number of shares, Options exercised 0 0 0 0 0

Options vested 200,673 375,319

Unrecognized share-based compensation expense $ 2,253,478 $ 2,253,478

Recognized weighted average service period 2 years 6 months

Pieris Plan [Member]

Stock Based Compensation [Line Items]

Common stock reserved for issuance 3,200,000

Share-based compensation description (i) 1,000,000 shares, (ii) 4% of the number of shares of the Company's common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company's common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014.

Common stock available for grant 583,265 583,265

Pieris Plan [Member] | Executive Officers And Directors [Member]

Stock Based Compensation [Line Items]

Number of shares, Options outstanding 1,470,235 1,470,235

Number of shares, Options granted 40,235

Pieris Plan [Member] | Other Employees and Consultants [Member]

Stock Based Compensation [Line Items]

Number of shares, Options outstanding 1,146,500 1,146,500

Number of shares, Options granted 32,000 25,000 1,089,500

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Authorized Description
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedDescription

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock Based Compensation [Line Items]
+ References
No definition available.
+ Details

Name: pirs_StockBasedCompensationLineItems

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=pirs_PierisPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=pirs_EmployeesAndConsultantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Accrued expenses

Accrued compensation expense $ 333,979 $ 332,892

Accrued audit and tax expenses 148,500 403,450

Other accrued expenses 153,082 7,523

Total accrued expenses, current 635,561 743,865

Accrued expenses non-current

Reserve for litigation TUM 302,273 327,937

Accrued expenses restoration 5,577 6,051

Total accrued expenses, non-current 307,850 333,988

Total accrued expenses $ 943,411 $ 1,077,853

X

- Definition
Accrued Tax Audit And Legal Fees
+ References
No definition available.
+ Details

Name: pirs_AccruedTaxAuditAndLegalFees

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 410

-SubTopic 30

-Section 50

-Paragraph 10

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 410

-SubTopic 30

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

+ Details

Name: us-gaap_LitigationReserveNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherAccruedLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) - Jun. 30, 2015 - USD ($)

Total

Total

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-option expense $ 268,039 $ 485,375

Research and Development [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-option expense 78,551 129,590

General and Administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-option expense $ 189,488 $ 355,785

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) - Jun. 30, 2015

Total

Total

Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]

Forfeiture rate 6.00% 6.00%

Dividend yield 0.00% 0.00%

Expected volatility 73.70% 74.10%

Weighted average risk-free interest rate 1.73% 1.71%

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]

Expected term 5 years 3 months 18 days 5 years 3 months 18 days

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]

Expected term 5 years 9 months 18 days 5 years 9 months 18 days

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate

Namespace Prefix: pirs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]
+ References
No definition available.
+ Details

Name: pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

The following is a summary of the significant accounting policies consistently applied in the preparation of the accompanying condensed consolidated financial statements.

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements.

In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period.

Use of estimates

The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.

Segment Reporting

Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit.

Milestone Payments and Royalties

At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount.

For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met.

Fair Value Measurement

ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.

Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents.

The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014.

Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09) which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements.

In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual items” (ASU 2015-01). The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”(ASU 2015-02). The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company is currently evaluating the impact of this new standard.

In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements” (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the “Codification”), correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail) - $ / shares
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares, Outstanding at beginning balance 2,544,500 2,519,500 2,519,500

Number of shares, Options granted 72,235 25,000

Number of shares, Options exercised 0 0 0 0 0

Number of shares, Options cancelled or expired 0 0

Number of shares, Outstanding at ending balance 2,616,735 2,544,500 2,616,735 2,519,500

Number of shares, Vested 799,068 799,068

Number of shares, Expected to vest 1,708,607 1,708,607

Number of shares, Exercisable 799,068 799,068

Weighted-Average Exercise Price, Outstanding at beginning balance $ 2.01 $ 2.00 $ 2.00

Weighted-Average Exercise Price, Options granted 2.89 2.85

Weighted-Average Exercise Price, Options exercised 0 0

Weighted-Average Exercise Price, Options cancelled or expired 0 0

Weighted-Average Exercise Price, Outstanding ending balance 2.03 $ 2.01 2.03 $ 2.00

Weighted-Average Exercise Price, Vested 2.03

Weighted-Average Exercise Price, Expected to vest 2.03

Weighted-Average Exercise Price, Exercisable $ 2.03 $ 2.03

Weighted-Average Contractual Life, Options granted 5 years 9 months 18 days

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-Average Contractual Life, Options granted 5 years 3 months 18 days

Weighted-Average Contractual Life, Outstanding 5 years 7 months 6 days 5 years 3 months 18 days 5 years 7 months 6 days

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-Average Contractual Life, Options granted 5 years 9 months 18 days

Weighted-Average Contractual Life, Outstanding 5 years 9 months 18 days 5 years 9 months 18 days 5 years 9 months 18 days

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber

Namespace Prefix: pirs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Out Standing Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: pirs_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm

Namespace Prefix: pirs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price
+ References
No definition available.
+ Details

Name: pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice

Namespace Prefix: pirs_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 10,027,305 $ 18,474,211

Other current assets 1,866,180 1,207,072

Prepaid expenses 732,221 109,332

Income tax receivable 16,015 14,810

Total current assets 12,641,721 19,805,425

Property and equipment, net 1,811,356 2,052,221

Deferred tax asset 24,446 26,522

Total assets 14,477,523 21,884,168

Current liabilities:

Trade accounts payable 2,058,458 1,260,015

Accrued expenses 635,561 743,865

Other current liabilities 304,012 242,755

Bank loan 1,270,605

Deferred tax liabilities 24,446 26,522

Total current liabilities 3,022,477 3,543,762

Other long-term liabilities 307,850 333,988

Total liabilities 3,330,327 3,877,750

Stockholders' equity

Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014 29,430 29,280

Additional paid-in capital 85,503,241 84,627,283

Accumulated other comprehensive loss (1,343,694) (843,097)

Accumulated deficit (73,041,781) (65,807,048)

Total stockholders' equity 11,147,196 18,006,418

Total liabilities and stockholders' equity $ 14,477,523 $ 21,884,168

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.5(c))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Subparagraph c

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 9

+ Details

Name: us-gaap_IncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_LoansPayableToBankCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Cash flows from operating activities:

Net loss $ (7,234,733) $ (3,661,542)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation 154,555 189,463

Non-cash interest expense 181,951

Stock-based compensation expense 485,374

Non-cash Restricted shares 390,734

Changes in operating assets and liabilities:

Restricted cash 13,091

Trade accounts receivable 68,553

Prepaid expenses (628,723) (72,570)

Other assets (768,905) (240,743)

Trade accounts payable 897,130 487,595

Accrued and other liabilities 30,481 (422,410)

Income taxes (2,365) 49,668

Net cash used in operations (6,676,452) (3,406,942)

Cash flows from investing activities:

Purchase of property and equipment (74,286) (4,961)

Net cash used in investing activities (72,286) (4,961)

Cash flows from financing activities:

Proceeds of loans 1,361,460

Repayment of debt (1,171,170) (136,900)

Net cash (used in)/provided by financing activities (1,171,170) 1,224,560

Effect of exchange rate change on cash and cash equivalents (524,998) (17,033)

Net decrease in cash and cash equivalents (8,446,906) (2,204,376)

Cash and cash equivalents at beginning of period 18,474,211 3,689,382

Cash and cash equivalents at end of period 10,027,305 1,485,006

Supplemental cash flow disclosures:

Cash paid for interest 4,224 41,132

Cash received for income taxes $ (1,206) $ (18)

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies - Additional Information (Detail)
6 Months Ended

Dec. 23, 2014

USD ($)

Dec. 23, 2014

EUR (€)

Jun. 30, 2015

USD ($)

Jun. 30, 2015

EUR (€)

Jun. 30, 2015

EUR (€)

Loss Contingencies [Line Items]

Counterclaim amount filed $ 3,060,827 € 2,529,400

Claims and counterclaims amount $ 4,235,350 € 3,500,000

Out License Fee [Member]

Loss Contingencies [Line Items]

Out-License Fee amount 400,000

TUM [Member] | Out License Fee [Member]

Loss Contingencies [Line Items]

Out-License Fee amount 3,400,000

Reserved liability $ 302,273 € 271,000

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of damages awarded to the plaintiff in the legal matter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyDamagesAwardedValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value (monetary amount) of the award the plaintiff seeks in the legal matter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name: us-gaap_LossContingencyDamagesSoughtValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deposits held by the entity for a related party (entity, shareholder, employee).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_RelatedPartyDepositLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_OutLicenseFeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Corporate Information - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended

Dec. 23, 2014

Dec. 31, 2014

Organization And Description Of Business [Line Items]

Exercise price of warrants $ 2.00 $ 2.00

Warrant exercisable period 5 years 5 years

Private Placement [Member]

Organization And Description Of Business [Line Items]

Stock issued 6,779,510

Sales of common stock, price per share $ 2.00

Proceeds from sale of stock $ 13,560

Common Stock [Member]

Organization And Description Of Business [Line Items]

Aggregate shares issued upon acquisition 542,360

X

- Definition
Organization And Description Of Business [Line Items]
+ References
No definition available.
+ Details

Name: pirs_OrganizationAndDescriptionOfBusinessLineItems

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrant Exercisable Period
+ References
No definition available.
+ Details

Name: pirs_WarrantExercisablePeriod

Namespace Prefix: pirs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)(4)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events - Additional Information (Detail)
3 Months Ended 6 Months Ended

Jul. 24, 2015

$ / shares

shares

Jul. 14, 2015

USD ($)

Jul. 14, 2015

EUR (€)

Jul. 06, 2015

USD ($)

$ / shares

shares

Jun. 30, 2015

USD ($)

shares

Mar. 31, 2015

shares

Jun. 30, 2014

USD ($)

shares

Jun. 30, 2015

USD ($)

shares

Jun. 30, 2014

USD ($)

shares

Subsequent Event [Line Items]

Number of shares, Options exercised | shares 0 0 0 0 0

Research and development expense $ 1,725,592 $ 1,118,920 $ 3,250,222 $ 2,341,666

Subsequent Event [Member]

Subsequent Event [Line Items]

Gross proceeds from issuance initial public offering $ 28,300,000

Net proceeds from issuance initial public offering $ 25,800,000

Subsequent Event [Member] | Cooperation Agreement [Member] | Milestone One [Member]

Subsequent Event [Line Items]

Research and development expense $ 48,698 € 43,660

Subsequent Event [Member] | Cooperation Agreement [Member] | Milestone Two [Member]

Subsequent Event [Line Items]

Research and development expense $ 130,301 € 116,820

Subsequent Event [Member] | IPO [Member]

Subsequent Event [Line Items]

Stock issued | shares 9,090,909

Sales of common stock, price per share | $ / shares $ 2.75 $ 2.75

Number of shares, Options exercised | shares 1,211,827

X

- Definition
Gross Proceeds From Issuance Initial Public Offering
+ References
No definition available.
+ Details

Name: pirs_GrossProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: pirs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: pirs_AgreementTypeAxis=pirs_CooperationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: pirs_MilestoneEventsAxis=pirs_MilestoneOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: pirs_MilestoneEventsAxis=pirs_MilestoneTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Revenues - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

May. 31, 2011

Sep. 30, 2010

Aug. 31, 2009

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2013

Deferred Revenue Arrangement [Line Items]

Revenues from product sales $ 0

Collaborative Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments $ 400,000 0 $ 400,000

Allergan Inc [Member] | Collaborative Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 0

Allergan Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments $ 13,000,000 13,000,000

Allergan Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, license revenue $ 10,000,000

Sanofi [Member] | Collaborative Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 0 0 0 300,000

Collaboration agreement, revenue recognized 0 200,000 $ 0 700,000

Description of factors in determining milestones substantive Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.

Collaborative arrangement, consideration $ 8,100,000

Sanofi [Member] | Collaborative Arrangement [Member] | Expired Option Agreement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, revenue recognized $ 700,000

Sanofi [Member] | Collaborative Arrangement [Member] | Options Exercised [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, revenue recognized $ 350,000

Collaborative arrangement, consideration $ 280,000

Sanofi [Member] | Collaborative Arrangement [Member] | Options, Exercised Price [Member]

Deferred Revenue Arrangement [Line Items]

Collaborative arrangement, consideration $ 1,100,000

Sanofi [Member] | Collaborative Arrangement [Member] | Licenses [Member]

Deferred Revenue Arrangement [Line Items]

Collaborative arrangement, consideration 3,500,000

Sanofi [Member] | Collaborative Arrangement [Member] | Options to Acquire Additional Licenses [Member]

Deferred Revenue Arrangement [Line Items]

Collaborative arrangement, consideration 1,400,000

Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member]

Deferred Revenue Arrangement [Line Items]

Research collaboration agreement, estimated period 2 years

Collaborative arrangement, consideration 3,200,000

Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member] | Extension Term [Member]

Deferred Revenue Arrangement [Line Items]

Research collaboration agreement, estimated period 40 months

Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 51,600,000

Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 1,900,000

Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 29,600,000

Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 20,100,000

Sanofi [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, license revenue $ 4,900,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Research collaboration agreement, estimated period 2 years

Collaboration agreement, revenue recognized $ 0 $ 400,000 $ 0 $ 1,100,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments $ 91,100,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 2,600,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 37,400,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 50,200,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, milestone payments 900,000

Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]

Deferred Revenue Arrangement [Line Items]

Collaboration agreement, license revenue $ 10,100,000

X

- Definition
Research Collaboration Agreement Period
+ References
No definition available.
+ Details

Name: pirs_ResearchCollaborationAgreementPeriod

Namespace Prefix: pirs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c(3)

-Article 5

+ Details

Name: us-gaap_ContractsReceivableClaimsAndUncertainAmounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueArrangementLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A description of the factors that the entity considered in determining whether the milestone or milestones are substantive.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodFactors

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pirs_AllerganIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pirs_SanofiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=pirs_ExpiredOptionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=pirs_OptionsExercisedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=pirs_OptionsExercisedPriceOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pirs_LicensingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pirs_LicenseOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=pirs_ExtensionTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_DevelopmentMilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_CommercialMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pirs_DaiichiSankyoIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_AdditionalMilestonePaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Corporate Information
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Corporate Information

1. Corporate Information

Pieris Pharmaceuticals, Inc. is a holding company incorporated in May 2013 under the name Marika Inc. On December 17, 2014 Pieris AG (a German company which was founded in 2001 by Prof. Dr. Arne Skerra, Professor at the Technical University of Munich, Germany, and Claus Schalper) became a wholly owned subsidiary of Pieris Pharmaceuticals, Inc., pursuant to the Acquisition (described below). The registered office of Pieris Pharmaceuticals, Inc. and the corporate headquarters and research facility of Pieris AG are located in Freising-Weihenstephan, Germany. Pieris Australia Pty Ltd., a wholly owned subsidiary of Pieris AG, was formed on February 14, 2014 to conduct research and development in Australia.

On December 17, 2014, Pieris Pharmaceuticals, Inc., Pieris AG, and the former stockholders of Pieris AG entered into an acquisition agreement, or the Acquisition Agreement. Pursuant to the Acquisition Agreement, on December 17, 2014, the stockholders of Pieris AG contributed all of their equity interests in Pieris AG to Pieris Pharmaceuticals, Inc. in exchange for shares of Pieris Pharmaceuticals, Inc. common stock, which resulted in Pieris AG becoming a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the “Acquisition”). Upon the closing of the Acquisition, Pieris Pharmaceuticals, Inc. ceased to be a “shell company” under applicable rules of the SEC. For more information on the acquisition, please refer to Note 3 Acquisition of the consolidated financial statements as of December 31, 2014 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

On December 17, 2014, Pieris Pharmaceuticals, Inc. entered into a securities purchase agreement, or the Securities Purchase Agreement, with certain accredited investors (the “Investors”) providing for the issuance and sale to such Investors of an aggregate of 6,779,510 shares of our common stock in a private placement offering conducted through a series of closings occurring on December 17, 18 and 23, 2014, at a purchase price per share of $2.00 and for aggregate gross proceeds of approximately $13.56 million (the “Private Placement”). Northland Securities, Inc. and Katalyst Securities, LLC served as co-exclusive placement agents (the “Placement Agents”) for the Private Placement. At the closings of the Private Placement we issued to the Placement Agents and their designees, warrants (the “Placement Warrants”), to acquire up to 542,360 shares of our common stock at an exercise price of $2.00 per share. Each of the Placement Warrants is exercisable at any time at the option of the holder until the five-year anniversary of its date of issuance.

Pieris Pharmaceuticals, Inc. and its consolidated subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of the Anticalin^® class of biotherapeutics for patients with diseases in which the Company believes there is high unmet medical need.

The Company´s core Anticalin^® technology and platform was developed in Germany, and the Company has partnership arrangements with major multi-national pharmaceutical companies headquartered in the U.S., Europe and Japan and with regional pharmaceutical companies headquartered in India.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 300,000,000 300,000,000

Common stock, shares issued 29,429,522 29,279,522

Common stock, outstanding 29,429,522 29,279,522

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events
6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Public Offering

On July 6, 2015 the Company closed a public offering of an aggregate of 9,090,909 shares of the Company´s common stock at a purchase price of $2.75 per share. All shares of common stock were offered by the Company. On July 24, 2015 the underwriters exercised their over-allotment option to purchase 1,211,827 additional shares of the Company’s common stock at the public offering price of $2.75, which sale closed on July 28, 2015.

Gross proceeds raised by the Company in the offering, including the exercise of the over-allotment option, were $28.3 million and net proceeds are expected to be approximately $25.8 million. The Company intends to use the net proceeds from the offering to fund research and development, including preclinical and clinical research and development of its drug candidates, working capital and general corporate purposes.

Milestone payment

On July 8, 2015 the Company announced that it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed due to the confidential treatment of this agreement. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates. The Company expects to receive this milestone payment in the third quarter of 2015.

Cooperation Agreement

On July, 14 the Company entered into a Cooperation Agreement (the “Cooperation Agreement”) with the University of Cologne. The University of Cologne provides research services to the Company for which it will receive up to two milestone payments. For the research services under Milestone 1, the Company shall pay the University a net amount of $48,698 (€43.660) in two installments. Within thirty days following achievement of Milestone 1, the Company and University shall mutually agree whether to continue with the Cooperation Project. Having agreed on continuing with Milestone 2, the Company shall pay the University a net amount of $130,301 (€116,820) in two installments.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Aug. 13, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol PIRS

Entity Registrant Name PIERIS PHARMACEUTICALS, INC.

Entity Central Index Key 0001583648

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 39,732,258

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: pirs_DocumentAndEntityInformationAbstract

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis of Consolidation

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements.

In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period.

Use of estimates

Use of estimates

The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.

Segment Reporting

Segment Reporting

Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit.

Milestone Payments and Royalties

Milestone Payments and Royalties

At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount.

For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met.

Fair Value Measurement

Fair Value Measurement

ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.

Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents.

The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014.

Income taxes

Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09) which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements.

In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual items” (ASU 2015-01). The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”(ASU 2015-02). The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company is currently evaluating the impact of this new standard.

In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements” (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the “Codification”), correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard.

Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

X

- Definition
Disclosure of accounting policy for basis of consolidation policy.
+ References
No definition available.
+ Details

Name: pirs_BasisOfConsolidationPolicyTextBlock

Namespace Prefix: pirs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition related to alternative revenue programs. The major alternative revenue programs can generally be segregated into two categories, programs that adjust billings for the effects of weather abnormalities or broad external factors or to compensate the utility for demand-side management initiatives (for example, no-growth plans and similar conservation efforts); and programs that provide for additional billings (incentive awards) if the utility achieves certain objectives, such as reducing costs, reaching specified milestones, or demonstratively improving customer service.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 605

-Section 25

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=45278178&loc=d3e50180-110409

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 605

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=45278178&loc=d3e50159-110409

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 605

-Section 25

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=45278178&loc=d3e50187-110409

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 605

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=45278178&loc=d3e50174-110409

+ Details

Name: us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Statement [Abstract]

Revenue $ 160,244 $ 698,227 $ 377,864 $ 2,071,106

Operating costs and expenses

Research and development (1,725,592) (1,118,920) (3,250,222) (2,341,666)

General and administrative (1,969,082) (2,349,232) (4,363,405) (3,170,582)

Costs and expenses (3,694,674) (3,468,152) (7,613,627) (5,512,248)

Loss from operations (3,534,430) (2,769,925) (7,235,763) (3,441,142)

Other income (expense)

Interest expense (53) (113,793) (4,223) (223,083)

Other income, net 4,484 2,081 5,253 2,665

Loss before income taxes (3,529,999) (2,881,637) (7,234,733) (3,661,560)

Income tax benefit 18

Net loss $ (3,529,999) $ (2,881,637) $ (7,234,733) $ (3,661,542)

Net loss per share Basic and diluted $ (0.12) $ (0.24) $ (0.25) $ (0.31)

Weighted average number of common shares outstanding Basic and diluted 29,429,522 11,828,974 29,361,566 11,828,974

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued expenses
6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Accrued expenses

6. Accrued expenses

The Company has recorded the following accrued expenses as of June 30, 2015 and December 31, 2014, respectively:

 June 30,
2015 December 31,
2014

Accrued expenses


Accrued compensation expense
 $ 333,979 $ 332,892

Accrued audit and tax expenses
 148,500 403,450

Other accrued expenses
 153,082 7,523





Total accrued expenses, current
 635,561 743,865





Accrued expenses non-current


Reserve for litigation TUM
 302,273 327,937

Accrued expenses restoration
 5,577 6,051

Total accrued expenses, non-current
 307,850 333,988





Total accrued expenses
 $ 943,411 $ 1,077,853





X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt
6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Debt

5. Debt

TBG Loan

As of April 3, 2014, the Company and tbg Technologie-Beteiligungs-Gesellschaft mbH (“TBG”), the subsidiary of KfW Bank, Frankfurt (“KfW”), signed a repayment agreement concerning the Company’s repayment of its liabilities to TBG outstanding at December 31, 2013 in a total amount of €1.2 million ($1.34 million). The principal amount bore interest at a rate of 10.53%. Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016. On December 11, 2014, the Company and TBG entered into an accelerated repayment agreement in respect of the claims of TBG against the Company. Pursuant to terms of the accelerated repayment agreement, conditioned upon closing of the Acquisition, the Company was obligated to pay €1,050,000 ($1.17 million), the outstanding amount under the repayment agreement, in two tranches as follows: €600,000 ($669,240) plus accrued interest on January 31, 2015 and €450,000 ($501,930) on March 31, 2015. The outstanding principal amount for the first and the second tranches, net of capital gain tax withheld, was repaid in full in the first quarter ending March 31, 2015 in the amount of €931,312 ($1,038,785). The capital gain tax withheld in the amount of €118,688 ($132,385) was paid on April 9, 2015 and with that the TBG loan was repaid in full.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended

Jun. 30, 2015

USD ($)

Segment

Dec. 31, 2014

USD ($)

Summary Of Significant Accounting Policies [Line Items]

Number of Operating segment | Segment 1

Milestones arrangement, categories description Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.

Effective tax rate 0.00%

Fair Value, Inputs, Level 1 [Member]

Summary Of Significant Accounting Policies [Line Items]

Cash and Cash Equivalents, Fair Value $ 78,403 $ 4,800,573

X

- Definition
Summary Of Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: pirs_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: pirs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
A description of each milestone and related contingent consideration as well as a description of whether or not each milestone(s) is considered substantive.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodMilestone

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Related-Party Transactions (Tables)
6 Months Ended

Jun. 30, 2015

Related Party Transactions [Abstract]

Related Party Expenses

The Company has incurred the following expenses related to TUM (excluding value added taxes):


Three months ended

June 30,
 Six months ended
June 30,

 2015 2014 2015 2014

Transfer of licenses and protective rights
 $ 13,836 $ 17,145 $ 27,893 $ 34,276









Total expenses incurred with TUM
 $ 13,836 $ 17,145 $ 27,893 $ 34,276









X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Warrants
6 Months Ended

Jun. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Warrants

9. Warrants

In connection with the Private Placement in December 2014, the Company issued the Placement Warrants to acquire combined up to 542,360 shares of its common stock at an exercise price of two dollars per share ($2.00) to the Placement Agents and their designees during December 2014. The Placement Warrants are exercisable at any time at the option of the holder until the five year anniversary of its date of issuance. The number of shares of common stock issuable upon the exercise of each Placement Warrant is adjustable in the event of certain stock dividends, stock splits, combinations of shares and similar transactions. Upon exercise, the aggregate exercise price of the warrants issued are payable by the holders in cash.

The Company estimated the fair value of the Placement Warrants as of the grant date to be $664,064 and recognized the full amount in general and administrative expense for the year ended December 31, 2014.

X

- Definition
Class Of Warrants And Rights [Text Block]
+ References
No definition available.
+ Details

Name: pirs_ClassOfWarrantsAndRightsTextBlock

Namespace Prefix: pirs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based compensation
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based compensation

7. Stock-based compensation

In December 2014, the Board of Directors and stockholders of Pieris Pharmaceuticals, Inc. adopted the 2014 Employee, Director and Consultant Equity Incentive Plan (the “Pieris Plan”), which became effective upon closing of the Acquisition. The Pieris Plan is intended to encourage ownership of common stock by the Company’s employees and directors and certain of their consultants, including employees of Pieris AG, in order to attract and retain such people, to induce them to work for the benefit of the Company and to provide additional incentive for them to promote the Company’s success. The Pieris Plan reserves 3,200,000 shares of the Company´s common stock for issuance. In addition, the Pieris Plan provides for an “evergreen” provision whereby the number of shares of the Company´s common stock reserved for issuance under the Pieris Plan shall be automatically increased on January 1 of each of year commencing in fiscal 2016 by the lesser of (i) 1,000,000 shares, (ii) 4% of the number of shares of the Company´s common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company´s common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014. In addition, options to purchase 1,146,500 shares are outstanding under the Pieris Plan to other employees and consultants. 25,000 of these shares were granted during the first quarter of 2015, 32,000 of these shares were granted during the second quarter of 2015 and 1,089,500 were granted during the fourth quarter of 2014. As a result of such grants, 583,265 of the Company´s common stock remain available for future issuances under the Pieris Plan.

Stock options granted under the Pieris Plan may be either incentive stock options (“ISOs”), or nonqualified stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally three years) and the exercise prices. Options have a maximum term of ten years. The exercise price of stock options granted under the Pieris Plan must be at least equal to the fair market value of the common stock on the date of grant. The Pieris Plan become effective in December 2014, therefore there was no stock-based compensation expense in the three and six months ended June 30, 2014.

Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three and six months ended June 30, 2015, was comprised of the following:

 Three months ended Six months ended

 June 30, 2015 June 30, 2015

Research and Development
 $ 78,551 $ 129,590

General and administrative
 189,488 355,785





Total stock-option expense
 $ 268,039 $ 485,375





The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three and six months ended June 30, 2015:

 Three months ended Six months ended

 June 30, 2015 June 30, 2015

Forfeiture rate
 6.0 % 6.0 %

Dividend yield
 0.0 % 0.0 %

Expected volatility
 73.7 % 74.1 %

Weighted average risk-free interest rate
 1.73 % 1.71 %

Expected term
 5.3 - 5.8 years 5.3 - 5.8 years

A summary of the Company’s stock option activity and related information is as follows:

 Number of
shares Weighted-
Average
Exercise Price Weighted-
Average
Contractual
Life

Outstanding at December 31, 2014
 2,519,500 $ 2.00 5.6 - 5.8 years

Options granted
 25,000 $ 2.85 5.8 years

Options exercised
 — — —

Options cancelled or expired
 — — —

Outstanding at March 31, 2015
 2,544,500 $ 2.01 5.6 - 5.8 years

Options granted
 72,235 $ 2.89 5.3 - 5.8 years

Options exercised
 — $ — —

Options cancelled or expired
 — $ — —

Outstanding at June 30, 2015
 2,616,735 $ 2.03 5.3 - 5.8 years

Vested at June 30, 2015
 799,068 $ 2.03 —

Expected to vest after June 30,2015
 1,708,607 $ 2.03 —

Exercisable at June 30, 2015
 799,068 $ 2.03 —

The weighted-average grant date fair value for awards granted during the three and six months ended June 30, 2015 was $130,456 and $176,898, respectively. There were no options exercised during the three and six months ended June 30, 2015 and 2014. 200,673 and 375,319 shares were vested in the three and six months ended June 30, 2015, respectively.

The unrecognized share-based compensation expense related to employee stock option awards at June 30, 2015, is $2,253,478, which will be recognized over a weighted-average service period of 2.5 years.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consulting Shares
6 Months Ended

Jun. 30, 2015

Equity [Abstract]

Consulting Shares

8. Consulting Shares

On March 6, 2015, the Company entered into an independent consulting agreement (the “Consulting Agreement”) with the Del Mar Consulting Group, Inc. and Alex Partners, LLC (the “Consultants”), pursuant to which the Company issued 150,000 restricted shares of its common stock (par value $0.01 per share) to the Consultants (the “Consulting Shares”). The Company agreed to retain the Consultants to provide investor relations consulting to the Company for a period commencing on March 6, 2015 (the “Commencement Date”) and ending thirteen months after the Commencement Date (such period, the “Term”). The shares issued in connection with the Consulting Agreement were deemed to be exempt from registration in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving any public offering.

The terms of the Consulting Agreement state, that the Company has the right to terminate this agreement at any time during the Term of the Consulting Agreement, upon providing Consultants ten days’ written notice of Company’ intention to terminate or immediately upon notice in the event of a breach of this agreement by either consultant. If the Company delivers notice to terminate this agreement for any reason within one hundred eighty days (180) following the effective date (the “Return Date”), then each Consultant will promptly return and surrender to the Company forty percent (40%) of the number of Consulting Shares issued to it. Therefore 60,000 of these shares are subject to certain forfeiture provisions within 180 days following the date of entry into the Consulting Agreement.

The Company, using the Black-Scholes method, estimated the fair value of the 90,000 non-cancellable Consulting Shares to be $284,400 based on the closing price per share of $3.16 as quoted on the OTCQB tier of the OTC Markets Group Inc., or the OTCQB, on the grant date, March 6, 2015. The Company estimated the fair value of the 60,000 cancellable Consulting Shares to be $192,000 based on the closing price per share of $3.20 as quoted on the OTCQB on the interim financial reporting date, March 31, 2015. Therefore, the Company estimated the total fair value of the Consulting Shares to be $476,400 and recognized the 90,000 vested non-cancellable Consulting Shares, or sixty percent (60%) of the Consulting Shares in an amount of $284,400, as general and administrative expense for the six months ended June 30, 2015. The remaining forty percent (40%), or 60,000 Consulting Shares in the amount of $192,000, will be recognized as general and administrative expenses with an offsetting credit to equity on a straight-line basis over 180 days. If the Company exercises the option to terminate the Consulting Agreement within the 180 days, resulting in the cancellation of forty percent (40%) of the Consulting Shares, expense for cancelled, unvested shares will be reversed.

On June 30, 2015 the Company revalued the fair value of the unvested and forfeitable 40% of the shares. As of June 30, 2015 the estimated fair value of the 60,000 unvested and forfeitable shares was $165,000. Therefore the Company recognized expenses in connection with the Consulting Shares of $79,666 in general and administrative expenses for the cancellable Consulting Shares during the three months ended June 30, 2015. For the six months ended June 30, 2015 the Company recognized $390,733 in general and administrative expenses, including $284,400 for the non-cancellable Consulting Shares and $106,333 for the cancellable shares.

X

- Definition
Consulting Shares Disclosure [Text Block]
+ References
No definition available.
+ Details

Name: pirs_ConsultingSharesDisclosureTextBlock

Namespace Prefix: pirs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

Arbitration

On March 20, 2014, the Company instituted arbitration proceedings, or the TUM Arbitration, against Technische Universität München, or Munich Technical University and hereafter TUM, to address issues regarding the calculation of payments due from the Company to TUM under the Company’s Research and Licensing Agreement with TUM, as amended, or the TUM License Agreement. Pursuant to the terms of the TUM License Agreement, the arbitration is proceeding in Munich, Germany and governed by German law, in accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit.

On July 4, 2003, or the Effective Date, the Company and TUM entered into the TUM License Agreement, as superseded and replaced on July 26, 2007, under which TUM has exclusively licensed, or in some cases assigned, to the Company certain intellectual property and know-how that has become part of the Anticalin^® proprietary technologies. In return, the Company agreed to pay to TUM certain annual license fees, milestones and royalties for its own proprietary drug development and sales, as well as an variable fee as a function of out-licensing revenues, or the Out-License Fee, where such Out-License Fees are creditable against annual license payments to TUM.

As required by the TUM License Agreement, the Company provided to TUM its calculation of the Out-License Fee owed by the Company to TUM for the period beginning on the Effective Date and ending on December 31, 2012, the Dispute Period, in the amount of $0.4 million excluding value-added tax. TUM has asserted that, under the TUM License Agreement, the Out-License Fee due to TUM for the Dispute Period amounts to $3.4 million excluding value-added tax in the aggregate and has threatened to terminate the TUM License Agreement if the Out-License Fee is not paid. We believe that if TUM sought to terminate the license agreement for cause as a result of this dispute, it would potentially face wrongful termination claims for substantial damages if the arbitration tribunal in the TUM Arbitration sides with Pieris in its final decision regarding the proper amount of the Out-License Fee, but we can provide no assurance regarding the timing, nature or consequences of such decision. The Company instituted the TUM Arbitration to request the arbitration tribunal to hold that the Company’s calculation of the payments owed to TUM is accurate and shall govern all current and future payments due in respect of the Out-License Fee under the TUM License Agreement. The Company has reserved a liability on its balance sheet’s position other long-term liabilities in respect of such payment in the amount of €271,000 ($302,273). An adverse ruling in the TUM Arbitration could have a material adverse effect on the Company’s results of operations and financial condition.

In April 2014, TUM argued to the arbitrators that it is not the proper party to be sued under the action for a declaratory arbitration decision brought by the Company in relation to the Research and Licensing Agreement, and that instead, it is the Free State of Bavaria that is the proper respondent to the action. The Company has responded that TUM has capacity to be sued in relation to any disputes arising from and regarding contractual provisions of the Research and Licensing Agreement and is thus also the proper respondent in the action. In accordance with the arbitration rules of the Deutsche Institution für Schiedsgerichtsbarkeit, each party to the arbitration proceeding has appointed one arbitrator and the party-named arbitrators collectively selected the third arbitrator as the chairman of the arbitration panel.

On December 1, 2014, TUM filed its statement of defense, maintaining its earlier calculation of the Out-License Fee. On December 23, 2014, TUM filed a counterclaim in the amount of €2,529,400 ($3,060,827) to suspend the statute of limitations on its claims. On January 12, 2015, the Company filed a reply brief in response to TUM’s defense.

The arbitration panel held its first hearing in Munich, Germany on January 20, 2015, however the arbitration panel did not come to a conclusion on whether TUM is the proper respondent in the action or on the merits of the case. The panel had previously indicated that it will first decide the issue of whether TUM is the proper respondent in this action. The panel resolved that the value in dispute for both parties’ claims and counterclaims would be fixed at €3,500,000 ($4,235,350), as the calculation of the outstanding Out-Licensing Fee also impacts future payments. On March 3, 2015, the Company submitted a reply brief responding to TUM’s statement of defense and counterclaim.

On March 31, 2015, TUM submitted a rebuttal brief. The panel requested that both the Company and TUM indicate to the panel by April 27, 2015 whether proceedings should be stayed as a result of settlement negotiations. On April 27, 2015, the Company submitted a reply brief requesting proceedings to continue without disruption and moving for leave to comment on TUM’s submission. Following an approved extension by the panel for TUM’s submission, TUM submitted its proposal on May 4, 2015, requesting that the panel conduct a mediation hearing and assist the parties in negotiating a settlement. On May 8, 2015, the arbitration tribunal set June 1, 2015 as the deadline for final briefs and offered to schedule another oral hearing in mid-June for the purpose of supporting further settlement negotiations if both parties are in favor of holding a hearing. The Company submitted its brief on June 1, 2015. On June 8, 2015, the arbitration tribunal issued a procedural order indicating they will proceed with the arbitration without another oral hearing. TUM did not file its brief by the June 1 deadline set by the panel, and instead filed another submission on June 23, 2015. In its procedural order issued on the same day, the tribunal panel reserved the right to reject TUM’s new submission based on the content of its brief. The tribunal’s subsequent procedural order of June 25, 2015 provided that the tribunal will close the proceedings on July 10, 2015. The order clarified that any further pleadings or submissions will not be admissible after this date. The Company submitted its final brief on July 10, 2015 to address TUM’s arguments raised in its latest submission to provide the tribunal with an overview its costs incurred in this arbitration proceeding. On the same day, TUM submitted its summary of its costs incurred in this arbitration proceeding and subsequently, on July 23, 2015, filed an additional brief to correct some of its earlier submissions on costs and comment on the Company’s cost overview of July 10, arguing that attorneys’ fees claimed by the Company are disproportionately high. The Company replied to the TUM’s on [August, 7], pointing out that the higher attorneys’ fees are justified and resulted from the Company’s submissions on TUM’s standing to be sued and translation costs are also reimbursable in this case.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Warrants - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended

Dec. 23, 2014

Dec. 31, 2014

Dec. 31, 2014

Equity [Abstract]

Number of common stock purchased 542,360 542,360

Exercise price of warrants $ 2.00 $ 2.00 $ 2.00

Warrant exercisable period 5 years 5 years

Warrant expense recognized $ 664,064

X

- Definition
Warrant Exercisable Period
+ References
No definition available.
+ Details

Name: pirs_WarrantExercisablePeriod

Namespace Prefix: pirs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 46 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-based compensation (Tables)
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan

Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three and six months ended June 30, 2015, was comprised of the following:

 Three months ended Six months ended

 June 30, 2015 June 30, 2015

Research and Development
 $ 78,551 $ 129,590

General and administrative
 189,488 355,785





Total stock-option expense
 $ 268,039 $ 485,375





Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted

The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three and six months ended June 30, 2015:

 Three months ended Six months ended

 June 30, 2015 June 30, 2015

Forfeiture rate
 6.0 % 6.0 %

Dividend yield
 0.0 % 0.0 %

Expected volatility
 73.7 % 74.1 %

Weighted average risk-free interest rate
 1.73 % 1.71 %

Expected term
 5.3 - 5.8 years 5.3 - 5.8 years

Schedule of Information Regarding Stock Option Activity

A summary of the Company’s stock option activity and related information is as follows:

 Number of
shares Weighted-
Average
Exercise Price Weighted-
Average
Contractual
Life

Outstanding at December 31, 2014
 2,519,500 $ 2.00 5.6 - 5.8 years

Options granted
 25,000 $ 2.85 5.8 years

Options exercised
 — — —

Options cancelled or expired
 — — —

Outstanding at March 31, 2015
 2,544,500 $ 2.01 5.6 - 5.8 years

Options granted
 72,235 $ 2.89 5.3 - 5.8 years

Options exercised
 — $ — —

Options cancelled or expired
 — $ — —

Outstanding at June 30, 2015
 2,616,735 $ 2.03 5.3 - 5.8 years

Vested at June 30, 2015
 799,068 $ 2.03 —

Expected to vest after June 30,2015
 1,708,607 $ 2.03 —

Exercisable at June 30, 2015
 799,068 $ 2.03 —

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Related-Party Transactions - Related Party Expenses (Detail) - TUM [Member] - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Related Party Transaction [Line Items]

Transfer of licenses and protective rights $ 13,836 $ 17,145 $ 27,893 $ 34,276

Total expenses $ 13,836 $ 17,145 $ 27,893 $ 34,276

X

- Definition
Costs of sales and operating expenses for the period incurred from transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpensesRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pirs_TumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consolidated Statements of Comprehensive Income (Loss) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Statement of Comprehensive Income [Abstract]

Net loss $ (3,529,999) $ (2,881,637) $ (7,234,733) $ (3,661,542)

Other comprehensive loss

Foreign currency translation adjustments 102,135 6,654 (500,597) 3,027

Total other comprehensive loss, after tax 102,135 6,654 (500,597) 3,027

Comprehensive loss $ (3,427,864) $ (2,874,983) $ (7,735,330) $ (3,658,515)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a-c)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Related-Party Transactions
6 Months Ended

Jun. 30, 2015

Related Party Transactions [Abstract]

Related-Party Transactions

4. Related-Party Transactions

Research and License Agreement with Technische Universität München (“TUM”)

On July 4, 2003, the Company entered into a research and licensing agreement with TUM, which was subsequently renewed and, on July 26, 2007, superseded and replaced. The agreement established a joint research effort led by Prof. Arne Skerra, Chair of Biological Chemistry of TUM, to optimize Anticalin® technologies for use in therapeutic, prophylactic and diagnostic applications and as research reagents, and to gain fundamental insights in lipocalin scaffolds. Prof. Dr. Skerra was a member of Pieris AG’s supervisory board when the parties entered into such agreement. The Company provided certain funding for TUM research efforts performed under the agreement.

As a result of research efforts to date under the agreement, the Company holds a worldwide exclusive license under its license agreement with TUM to multiple patents and patent applications, including an exclusive license to an issued U.S. patent, which patent will expire in 2027 (subject to a possible term adjustment period). Pieris AG also holds an exclusive license to an issued U.S. patent No. 8,420,051, which patent is expected to expire in 2029. The Company bears the costs of filing, prosecution and maintenance of patents assigned or licensed to the Company under the agreement.

As consideration for the assigned patents and licenses above, the Company is required to pay certain development milestones to TUM. The Company also is obliged to pay low-single-digit royalties, including annual minimum royalties, on sales of such products incorporating patented technologies. If the Company grants licenses or sublicenses to those patents to third parties, the Company will be obliged to pay a percentage of the resulting revenue to TUM. The Company’s payment obligations are reduced by the Company’s proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the agreement. The Company can terminate the licenses to any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the agreement does not terminate the rights in patents assigned to the Company.

The Company has incurred the following expenses related to TUM (excluding value added taxes):


Three months ended

June 30,
 Six months ended
June 30,

 2015 2014 2015 2014

Transfer of licenses and protective rights
 $ 13,836 $ 17,145 $ 27,893 $ 34,276









Total expenses incurred with TUM
 $ 13,836 $ 17,145 $ 27,893 $ 34,276









The Company has accrued $302,273 and $370,999 as of June 30, 2015 and 2014, respectively, related to the amounts due under the research and license agreement (see Note 9 Commitments and Contingencies).

The part of the agreement requiring the Company to make payments for research conducted by TUM expired in February 2013 with no further obligations by Pieris AG.

Consulting Contract between Prof. Dr. Arne Skerra and Pieris AG

In 2001, the Company entered into a Consulting Agreement with Prof. Dr. Arne Skerra, pursuant to which Prof. Dr. Arne Skerra provides advice regarding the use of new proteins, in particular Anticalin® proteins and antibodies, for the purpose of research and development. The Consulting Agreement has an unlimited term but can be terminated by the Company upon three months’ notice with effect from the end of a month and by Prof. Dr. Arne Skerra upon one year’s notice with effect from the end of a year. Under the Consulting Agreement, the Company incurred and paid to Prof. Dr. Skerra consulting fees of $11,157 and $13,711 for the six months ended June 30, 2015 and 2014, respectively. For the three months ended June 30, 2015 and 2014 the Company incurred and paid Prof. Dr. Skerra consulting fees of $5,534 and $6,858, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt - Additional Information (Detail) - Tbg [Member]
6 Months Ended

Dec. 11, 2014

USD ($)

Tranches

Jun. 30, 2015

USD ($)

Jun. 30, 2015

EUR (€)

Mar. 31, 2015

USD ($)

Mar. 31, 2015

EUR (€)

Jan. 31, 2015

USD ($)

Jan. 31, 2015

EUR (€)

Dec. 11, 2014

EUR (€)

Apr. 03, 2014

USD ($)

Apr. 03, 2014

EUR (€)

Debt Instrument [Line Items]

Amount of repayment to TBG outstanding $ 1,170,000 € 1,050,000 $ 1,340,000 € 1,200,000

Principal amount, interest rate 10.53% 10.53%

Repayment agreement description Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016. Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016.

Capital gain tax withheld $ 132,385 € 118,688

Number of tranches 2

Repayment amount of debt $ 1,038,785 € 931,312

Debt Instrument, Redemption, Period One [Member]

Debt Instrument [Line Items]

Amount of repayment to TBG outstanding $ 669,240 € 600,000

Debt Instrument, Redemption, Period Two [Member]

Debt Instrument [Line Items]

Amount of repayment to TBG outstanding $ 501,930 € 450,000

X

- Definition
Number Of Tranches
+ References
No definition available.
+ Details

Name: pirs_NumberOfTranches

Namespace Prefix: pirs_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 25

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

+ Details

Name: us-gaap_AccountsPayableInterestBearingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The undiscounted sum of all amounts, including amounts deemed principal, interest, fees, penalties, and other under the loan, owed to the investor at the reporting date, whether or not currently due and whether or not any such amounts have been written or charged off by the investor. This relates to loans not accounted for as debt securities, with evidence of deterioration of credit quality since origination that were acquired by completion of a transfer for which it is probable, at acquisition, that the investor will be unable to collect all contractually required payments receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 15

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27045933&loc=d3e13503-111538

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

+ Details

Name: us-gaap_CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesOutstandingBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Current period income tax expense or benefit pertaining to a gain (loss) on an extinguishment of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

+ Details

Name: us-gaap_ExtinguishmentOfDebtGainLossIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CounterpartyNameAxis=pirs_TbgMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 110 187 1 false 41 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.pieris.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.pieris.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.pieris.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.pieris.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.pieris.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - Corporate Information Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Corporate Information Notes 7 false false R8.htm 109 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Revenues Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Revenues Notes 9 false false R10.htm 111 - Disclosure - Related-Party Transactions Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related-Party Transactions Notes 10 false false R11.htm 112 - Disclosure - Debt Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt Notes 11 false false R12.htm 113 - Disclosure - Accrued expenses Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued expenses Notes 12 false false R13.htm 114 - Disclosure - Stock-based compensation Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-based compensation Notes 13 false false R14.htm 115 - Disclosure - Consulting Shares Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsConsultingSharesDisclosureTextBlock Consulting Shares Notes 14 false false R15.htm 116 - Disclosure - Warrants Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsClassOfWarrantsAndRightsTextBlock Warrants Notes 15 false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 16 false false R17.htm 118 - Disclosure - Subsequent Events Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 17 false false R18.htm 119 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 18 false false R19.htm 120 - Disclosure - Related-Party Transactions (Tables) Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables Related-Party Transactions (Tables) Tables http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Accrued expenses (Tables) Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued expenses (Tables) Tables http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Stock-based compensation (Tables) Sheet http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-based compensation (Tables) Tables http://www.pieris.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 21 false false R22.htm 123 - Disclosure - Corporate Information - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureCorporateInformationAdditionalInformation Corporate Information - Additional Information (Detail) Details 22 false false R23.htm 124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) Details 23 false false R24.htm 125 - Disclosure - Revenues - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureRevenuesAdditionalInformation Revenues - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Related Party Transaction - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation Related Party Transaction - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Related-Party Transactions - Related Party Expenses (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureRelatedPartyTransactionsRelatedPartyExpenses Related-Party Transactions - Related Party Expenses (Detail) Details 26 false false R27.htm 128 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 28 false false R29.htm 130 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation Stock-based Compensation - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfTotalStockBasedCompensationExpenseRelatedToShareBasedAwardsUnderThePierisPlan Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) Details 30 false false R31.htm 132 - Disclosure - Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedForCalculatingValueOfOptionsGranted Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) Details 31 false false R32.htm 133 - Disclosure - Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfInformationRegardingStockOptionActivity Stock-based Compensation - Schedule of Information Regarding Stock Option Activity (Detail) Details 32 false false R33.htm 134 - Disclosure - Consulting Shares - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureConsultingSharesAdditionalInformation Consulting Shares - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureWarrantsAdditionalInformation Warrants - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.pieris.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 36 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. pirs-20150630.xml pirs-20150630_cal.xml pirs-20150630_def.xml pirs-20150630_lab.xml pirs-20150630_pre.xml pirs-20150630.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued expenses (Tables)
6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The Company has recorded the following accrued expenses as of June 30, 2015 and December 31, 2014, respectively:

 June 30,
2015 December 31,
2014

Accrued expenses


Accrued compensation expense
 $ 333,979 $ 332,892

Accrued audit and tax expenses
 148,500 403,450

Other accrued expenses
 153,082 7,523





Total accrued expenses, current
 635,561 743,865





Accrued expenses non-current


Reserve for litigation TUM
 302,273 327,937

Accrued expenses restoration
 5,577 6,051

Total accrued expenses, non-current
 307,850 333,988





Total accrued expenses
 $ 943,411 $ 1,077,853





X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Consulting Shares - Additional Information (Detail)	3 Months Ended		6 Months Ended
Consulting Shares - Additional Information (Detail)	Jun. 30, 2015 USD ($) $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares	Mar. 06, 2015 $ / shares shares	Dec. 31, 2014 $ / shares shares
Related Party Transaction [Line Items]
Common stock, shares issued \| shares	29,429,522		29,429,522		29,279,522
Common stock par value of issued shares \| $ / shares	$ 0.001		$ 0.001		$ 0.001
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Common stock, shares issued \| shares				150,000
Common stock par value of issued shares \| $ / shares				$ 0.01
Agreement termination notice period			180 days
Termination agreement percentage of shares returned			40.00%
Shares subject to forfeiture \| shares			60,000
Estimated fair value of non-cancellable shares, Shares \| shares		90,000
Estimated fair value of non-cancellable shares, Value		$ 284,400
Estimated fair value cancellable shares, Shares \| shares		60,000
Estimated fair value of cancellable shares, Value		$ 192,000
Estimated fair value of consulting shares			$ 476,400
Percentage of consulting shares recognizable as general and administrative expense			60.00%
Percentage of consulting shares recognizable as general and administrative expense offsetting credit to equity			40.00%
Revalued unvested and forfeitable shares, percent			40.00%
Number of unvested and forfeitable shares for revaluation			60,000
Estimated fair value of unvested and forfeitable shares, Value			$ 165,000
General and administrative expense recognized in consulting shares			390,733
Consulting Agreement [Member] \| Non Cancellable Shares [Member]
Related Party Transaction [Line Items]
Share price \| $ / shares		$ 3.16
Estimated fair value of consulting shares			284,400
General and administrative expense recognized in consulting shares			284,400
Consulting Agreement [Member] \| Cancellable Shares [Member]
Related Party Transaction [Line Items]
Share price \| $ / shares		$ 3.20
Estimated fair value of consulting shares			192,000
General and administrative expense recognized in consulting shares	$ 79,666		$ 106,333

Related Party Transaction - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Patent No. 8,420,051 [Member]
Related Party Transaction [Line Items]
Expected patent expiration year			2029
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Consulting agreement fees paid to Prof. Dr. Skerra	$ 5,534	$ 6,858	$ 11,157	$ 13,711
TUM [Member]
Related Party Transaction [Line Items]
Patent expiration year			2027
TUM [Member] \| License Agreement [Member]
Related Party Transaction [Line Items]
Contingent accrual liability for research and licensing agreement	$ 302,273	$ 370,999	$ 302,273	$ 370,999

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock Based Compensation [Line Items]
Number of shares, Options outstanding	2,616,735	2,544,500	2,519,500		2,616,735
Number of shares, Options granted	72,235	25,000
Share-based payment award, award vesting period					3 years
Maximum term of stock options					10 years
Weighted average grant date fair value	$ 130,456				$ 176,898
Number of shares, Options exercised	0	0		0	0	0
Options vested	200,673				375,319
Unrecognized share-based compensation expense	$ 2,253,478				$ 2,253,478
Recognized weighted average service period					2 years 6 months
Pieris Plan [Member]
Stock Based Compensation [Line Items]
Common stock reserved for issuance			3,200,000
Share-based compensation description					(i) 1,000,000 shares, (ii) 4% of the number of shares of the Company's common stock outstanding on such date, and (iii) such other amount determined by the Compensation committee of the Board of Directors. As of June 30, 2015, options to purchase 1,470,235 shares of the Company's common stock are outstanding under the Pieris Plan to its executive officers and directors. 40,235 of these shares were granted during the second quarter of 2015. All other shares were granted in the fourth quarter of 2014.
Common stock available for grant	583,265				583,265
Pieris Plan [Member] \| Executive Officers And Directors [Member]
Stock Based Compensation [Line Items]
Number of shares, Options outstanding	1,470,235				1,470,235
Number of shares, Options granted	40,235
Pieris Plan [Member] \| Other Employees and Consultants [Member]
Stock Based Compensation [Line Items]
Number of shares, Options outstanding	1,146,500				1,146,500
Number of shares, Options granted	32,000	25,000	1,089,500

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued expenses
Accrued compensation expense	$ 333,979	$ 332,892
Accrued audit and tax expenses	148,500	403,450
Other accrued expenses	153,082	7,523
Total accrued expenses, current	635,561	743,865
Accrued expenses non-current
Reserve for litigation TUM	302,273	327,937
Accrued expenses restoration	5,577	6,051
Total accrued expenses, non-current	307,850	333,988
Total accrued expenses	$ 943,411	$ 1,077,853

Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan (Detail) - Jun. 30, 2015 - USD ($)	Total	Total
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-option expense	$ 268,039	$ 485,375
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-option expense	78,551	129,590
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-option expense	$ 189,488	$ 355,785

Stock-based Compensation - Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted (Detail) - Jun. 30, 2015	Total	Total
Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]
Forfeiture rate	6.00%	6.00%
Dividend yield	0.00%	0.00%
Expected volatility	73.70%	74.10%
Weighted average risk-free interest rate	1.73%	1.71%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]
Expected term	5 years 3 months 18 days	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]
Expected term	5 years 9 months 18 days	5 years 9 months 18 days

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 10,027,305	$ 18,474,211
Other current assets	1,866,180	1,207,072
Prepaid expenses	732,221	109,332
Income tax receivable	16,015	14,810
Total current assets	12,641,721	19,805,425
Property and equipment, net	1,811,356	2,052,221
Deferred tax asset	24,446	26,522
Total assets	14,477,523	21,884,168
Current liabilities:
Trade accounts payable	2,058,458	1,260,015
Accrued expenses	635,561	743,865
Other current liabilities	304,012	242,755
Bank loan		1,270,605
Deferred tax liabilities	24,446	26,522
Total current liabilities	3,022,477	3,543,762
Other long-term liabilities	307,850	333,988
Total liabilities	3,330,327	3,877,750
Stockholders' equity
Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at June 30, 2015 and December 31, 2014	29,430	29,280
Additional paid-in capital	85,503,241	84,627,283
Accumulated other comprehensive loss	(1,343,694)	(843,097)
Accumulated deficit	(73,041,781)	(65,807,048)
Total stockholders' equity	11,147,196	18,006,418
Total liabilities and stockholders' equity	$ 14,477,523	$ 21,884,168

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (7,234,733)	$ (3,661,542)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	154,555	189,463
Non-cash interest expense		181,951
Stock-based compensation expense	485,374
Non-cash Restricted shares	390,734
Changes in operating assets and liabilities:
Restricted cash		13,091
Trade accounts receivable		68,553
Prepaid expenses	(628,723)	(72,570)
Other assets	(768,905)	(240,743)
Trade accounts payable	897,130	487,595
Accrued and other liabilities	30,481	(422,410)
Income taxes	(2,365)	49,668
Net cash used in operations	(6,676,452)	(3,406,942)
Cash flows from investing activities:
Purchase of property and equipment	(74,286)	(4,961)
Net cash used in investing activities	(72,286)	(4,961)
Cash flows from financing activities:
Proceeds of loans		1,361,460
Repayment of debt	(1,171,170)	(136,900)
Net cash (used in)/provided by financing activities	(1,171,170)	1,224,560
Effect of exchange rate change on cash and cash equivalents	(524,998)	(17,033)
Net decrease in cash and cash equivalents	(8,446,906)	(2,204,376)
Cash and cash equivalents at beginning of period	18,474,211	3,689,382
Cash and cash equivalents at end of period	10,027,305	1,485,006
Supplemental cash flow disclosures:
Cash paid for interest	4,224	41,132
Cash received for income taxes	$ (1,206)	$ (18)

Commitments and Contingencies - Additional Information (Detail)			6 Months Ended
	Dec. 23, 2014 USD ($)	Dec. 23, 2014 EUR (€)	Jun. 30, 2015 USD ($)	Jun. 30, 2015 EUR (€)	Jun. 30, 2015 EUR (€)
Loss Contingencies [Line Items]
Counterclaim amount filed	$ 3,060,827	€ 2,529,400
Claims and counterclaims amount			$ 4,235,350	€ 3,500,000
Out License Fee [Member]
Loss Contingencies [Line Items]
Out-License Fee amount			400,000
TUM [Member] \| Out License Fee [Member]
Loss Contingencies [Line Items]
Out-License Fee amount			3,400,000
Reserved liability			$ 302,273		€ 271,000

Corporate Information - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Dec. 23, 2014	Dec. 31, 2014
Organization And Description Of Business [Line Items]
Exercise price of warrants	$ 2.00	$ 2.00
Warrant exercisable period	5 years	5 years
Private Placement [Member]
Organization And Description Of Business [Line Items]
Stock issued	6,779,510
Sales of common stock, price per share	$ 2.00
Proceeds from sale of stock	$ 13,560
Common Stock [Member]
Organization And Description Of Business [Line Items]
Aggregate shares issued upon acquisition	542,360

Subsequent Events - Additional Information (Detail)					3 Months Ended			6 Months Ended
Subsequent Events - Additional Information (Detail)	Jul. 24, 2015 $ / shares shares	Jul. 14, 2015 USD ($)	Jul. 14, 2015 EUR (€)	Jul. 06, 2015 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) shares	Mar. 31, 2015 shares	Jun. 30, 2014 USD ($) shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2014 USD ($) shares
Subsequent Event [Line Items]
Number of shares, Options exercised \| shares					0	0	0	0	0
Research and development expense					$ 1,725,592		$ 1,118,920	$ 3,250,222	$ 2,341,666
Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds from issuance initial public offering				$ 28,300,000
Net proceeds from issuance initial public offering				$ 25,800,000
Subsequent Event [Member] \| Cooperation Agreement [Member] \| Milestone One [Member]
Subsequent Event [Line Items]
Research and development expense		$ 48,698	€ 43,660
Subsequent Event [Member] \| Cooperation Agreement [Member] \| Milestone Two [Member]
Subsequent Event [Line Items]
Research and development expense		$ 130,301	€ 116,820
Subsequent Event [Member] \| IPO [Member]
Subsequent Event [Line Items]
Stock issued \| shares				9,090,909
Sales of common stock, price per share \| $ / shares	$ 2.75			$ 2.75
Number of shares, Options exercised \| shares	1,211,827

Revenues - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Revenues - Additional Information (Detail) - USD ($)	May. 31, 2011	Sep. 30, 2010	Aug. 31, 2009	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2012	Dec. 31, 2011	Feb. 28, 2013
Deferred Revenue Arrangement [Line Items]
Revenues from product sales						$ 0
Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments					$ 400,000	0	$ 400,000
Allergan Inc [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments						0
Allergan Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments				$ 13,000,000		13,000,000
Allergan Inc [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue			$ 10,000,000
Sanofi [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments				0	0	0	300,000
Collaboration agreement, revenue recognized				0	200,000	$ 0	700,000
Description of factors in determining milestones substantive						Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.
Collaborative arrangement, consideration		$ 8,100,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Expired Option Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, revenue recognized									$ 700,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options Exercised [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, revenue recognized								$ 350,000
Collaborative arrangement, consideration										$ 280,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options, Exercised Price [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration										$ 1,100,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Licenses [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration		3,500,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options to Acquire Additional Licenses [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration		1,400,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Research Services [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period								2 years
Collaborative arrangement, consideration		3,200,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Research Services [Member] \| Extension Term [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period								40 months
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments		51,600,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Research Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments		1,900,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Development Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments		29,600,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments		20,100,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue		$ 4,900,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period						2 years
Collaboration agreement, revenue recognized				$ 0	$ 400,000	$ 0	$ 1,100,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	$ 91,100,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Research Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	2,600,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Development Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	37,400,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	50,200,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Additional Diagnostic Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	900,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue	$ 10,100,000

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	29,429,522	29,279,522
Common stock, outstanding	29,429,522	29,279,522

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 13, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	PIRS
Entity Registrant Name	PIERIS PHARMACEUTICALS, INC.
Entity Central Index Key	0001583648
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		39,732,258

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals Inc. and its wholly owned subsidiaries were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. All significant intercompany balances and transactions have been eliminated in the consolidation. Certain information and footnotes normally included in financial statement prepared in accordance with U.S. GAAP have been omitted pursuant to the Securities and Exchange Commission rules and regulations. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited condensed consolidated financial statements for the year ending December 31, 2014, and all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of Pieris Pharmaceuticals, Inc.’s unaudited interim consolidated financial statements have been included. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period.
Use of estimates	Use of estimates The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
Segment Reporting	Segment Reporting Pieris Pharmaceuticals, Inc. operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker (CODM) makes decisions based on the Company as a whole. Accordingly, Pieris Pharmaceuticals, Inc. operates and makes decisions as one reporting unit.
Milestone Payments and Royalties	Milestone Payments and Royalties At the inception of each agreement that includes milestone payments, Pieris Pharmaceuticals, Inc. evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Pieris Pharmaceuticals, Inc. evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale or certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount. For revenues from research and development milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, such amounts are recognized entirely upon successful accomplishment of the milestones. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the period of performance. To date, Pieris Pharmaceuticals, Inc. has determined all milestones are substantive. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Royalty payments are recognized in revenues based on the timing of royalty payments earned in accordance with the agreements; which typically is the period when the relevant sales occur, assuming all other revenue recognition criteria are met.
Fair Value Measurement	Fair Value Measurement ASC Topic 820 Fair Value Measurement defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. Pieris Pharmaceuticals, Inc. applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. Cash equivalents recorded by Pieris Pharmaceuticals, Inc. consist of highly liquid money market funds and are measured at fair value on a recurring basis. These funds are classified as Level 1 in the fair value hierarchy because they are valued using quoted prices for the periods ended June 30, 2015 and December 31, 2014. The carrying amounts of $78,403 and $ 4,800,573 as of June 30, 2015 and December 31, 2014, respectively, equal the fair value of the cash equivalents. The Company’s other financial instruments include debt instruments, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities and are classified as Level 2 within the fair value hierarchy. The fair value of these instruments was determined using the discounted cash flow method based on contractual cash flows and the current rate at which debt with similar terms could be issued. The fair values for these debt instruments approximated carrying values as of June 30, 2015 and December 31, 2014.
Income taxes	Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to the same amount as deferred tax liabilities and determines an effective tax rate of zero percent.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09) which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. The Company is currently assessing the potential impact the adoption of this standard will have on their financial statements. In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual items” (ASU 2015-01). The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”(ASU 2015-02). The amendments in ASU 2015-02 are intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December, 15, 2017. The company is currently evaluating the impact of this new standard. In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements” (ASU 2015-10). The amendments in ASU 2015-10 represent changes to clarify the FASB Accounting Standards Codification (the “Codification”), correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. In addition, some of the amendments are intended to make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The company is currently evaluating the impact of this new standard. Pieris Pharmaceuticals, Inc. has considered other recent accounting pronouncements and concluded that they are either not applicable to the business, or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015 USD ($) Segment	Dec. 31, 2014 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of Operating segment \| Segment	1
Milestones arrangement, categories description	Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.
Effective tax rate	0.00%
Fair Value, Inputs, Level 1 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash and Cash Equivalents, Fair Value	$ 78,403	$ 4,800,573

Warrants - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
Warrants - Additional Information (Detail) - USD ($)	Dec. 23, 2014	Dec. 31, 2014	Dec. 31, 2014
Equity [Abstract]
Number of common stock purchased		542,360	542,360
Exercise price of warrants	$ 2.00	$ 2.00	$ 2.00
Warrant exercisable period	5 years	5 years
Warrant expense recognized			$ 664,064

Debt - Additional Information (Detail) - Tbg [Member]		6 Months Ended
Debt - Additional Information (Detail) - Tbg [Member]	Dec. 11, 2014 USD ($) Tranches	Jun. 30, 2015 USD ($)	Jun. 30, 2015 EUR (€)	Mar. 31, 2015 USD ($)	Mar. 31, 2015 EUR (€)	Jan. 31, 2015 USD ($)	Jan. 31, 2015 EUR (€)	Dec. 11, 2014 EUR (€)	Apr. 03, 2014 USD ($)	Apr. 03, 2014 EUR (€)
Debt Instrument [Line Items]
Amount of repayment to TBG outstanding	$ 1,170,000							€ 1,050,000	$ 1,340,000	€ 1,200,000
Principal amount, interest rate									10.53%	10.53%
Repayment agreement description		Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016.	Under the repayment agreement, the Company has agreed to a payment schedule pursuant to which it will make semi-annual payments until 2016.
Capital gain tax withheld		$ 132,385	€ 118,688
Number of tranches	2
Repayment amount of debt				$ 1,038,785	€ 931,312
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Amount of repayment to TBG outstanding						$ 669,240	€ 600,000
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Amount of repayment to TBG outstanding				$ 501,930	€ 450,000